BUSINESS FORUM OvERvIEw

Comments

Transcription

BUSINESS FORUM OvERvIEw
FINAL PROGRAM
2013. 09. 11[Wed] ~ 13[Fri] KINTEX
MANAGED BY
PROGRAM
BIO KOREA Organizing Committee
Conference
Business Forum
Exhibition
Pharm Fair
Invest Fair
Job Fair
• Amino Acids
• Biological Buffers
• Chromatography Media
• Column Cleaning Reagents
• Lysing Agents
• Minerals & Nutrients
• pH Adjusters
• Preservatives
• Sugars
• Surfactants
improving
improving
lives
In the hands of farmers, better seeds can help protect natural resources and promote
biodiversity. Our rapidly growing population is putting limited resources — such as land,
water and energy — under increased pressure. But with the right tools, farmers can
conserve more for future generations.
That’s improving agriculture. That’s improving lives. And that’s what Monsanto is all about.
Pharma
Confidence
A formulation is only as good as the ingredients that comprise it. When
creating your drug, improving patient welfare is your mission. Every molecule
that goes into your product matters. By providing the right materials for
every stage of drug development, from discovery to production, we help
you formulate, manufacture and innovate with confidence.
Learn more at www.avantormaterials.com/Pharmaceutical-Chemicals
Avantor Performance Materials Int’l Inc. Korea Branch
8F, Wooduck Building, 832-2 Yeoksam-dong,
Gangnamgu, Soeul, Korea
Tel: +82 2-2052-0483
Fax: +82 2-571-5401
web: www.avantormaterials.com
Trademarks are owned by Avantor Performance Materials, Inc. or its affiliates unless otherwise noted.
©2013 Avantor Performance Materials, Inc.
Monsanto and Vine Design® is a registered trademark of Monsanto Technology LLC. ©2011 Monsanto Company.
Visit us at BIO KOREA 2013
Booth C30
KINTEX Exhibition Center II
Presentations in Room 307A:
Controlling Raw
Material Variation
9/11/13, 11:15 a.m.
Improving Downstream
Processing Performance
9/12/13, 11:15 a.m.
C
·
O
·
N
·
T
·
E
·
N
·
T
·
S
INTRO
CONFERENCE
BUSINESS FORUM
EXHIBITION
008 Welcome Message
023 Conference Overview
059 Business Forum Overview
071 Exhibition Overview
009 모시는 글
024 Conference Program at a Glance
061 Floor Plan for Business Forum
072 Floor Plan for Exhibition
010 BIO KOREA 2013 Overview
026 Conference Track List
062 Presentation Schedule at a Glance
074 List of Exhibitor
013 BIO KOREA 2013 행사개요
029 Conference Plenary Speech
016 BIO KOREA 2013 Schedule at a Glance
030 Conference Program
065 Partnering Participation Status
019 BIO KOREA 2013 Floor Plan
055 Special Session
Business/Technology/Int'l Country Partner Forum
Job Fair
SPECIAL EVENT
221 Job Fair Overview
237 The Entrepreneuship Boot Camp 2013
231 BIO KOREA 2013 Official Sponsors
223 Floor Plan for Job Fair
Welcome Reception
232 BIO KOREA Shuttle Bus Service
Bio-microphotography Exhibition
BIO KOREA 2014 Poster Contest
Welcome Message
모시는 글
It is our greatest pleasure to invite you to the largest Bio Event in Korea, the 8th BIO KOREA International
Convention, with distinguished bio experts from all over the world.
세계적인 바이오 관련 전문 컨벤션으로 성장하고 있는 BIO KOREA가 올해로 8회째를 맞이하게 되었습니다.
전 세계 제약 · 바이오 산업은 고령화 의료보험 확대 등의 환경적 요인을 기반으로 전 세계적 경기침체에도 불구하고 관련
The global pharma · bio industry has been continuously growing with the rising of population aging and
importance of healthcare, and its market size has reached 85 trillion and expanded to Asian and South
American region in despite of the global economic crisis.
Accordingly, Korean government has set the ultimate goal to become one of the top 7 leading bio nations
by 2020 and been putting aggressive efforts to propel the Korean bio-industry by supporting R&D, funding,
and any possible way.
시장은 아시아 및 중남미 지역으로 확대되어 지난 2012년 기준 약 800조원 규모로 성장 해 왔습니다.
이에 발맞춰 정부는 R&D 지원과 적극적인 보건산업 투자를 통해 글로벌 시장 속 대한민국의 위상을 높여 2020년 세계
7대 제약 바이오 강국으로 도약을 목표로 박차를 가하고 있습니다.
이러한 흐름과 변화 속에서 충청북도와 한국보건산업진흥원이 공동 주최하는 이번 BIO KOREA 2013은 미래 성장동력의
중추적인 역할로서의 보건산업이 앞으로 나아가야 할 방향을 제시할 훌륭한 나침반의 역할을 할 것이라 생각합니다.
In the middle of this dramatic change, Chungbuk [Chungchoengbuk-do] and KHIDI [Korea Health Industry
Development Institute] play pivotal roles to promote Korean bio-industry as the next future growth engine.
BIO KOREA 2013 consists of conference, business forum, exhibition, and various bio-co-located events and
visualizes the present and future of global bio world. It will be the most precious time and experience for the
bio experts all over the world to learn the cutting edge information and attract many possible international
business partners.
최신 국제 전문기술의 정보교류, 실질적인 비즈니스 창출을 위해 구성된 컨퍼런스, 비즈니스포럼, 전시회를 비롯하여
보건산업의 기술흐름을 파악할 수 있는 다양한 프로그램으로 구성된 BIO KOREA 2013은 세계 바이오 시장의 현황을
파악하고 미래를 예측할 수 있는 유익한 시간이 될 것 입니다.
BIO KOREA 2013 개최를 통해 대한민국 제약 · 바이오 산업이 더욱 발전하기를 바라며, 참가하신 모든 분들께 행운이
함께 하시길 기원합니다.
We sincerely hope that Korea bio industry will grow further through this meaningful event, and would like to
take this opportunity to deliver our best wishes to all of you.
Thank you.
Yours sincerely
Lee Si-Jong Ko Kyung-Hwa
Governor of Chungcheongbuk-do & Co-Chairman BIO KOREA Organizing Committee
President of Korea Health Industry Development Institute & Co-Chairman
BIO KOREA Organizing Committee
008
이시종
고경화
충청북도 도지사
BIO KOREA 조직위원회 공동대표 한국보건산업진흥원 원장
BIO KOREA 조직위원회 공동대표
009
BIO KOREA 2013 Overview
Main Program
BIO INDUSTRY, the next generation growth engine for the future!
Welcome to BIO KOREA 2013 International Convention at KINTEX. This 8th BIO KOREA, one of the most
comprehensive bio technology events, will be held from September 11th to 13th.
Conference
D A T E
September 11 (Wed) ~ 13 (Fri), 2013
V E N U E
3 ~ 4F, KINTEX Exhibition Center II
companies and leading Korean research institutions.
E xpected
Participants
Approximately, 3,500 experts from Bio industry, research institutes, academia, and
interested individuals from all over the world.
We greatly appreciate your interest in BIO KOREA 2013 and hope this event to be an enjoyable time for your
Special Session
BIO KOREA 2013 International Country Partner Forum, Osong International Bio Symposium,
First started in 2006, annual BIO KOREA became the most influential and well known event in Asia, this event
would provide a great opportunity for both domestic and foreign investors to meet fast growing Korean bio
on sake.
Pharmaceuticals specialized school seminar for the career development, Daekyung·Osong
Title BIO KOREA 2013 International Convention
Period September 11 (Wed) ~ 13 (Fri), 2013
Venue KINTEX Exhibition Center II
Collaboration BIO Forum, Denmark Bio & Medtech Investment Seminar
Business Forum
D A T E
September 11 (Wed) ~ 13 (Fri), 2013
V E N U E
Hall 7, 8A, KINTEX Exhibition Center II (Business Forum Center)
Program Conference, Business Forum, Exhibition, Pharm Fair, Invest Fair, Job Fair
E xpected
Participants
Bio(Venture) Companies from Korea & Abroad, Bio-Clusters, Local Governments, Embassies,
Investors, Research Institutes
SUPPORTED BY
PROGRAM
1:1 Partnering, Business / Technology Presentation, BIO KOREA 2013 nternational Country
Organized by Chungcheongbuk-do, Korea Health Industry Development Institute
Managed by BIO KOREA Organizing Committee
Partner Forum
Ministry of Health & Welfare
Ministry of Trade, Industry and Energy
Ministry of Food and Drug Safety
Korean Intellectual Property Office
Rural Development Administration
GyongGi-Do
Ministry of Health & Welfare
Ministry of Health & Welfare
Ministry of Trade, Industry and Energy
Ministry of Trade, Industry and Energy
Ministry of Food and Drug Safety
Ministry of Food and Drug Safety
Korean Intellectual Property Office
Korean Intellectual Property Office
Rural Development Administration
Rural Development Administration
GyongGi-Do
GyongGi-Do
Korea Research Institute of
Bioscience & Biotechnology
Korea Research Institute of
Korea Research
Institute of
Bioscience
& Biotechnology
Bioscience & Biotechnology
Korea Institute of Oriental Medicine
Patent Information Promotion Center
Korea Institute of Oriental Medicine
Korea Institute of Oriental Medicine
Patent Information Promotion Center
Patent Information Promotion Center
Osong Medical Innovation Foundation
Kintex
Osong Medical Innovation Foundation
Osong Medical Innovation Foundation
Kintex
Kintex
Korea Research Institute of
Chemical Technology
Korea Research Institute of
Korea
Research
Institute of
Chemical
Technology
Chemical Technology
Daegu-Gyeongbuk
Medical Innovation Foundation
Daegu-Gyeongbuk
Daegu-Gyeongbuk
Medical
Innovation Foundation
Medical Innovation Foundation
National Cancer Center
National Cancer Center
National Cancer Center
Exhibition
D A T E
September 11 (Wed) ~ 13 (Fri), 2013
V E N U E
Hall 7, 8A, KINTEX Exhibition Center II
E xhibition
Categories
Pharmaceuticals & Drug Discovery, Medical devices & Lab Equipment, Food, Cosmetics,
Bio Convergence, Law firm, Government organization, CMO, CRO, Consulting Services,
Venture Capital, Academic Research Centers, Bio Product, Bio Process, Business Services,
Clinical Trial, Bio IT, Bio Research, etc.
Kroea Pharmaceutical
Manufacturers Association
Kroea Pharmaceutical
Kroea Pharmaceutical
Manufacturers
Association
Manufacturers Association
Korea Medical Devices
Industry Association
Korea Medical Devices
Korea
Medical
Devices
Industry
Association
Industry Association
010
World Korean Medical
Organization
World Korean Medical
WorldOrganization
Korean Medical
Organization
Korea Drug Research Association
Korea Biomedicine Industry Association
Korea Drug Research Association
Korea Drug Research Association
Korea Biomedicine Industry Association
Korea Biomedicine Industry Association
Korean Hospital Association
Korea Academy of Medical Science
Korean Hospital Association
Korean Hospital Association
Korea Academy of Medical Science
Korea Academy of Medical Science
Korea International
Medical Association
Korea International
Korea International
Medical
Association
Medical Association
Korea Phamaceutical Traders Association
Korea Phamaceutical Traders Association
Korea Phamaceutical Traders Association
Korea Health Supplements
Association
Korea Health Supplements
Korea Health
Supplements
Association
Association
Korea Food Industry Association
Korea Cosmetic Association
Korea Food Industry Association
Korea Food Industry Association
Korea Cosmetic Association
Korea Cosmetic Association
Korea Medical Devices
Industrial Coop. Association
Korea Medical Devices
Korea Medical
Devices
Industrial
Coop. Association
Industrial Coop. Association
Korea Research-based Pharm
Industry Association
Korea Research-based Pharm
KoreaIndustry
Research-based
Pharm
Association
Industry Association
Korea Medical Association
Korea Biotechnology
Industry Organization
Korea Biotechnology
Korea Biotechnology
Industry
Organization
Industry Organization
Osong Bio Promrtion Foundation
Korea Medical Association
Korea Medical Association
Pharm Fair
D A T E
September 11 (Wed) ~ 13 (Fri), 2013
V E N U E
3 ~ 4F, KINTEX Exhibition Center II
PROGRAM
Pharma Korea 2020 Forum, PIN Conference, Invited Symposium by GPKOL, Global Night
(Regional Networking Dinner), Signing Ceremony
Osong Bio Promrtion Foundation
Osong Bio Promrtion Foundation
011
BIO KOREA 2013 행사개요
INVEST FAIR
2013년 대한민국은 새 정부 출범과 함께 창의성과 융합을 앞세운 ‘창조경제’라는 새로운 패러다임을 맞이하였습니다.
D A T E
September 11 (Wed) ~ 13 (Fri), 2013
국내 보건산업도 이러한 변화에 발맞춰 창조경제의 중심에 서기 위한 도약을 준비하고 있으며, 정부 또한 국내 바이오 기업들이
V E N U E
4F & Hall 7, KINTEX Exhibition Center II
국내 시장을 넘어 세계로 나아가는 글로벌 기업으로 거듭날 수 있도록 지원하기 위해 다양한 방안을 모색하고 있습니다.
PROGRAM
HI Korea Investment Forum, Global Convergence Show-case
보건산업의 정책과 제도 개선, R&D 지원, 글로벌 제약산업 육성펀드 조성, 제약산업 육성 5개년 계획 등 정부의 적극적인 지원
속에 대한민국은 2020년, 7대 바이오 강국으로 거듭남을 준비하고 있습니다.
Job Fair
이러한 시대의 흐름에 맞춰, 대한민국의 대표 바이오 컨벤션인 BIO KOREA는, 국내·외 제약·바이오산업의 전반을 아우르는
D A T E
September 11 (Wed) ~ 12 (Thur), 2013
V E N U E
Hall 8A, KINTEX Exhibition Center II
E xpected
Participants
Recruiting Companies & Organizations from Bio Industry, and Job Seekers
Special Program
Opening Ceremony
D A T E
September 11 (Wed), 2013, 10:00 ~ 11:00
V E N U E
Hall 6, KINTEX Exhibition Center II
보건산업의 허브로 거듭나기 위하여 다채로운 모습으로 제 8회 BIO KOREA를 2013년 개최하고자 합니다.
바이오산업의 활력을 불어넣는 실질적인 비즈니스의 장(場), 국제적 정보교류 및 기술거래의 장(場)으로서 그 역할을 훌륭히
수행해오고 있는 BIO KOREA 2013에서 바이오 산업의 현주소와 미래를 만나보시길 바랍니다.
기 간
2013년 9월 11일 (수) ~ 13일 (금), 3일간
장 소
KINTEX 제 2 전시장
주 최
충청북도, 한국보건산업진흥원
주 관
BIO KOREA 사무국
프로그램
컨퍼런스, 비즈니스포럼, 전시회, 팜페어, 인베스트 페어, 잡페어
후원기관
Welcome Reception
D A T E
September 11 (Wed), 2013, 18:00 ~ 20:30
V E N U E
Outdoor Fountain Square, KINTEX Exhibition Center II
E V E N T S
Opening Performance, Welcoming remarks and Toast
Co-located event
• Bio-microphotography Exhibition
D A T E
September 11 (Wed) ~ 13(Fri), 2013
V E N U E
Hall 8A, KINTEX Exhibition Center II
• The Entrepreneurship Boot Camp 2013
D A T E
September 10 (Tue), 2013, 10:00 ~ 17:00
V E N U E
Conference Rm. 303, KINTEX Exhibition Center II
Organized by
KHIDI, ERA Consulting Group
012
013
주요 프로그램 안내
컨퍼런스
잡페어
일
시
2013년 9월 11일 (수) ~ 12일 (목), 2일간 10:00 ~ 17:00
소
KINTEX 제 2전시장 8A 홀
일
시
2013년 9월 11일 (수) ~ 13일 (금)
장
장
소
KINTEX 제 2전시장 3, 4층 컨퍼런스 룸
참가
대상
보건의료, 바이오 관련 학과 졸업예정자 및 신입/경력 구직자
참가
국내외 바이오산업 종사자, 연구기관, 학술단체 및 관심 있는 개인 등 국내외 약 3,500명
참가
기업
보건의료 및 바이오 산업 40개 우수기업
스페셜 세션
규모
B
IO KOREA 2013 International Country Partner Forum, 오송 국제 바이오 심포지움, 제약산업특성화대학원
공동 국제 컨퍼런스, 대경·오송 바이오 공동 포럼, 한-덴마크 바이오 협력 세미나
스페셜 프로그램 안내
비즈니스 포럼
일
시
2013년 9월 11일 (수) ~ 13일 (금)
장
소
KINTEX 제 2전시장 7, 8A 홀 (Business Forum Center)
일
시
2013년 9월 11일 (수), 10:00 ~ 11:00
참가
바이오(벤처)기업, 제약기업, 클러스터, 지방자치단체, 각국 대사관, 투자기관, 연구기관 등
장
소
KINTEX 제 2전시장 6B 홀, 7 홀 앞
프 로 그 램
대상
개막행사
파트너링, 사업/연구 발표회, BIO KOREA 2013 International Country Partner Forum
전시회
환영만찬
일
시
2013년 9월 11일 (수) ~ 13일 (금)
장
소
KINTEX 제 2전시장 7, 8A 홀
전시
품목
의약품, 의료기기, 식품, 화장품, 융합 바이오, 컨설팅, 벤처캐피털, 대학 및 연구소, 병원, 로펌, 정부기관,
일
시
2013년 9월 11일 (수), 18:00 ~ 20:30
장
소
KINTEX 제 2전시장 앞 야외 분수 광장
프 로 그 램
식전공연, 환영사, 건배제의 등
CMO, CRO, Bio Process, Business Service, Clinical Trial, Bio IT, Bio Research
부대행사
팜페어
일
시
2013년 9월 11일 (수) ~ 13일 (금)
장
소
KINTEX 제 2전시장, 3, 4층 컨퍼런스 룸
프 로 그 램
일
시
2013년 9월 11일 (수) ~ 13일 (금)
장
소
KINTEX 제 2전시장 8A 홀
Pharma Korea 2020 Forum, PIN Conference, Invited Symposium by GPKOL, Global Night (Regional
Networking Dinner), Signing Ceremony
인베스트 페어
일
시
2013년 9월 11일 (수) ~ 13일 (금)
장
소
KINTEX 제 2전시장 7홀 & 컨퍼런스 룸 4층
프 로 그 램
014
바이오 현미경 사진
The Entrepreneurship Boot Camp 2013
일
시
2013년 9월 10일 (화), 10:00 ~ 17:00
장
소
KINTEX 제 2전시장 컨퍼런스 룸 303호
주
관
한국보건산업진흥원, ERA Consulting Group
HI Korea Investment Forum, 융복합 창조기술 Show Case
015
BIO KOREA 2013 Schedule at a Glance
September 10 (Tue)
September 12 (Thur)
Program
Registration
Boot Camp, Conference & Business Forum, Exhibition
The Entrepreneurship The Entrepreneurship Boot Camp 2013
Boot Camp 2013
: De Risking Your Globalisation Strategies
-for Korean Life Science Companies
VenueTime
Program
Registration
Conference & Business Forum, Exhibition, Job Fair
Program
VenueTime
Lobby 2F
09:00~18:00
Registration
Conference & Business Forum, Exhibition, Job Fair
Lobby 2F
09:00~18:00
Rm. 303
10:00~17:00
Conference
u-Health
Rm. 301
09:30~18:00
Translational Research
Rm. 302
09:30~17:30
Medicinal Bio-convergence and Mouse Phenotype Analysis Rm. 303
09:30~11:30
Technology Licensing
Rm. 303
13:00~17:15
09:00~18:00
Pharma & Biotech Intellectual Property
Rm. 304
09:30~17:30
10:00~11:00
Finance - HI KOREA Investment Forum (Free Admission)
Rm. 401, 402
10:00~17:00
Business Forum
1:1 Partnering
Hall 8A
10:00~18:00
10:30~18:00
Hall 7 & 8A
10:00~18:00
September 11 (Wed)
VenueTime
Lobby 2F
Opening Ceremony Plenary Speech
Hall 6B
Exhibition Opening Ceremony
Hall 7
Conference
Vaccine
Rm. 301
13:00~16:50
Medicinal Bio-convergence and Mouse Phenotype Analysis Rm. 302
13:00~17:30
Beauty
Rm. 303
13:00~17:30
Business / Technology Presentation
Hall 7
(Open stage I)
BIO KOREA 2013 International Country Partner Forum
Medical Device
Rm. 304
13:00~16:10
Exhibition
Exhibition
Pharm Fair
CONFERENCE - PIN (Pharmerging Innovative Networking)
Conference (Free Admission)
Rm. 403, 404
09:00~18:00
Global Night - Reginal Networking Dinner (Invited Only)
Rm. 406, 407
18:00~20:30
Job Fair
Consulting for Candidates (Resume, Interview, and Image Making etc.)
Hall 8A (Job Fair Zone)
10:00~17:00
Special Lecture : “Consilience: The Unity of Knowledge “
11:00~12:00
Hall 8A
Jae Chun Choe, Professor, Ewha Womans University
(Open stage 2)
Pharmaceutical Specialized Graduate School Conference 14:10~16:00
: Pharmaceutical Education & Career Development
Business Forum
1:1 Partnering
Hall 8A
10:00~18:00
(Business Forum Center)
Business/Technology Presentation
Exhibition
Exhibition
Pharm Fair
FORUM - Phrama Korea 2020 Forum
Job Fair
Consulting for Candidates (Resume, Interview, and Image Making etc.)
Special Lecture : “Future Social Mega-Trends And Future Jobs” Hall 8A 14:00~15:00
Young Sook Park, Chair, Millennium Project Korea
(Open stage 2)
Healthcare Industry Job Presentation
15:30~17:00
Special Session
London Health Forum (Free Admission)
14:00~17:30
Co-located Events
Welcome Reception
Export Marketign Conference for Medical Device
Rm.308
15:00~18:00
BIO KOREA 2014 Poster Contest
Hall 8A
10:00~18:00
Bio-microphotography Exhibition
Hall 8A
10:00~18:00
016
Hall 7 (Open stage I)
13:00~18:00
Hall 7 & 8A
10:00~18:00
Hall 6B
13:30~18:30
Hall 8A (Job Fair Zone)
10:00~17:00
Rm. 405
Outdoor fountaion Square 18:00~20:30
Co-located Events Denmark Bio & Medtech Investment Seminar Rm. 308
09:00~18:00
Rm. 406, 407
09:00~16:00
10:00~18:00
IP Technology Seminar
BIO KOREA 2013 Poster Contest
Hall 8A
Bio-microphotography Exhibition
Hall 8A 10:00~18:00
017
BIO KOREA 2013 Floor Plan
September 13 (Fri)
Program
Registration
Conference & Business Forum, Exhibition
VenueTime
Lobby 2F
Biotech Crops
Rm. 301
10:00~17:30
Therapeutic Antibodies
Rm. 302
10:00~17:30
Stem Cell
Rm. 303
13:00~18:00
Finance - HI KOREA Investment Forum (Free Admission)
Rm. 401, 402
09:30~16:00
Business Forum
1:1 Partnering
Hall 8A
10:00~18:00
Business/Technology Presentation
Hall 8A
(Open stage I)
BIO KOREA 2013 International Country Partner Forum
Exhibition
Exhibition
Room 401~407
402
407
Conference
Special Session
406
403
405
404
10:30~18:00
Room 301~304, 307~308
10:00~17:00
Pharm Fair
SYMPOSIUM (Invited Symposium by GPKOL)
Rm. 303, 304
09:00~12:30
MOU SIGNING CEREMONY
Rm. 403, 404
10:00~12:30
Rm. 406, 407
09:00~18:00
Co-located Events IP Technology Seminar
401
09:00~18:00
Hall 7 & 8A
4F
BIO KOREA 2013 Poster Contest
Hall 8A
10:00~18:00
Bio-microphotography Exhibition
Hall 8A 10:00~17:00
3F
Conference
301
308
307
302
The Entrepreneurship Boot Camp 2013
Special Session
Room 305
306
303
305
304
BIO KOREA Secretariat (Conference)
Room 306
Speaker's Registration
Preview Room
1F
Hall 6
6
Opening Ceremony
2F
10
7
Hall 7, 8A
Exhibition
8A
9
8B
018
Business Forum
Job Fair
Registration Desk (2F Lobby)
019
MEMO
Conference
Overview
Conference Overview
Conference Program at a Glance
Conference Track List
Plenary Speech
Conference Program
020
Conference Overview
The key strategic industry of Korea in the 21st Century!
Covering a diverse range of applications and areas such as pharmaceuticals, biomedicines, medical services,
food, agriculture, energy, chemical and environment, the Bio industry has become the future growth engine,
fueled by the growth of Information Technology (IT) and Nano Technology (NT).
BIO KOREA 2013 Conference will be a place to discuss and acquire the cutting edge knowledge on various
topics including Vaccines, Therapeutic Antibodies, Biotech Crops, Stem Cell, Bio-convergence, u-Health and
so on to firmly secure the global competitiveness.
DATE:
September 11 (Wed) ~ 13 (Fri), 2013
Venue:
3~4F, KINTEX Exhibition Center II
MAY 28 ~ 30, 2014 / KINTEX
Brand New Start in MAY!
Expected No. of Participants:
Approximately, 3,500 experts from Bio industry, research institutes, academia, and interested
individuals from all over the world.
Official Languages:
English, Korean
023
Conference Program at a Glance
Paid Admission
DATE
Conference Room 3, 4 F, KINTEX Exhibition Center II
Rm. 301
Rm. 302
Sep. 12
(Thur)
Conference Room 3, 4 F, KINTEX Exhibition Center II
Rm. 303
Track 5. Medicinal Bio-convergence and
Mouse Phenotype Analysis
(S1) In Vivo-mimic 3D Cell
Culture System
Track 12. Beauty
(S1) Convergence & Fundamental Technology
for Cosmetics - Technology Application
for Cosmetics - Screening, Evaluation &
Formulation
13:00~15:00
13:00~15:00
13:00~15:00
(S2) Regulatory Issues on Vaccine
(S2) Mouse Models for the Novel Drug
Development
(S2) Functional & Fermented Cosmetics Functional & Fermented Cosmetic Ingredient
through Fermentation Technology
Rm. 402
Rm. 403
Rm. 404
Track 8. Medical Device
(S1) Medical Device Industry
as a Driving Force for
National Growth: Strategies
for Medical Device R&D in
Korea and Japan
13:00~15:05
(S2) Medical Equipment
Industry as a Driving Force
for National Growth:
(Eastern Asia) National
Strategies for Development
of Medical Equipment
15:30~16:10
15:30~16:50
15:30~17:30
15:30~17:30
Track 6. u-Health
(S1) Health Big Data as a
National Asset-Pitfalls and Challenge on
Public Health Data Sharing
Track 7. Translational Research
(S1) Translational Research - Concept and
practice of TR
Track 5. Medicinal Bio-convergence and
Mouse Phenotype Analysis
(S3) Mouse Phenogenomics for Drug
Development
09:30~11:00
09:30~11:30
09:30~11:00
10:00~11:20
10:20~11:40
(S2) Consumer-centered Personal Health
Records and Health Data Platforms – From
Personal Health Records to Big Data
(S2) Translational Research
- Translation from Animal Model to Human
Track 10. Technology Licensing
(S1) Strategy and Support for Steps to
Promote the Commercialization from Early
Stage Innovations
13:00~15:00
(S2) Recent Trends of Court
Decision and Presecution/
Examination Practice Regarding
Pharmaceutical Patent
13:00~14:30
(S2) Company IR
(Public Company)
(S2)Technology Transfer Organization's
Experiences and Cases of Increasing Value
(S3) Major Antitrust Issues
on Pharmaceutical Industry
13:00~14:30
13:00~15:00
(S3) PHR and Big Data-Use of Data and
Management of Personal Health Record
in the Medical Environment
(S3) Clinical Application of Novel Targeted
Agents Based on Genomics
- Personalized Medicine
14:45~16:15
15:30~17:30
Track 9. Pharma & Biotech
Track 11. Finance -HI
Track 11. Finance -HI
Intellectual Property
KOREA Investment Forum KOREA Investment Forum
(S1) FDA ANDA Approval
(S1) Korea Bio Pharma Fund
Partnering
Procedure and Patent
Sources & Investment Trends
Infringement Case Study
in 2013
Partnering
Track 13. PIN (Pharmerging Innovative Networking)
Conference
(S1) China · ASEAN Session
10:15~11:15
(S2) Latin America Session
11:15~12:15
(S3) Russia ∙ Kazakhstan Session
13:45~14:45
(S4) Eastern Europe Session
13:00~17:30
14:45~15:30
(S5) Middle East Session
15:40~16:40
15:15~17:15
(S6) Special Session
(IO Procurement and PCI/S Membership Application)
16:40~17:20
14:45~15:45
(S4) Global Strategy
for Intellectual Property
Licensing
16:00~17:30
16:30~18:00
Track 3. Bio Crops
(S1) Understanding Climate Changes and
Adapting Future Agricultural Production
024
Rm. 401
10:00-17:00
Track 1. Vaccine
(S1) Vaccine R&D
(S4) The Current Status of Smart Health Care
Sep. 13
(Thur)
Rm. 304
The Entrepreneurship Boot Camp 2013
Sep. 10
(Tue)
Sep. 11
(Wed)
Free Admission
Track 2 Therapeutic Antibodies
(S1) Therapeutic Antibodies
Track 4. Stem Cell
(S1) Tissue Specific Mesenchymal Stem Cells
and Their Clinical Application
Track 11. Finance - HI
Track 11. Finance - HI
KOREA Investment Forum KOREA Investment Forum
(S3) Korea Bio Pharma Fund
Partnering
Sources & Investment Trends
in 2013
10:00~11:50
10:00~11:50
10:10~11:40
13:00~14:00
(S2) Managing Food Sustainability in a
Climate Constrained World via Technical
Advances
13:30~14:50
(S2) Innovative Application of Anitbodies
(S2) Tissue Engineering Using Biomaterials
and Stem Cells
(S4) Company IR
(Private Company)
13:30~15:00
14:30~15:30
13:20~16:00
(S3) Development and Commercialization of
Biotech Crops
(S3) Antibodies and Beyond
(S3) Clinical Application of Tissue Specific
Stem Cells
15:30~17:30
15:30~17:30
16:00~18:00
Partnering
025
Conference Track List
01 Vaccine
06 u-Health
: Vaccine R&D and Regulatory Issues
: u-Health Convergence
Session 1 Vaccine R&D
Session 1 Health Big Data as a National Asset
Session 2Regulatory Issues on Vaccine
Session 2Consumer-centered Personal Health Records and Health Data Platforms
Session 3 PHR and Big Data
Session 4 The Current Status of Smart Health Care
02 Therapeutic Antibodies
: Therapeutic Antibodies
Session 1 Therapeutic Antibodies
Session 2Innovative Application of Antibodies
Session3
07 Translational Research
: Navigating Biomedical Discovery towards Clinical Practice
Session 1 Translational Research - Concept and Practice of TR
03 Biotech Crops
Session 2 Translational Research - Translation from Animal Model to Human
: Key Solutions for Climate Changes and Sustainable Agriculture
Session 1 Understanding Climate Changes and Adapting Future Agricultural Production
Session 3Clinical Application of Novel Targeted Agents Based on Genomics – Personalized
Medicine
Session 2Managing Food Sustainability in a Climate Constrained World via Technical Advances
Session 3Development and Commercialization of Biotech Crops
Antibodies and Beyond
04 Stem Cell
: Current Development of Stem Cell Therapy and Tissue Regeneration
Session 1 Tissue Specific Mesenchymal Stem Cells and Their Clinical Application
Session 2Tissue Engineering Using Biomaterials and Stem Cells
Session 3 Clinical Application of Tissue Specific Stem Cells
05 Medicinal Bio-convergence and Mouse Phenotype Analysis
08 Medical Device
: Creative Economy and Medical Device Industry
Session 1 Medical Device Industry as a Driving Force for National Growth
Session 2Medical Equipment Industry as a Driving Force for National Growth
09 Pharma & Biotech Intellectual Property
: Top Legal Issues on Pharmaceutical Industry - Intellectual Property and Antitrust
Session 1 FDA ANDA Approval Procedure and Patent Infringement Case Study
Session 2Recent Trends of Court Decision and Presecution/Examination Practice Regarding
Pharmaceutical Patent
: Convergence Model System and Its Phenotype Analysis for Efficient Drug Discovery
Session 1 In Vivo-mimic 3D Cell Culture System
Session 2Mouse Models for the Novel Drug Development
Session 3 Major Antitrust Issues on Pharmaceutical Industry
Session 3 Mouse Phenogenomics for Drug Development
Session 4 Global Strategy for Intellectual Property Licensing
026
027
Plenary Speech
10 Technology Licensing
: Sustainable Value Chain in Technology Licensing from Bench to Market
Session 1Strategy and Support for Steps to Promote the Commercialization from Early Stage
Innovations
Session 2Technology Transfer Organization's Experiences and Cases of Increasing Value
Innovative Biomedical Futures for Korea
This talk presents forecasts for biomedical futures that offer the most
promise for Korea to take a lead role in science and industry. A new
understanding of health and disease will emerge at the periphery of
JONATHAN PECK
11 Finance
IAF (Institute for Alternative
Futures), President
today’s biological thought so that technologies that are conceived of today
become everyday means for improving health around the world. Biology
will advance through new theory that provokes research into healing,
: HI Korea Invest Forum 2013
Session 1 Korea Bio Pharma Fund Sources & Global Investment Trends in 2013
consciousness and modalities of care that improve wellbeing in ways that
Session 2 Company IR (Public Company)
are highly valuable to societies and communities yet often less costly than
Session 3 Cross-border VC and PE Fund Investment Opportunities and Strategies
current modalities. Along with new theory we can see remarkable tools
Session 4 Company IR (Private Company)
emerging as nanotechnology enables atomic and molecular advances
guided by the knowledge revolution that combines man and machine in
12 Beauty
: Recent Developments in Cosmetic R&D for Making a New Leap Forward
Session 1Convergence & Fundamental Technology for Cosmetics - Technology Application for
Cosmetics - Screening, Evaluation & Formulation
Session 2Functional & Fermented Cosmetics - Functional & Fermented Cosmetic Ingredient
through Fermentation Technology
new ways. Korea has natural advantages for leading a new value proposition
for success rather than following the well-worn medical path that only leads
to more unaffordable disease treatments which will be harder to sell as
markets and governments get smarter.
D A T E
September 11 (Wed), 2013 10:20~11:00
V E N U E
Hall 6B, KINTEX Exhibition Center II
13 PIN (Pharmerging Innovative Networking) Conference
Session 1 China · ASEAN Session
Session 2 Latin America Session
Session 3 Russia · Kazakhstan Session
Session 4 Eastern Europe Session
Session 5 Middle East Session
Session 6 Special Session (IO Procurement and PCI/S Membership Application)
028
029
Conference Program
Sponsored by IVI
Session 2. Vaccine Regulatory Issues Track 01. Vaccine
: Vaccine R&D and Regulatory Issues
Sep. 11(Wed), 13:00~16:50
Historically, vaccines have been reduced, eliminated and eradicated infectious diseases, therefore continuing
efforts are being made in the research & development in vaccines. Now, vaccines are expanding target
disease categories and improving technologies; cancer, chronic diseases, therapeutics and personalized
or specialized and so on. This vaccine track symposium will give an overview of vaccine research and
development (R & D) with new approaches and diseases. In addition to the R & D, regulatory affairs will be
discussed what is being revised and updated in regards to registering and approving vaccines. This track will
be of particular interest to participants from research, academia, pharmaceutical and bio-venture company,
government authorities.
Session 1. Vaccine R&D
15:30~16:50
This second session will share knowledge and experiences of regulatory affairs of vaccines and serve as a linkage to
the first session. During this session, speakers will present general and specific issues of regulatory affairs, regulatory
requirements, preparing dossiers to national authorities and review procedures and other related issues. Therefore, this
session will provide and be understood changes or revisions of regulatory affairs to the participants who are interested in
vaccines.
Session Chair Soon Ae Kim, Research Scientist, Translational Research Division, International Vaccine Institute (IVI)
15:30~16:10 Regulatory Aspects of Vaccine Development
Stephen W Cook, Vice President, Vaccine Global Regulatory, Head of International Region (EMAP /
Japan / WHO)
16:10~16:50 Current Status of Approval Process and Policy Direction for Vaccine in Korea
SeungHwa Hong, Director, Korea Food and Drug Administration, Biologics Division
13:00~15:00
This first session will give some perspectives including outcomes and opportunities of vaccine research and development
(R & D) with new approaches and target disease. Topics will be provided on vaccine research and development for
prevention of co-infection with virus and bacteria, current outcomes and perspectives about new technological
approaches such as DNA vaccine, and new vaccine R & D. This session will provide understanding trends of new
approaches and challenges in vaccine R & D.
Session Chair Thomas F. Wierzba, Deputy Director General, International Vaccine Institute, Development and Delivery
13:00~13:40
Adenovirus Vector-induced Innate-adaptive Protective Immunity duo Against Viral and
Bacterial Infections
De-Chu Christopher Tang, Korean Brain Pool Program Scientist, International Vaccine Institute,
Laboratory Science Division
13:40~14:20 Synthetic DNA Vaccines for Difficult Targets
David B. Weiner, Professor, Department of Pathology and Laboratory Medicine, University of Pennsylvania
Perelman School of Medicine
14:20~15:00 Development of and Target Product Profile Considerations for Human CMV Vaccines
Paul Kilgore, Associate Professor, Department of Pharmacy Practice, Eugene Applebaum College of
Pharmacy and Health Sciences, Wayne State University
030
031
Session 2. Innovative Application of Antibodies
Track 02. Therapeutic Antibodies
: Therapeutic Antibodies
Sep. 13(Fri), 10:10~17:30
Therapeutic antibodies, the main-stream format of drug developments, take up 37% of total biological drug
in developing process and 20% of biological drugs waiting for FDA approval. According to estimation by
Global Industry Analysts, therapeutic antibody market will reach 200 billion dollars by 2013. Currently there
are 33 therapeutic antibodies in use and it is estimated there will be 55 therapeutic antibodies in market
by 2018. Since demand for therapeutic antibodies are increasing constantly, multi-national pharmaceutical
companies and Korean pharmaceutical companies are working actively to develop novel therapeutic
antibody drugs. Through this track, we will look into current research focus and status of scientists in
antibody developments. New applications using therapeutic antibodies and second generation antibodies
will also be discussed.
Session 1. Therapeutic Antibodies
10:10~11:40
Therapeutic antibodies are new paradigms for drug development. Technologies regarding development of therapeutic
antibodies are rapidly. Through this session, top-tier scientists working in active field of therapeutic antibody drug
development will present their research focus and results.
Session Chair JunHo Chung, Professor, Seoul National University, Department of Biochemistry and Molecular Biology
10:10~10:40
Probing Affinity and Fine-Specificity of TCR Multimers and a TCR-like Antibody with PeptideHLA Libraries
Gijsbert Grotenbreg, Assistant professor, National University of Singapore, Microbiology
10:40~11:10 Bispecific Antibodies Co-targeting HER2 and IGF-IR for Cancer Treatment
Mei-Yun, Assistant professor, Hong Kong University, Microbiology Li Ka Shing Faculty of Medicine
11:10~11:40 Development of Therapeutic Antibodies Against Human C5
Dong Jo Kim, Team Leader(Senior Manager), Celltrion, Biotech R&D Institute
032
13:30~15:00
Various application and modification of antibodies to enhance affinity and specificity are being tried actively. We will be
able to take a peak into up-to-date therapeutic antibody modification researches through this session.
Session Chair Yong-Sung Kim, Professor, Ajou University, Applied Chemistry and Biological Engineering
13:30~14:00 Humanized Mouse Technology for Drug Development
Jianzhu Chen, Professor, Massachusetts Institute of Technology, Koch Institute for Integrative Cancer
Research
14:00~14:30 C
omputational Design and Characterization of Artificial Selenoenzyme Based on Antibody
Scaffold
Quan Luo, Assistant Professor, Jilin University, Department of Chemistry
14:30~15:00 Platform Technology for Next Generation Antibody Therapeutics
Byeong Doo Song, President, Scripps Korea Antibody Institute, Division of Research Program
Session 3. Antibodies and Beyond 15:30~17:30
Many innovative approaches using antibodies were suggested recently. Scaffolds or aptamers with characters similar
to antibodies are being actively developed. This session will concentrate on new views and formats of antibodies and
therapeutics molecules.
Session Chair Byeong Doo Song, President, Scripps Korea Antibody Institute, Division of Research Program
15:30~16:10
Platform Technology for the Next Generation Therapeutic Antibody Targeting Solid Tumors
Yong-Sung Kim, Professor, Ajou University, Applied Chemistry and Biological Engineering
16:10~16:50 Biomedical Applications of a Novel Class of High-affinity Peptides (Aptides)
Sangyong Jon, Professor, KAIST, Department of Biological Sciences
16:50~17:30 Non-antibody Scaffold for Developing Therapeutic Agents
Hak-Sung Kim, Professor, KAIST, Department of Biological Sciences
033
Sponsored by Rural Development Administration, Monsanto Korea Inc., ILSI Korea
Session 2. Managing Food Sustainability in a Climate Constrained World via Technical Advances
13:30~14:50
Track 03. Biotech Crops
: Key Solutions or Climate Changes and Sustainable Agriculture
Sep. 13(Fri), 10:00~17:20
Climate changes, often unusual and extreme in nature, have been growingly observed around the world,
threatening sustainable food production and subsequently having impacts on global and national food
security. Global grain prices have been fluctuated significantly in part due to the instability in grain supply
regulating from global warming and climate change. It is of utmost importance to address this issues, which
has driven many research to overcome these increasing challenges especially via technical advances.
Therefore, these scientific sessions are planned to review the current status of climate changes from the
perspectives of food production and economic aspects; to highlight key technical advances such as agriculture
modeling and/or developing abiotic stress resistant biotech crops such as drought tolerant as one way to
stabilize food supply against climate change; and to evaluate biotech crops as a mean to resolve instability of
food supply from climate change in terms of benefits and/or limits.
Session 1. Understanding Climate Changes and Adapting Future Agricultural Production
10:00~11:50
Climate changes have been growingly observed around the world, threatening sustainable food production. Demand
for food crops continuously increases due to the increase in global population and changes in diet patterns from income
growth. This session is planned to review the current status of climate changes from the perspectives of food production
and economic aspects, which in turn help develop adaptation models and/or national policies to address the issues.
Session Chair Kyu Hang Kyung, Professor, Sejong University, Food Science
10:00~10:30 Overview on Climate Change Adaptation in Agricultural Production
Young Han Kwon, Director General, Korea Environment Institute, Korea Adaptation center for Climate
Change
10:30~11:10 Impacts of Climate Change on Food Security and Livelihoods and Policy Responses
Mark Rosegrant, Director, International Food Policy Research Institute(IFPRI)
11:10~11:50 Assessing Options for Adapting Agriculture and Food Systems to Climate Change James Jones, Distinguished Professor, University of Florida, Florida Climate Institute
034
This session is planned to introduce the trends in research, global and local, on technical advances and modeling for
adaptation to climate changes from the perspectives of sustainable agricultural production. Also discussed will be what
the research gaps would be for improved sustainable agriculture.
Session Chair Ki Hwan Park, Professor, Chung-ang University, Food Science and Technology
13:30~14:10
Managing Future Crop Productivity under Changing Climate in Korea - Focusing on Rice
Genetic Improvement for Heat Tolerance
Hee Jong Koh, Director, Seoul National University, Plant Molecular Breeding Center
14:10~14:50
Increasing Sustainable Agriculture Productivity through Agricultural Technology Generation
Jerry Hjelle, President, International Life Science Institute
Session 3. Development and Commercialization of Biotech Crops 15:20~17:20
In this session, there will be interesting presentations about the current status of developing and commercialized Biotech
crops, especially against climate changes. The session will provide global and local cases to evaluate biotech crops as a
mean to resolve instability of food supply from climate change in terms of benefits and/or limits.
Session Chair Yang Do Choi, Professor, Seoul National University, Department Agricultural Biotechnology
15:20~15:40 Current Status of GM Crop Development in Korea
Soo Chul Park, Director, National Center for GM Crops, Rural Development Administration
15:40~16:10 Development of Biotech Crops against Climate Changes in Korea Yeon Hee Lee, Chief, National Academy of Agricultural Science, RDA, Agricultural Biotechnology
16:10~16:40
Introduction of Monsanto Pipeline for the Sustainable Yield from Climate Change
Min Sang Lee, Regulatory Affairs Manager, Monsanto Korea, Regulatory Affairs
16:40~17:20 Q&A/General Discussion
035
Session 2. Tissue Engineering Using Biomaterials and Stem Cells
Track 04. Stem Cell
: Current Development of Stem Cell Therapy and Tissue Regeneration
Sep. 13(Fri), 13:00~18:00
It is widely recognized that stem cells are present in a variety of tissues in the human body. Typical examples
are bone marrow, fat, muscle, and cardiac tissue. The major research fields encompass stem cell isolation,
purification, large expansion, specific lineage differentiation, and clinical applications. Although stem cells
are a very promising tool in disease treatment and tissue regeneration, it is still unclear about the efficacy
of stem therapy. One of the main issue is that the majority of transplanted cells fails to survive at the target
site and thus engraft rate of transplanted cells is extremely low. Therefore a plausible solution using tissue
engineering approach is to combine stem cells with biomaterials. This track introduces current development
of stem cell therapy and tissue engineering, specifically 1) Tissue specific mesenchymal stem cells and their
clinical application, 2) Tissue engineering using biomaterials and stem cells and 3) Clinical application of tissue
specific stem cells.
Session 1. Tissue Specific Mesenchymal Stem Cells and Their Clinical Application 13:00~14:00
It is widely recognized that stem cells are present in a variety of tissues in the human body. Typical examples are bone
marrow, fat, muscle, and cardiac tissue. The major research fields encompass stem cell isolation, purification, large
expansion, specific lineage differentiation, and clinical applications. Specifically bone marrow or adipose-derived stem
cells are commercialized and many cases of clinical trials are underway worldwide. In this session, studies using tissue
specific adult stem cells will be introduced and some related issues are discussed.
Session Chair Gun-il Im, Professor, Dongguk University Ilsan Hospital, Orthopaedics
13:00~13:30Innate Differentiation Propensity of Tissue-Resident Stem Cells & Its Application for
Regenerative Strategy
Young-il Yang, Professor, Paik Institute for Clinical Research, Inje University, School of Medicine,
Pathology
13:30~14:00 Regenerating Articular Cartilage - the Challenge of Creating the Stable Chondrocyte Phenotype
Brian Johnstone, Professor, Oregon Health and Science University, Orthopaedics and Rehabilitation
14:15~15:15
Although stem cells are a very promising tool in disease treatment and tissue regeneration, it is still unclear about the
efficacy of stem therapy. One of the main issue is that the majority of transplanted cells fails to survive at the target site
and thus engraft rate of transplanted cells is extremely low. Therefore a new option using tissue engineering approach is
to combine stem cells with biomaterials. In this session, some approaches utilizing biomaterials to manipulate stem cells
is introduced and relevant issues, including clincical implications and commercialization will be discussed.
Session Chair Jin Ho Lee, Professor, Hannam University, Dept. of Advanced Materials
14:15~14:45 Biofunctional Materials for Tissue Engineering Applications
Heungsoo Shin, Associate Professor, Hanyang University, Bioengineering
14:45~15:15 Stem Cell Commitments in 3D ECM-hydrogels
Nathaniel S. Hwang, Assistant Professor, Seoul National University, School of Chemical and Biological
Engineering
Session 3. Clinical Application of Tissue Specific Stem Cells 15:30~17:30
Stem cells residing in diverse tissues in our body are highly valuable resources in regenerative medicine. It is believed
that stem cells derived from a target tissue can be more potent in therapeutic effect for the same target regeneration.
Therefore this session overviews the recent development of clincial applications of specific tissue-derived stem cells and
trend of stem cell-based gene therapy. Especially some barriers in developing stem cell therapy and possible technical and
clinical solutions will be discussed.
Session Chair Shin-Yoon Kim, Professor, Orthopedic Surgery, Kyungpook National University, College of Medicine
15:30~16:00 Tonsil-derived Mesenchymal Stromal Cells: Successful Banking & Clinical Application
Hae Sang Park, Clinical Assistant Professor, Otorhinolaryngology - Head & Neck Surgery, Ewha Womans
University Mokdong Hospital
16:00~16:30 Neural Stem Cells and Translational Research
Kook In Park, Professor, Yonsei University College of Medicine, Pediatrics
16:30~17:00 More Insights into Mesenchymal Stem Cells as Therapeutics
Ki Chul Hwang, Professor, Yonsei University Collage of Medicine, Severance Biomedical Institute
17:00~17:30
Umbilical Cord Blood Therapy Potentiated with Erythropoietin for Children with Cerebral Palsy
MinYoung Kim, Professor, CHA University, Rehabilitation Medicine
036
037
Sponsored by IMPC / KMPC
Session 2. Mouse Models for the Novel Drug Development
Track 05.
Medicinal Bio-convergence and Mouse Phenotype Analysis
: Convergence Model System and Its Phenotype Analysis for Efficient Drug Discovery
Sep. 11(Wed), 13:00~17:30 / Sep. 12(Thur), 09:30~11:30
Despite the constant increase in R&D investment for new drug discovery, the investment return is getting
lower in the pharmaceutical industry. This is a crisis not only to the industry itself but also to human health
and welfare. The difficulty mainly results from the high failure rate and long term R&D periods involved
in drug discovery. In order to overcome this crisis, NT, IT convergence & multi-omics data integration being
presented as an alternative technology innovation. In this track, experts from various discipline will share
their knowledge about 3D cell culture systems, mouse model development and systematic mouse phenotype
analysis in drug discovery.
Session 1. In Vivo-mimic 3D Cell Culture System
High failure rate in clinical trials of the drug development process is a major burden in respect of cost and time. Animal
disease models used in the preclinical trials have limitations in recapitulating human disease because they are different in
the pathological processes in various aspects. To improve those limitations of disease model, in this session, we discuss how
to generate proper mouse models and analyze them efficiently.
Session Chair Sunghoon Kim, Professor, Seoul National University, College of Medicine
15:30~16:10 Mouse Models for the Novel Drug Development
Ho Jun Seol, Associate professor, Sungkyunkwan University School of Medicine, Samsung Medical Center
16:10~16:50In Vivo Fluorescence Cellular Imaging of Animal Model for Human Disease by Intravital
Microscopy
Pilhan Kim, Professor, KAIST, Graduate School of Nanoscience and Technology
16:50~17:30 DNA Damage Pathway in Cancer, Aging, and Development
Ho Lee, Senior Scientist, National Cancer Center, Biomolecular Function Research Branch
Session 3. Mouse Phenogenomics for Drug Development
13:00~15:00
Recently, Drug development takes increased money, but the number of approved drug is decreased. This situation is
caused by the gap between basic research and clinical trials. Basic scientists usually use cell line for their convenience, but
there are many different cellular response between conventional cell culture system and in vivo system. To solve this gap,
in vivo-mimic 3 dimensional cell culture being presented as an alternative platform. In this session, experts from various
discipline will share their thechnologu and knowledge to narrow the gap in drug development.
15:30~17:30
09:30~11:00
13:00~13:40 3D Culture of Blood Vessels; Perfusable Blood Vessels on a Chip
Noo Li Jeon, Professor, Seoul National University, School of Mechanical and Aerospace Engineering
The laboratory mouse as a model of human disease has proved to be a powerful tool for drug development, with dozens of
the top selling medicines generated in part through the application of a mouse model. However, There are still many challenges
ahead to maximize the value of the mouse as a model, particularly for drug development. These involve limited understanding
of phenotype of mouse in genotypic, systemic and systematic level.
To overcome this, we need phenogenomic approach, which is the functional annotation of human genome by the
phenotype assessment of mutant mice. Systematic phenotype assessments in mutant mouse allow us to find new
function of human gene leading to development of new drugs.
In this session we will discuss how genotype-phenotype analysis and high throughput screens in the mouse are being
used in translational research and where they can help advance the drug discovery process.
13:40~14:20
High-Throughout, Microarray-Based Platforms for Predictive 3D Cell-based Screening
Bosung Ku, Principal Engineer, Samsung Electro-Mechanics
14:20~15:00 In vitro 3D Heterotypic Cell Culture Assay
Seok Chung, Associate Professor, Korea University, School of Mechanical Engineering
09:30~10:00 International Mouse Phenotyping Consortium: Defining Gene Function Using KO mice
Mark Moore, Executive Director, IMPC
Session Chair Sunghoon Kim, Professor, Seoul National University, College of Medicine
Session Chair Je Kyung Seong, Professor, Seoul National University, Veterinary Medicine
Han Woong Lee, Professor, Yonsei University, Biochemistry
10:00~10:30 Mouse Metabolic and Sensory Phenotyping in Korea Mouse Phenotype Consortium (KMPC)
Je Kyung Seong, Professor, Seoul National University, Veterinary Medicine
10:30~11:00 Knockout Mice Created by TALEN-mediated Gene Targeting
Han Woong Lee, Professor, Yonsei University, Biochemistry
038
039
Session 3. PHR and Big Data-Use of Data and Management of Personal Health Record in the Medical
Session 2. Environment
14:45~16:15
Track 06. u-Health
: u-Health Convergence
Sep. 12(Thur), 09:30~18:00
There have been many of attempts to enhance the quality of human life with the great store of information
in the 21st century. The continuously growing amount of information has turned in to the 'Big Data' and
it has been resulted in outstanding progress in many of health fields such as PHR, disease prevention, and
quality health service, and accordingly, the international stand of Korean health industry in the global
world has been escalated. These sessions will review and discuss about the current status and prosperity of
u-Health, emerged from the convergence of IT and BT.
Session 1. Health Big Data as a National Asset - Pitfalls and Challenge on Public Health Data Sharing
09:30~11:00
In the era of “Big Data”, the government is responsible for utilizing the medical data in treating disease and providing optimal
health environment to the public. The policies in deploying the health and medical data in the advanced countries would be
discussed and review what are the concern and legal and administrative measures regarding the governmental use of medical
data. Moreover, it will cover the convergence of u-Health and information technology as a health information.
Session Chair Seung Hoon Lee, Director, National Cancer Center, Office of Public Relations and Collaboration
09:30~10:00Health Data Utilization in Public Organizations, and Ict, Creative Economy in Fast Growing
Information Society
Young Sung Lee, Professor, Chungbuk National University, Department of Health Informatics and
Management/College of Medicine
10:00~10:30
Use of Public Data and Protection of Privacy in Healthcare
Hyoung Wook Park, Assistant Professor, Dankook University Medical College, Department of Social Medicine
10:30~11:00
Telemedicine Based on T(-ele) Shirt Gi-Soo Chung, Korea Institute of Industrial Technology
Session 2. Consumer-centered Personal Health Records and Health Data Platforms - From Personal Health Records to Big Data
13:00~14:30
As consumers are becoming more empowered by information and technology, it is starting to consolidate health data
siloed in various healthcare organizations into personal health records. The cost of personal health devices is constantly
decreasing and the development of mobile health apps is spurring with the penetration of smartphones. Now, consumers
need a health data platform to aggregate and manage diverse data regarding one's health, including genetic information.
Cloud-based health data platforms can fulfill these needs, turning personal health records into big data with genotypic and
phenotypic information of numerous individuals. In this session, the speakers will introduce the concept of a consumercentered personal health record, and explain how a health data platform can create an ecosystem. The speakers will also
share some characteristics of Korean consumers through the case of a personal health record system in Korea.
Session Chair 13:00~13:30
13:30~14:00
14:00~14:30
040
Suk Hwa Kim, Professor, Seoul National University Hospital Plastic Surgery
The What and Why of a Consumer-centered Personal Health Record
Suk Hwa Kim, Professor, Seoul National University Hospital Plastic Surgery
An Open Health Data Platform and Its Ecosystem
James G. Boram Kim, Researcher, Seoul National University, College of Medicine
My Chart in My Hand: Hospital Tethered Mobile Health Record Application
Soo Yong Shin, Research Assistant Professor, Asan Medical Center, Biomedical Informatics
Environment can be provided in more convenient and efficient, as m-Health and u-Health through smart IT fusion
are provided medical services recently, personal health records has become a hot topic in the medical field studies the
application of technology to take advantage of big data that has been investigated. By integration analysis of data to
generate knowledge and verifying, use of big data in the medical environment in the future, in order to provide medical
services according to the patient that the physician can make a medical accurate and it is predicted that would be an
important analytical tool.
In this session, you can be utilized how they are managed future, we will try and check at the moment, personal health
records of these attempts to provide a forum for active exchange.
Session Chair Il Kon Kim, Professor, Kyungpook National University, School of Computer and Science
14:45~15:15 Overview of Global PHR Platform and Big Data
Jeong-Whun Kim, Associate Professor, Seoul National University Bundang Hospital, Otorhinolaryngology
15:15~15:45 Clinical Data Warehouse System for Personalized Care Guideline Development
In Young Choi, Assistant Professor, The Catholic University of Korea, Graduate School of Health
Management and Policy
15:45~16:15 Big Data Business Model
Jung Kim, CEO, DBdiscover
Session 4. The Current Status of Smart Health Care 16:30~18:00
A report published by GSMA(GSM Association) and PricewaterhouseCoopers predicted that mHealth could save over 1
million lives in Sub-Saharan Africa over the next five years and help cut healthcare costs in OECD countries by over 400
billion USD in 2017.
In this session, three topics of smart healthcare using smart devices for mHealth will be discussed, those are, Hospital
information system for smart healthcare, Trend of ICT for smart healthcare, and Mobile emergency care on board.
Session Chair Tae Soo Lee, Professor, Chungbuk National University, College of Medicine
16:30~17:00 Seamless Healthcare Model : Connecting Patients and Professionals for Better Care
Hye-Jeong Jeong, Research Professor, Yonsei University
17:00~17:30 The Evolution Path of Smart Mobile Health and Case Studies
Seungsu Baek, Director, Health Connect Co.Ltd, Healthcare Business Development Division
17:30~18:00 Mobile Emergence Care in Ambulance
Dong Keun Jung, Professor, Dong-A University, College of Medicine, Department of Medical Engineering
041
Session 2. Translational Research - Translation from Animal Model to Human
Track 07. Translational Research
: Navigating Biomedical Discovery towards Clinical Practices
Sep. 12(Thur), 09:30~17:30
The core goal of translational research in medicine is to develop the products solving medically unmet needs
(T1) and to verify the feasibility of research products to medicine (T2). T1 translational research can be
achieved by integrative and cooperative studies performed by the associative specialists in basic, clinical, and
industrial sectors and T2 translational research is for the improvement of people's health status.
Translational research has recently become a focus of concern because of growing awareness of a widening gap
between advances in basic science and the practical application of that knowledge. One manifestation of this gap is
the lack of growth of new drug approvals despite a more than 10-fold increase in spending by the pharmaceutical and
biotechnology industries over the past 40 years. One of factors contributing to this R&D productivity crisis is the difficulty
of crossing the valley of death: the gulf between finding a promising new agent and demonstrating its safety and efficacy
in humans. In this session, scientific requirements and developmental strategies required to cross the valley of death, thus
leading to the successful clinical investigation of anti-cancer drugs, will be presented.
Session Chair The scope of translational research is not restricted to a certain stage of technology relevant level (TRL)
of healthcare R&D. It requires holistic approaches to resolve medically unmet needs and to maximize the
efficiency and productivity of R&D.
13:00~15:00
J ang-Seong Kim, Principal Scientist, Korea Research Institute of Bioscience and Biotechnology Research
Center for Integrated Cellulomics
13:00~13:40 Targeting Tumor Microenvironment for Pancreatic Cancer Treatment
Sang Seok Koh, Principal Investigator, Korea Research Institute of Bioscience and Biotechnology
Immunotherapy Research Center
13:40~14:20
Inhibition of Tumor Progression by a Novel Anti-cancer Therapeutic antibody Targeting VEGF and
Dll4
Weon-Kyoo You, Principal Research Scientist, Hanwha Chemical, Biologics R&D Center
14:20~15:00
Fulfilling the Promise of Drug Discovery and Development: Role of PK/PD and Biomarkers in
Early Decision
Sang Hoon Lee, VP and Co-founder, PharmAbcine, Management
Session 1. Translational Research - Concept and Practice of TR
09:30~11:30
Session 3. Clinical Application of Novel Targeted Agents Based on Genomics - Personalized Medicine
15:30~17:30
Many scientific discoveries from genetic and molecular biological laboratories had not been successfully linked to the
medical use such as prevention, diagnosis, and therapeutic treatment of disease. The concept of translational research
has been emerged to solve this problem. Translational research can effectively promote the clinical application of R&D
outcomes from basic science to valuable medical products.
Session Chair Byung Soo Kim, Director, KHIDI, Department of Translational Research
09:30~10:00 Bench to Bedside – Drug Discovery & Development in Singapore
Louise Sarup, Head of Business Development & Licensing, A*STAR
10:00~10:30 Mechanism of Action of Novel Insulin Sensitizers
Patrick R. Griffin, Professor and Chair, The Scripps Research Institute, Scripps Florida, Molecular Therapeutics
10:30~11:00 The Role of New Drug Development Center of DGMIF : Promotion of Translational Research
Seong Heon Kim, Director of Medicinal Chemistry, DGMIF, New Drug Development Center
11:00~11:30 The Conceptual Debate of Translational Research
uk Kwan Kim, Director, Science & Technology Policy Institute (STEPI), Division for Industrial Innovation
S
Research
042
With tremendous progress of biotechnology and genomics, molecular targeted agents are the mainstream of the new
drugs in cancer treatment resulting in improving clinical outcome. However, still there are many problems exist including
the proper assay for target identification, drug resistance from tumor heterogeneity, and different drug toxicity profiles
from cytotoxic agents with ethnic differences. Hence the effort for personalized therapy based on the patients’ and tumor
characteristics for maximizing antitumor effect and minimizing drug toxicity is necessary. We need the development of
proper biomarker assay, biomarker driven clinical trials, especially multinational trials. In this session, we will discuss the
current status of personalized medicine in cancer and proper strategy to overcome the limitations in development of
novel molecular targeted agents through multinational trials.
Session Chair Hyun Cheol Chung, Professor, Yonsei Cancer Center, Yonsei University College of Medicine, Yonsei
University Health System, Division of Medical Oncology
15:30~16:10 Global Development on Monoclonal Antibody Biosimilar Ho Ung Kim, Department Leader, Celltrion Inc. Clinical Planning, Clinical Statistics, Medical Affairs
16:10~16:50 Challenges in Multinational Trials
Atsushi Ohtsu, Professor, National Cancer Center Hospital East
16:50~17:30 Development of Novel Anticancer Drugs from Whole Genome Sequencing
Yeul Hong Kim, Professor, Korea University, Oncology-Hematology
043
Sponsored by The Korean Society of Medical & Biological Engineering,
Korean Society of Biomaterials, The Korean Society of Mechanical Engineering,
The Institute of Electronics Engineers of Korea
Session 2. M
edical Equipment Industry as a Driving Force for National Growth
Session 2. : (Eastern Asia) National Strategies for Development of Medical Equipment15:30~16:10
Track 08. Medical Device
: Creative Economy and Medical Device Industry Sep. 11(Wed), 13:00~16:10
The track will discuss the issues regrading medical device R&D and industrization. The medical device industry
will encourage the creative economy and contribute to the future growth engines of Korea.
Session 1. Medical Device Industry as a Driving Force for National Growth
Session 2. : Strategies for Medical device R&D in Korea and Japan Medical equipment industry is a capital-technology dependent industry, with a long expense retrieval period due to a
long development period before production (3~5 years). Continued investments are crucial due to high initial expenses,
small market, and short product lifespan. Another obstacle is the different regulations between different countries, which
hinders international trade. Numerous specialized, small-to-middle sized companies dominate the department-based
research market, while the market for relatively expensive parts and products are controlled by larger companies. We
invite experts from across the societies to discuss the policies suggested by the government to promote R&D support,
regulation and registration, and balanced market growth.
Session Chair 13:00~15:05
The medical equipment industry is a part of public health industry, aiming to improve the quality of human lives through
combined efforts of the medical field and various fields of engineering. The production of medical equipments require
cooperation of various fields of science such as clinical studies and engineering, including but not limited to electrical,
electronic, mechanical, material, and optical technology. Furthermore, government regulations must be maintained on
the medical equipment industry as it directly impacts and is influenced by the overall health and wellness of the patients.
Therefore, the government encourages development, production and clinical trials while regulating safety, sales, efficacy,
and ensuring the ownerships of intellectual properties. We invite experts to discuss future strategies for development of
medical equipments, optimization, and fusion and application of various fields of engineering. We also invite experts to
discuss government-involved development of medical equipments in Korea and Japan.
Session Chair Zang-Hee Cho, Professor, Gachon University, Neuroscience Research Institute
13:00~13:02 Opening Adress
Kyung Sun, Professor, Korea University
13:02~13:05 Congratulatory Adress
Dae-Kyung Kim, Chair, NSTC, Expert Councilon Life Science and Welfare
13:05~13:35 Action Plan of Promotion of Medical Device Innovation in Japan
Yoshiyuki Taenaka, Director, National Cerebral and Cardiovascular Center, Research and Development
Initiative Center
Panel
Kui Won Choi, Director, Korea Institute of Science and Technology, Biomedical Research Institute
Panel Discussion
oung Huh, Program Director, Korea Evaluation Institute of Industrial Technology, Emerging Industry PD
Y
Group
Mi Na Ha, Director, Korea Health Industry Development Institute, Department of Infrastructure Development
un-jong Cha, Division Director, Division of Electrical Engineering, Information Science, and Convergence
E
Research, Directorate for Basic Research in Science and Engineering, National Research Foundation of
Korea
Hee Chan Kim, Professor, Seoul National University, Department of Biomedical Engineering, College of
Medicine
Ki Dong Park, Professor, Ajou University, Molecular Science and Technology
Doo Yong Lee, Professor, KAIST, Mechanical Engineering
Chang-Hyun Oh, Professor, Korea University, Department of Electronics and Information Engineering
Hee Byoung Park, Director, Korea Medical Devices Industrial Cooperative Association
Tae-Geon Kang, Director, Korea Medical Devices Industry Association, Industry Development Department
13:35~14:05 National R&D Strategies of Medical Devices
Bong Soo Kim, Director, Ministry of Science, ICT and Future Planning, Expert Council on Life Science and Welfare
14:05~14:20
Role and Responsibility of Biomedical Engineer for the Development of Domestic Medical Device
Industry
Hee Chan Kim, Professor, Seoul National University, Department of Biomedical Engineering, College of Medicine
14:20~14:35 Recent Advances in Biomaterials-based Medical Devices
Ki Dong Park, Professor, Ajou University, Molecular Science and Technology
14:35~14:50 Toward Open Innovation in the Medical Devices Industry Doo Yong Lee, Professor, KAIST, Mechanical Engineering
14:50~15:05 Present and Future of Research and Development of Medical Electronic Systems
Chang-HyunOh, Professor, Korea University, Department of Electronics and Information Engineering
044
045
Session 2. Recent Trends of Court Decision and Presecution/Examination Practice Regarding
Session 2. Pharmaceutical
Patent
13:00~14:30
Track 09. Pharma & Biotech Intellectual Property
: Top Legal Issues in Pharmaceutical Industry - Intellectual Property and Antitrust
Sep. 12 (Thur), 10:00~17:30
The pharmaceutical industry can sustain its growth through protecting intellectual property rights of research
and development in the field. First, we should know how they are protected. It is important to understand
what protections foreign and domestic courts grant to intellectual property rights in the pharmaceutical field,
and what recent trends are in presecution/examination process. Also, we should understand the limits of
protection. Understanding the proper scope of rights through knowing recent regulation trends is necessary.
Lastly, we should take a look at the exercise of intellectual property rights through licensing.
This section will take a look at recent court decisions involving pharmaceutical patents in Republic of Korea and the
United States. Court decisions about probability of obtaining a patent grant (in particular, the recent Supreme Court’s
Myriad decision) or ones regarding interpretations of patent claims are essential for requesting protection through patent
in future. Also, the section will examine trends of presecution/examination practices by Korean Intellectual Property Office
and U.S. Patent and Trade Office, thereby having time to find out a desirable way to apply for a patent.
Session Chair Junghi Park, Partner, BAE, KIM & LEE LLC
13:00~13:30 The Analysis of Korean Court Cases in the Area of Pharmaceuticals for Recent 3 Years
So Young Ahn, Patent Attorney, Dr. Ahn International Patent Law Office, Patent
13:30~14:00
Recent Trends on Patent Applications and Examination Practices in the Field of Pharmaceuticals
in Korea Yong Kim, Patent Examiner, Korean Intellectual Property Office, Pharmaceutical Exmination Division
Session 1. FDA ANDA Approval Procedure and Patent Infringement Case Study 10:00~11:20
Some of issues that arise in ANDA patent litigation are common to patent litigation in general, many more, however,
derive uniquely from the Hatch-Waxman Act and the regulations associated with FDA approval of a patented or generic
pharmaceutical drug. Combining the elements successfully requires considerable expertise.
This session details the process at the intersection between the statutory and regulatory scheme governing approval
of pharmaceutical drugs and U.S. patent law in the context of ANDA patent litigation. Specific emphasis is placed on
presenting the issues, the strategies, and the tactics from the perspective of both branded and generic pharmaceutical
companies.
For the pharmaceutical companies, the federal courts and other governing bodies (the arbiters in this litigation), and
even the consumers, the work represents an insiders’ guide to the process as a means of offering understanding and
perspective.
Session Chair 14:00~14:30 The Future of Biotech Patents after Recent U.S. Supreme Court Decisions
Judith Kim, Partner, Sterne Kessler Goldstein & Fox, Bio
Session 3. Major Antitrust Issues in Pharmaceutical Industry 14:45~15:45
Recently, the Fair Trade Commission is tightening regulations on unfair trades in the pharmaceutical field. The Fair Trade
Commission particularly notified Guidelines for Fair Trades in the Pharmaceutical Field. This section will examine why the
guideline is enacted and what it is about, and furthermore take a look at major fair trade issues in the field.
Session Chair Eric Eui-Kwon Kim, Attorney at law, Dong-A Pharmaceutical, Legal Affairs Team
14:45~15:15 EU Competition Law Enforcement in the Pharmaceutical Industry
Hee-Eun Kim, Attorney, Covington & Burling LLP, Brussels Office
15:15~15:45 The Trend of Antitrust Law Enforcement in the Pharmaceutical Sector
Il Kang, Partner, BAE, KIM & LEE LLC, Antitrust Team
Kyung Ae Yoon, Patent Attorney, Yul Chon LLC, IP group
10:00~10:40 FDA ANDA Approval Procedure and Patent Infringement Case Study
Heajin Jung, Attorne, Heajin Jung Law Firm, LLC
10:40~11:20 Hatch-Waxman Practice: Practical Considerations and Strategies
Ari Zytcer, Attorney-at-Law, Vorys, Sater, Seymour and Pease, Pharma/Biotech Patent Group
Session 4. Global Strategy for Intellectual Property Licensing 16:00~17:00
IP Licensing is an important opportunity for domestic pharmaceutical firms to make profits. The first step is to secure a
strong patent for licensing. Due diligence, an investigation conducted during licensing process with foreign businesses,
should be thoroughly prepared as well. Licensing negotiation strategy is also necessary. This session will examine major
issues one should know for IP licensing.
Session Chair Chiho Choi, Director, Management Planning, KAIST
16:00~16:30 Pitfalls in Pharmaceutical Licensing
Chiho Choi, Director, Management Planning, KAIST
16:30~17:00 IP Due Diligence in Pharma/Biotech Out-licensing
Mihsun Koh, Patent Attorney, Vorys, Sater, Seymour and Pease LLP, Pharma/Biotech Patent Group
17:00~17:30 Intercultural Challenges for Asian Companies in Partnerring with European Companies
Sebastian Fernandez, Founder, Atenea Management Services
046
047
Sponsored by MSD
Session 2. T echnology Transfer Organization's Experiences and Cases of Increasing Value
Track 10. Technology Licensing
: Sustainable Value Chain in Technology Licensing from Bench to Market
Sep. 12 (Thur), 13:00~17:15
The ecosystem of bio technology & pharmaceutical value chain include inventors (academic and research
institutes), technology transfer organization, and companies in need. It is critical to oversee the organic
structure and each component and the strategy to add value. These sessions will discuss the ideal approach
for a successful technology licensing and transfer.
15:15~17:15
Among the key components of successful technology transfer are competency and experiences of Technology Transfer
Organization (TTO). Experienced TTOs are significantly involved beyond the initial technology transfer. From experiences
of recognized institutions, an insight can be learned for what can be done for next steps for enhancing the capacities of
Korean TTOs.
Session Chair Jangyoung Lee, Medi-post, Business Development
15:15~15:45 From Research to Commercialization – The Technion Experience
Benjamin Soffer, CEO, Technion Technology Transfer
15:45~16:15
Commercialization of University's Technology & Role of Techno Holding Company
Moon Kyu Lee, Director, Sogang University Holdings, Headquarters
16:15~16:45
External Opportunity in Asia : Key Considerations in Early Stage Collaboration, Big Pharma
Perspectives
Yuan-Hua Ding, Senior Director, Pfizer, Worldwide R&D
16:45~17:15 K
ey Considerations for Early Stage Collaboration, Korea Bioventure perspectives, Stories of
PharmAbcine Development Strategies and Partnership
Jin-SanYoo, CEO, PharmAbcine
Session 1. Strategy and Support for Steps to Promote the Commercializationfrom Early Stage
Session 2. Innovations
13:00 ~ 15:00
Despite the overall increase of R&D budgets, the whole pharmaceutical industry has faced the challange of decreased
productivity. Development and commercialization of early-stage innovations are exposed to high risks of failures
at various stages. From the experiences of global organizations, we would learn the know-how and strategies for
overcoming hurdles and successful commercialization of innovative medicinal products.
Session Chair Dongho Lee, CEO, Korea Drug Development Fund
Pleanary Speaker Partnering for Innovation; Merck's Strategy and Experiences in Early Stage Alliance
13:00~13:30Greg Wiederrecht, Vice President, Merck Research Laboratories, WWL&A/ESA
13:30~14:00 Sigapore's Biomedical Industry : The Role of A*STAR
Benjamin Seet, Executive Director, Agency for Science, Technology and Research, Biomedical Research
Council
14:00~14:30 Israel’s Incubator Program
Ofer Fohrer, Commercial Attaché, Embassy of Israel
14:30~15:00 A Strategy for Biotechnology Transfer and Commercialization Hyun Mo Yang, Director, TechnoValue, MoT Department
048
049
Special Sponsor: Ministry of Health & Welfare
Session 3. Cross-border VC anc PE Fund Investment Opportunities and Strategies
Track 11. Finance
: HI Korea Invest Forum 2013
Sep. 13. (Fri) 10:00~11:50
Sep. 12 (Thur) 10:00~17:00 / Sep. 13 (Fri) 09:30~16:00
Bio Korea 2013 will host the Bio Invest Forum Sessions, featuring presentations and panel discussions to
help identify and understand Korean Pharma PE & biotech VC fund sources and investment opportunities.
Participants include global and local venture capitalists, investment bankers, government representatives
and company executives who are looking for cross-border strategic and financial alliances and network
opportunities.
Session Chair Ike Whan Lee, Person CEO of Alopax Bio-Consulting, Inc.
10:00 - 10:20An Investment Banker’s View on the Future Growth for Biotech and Pharma, and the Areas of
Greatest Opportunity for Korean Companies
Billy Cho, Vice President of Citi Group, Hongkong
10:20 - 10:40 Israel’s Life Science Industry
Guy Shinar, Venture Partner of YozmaGroup
10:40 - 11:00 Global B2B to Eong-term Outperform Ji-Hyun Kim, Analyst of Kiwoom Securities Co., Ltd
Session 1. Korea Bio Pharma Fund Sources & Investment Trends in 2013
Session Chair Sep. 12. (Thur) 10:20~11:40
11:20 - 11:40The Biotechnology Capital Raising Environment Globally and in Asia Pacific - Outlook and
Recent Developments
Vijay Karwal, Managing Director of Head of Industrials, Consumer & Healthcare Asia Pacific, CIMB
Investment Bank
11:40~11:50 Break
Dong-Su Jeong, Attorneys at Law YULCHON
Panel
10:20 - 10:40 Investment Overview on Korea Bio/Pharma Companies
Youn-hoon Joo, Health Industry Leader of Samil/PwC Advisory Korea
Panel Discussion
11:50~12:30 B. Christopher Kim, Partner, Oxford Bioscience Partners (Moderator)
10:40 - 11:00Introducing KoFC Fund for Strengthening the Competitiveness of Korean Pharmaceutical
Industry
Jin-Woo Park, Manager of Korea Finance Corporation
Caleb Winder, Director, Excel Venture Management
Timothy E. Sullivan, Head of Life Science, RBS Citizen
Patrick Keenan, Director and Chief Counsel, Nomoda Capital Innovations
11:00 - 11:20 InterVest Global Pharmaceutical Fund 2013
Myung-Kee Kim, Executive Managing Director of InterVest Co., Ltd.
Billy Cho, Vice President, Citi Group
11:20 - 11:40 Global Bio-Pharma Investment Trends and Strategy
Hongbo Lu, Executive Director of OrbiMed Advisors LLC
Session 2. Company IR (Public Company)
Sep. 12. (Thur) 13:00~17:00
13:00~17:00 Participating Companies
LegoChem, Cristal genomics, Hanmi pharmaceuticals and etc. (Total 8 companies)
050
Session 4. Company IR (Private Company)
Sep. 13. (Fri) 13:20~16:00
13:20~16:00 Participating Companies
PharmAbcine, Corestem, ChunLab and etc. (Total 8 companies)
051
Session 2. Functional & Fermented Cosmetics - Functional & Fermented Cosmetic Ingredient through
Session 2. Fermentation
Technology
15:30~17:30
Track 12. Beauty
: Recent Developments in Cosmetic R&D for Making a New Leap Forward
Sep. 11 (Wed), 13:00~17:30
Cosmetics industry that fits well to realize creative economy has a good potential to become a Nation’s future
growth engine. Cosmetics industry of most advanced countries are well developed. It needs innovative and
creative convergence technology and also is significantly influenced by cultural factors. Developments of
various platform technologies and leading edge innovative technologies are necessary in cosmetic R&D. NCR
has provided supports for the cosmetic R&D in order to transform domestic cosmetics industry into export
oriented industry.
Fermentation technology, a key process for the production of valuable bioactive compounds, plays an important role in
the cosmetics industry recently. Due to its natural process and skin effective products, many companies are developing
fermentation-based ingredient production. Pitera from SK-II is an example of fermentation-based ingredients. This
session provides recent research and developing trends from cosmetics industry.
Session Chair Wan Goo Cho, Professor, Jeonju University, College of Alternative Medicine
15:30~16:00 Patent Map of Functional & Fermented Cosmetic Ingredient Hyang-Bok Lee, Research Professor, Inha University, Biological Engineering, College of Engineering
16:00~16:30
Skin Effects of Hydrolysed Ginseng Saponins Produced by the Enzymatic Hydrolysis of
Ginseng Saponins
Myeong Hun Yeom, Amorepacific Corporation R&D Center, Hanbang Application Research Team / Skin
Research Institute
16:30~17:00 Fermentation Technology and Cosmetic Ingredients Seung-jin Hwang, Senior Researcher, Fermentation & Oriental Herb Team, Skinomics Research Center,
LG Household & Health Care Research Park
Session 1. Convergence & Fundamental Technology for Cosmetics - Technology Application for
Session 2. Cosmetics - Screening, Evaluation & Formulation
13:00~15:00
17:00~17:30 About Development Natural Cosmetics through Fermentation Technology and Its Insights
Dong-Il Jang, CEO, COTDE Co., Ltd
Cosmetics industry is a convergence industry that requires innovative convergence technology consisting of diverse
disciplinary science and technology fields, which are cell engineering, biotechnology, surface chemistry, natural product
research, fermentation technology, nano technology, human sensibility ergonomics, mechanical engineering, information
technology, etc.
Especially in recent years, it is becoming important to develop platform technologies such as high throughput screening,
efficacy & safety evaluation, formulation technology for enhancing delivery or sensory properties.
In this session, the recent progress of some of the NCR projects in this area will be presented.
Session Chair Ih-Seop Chang, CTO, Bioland, Ochang Factory
13:00~13:30
Effects of melanosomal P protein on the melanin production and melanosome maturation in
Melan-A cell
Eun-Ki Kim, Professor, Inha University, Biological Engineering
13:30~14:00
Development of Systems Skin Toxicology-based Alternative Methods for the Advancement of
Animal Welfare
Ai-Young Lee, Professor, Dongguk University Graduate School of Medicine, Department of Dermatology
14:00~14:30 Methods/Guidelines for Evaluating Skin and Lip Moisturization
Biedermann Kim, Senior Director, Franchise Medical Lead, Pfizer Consumer Healthcare R&D, Personal
Care and Respiratory
14:30~15:00 Providing Functionalities to Polysaccharides
Jonghwi Lee, Professor, Chung-Ang University, Chemical Engineering and Materials Science
052
053
Special Session
Track 13. PIN (Pharmerging Innovative Networking) Conference
Sep.12 (Thu) 10:00-17:20
• London Health Forum
• Denmark Bio&Medtech Investment Seminar
• Osong International Bio Symposium
The conference this year reflected pharmaceutical companies' regional-based needs. As a result, the
conference will cover more comprehensive topics in depth such as, procurement of pharmaceutical products,
marketing strategies, and regulatory affairs.
10:15~11:15
Session 1
11:15~12:15 Session 2 Latin America Session
13:45∼14:45 Session 3 Russia · Kazakhstan Session
14:45~15:30
Session 4 Eastern Europe Session
15:40~16:40 Session 5 Middle East Session
16:40~17:20 Session 6 Special Session (IO Procurement and PCI/S Membership Application)
054
• Daekyung·Osong Collaboration BIO Forum
China · ASEAN Session
055
MEMO
BUSINESS FORUM
Overview
Business Forum Overview
Floor Plan for Business Forum
Presentation Schedule at a Glance
Business / Technology / Int'l Country Partner Forum
Partnering Participation Status
056
Business Forum Overview
Bio industry!
The next generation growth engine for the future!
The global Bio industry has had an average annual growth of 10% for the past 20 years. The number of biorelated businesses has increased by about 7 times, multiplying the overall value of bio-industry and playing a
pivotal role in global economic growth.
Bio industry is directly related to many challenges of humanity in fields such as medicine, agriculture and
environment. Widely considered as a high-value added industry of the future, bio industry is expected to
receive increased government funding, resulting in its diversification and further growth. Bio industry will aid
in a virtuous circle of economic growth and technology advancements. BIO KOREA 2013 Business Forum is
the place to discover the latest trends of bio-technology for the future grow of your company.
Hundreds of companies will showcase their advanced technology at BIO KOREA 2013. Bio-companies armed
with superior products and technologies will attend business presentations and exchange information at
partnering meetings, building strategic business relationships through 1 on 1 meeting and collaborating on
MAY 28 ~ 30, 2014 / KINTEX
Brand New Start in MAY!
multi-scale projects.
BIO KOREA 2013 Business Forum celebrates its eighth anniversary. The Business Forum, consisting of
partnering and Business / Technology presentation, will serve as a venue where corporations with advanced
technologies can meet with research institutions and other bio business leaders to share knowledge and to
encourage further innovation in the bio-industry.
058
059
Floor Plan for Business Forum
Partnering
Partnering provides an opportunity to meet with potential business and technology partners to
discuss mutual interests through pre-scheduled one-on-one meetings.
D A T E
V E N U E
Partnering Time
Sep. 11 (Wed) ~ 13 (Fri), 2013
Hall 7, 8A, KINTEX Exhibition Center II (Business Forum Center)
30min.
• Find a potential business partner through online pre-matching System
• Effective meeting schedule management through the pre-scheduling system
• Independent offline meeting at on-site booth
Business / Technology Presentation
Preview
Room
Pharm
Fair
Zone
BIO KOREA 2013 Business Presentation is the place to meet domestic and international frontrunners who have new products, technologies, business strategies and projects.
D A T E
V E N U E
Partnering Time
Partnering Zone
Business Forum Center
Sep. 11 (Wed) ~ 13 (Fri), 2013
Hall 7, 8A, KINTEX Exhibition Center II (Open stage 1)
30min. (Including Q&A)
• Discover potential investors via advanced technology and business strategy presentation
• Exchange the latest cutting edge technology and information
• The critical opportunity to benchmark successful business strategy
International Country Partner Forum
International Country Partner Forum is for the global biotechnology industry leaders to enhance international awareness
and competitiveness.
D A T E
V E N U E
Sep. 12 (Thur) ~ 13 (Fri), 2013
Hall 7, 8A, KINTEX Exhibition Center II (Open stage 1)
Global Data, Frost&Sullivan's Presentation
The presentation is mainly focus on the bio-pharmaceutical, M&A, APAC Market Trend, and Licensing.
060
Cafeteria
Sponsor
Zone
Partnering
Center
Internet
Lounge
Info-Desk
Global Data, Global Life Science Trends and Opportunities
Trends in Deals-Healthcare Market Asia-Pacific Region, Dr. Vikas Bedi
Asia Pacific Market Outlook, Mr. Joshua Owide
Biotech Market Research Report
Global Life Science Trends and Opportunities, Mrs. Geeta Dhanoa
061
Business / Technology Presentation & International Country Partner Forum
Schedule at a Glance
Biz
Tech
Company
Time
Country
Name
September 11 (Wed), Open Stage I
Company
Time
Country
Name
United States
13:00~13:30
of America
Eli Lilly and Company
13:30~14:00
September 12 (Thu), Open Stage I
ICPE
Presentation
Presentation Title
India
Global Data
Trends in Deals-Healthcare Market Asia-Pacific Region
10:30~12:00United
Global Data
Asia Pacific Market Outlook
Kingdom
Presentation
Presentation Title
Open Innovation at Eli Lilly
13:00~13:05
India
Association of Biotechnology Introduction to the India Session
Led Enterprises
Republic
Aprilbio Co.
of Korea
Republic
of Korea
Kolon Life
14:00~14:30
Science
Utilization of Safa Technology for Developing a Long-Acting
Human Growth Hormone by Extending Serum Half-Life
13:07~13:17
Biotechnology Industry Research Assistance Council
Catalysing the Growth of an Innovation Driven Biotech
Enterprise
Tissuegene-C (Tg-C) a Cell-Mediated Gene Therapy for Osteoarthritis
Cold Chain Solution for Bio-Industry
Centre for Cellular and Molecular Platforms
C-CAMP: An Enabler of Cutting Edge Life Science Research
in India
14:30~15:00
13:19~13:29
13:31~13:41
Arjuna Natural Extracts
13:43~13:53
India
13:55~14:05
Aaranya Biosciences Private Limited
14:07~14:17
Indian Council of Agricultural Research
14:19~14:29
Criyagen Agri & Biotech
14:29~14:30
Association of Biotechnology Summary and Conclusion
Led Enterprises
15:00~15:30
Republic
of Korea
15:30~16:00
Tnt Express
Center for Nutraceutical and
Introduction of Next-Generation BioGreen21 Project
Pharmaceutical & Cnpm
Materials
Seoul Metropolitan Seoul Magok R&D Industrial Complex Ir
Government
Wips Co., Ltd
16:00~16:30
India
16:30~16:45
16:45~17:00
India
17:00~17:15
17:15~17:30
17:30~18:00
062
Republic
of Korea
Association of Biotechnology Led Enterprises
Department of Biotechnology
Methodologies for Establishing Patent Strategies in
the Field of Biology and Best Practices
India's African Pharmaceutical Safari
- An Able Strategy for Developing Markets
Biotechnology in India. Opportunities, Challenges and
the Roadmap Ahead
BiracCatalysing The Growth of an Innovation Driven Biotech
Enterprise
Indian Council of Agricultural Research
Harnessing Agricultural Innovation
Automatic Identification of N-Linked Glycopeptides in
Kbsi (Korea Basic
Biosimilar Pharmaceuticals: Glycoprotein Analysis (Gpa)
Science Institute)
System
14:30~15:30
Denmark
15:30~16:30China
BCM-95 - The Bio-Available Curcumin
Biosimilars & Biobetters Outsourcing Models, Opportunities and Challenges in India
Translational Health Science & THSTI, CDSA and Clinical Research in India
Technology Institute
DTU
Harnessing Agricultural Innovation
Agriculturally Important Microbes (Aims) for Nutrition and Biotic S tress Management in Crop Plants
The Danish Farm to Fork Approach and Food Security
Technologies from Novozymes to Enable Development of
Novozyme
Biobetters and Biosuperiors
PKUCare
Health Industrial Park
Shenogen
Pharma Group
United StatesKbi
16:30~17:00
of America
Biopharma, Inc.
Republic
17:00~17:30
BIOTOXTECH
Republic
of Korea
of Korea
17:30~18:00
SCAS-BTT Bioanalysis
Promoting Investment in Beijing, China
Shenogen Pharma Group
CMC Strategies for Therapeutic Antibody Development
Innovative Engine for Oncology Drug Discovery
Unique Translational Model in CVMD Research
063
Partnering Participation Status
2013 Partnering Participating Company List
September 13 (Fri), Open Stage I
Company
Time
Country
Name
10:30~11:10
Malaysia
Frost & Sullivan
Presentation
Presentation Title
Global Life Science Trends and Opportunities
The Market Information of Spain : Strategies for the Novel
Drug Licensing in-and-out for Korean Pharmaceuticals
11:15~12:15
Spain
Pharmaphenix
Introduction of PARCDEL'ALBA (Barcelona Synchrotron Park)
13:00~13:10
13:10~13:20
13:20~13:30
United
13:30~13:40
Arab
13:40~13:50
Emirates
Oncopharma Urban Pharmacy
Propharma Planet Pharmacy AMMC(Iraq)
13:50~14:00
Pharmastore 14:00~14:10
Al-Hayat
14:10~14:20 Life Pharma
14:30~15:00
Republic
National Culture of Korea
Collection for Pathogens
Republic
of Korea
Kbsi (Korea Basic 15:00~15:30
Science Institute)
15:30~16:00Switzerland
16:00~16:30
Republic
Of Korea
Republic
of Korea
16:30~17:00
064
Introduction of Products and Services of Pharmaphenix
Debiopharm International S.A.
Korea Institute of Oriental Medicine
Introduction of U.A.E Companies
A
Bukwang Pharmaceutical Co.,Ltd
Aaranya Biosciences Private Limited
ACTUS Biotechnologies
C
Ahn-gook pharmaceutical
Center for Nutraceutical and Pharmaceutical Materials
AJU IB INVESTMENT Center for Nutraceutical and Pharmaceutical Materials
Al-Hayat
Center for Nutraceutical and Pharmaceutical Materials
ALK Abelló
Center for Nutraceutical and Pharmaceutical Materials
Ampliqon A/S
Centre for Cellular and Molecular Platforms
AMRI
Changzhou Siyao Pharm.
AMRI
Chong Kun Dang
AMRI Chong Kun Dang
Amway Korea
Chong Kun Dang
AngioLab, Inc.
Chong Kun Dang (Out-licensing)
APEXEL CO.,LTD
Chong Kun Dang Pharmaceutical Corp.
AprilBio Co.
Chuncheon Bioindustry Foundation
Arjuna Natural Extracts Ltd
CLINICAL QA & WRITING
Asan Medical Center
Clinigene International Limited
Association of Biotechnology Led Enterprises
CMC Biologics A/S
atenea Management Services
Criyagen Agri & Biotech Pvt Ltd
Cure Medical Supplies
B
Introduction to National Culture for Pathogens (Nccp)
in Korea
A Novel Innovative Technology for Protein-Protein
Interaction in Live Cells
Debiopharm Group™- We Develop for Patients
Preventive and Treatment Medicine for Diabetic Complications
World’s First Allogeneic Stem Cell Drug From Cord Blood and
MediPost Co., Ltd.
The Path To Successful Commercialization
Beijing JiaLin Pharmaceutical Company
D
Beijing Tide Pharmaceutical Co.,Ltd. Daewon Pharm
Beijing Tide Pharmaceutical Co.,Ltd
Daewoong Pharmaceutical Lifescience Research Insti
BINEX
Daewoong Pharmaceuticals Co. Ltd
BINEX
Daeyeon Chemicals Co.,Ltd
BioModics
Dako
Bioneer A/S
Darae law & IP Firm
Bionutrigen Co.,Ltd.
Debiopharm International S.A.
Bio-Synectics, Inc.
DELPHI GENETICS
Biotechnology Industry Reserach Assistance Council
DeltaTech-Korea Ltd
BIOTOXTECH
Department of Biotechnology
Boehringer Ingelheim
Dong Wha Pharm
Boryung Pharmaceutical Co.,Ltd.
Dong-A ST
Boryung Pharmaceutical Co.,Ltd.
DTU - Technical University of Denmark
065
E
ImmuneMed, Inc.
KOREA UNIVERSITY MEDICAL CENTER
P
Ecron Acunova
Indian Council of Agricultural Research
KOREA UNIVERSITY MEDICAL CENTER
PCI Biotech
Ecron Acunova A/S
INDUSTRY-ACADEMIC COOPERATION FOUNDATION,
KRIBB
PCL, Inc.
Efficient Pharma Management Corp. AJOU UNIV
KRIBB
Peptron Eli Lilly and Company Industry-University Cooperation Foundation HYU KWANGDONG PHARMACETUICAL CO.,LTD
PHARMA STORES
ERA Consulting Group
Intelligent Pharma
EternoGen
Pharmaphenix
L
Pharmaphenix S.L.
Eubiologics Co.,Ltd.
J
Leiden Bio Science Park Pharmatory Ltd.
EyeGene, Inc.
JEIL Pharmaceutical Co.,Ltd.
LG Life Sciences Pharmatory Ltd.
F
JUNGJIN INT'L IP LAW FIRM
LG Life Sciences
Planet Pharmacies
F.Hoffmann-La Roche Ltd, Roche Pharma Japan
JW Pharmaceutical Corp.
LIFEPHARMA
PRA
Lonza
Propharma Medcal Supplies
Fermentec
FIC at University of Ulsan K
Fit.Life Inc
KBI Biopharma, Inc.
M
S
KBSI(Korea Basic Science Institute)
Meabco A/S
Samyang Biopharmaceuticals Corp. G
KBSI(Korea Basic Science Institute)
MEDIPOST Co.,Ltd.
Samyang Biopharmaceuticals Corporation
GCB
KCRN Research
MetaBio, Inc.
sanofi aventis
Gill Jennings & Every LLP
KCRN Research
MicroDigital
Sathguru Inc.
GNU Office of Academy & industry Collaboration
Kem-En-Tec Diagnostics
MorphoSys AG
SCAS-BTT Bioanalysis
Green Cross
KEOSYS Medical Imaging
MSD (Merck Sharp Dohme Corp)
SEOBONG Bio Bestech Co.,Ltd.
Green Cross
KHIDI(Korea Health Industry Development Institute)
MSD (Merck Sharp Dohme Corp.)
Seoul Metropolitan Government
Green Cross Corporation
K-MAC
GVK BIOSCIENCES PRIVATE LIMITED
KOLMAR KOREA
N
Seoul Pharma Co.,Ltd. Seoul Pharma Co.,Ltd.
Kolon Life Science
Nairoukh Pharma
SEOUL PHARMA.CO.LTD H
Korea Biomedicine Industry Association
National Culture Collection for Pathogens
Servier
Han Wha Pharma Co.,Ltd.
Korea Drug Development Fund
National OncoVenture
Shandong Hongjitang Medicine Group
Hanmi Pharmaceuticals
Korea Institute of Oriental Medicine
National OncoVenture
Shandong Pallet Environmental Engineering Company
Hanmi Pharmaceuticals
Korea Institute of Oriental Medicine
Nippon Boehringer Ingelheim (Bio Manufacture Div)
Shandong Pepway Medicine Company
Hanmi Pharmaceuticals
Korea Intellectual Properties Strategy Institute
Novo Nordisk
Shandong Qidu Pharmaceutical Co.,Ltd
KOREA UNIVERSITY MEDICAL CENTER
Novozymes Biopharma A/S
Shenogen Pharma Group
I
KOREA UNIVERSITY MEDICAL CENTER
ILDONG Pharm. Co.,Ltd. (Biologics)
KOREA UNIVERSITY MEDICAL CENTER
O
SK Biopharmaceuticals
ILDONG Pharm. Co.. LTD
KOREA UNIVERSITY MEDICAL CENTER
OliPass Corporation
SK Biopharmaceuticals
ILDONG PHARMACEUTICAL Co.,Ltd.
KOREA UNIVERSITY MEDICAL CENTER
OliPass Corporation
SK Chemicals Co. Ltd.
ILDONG PHARMACEUTICAL Co.,Ltd.
KOREA UNIVERSITY MEDICAL CENTER
ONCOPHARMA MIDDLE EAST
Stemgent | Asterand
IL-YANG PHARMACEUTICAL Co.,Ltd.
KOREA UNIVERSITY MEDICAL CENTER
ORTHO-LINK
IL-YANG PHARMACEUTICAL Co.,Ltd.
KOREA UNIVERSITY MEDICAL CENTER
066
Sinensis Life Sciences BV 067
T
TAEJOON PHARM.Co.,Ltd
The Catholic University of Korea Industry-Academic The Catholic University of Korea Industry-Academic The Catholic University of Korea Industry-Academic Tracer Pharma
Translational Health Science & Technology Institute
U
UTR Investment & Research Group
V
ViroMed Co.,Ltd.
Vivagen Co.,Ltd
W
WIPS Co.,Ltd
WON INTERNATIONAL PATENT & LAW FIRM
*Companies above completed registration before September 3 before September 3, 2013
068
Exhibition
Overview
Exhibition Overview
Floor Plan for Exhibition
List of Exhibitor
Exhibition Overview
Exhibition Overview
BIO KOREA 2013 Exhibition expects to host 300 companies and 20,000 visitors from all over the world.
This event will be an outstanding exhibition of an international lever embracing every field of the bio
industry.
D A T E
September 11 (Wed) ~ 13 (Fri), 2013
V E N U E
Hall 7 & 8A, KINTEX Exhibition Center II
Exhibition Categories
Pharmaceutics
Bio-Technology
Hospital
Governments
Food
Lab Equipment
Cosmetics
Medical Device
Consulting Service
Logistics
Venture Capital
Chemicals
Policy
Academic Research
Clinical Trial
MAY 28 ~ 30, 2014 / KINTEX
Brand New Start in MAY!
EXHIBITION ZONE
Country Pavilion / Innovative Pharmaceuticals Zone / NET·GH Zone / Convergence Zone / Special Zone /
Business Forum Zone / Job Fair Zone / Bio Industry Zone, etc
Exhibition & On-Site Registration Hours
Dates
Exhibition Hour
On-site Registration
Sep.11 (Wed)
10:00 ~ 18:00
09:00 ~ 18:00
Sep.12 (Thur)
10:00 ~ 18:00
09:00 ~ 18:00
Sep.13 (Fri)
10:00 ~ 17:00
09:00 ~ 16:00
071
Floor Plan for Exhibition
KINTEX Hall 7 & 8A
Open Stage I
Preview
Room
PR Lounge & Food Court
C48 C43
A40
B46
A36
B45
C45 C40
B40
D47
D43
D42
A34
A33
E46
D45 D40
E45
A24
E40
F47 F42
F45
F41
F40
G47 G42
H47 H42
I47 I42
J47 J42
G40
H40
I40
J40
B38
B37
B33
C33
D38 D33
E38
E34
F39 F34
G39
E33
F38 F33
G38
E37 E32
B36
B35
B30
C30
D30
E36 E31
Business Forum Center
BIO Job Fair
Cafeteria
Convergence Technology Exhibition
Korea Innovative Pharmaceutical Company
A31
A30
E47 E42
D46 D41
A35
G33
K30
G37 G32
G35 G30
E35 E30
A21
A20
A15
L39 L34
M39 M34
N39 N34
L38 L33
M38 M33
N38 N33
Sponsor
Zone
L37 L32
F30
A23
A22
Partnering Zone
Pharm
Fair
Zone
L36 L31
N36 N31
L35 L30
N35 N30
Partnering
Center
Info-Desk
B25 B22
B24 B21
G22
C23 C20
D20
E20
F20
G24 G20
H22
H23 H20
L22
I20
J20
K20
B23 B20
M25 M22
L24 L21
M24
L23 L20
M23
M20
N25
N23
O25 O22
N20
O23 O20
P25 P22
Q22
R25 R22
P24 P21
Q23 Q21
R23 R21
P20
A14
A13
B13
C13
A10
A
072
O18 O13
D10
A12
A11
Internet
Lounge
B10
C10
B
C
E10
F10
G10
H10
I10
J10
K10
P13
N10
O10
P11
P10
E
F
G
H
I
J
K
R20
Q19 Q14
R19 R14
Q18 Q13
R18 R13
L10
M10
D
Q20
L
M
N
O
P
Q15 Q10
R15 R10
Q
R
Bio-micro
photography
Exhibition
BIO
KOREA
2014
Poster
Contest
S
Open Stage II
T
U
073
List of Exhibitor
N38 Aaranya Biosciences Pvt. Ltd. D43 AccugenHealthcare Inc.
(주)아큐젠헬스케어
E10 AG SKIN LAB Co., Ltd.
에이지스킨랩(주)
L30 AL HAYAT PHARMACEUTICALS
L10 ALK Abello
에이엘케이 아벨로
A31 Allbalance Inc.
주식회사 올 발란스
L10 Ampliqon A/S
엠플리콘
D46 Antibody and Receptor Therapeutics Co.
(주)에이앤알쎄라퓨틱스
A22 AnyGen Co., Ltd.
애니젠(주)
R18 APEXEL Co., Ltd.
에이펙셀(주)
M33 Arjuna Natural Extracts Ltd E20 Asan Medical Center
서울아산병원
M39 Association of Biotechnology Led Enterprises
R22 AT LAB Co., Ltd.
(주)에이티랩
Q10 BioCore Co., Ltd.
바이오코아(주)
N20 BioHealth Innovation (BHI)
바이오헬스이노베이션
L37 BioMed Central
C10 Bio-Med Connect Center(BMCC)
삼성서울병원 바이오-의료커넥트센터
A40 Biomedical IT Convergence Center
IT의료융합기술사업단
E10 Biometrix Technology Inc.
(주)바이오메트릭스테크놀로지
L10 BioModics ApS
바이오메딕스
L10Bioneer
바이오니어
R14 Biorhythm Co., Ltd.
(주)바이오리듬
D45 Bionutrigen Co., Ltd.
(주)바이오뉴트리젠
N39 Biotech Industry Research Assistance Council (BIRAC)
R25 Biotechnology Industrialization Center
생물자원산업화센터(주)
A21 Biotoxtech Co., Ltd.
바이오톡스텍
N34 Center for Cellular and Molecular Platforms (CCAMP)
D47 DAEJEON TECHNOPARK
(재)대전테크노파크
E10 Chuncheon Bioindustry Foundation
(재)춘천바이오산업진흥원
E36 Daewon Pharm.Co., Ltd.
대원제약
E40 Chungbuk National University Department of Industrial Parmacy
충북대학교 제약산업특성화대학원
G37 Daewoong Pharmaceutical Co., Ltd.
대웅제약
Q21 CHUNGBUK NATIONAL UNIVERSITY TLO
충북대학교 산학협력단
P20 Chungcheong Institute for Regional Program Evaluation
충청지역 의약바이오기업 클러스터
G10Chungcheongbuk-do
충청북도
E10 ChungDo Pharm. Co. Ltd.
(주)청도제약
P25 Chungnam technopark Bio Center
(재)충남테크노파크 바이오센터
L10 CMC Biologics
씨엠시 바이올로직스
B40CnS
(주)씨엔에스
K30 Convergence Technology Exhibition (KOREA HEALTH INDUSTRY DEVELOPMENT INSTITUTE)
융복합 기술전시관(한국보건산업진흥원)
L10 Copenhagen Capacity
코펜하겐 캐퍼시티
Q14 CoSeedBioPharm Co., Ltd.
(주)코씨드바이오팜
Q15 DAEYON CHEMICALS Co., Ltd.
대연화학(주)
P24 DAIN NATURAL Co., Ltd.
(주)다인내추럴
L10Dako
다코
D40Dbio.Inc
(주)대덕바이오
G47 Darae Law & IP firm
특허법인다래
M34 DEPARTMENT OF BIOTECHNOLOGY (Government of India)
E40 Department of Industrial Pharmaceutical Science, School of Pharmacy, SungKyunKwan University
성균관대학교 약학대학 제약산업학과
G30 DONG WHA PHARM
동화약품
A10 Dongguk Medical Device Innovation Center
동국대학교 의료기기 개발촉진 센터
L32 Dubai International Pharmaceuticals and Technologies Conference and Exhibition
두바이 제약 및 제약기기 전시회 & 컨퍼런스
O20 Covance Laboratories Korea Ltd.
코반스래버래토리 코리아(주)
L10 Ecron Acunova A/S
에크론 아쿠노바
L20 British Embassy Seoul / UK Trade & Investment
주한영국대사관
R23 CRH(Converging Research Headquarter) for Bio-
Pharmaceuticals
바이오제약사업본부
L22 Embassy of Canada
주한캐나다대사관
D20 Avison Biomedical Research 연세의료원(에비슨의생명연구센터)
G35 Boryung Pharmaceutical Co., Ltd.
보령제약 주식회사
M38 Criyagen Agri & Biotech Pvt. Ltd. F39 BCWORLD PHARM. Co., Ltd.
(주)비씨월드제약
H42 Cactus Communications Korea Ltd
G39 BINEX Co., Ltd.
D20 Cancer Hospital / GAP2014
연세의료원(암병원/GAP2014)
C45 ATMI LifeSciences
에이티엠아이
R15 BKT Co., Ltd.
C30 Avantor Performance Materials, Inc. 아반토 퍼포먼스 머티리얼즈 인터내셔널 인크, 한국지점
(주)바이넥스
(주)부강테크
(주)캑터스 커뮤니케이션즈 코리아
E42 Bio Convergence, Inc.
K30 CARIMA CO LTD
(주)바이오컨버전스
K30 Bio-Age Inc.
074
(주)바이오에이지
(주)캐리마
E30 Chong Kun Dang Pharmaceutical Corp.
K10 (주)종근당
N30 CRYO DIFFUSION
크리오 디푸젼
G32 DAE HWA PHARMACEUTICAL Co., Ltd.
대화제약 주식회사
O25 DAE YOUNG FOODS CO, LTD.
대영식품(주)
G40 Daegu-Gyeongbuk Medical Innovation Foundation
대구경북첨단의료산업진흥재단
L24 Embassy of Poland Trade & Investment Promotion Section
주한 폴란드대사관 무역/투자 진흥부
L21 Embassy of the Kingdom of the Netherlands
주한네덜란드 대사관
A35Encopharm
엔코팜
B25 EU Gateway Programme Korea Office
EU 게이트웨이 프로그램 사무국
B36 Eubiologics Co., Ltd.
유바이오로직스
075
E10 Farming association corp. BBKO
영농조합법인 비비코
F42IIAMHUB
E33 JW PHARMACEUTICAL
JW중외제약
K30 KOREA UNITED PHARM. INC.
한국유나이티드제약(주)
B10Fermentec
퍼멘텍
G33 ILDONG PHARMACEUTICAL Co., Ltd.
일동제약 주식회사
K30 JW PHARMACEUTICAL
JW중외제약
O10 Korea University Medical Center
고려대학교 의료원
K30 Fit.Life Inc.
휘트닷라이프
F45 IL-YANG PHARMACEUTICAL. Co., Ltd.
일양약품 (주)
M22 KBI BIOPHARMA
E35 Kwangdong Pharmaceutical Co., Ltd.
광동제약
Q20 Foundation of Research and Business, Chungnam National University
충남대학교 산학협력단
A12 Incheon Free Economic Zone 인천광역시 경제자유구역청
E10 Gangneoung Science Industry Foundation Marine Bio Industry Support Center
강릉과학산업진흥원
R25GinSeng
(주)진생
D41 GL Biotech Inc.
(주)지엘바이오테크
J10 Green Cross Corporation
녹십자
R19 Green-Growth Silkworm-Industry Regional Innovation System
충북대학교 녹색성장 누에산업 RIS사업단
L36 GVK Biosciences Private Limited
F10 Gyeonggi Institute of Science & Technology Promotion
재단법인 경기과학기술진흥원
E31 HANDOK Inc.
(주)한독
(주)이암허브
L10 Kem-En-Tec Diagnostics
캠엔택 다이그노스틱스
(주)경방
B37 Kyongshin Scientific Co. Ltd
경신과학(주)
A30K-MAC
케이맥(주)
O18 KYUNGPOOK NATIONAL UNIVERSITY HOSPITAL 경북대학교병원
E37 KOLMAR KOREA Co., Ltd.
한국콜마(주)
I20, LG Life Sciences
F33LG생명과학
B45 Korea Basic Science Institute
한국기초과학지원연구원
K30 Legochem Biosciences, Inc.
레고켐 바이오사이언스
H22 KITECH(Korea Institute of Industrial Technology)
한국생산기술연구원
N25 Marken Ltd
마켄
M24 International Pharmaceutical Federation (FIP)
A33 KOMA BIOTECH
고마바이오텍(주)
F41 Markpro co.
E10 International Scientific Standards
인터내셔널 사이언티픽 스탠다드
I10
N20 Maryland Bio Park 메릴랜드 바이오 파크
K30 IntroMedic Co., Ltd.
E45 Medical Korea 2014(Korea Health Industry Development Institute)
메디컬코리아 2014 (한국보건산업진흥원)
E10 ImmuneMed, Inc.
(주)이뮨메드
A13 Industry-academic Cooperation Foundation, Keimyung University
계명대학교 산학협력단
C10 Samsung Medical Center, Institute Refractory Cancer Research
삼성서울병원 난치암연구 사업단
(주)인트로메딕
C43 IWOO scientific coporation
(주)이우 과학교역
R21 JBK Natural medicine Institute
제이비케이자연의학연구소
O10 Health Industry TLO Council (KOREA HEALTH INDUSTRY DEVELOPMENT INSTITUTE)
보건의료 TLO협의체관(한국보건산업진흥원)
B20~ Jecheon Korean Medicine Bio Promotion B22Foundation
제천한방바이오재단
L35 HIMEDIA LABORATORIES PVT. T.D
R25 HMAX Inc
농업회사법인(주)에이치맥스
F20 Jeonnam BioPharmaceutical Research Center (JBRC)
전남생물산업진흥원 생물의약연구원
L23 Embassy of Hungary
주한 헝가리 대사관
N20 JG Business Link International 제이지 비지니스 링크 인터네셔널
P21 HV BIO
C23 JID Corporation Co., Ltd.
(주)제이아이디코퍼레이션
N20 Johns Hopkins University
존스 합킨스 대학교
Korea Drug Development Fund
범부처신약개발사업단
A14 Korea Biomedicine Industry Association
한국바이오의약품협회
J20 Korea Institute of Oriental Medicine
한국한의학연구원
G20 Korea Institute of Toxicology
안전성평가연구소
R25 Korea licorice farming association corporation
한국감초영농조합법인
E46 Korea International Medical Association
사단법인 한국국제의료협회
D10 Korea National Enterprise for Clinical Trials
국가임상시험사업단
I42
KOREA PHARM 2014
제4회 국제의약품전
H40 HYUNDAI Micro Co., Ltd.
현대마이크로 (주)
G42 JUNGJIN INT'L IP LAW FIRM
정진국제특허법률사무소
C13 Korea Research Institute of Bioscience and Biotechnology
한국생명공학연구원
F34 HYUNDAIPHARM. Co., Ltd.
현대약품(주)
E10 JW CreaGene Inc.
JW크레아젠
F20 Korea Testing & Research Institute
한국화학융합시험연구원
076
B20 Kyeong Bang Co., Ltd.
N35 KEOSYS Medical Imaging
Q22 Industry-Academic Cooperation Foundation JEJU NATIONAL UNIVERSITY
제주대학교 산학협력단
G38 HANLIM PHARM Co., Ltd.
한림제약(주)
F20 Hwasun County Vaccine Industry District (Regional Specialized Development District) 화순백신산업특구 (지역특화발전특구)
M25 KCRN Research, LLC
(주)마크프로
M20 MedClaris Inc.
(주)메드클래리스
L10 MEABCO A/S
미압코
E10 MEDIAN Diagnostics Inc.
(주)메디안 디노스틱
B46 Medical Writing
메디컬라이팅
B21 Mediogen Co., Ltd.
주식회사 메디오젠
N10 Merck Ltd. Korea
머크 주식회사
A24 META BIOMED
메타바이오메드
J42 MetaBio, Inc.
메타바이오 주식회사
C48 MicroDigital Co., Ltd.
마이크로디지탈
N23 State of Missouri
미국 미주리 주정부 사무소
P22 MODNSKIN Inc.
(주)모든스킨
077
N20 Montgomery County 몽고메리 카운티
L38 Pharmaphenix S.L.
파마페닉스
E38 SK Chemicals
에스케이케미칼
K30 Unhwa Co. ,Ltd.
B35 MPI Research
엠피아이 리서치
P11 PIPC (Patent Information Promotion Center)
한국특허정보원 특허정보진흥센터
R13 SNC-Lavalin Korea
에스엔씨라발린코리아
N20 University of Maryland School of Medicine
메릴랜드 약학 대학
Q18 NANOSCOPE SYSTEMS, INC.
나노스코프시스템즈(주)
N36 Piramal Healthcare Ltd.
Q23 Song Am Trading Corp.
송암교역
B23 VGX International, Inc.
브이지엑스인터내셔널(주)
O13 National Cancer Center
국립암센터
L31 Propharma Medical Supplies
B24 Soon Chun Hyang Lab-based Industry Cooperation
순천향대학교 LINC사업단
G22 Vivagen Co., Ltd.
R10 SPIRAXSARCO KOREA
한국스파이렉스사코(주)
H47 WONWOO SYSTEMS Co., Ltd.
F38 ST Pharm.Co., Ltd.
에스티팜(주)
G24 WORLD COURIER KOREA.,LTD.
월드쿠리어 코리아
K30 REGENPRIME Co., Ltd.
리젠프라임(주)
N23 Missouri Trade & Investment Office - South Korea
미국 미주리 주정부 사무소
F40 WIPS Co., Ltd.
주식회사 윕스
E10 Regeron, Inc.
L39 Strex, Inc.
I47
A15 Natural Bio-Materials Inc.
(주)엔비엠
H10 NET/GH CERTIFICATION (Korea Health Industry Development Institute)
NET.GH 인증관(한국보건산업진흥원)
K30NEOFECT
네오펙트
A11 NFEC (National Research Facilities & Equipment Center)
국가연구시설장비진흥센터
E47 Noanix Corporation
(주)노아닉스
K30NOUSCO
누스코
C20NOVAPRO.,Ltd
(주)노바프로
L10 NOVO Nordisk
노보노디스트
M23 PRA International
K30 ProteomeTech Inc.
(주)프로테옴텍
R20 Puretech P&T Co., Ltd.
(주)퓨어테크피앤티
(주)리제론
I40
REP. OF NEW BRUNSWICK SCIENTIFIC CO., INC
(주)한국 엔비에스
R25 REXGENE BIOTECH Co., Ltd.
(주)렉스진바이오텍
C10 Samsung Medical Center (Clinical Trial Center)
삼성서울병원(임상시험센터)
A34 Rev-Med, Inc
(주)레보메드
L10 Novozymes Biopharma DK A/S
노보자임 바이오파마
M10 SEDIA(Sabah Economic Development and Investment Authority
사바 경제개발 투자청
A23 NTS Co., Ltd.
엔티에스 주식회사
P13 Samwoo S&T
삼우에스앤티
R25 OUR HOME
A20 SCAS-BTT Bioanalysis
(주)아워홈
(주)스카스비티티바이오애널리시스
O22 OLYMPUS KOREA Co., Ltd.
올림푸스한국(주)
Q13 sellus Co., Ltd.
주식회사 셀루스
B30 Orient Bio Inc.
주식회사 오리엔트바이오
D30 SEOUL METROPOLITAN GOVERNMENT
서울특별시 마곡사업추진단
K30 PANAGENE, Inc.
주식회사 파나진
B13 Seoulin Bioscience
J47 PCL, Inc.
피씨엘(주)
D20 Severance Hospital Gene Bank
연세의료원(세브란스유전자은행)
L34 Pharma Line Inc
파마라인(주)
D20 Severance Integrative Research Institute for Cerebral & Cardiovascular Diseases(SIRIC)
연세의료원 (세브란스 뇌심혈관질환융합연구사업단)
N31 Pharma Stores LLC
K30Pharmabcine
078
(주)파멥신
(주)서린바이오사이언스
E32, SHIN POONG PHARM
F47 신풍제약(주)
N20 State of Maryland Business Office-Korea
메릴랜드주 한국무역통상부
Q19 Synex Consulting Ltd.
사이넥스
C40 TAEJIN ENG Co., Ltd.
(주)태진이엔지
E34 Taejoon Pharmaceutical Co., Ltd.
태준제약
L33 Taiwan Bio Industry Organization (BioTaiwan 2014)
(주)운화
(주)비바젠
(주)원우시스템즈
WON INTERNATIONAL PATENT & LAW FIRM
원 국제특허법률사무소
B22Yakchoin
약초인
D33 Yonsei Medical Device Development & Promotion Center
연세대학교 의료기기개발촉진센터
D20 Yonsei University Health System
연세의료원 (특허출원 및 기술사업화/연구중심병원)
D38 Yonsei University Wonju Severance Hospital
연세대학교 원주세브란스병원
C33 TEPIK (Transgovernmental Enterprise for Pandemic K20 Young Sciences, Inc.
Influenza in Korea)
(주)영사이언스
신종인플루엔자 범 부처 사업단
O23 YUJIN HITECH Co., Ltd.
L10 Technical University of Denmark
유진하이텍(주)
덴마크공과대학
B33ZETACORPORATION
H23 testo Korea Ltd.
주식회사 제타
테스토코리아
J40 (주)FMS-KOREA
L10 The Embassy of Denmark
(주)에프엠에스코리아
주한 덴마크 대사관
D42 (주)K-Greenbio
The National Project for Personalized Genomic (주)케이그린바이오
Medicine
R25 (재)충북테크노파크 바이오센터 제천감초산업육성사업단
차세대 맞춤의료 유전체 사업단
K30 BioInfra Inc.
H20 TNT Express
티엔티 익스프레스
L10 Tracer Pharma
트레이서 파마
(주)바이오인프라
K30 Boryung Pharmaceutical Co., Ltd.
보령제약 주식회사
N33 Translational Health Science and Technology Insitute (THSTI) K30 U&I CORPORATION
유앤아이(주)
079
N38
D43
Aaranya Biosciences Pvt. Ltd.
CEO
ADD
TEL
FAX
E-MAIL
URL
E
Savithiri Shivakumar
R eg office:4-1-216/154,G-1,Karthikeya Nagar,
Nacharam, Hyderabad, India, Pin:500076.
917207855908
914027151506
[email protected]
www.aaranyabiosciences.com
X
H
I
B
I
T
S
Participant
E10
L30
AccugenHealthcare Inc.
AG SKIN LAB Co., Ltd.
(주)아큐젠헬스케어
에이지스킨랩(주)
CEO
ADD
TEL
FAX
E-MAIL
URL
E
Mi Jin Sohn 손미진
#302, Daejeon Bioventure Town 461-8, Jeonmindong, Yuseong-gu, Daejeon, 305-811, Korea
82-42-364-5001
82-42-367-3030
[email protected]
http://www.accugen.co.kr
X
H
I
B
I
T
S
Surearly Self Test Devices 및 바이오의약품 분석 서비스
CEO
ADD
TEL
FAX
E-MAIL
URL
E
AL HAYAT PHARMACEUTICALS
Sunyoung, Lee 이선영
#101, 641-6, Saimdang-ro, Gangneung-si, Gangwondo, Korea
82-33.70.7545.2525
82-33.655.9673
[email protected]
http://cosmeticsoem.co.kr
X
H
I
B
I
T
S
Functional Basic Cosmetics & Mask Pack
CEO
ADD
TEL
FAX
E-MAIL
URL
E
Youngseo Park 박영서
3F, Dongam Building, 1485-14, Seocho-Dong,
Seocho-Gu, Seoul, 137-876, Korea
82-2-587-9923
82-2-587-9924
[email protected]
http://www.allbalance.co.kr
X
H
I
B
I
T
S
Laboratory instruments & Salvislab Cleaners
기초화장품 & 마스크팩
I
N
T
R
O
D
U
C
T
I
O
N
I
N
T
R
O
D
U
C
T
I
O
N
Provide research activities to both small and large -본 제품은 BT 및 IT 기술 융합에 의해 개발된 현장검사용 체외진단
분석기기로 바이오센서를 내장한 ready-to-use 형과 바이오센서
molecules include medicinal chemistry, assay development
를 교체할 수 있는 교체형의 두 가지 형태의 제품으로 개발되었음.
& screening, ADMET, physicochemical profiling, disease
models and safety.
-당사는 항체 개발, 면역분석법 확립 및 밸리데이션, 면역원성 분석
과 같은 바이오의약품의 분석 서비스를 수행하고 있음.
I
I
N
T
R
O
D
U
C
T
I
O
N
N
T
R
O
D
U
C
T
I
O
N
Allbalance Inc. is a company specializing in handling all
aspects of high-end measuring devices, laboratories &
industrial related equipment.
Cosmetics | Quasi-Drug | Personal Care
OEM. ODM Company
A SUCCESSFUL GLOBAL BUSINESS PARTNER, One stop full *We provide expert services and solutions to optimize
installations, ensure operational efficiencies and support
personalized service
to maintain prime condition of all of equipment we
handle.
Not only from Brand plan, Design, Production, Quality
*With extensive on-site field experiences we ensure best
management but to distribution consulting.
possible representation of your product to the end-user
customers.
[Major Business]
*At Allbalance we pride ourselves in providing only the
OEM Apply your brand and design
best products to industry clients.
ODM Inquire us development of your products.
OGM Original Global Management
안녕하십니까. 분석기기 전문업체 올발란스 입니다. 당사는 매틀러토
OBM Original Brand Manufacturing
레도, 밀레, 안톤파, 샐비스랩의 공식 대리점으로 국내 유수의 제약,
We can produce an only one product for you.
*It is possible to produce a Private Brand with a single
product.
*It is possible to produce any products around the world
whatever you want.
*It is possible to produce popular products of ME TOO.
*Supplying seperate formulas of skin care in bulk.
*Supplying seperate formulas of make up in bulk.
화학, 식품, R&D 분야로의 많은 기술적 경험을 가지고 있습니다. 또
한 GLP, GMP, HACCP 및 USP등의 다양한 규정 하에서 요구되는
실험 장비와 관련된 문제점으 다양한 노하우와 최선의 서비스로 카
운셀링 합니다. 변함없는 고객 여러분의 신뢰와 사랑을 바탕으로 최
고의 제품과 서비스로 보답하겠습니다. 감사합니다.
피부생리활성에 근거한 기능성화장품만을 공급함으로써 피부친화주
의를 실현하고 아울러 피부에대한 깊은 관심과 이해를 바탕으로 끊
임없는 연구발전을 거듭하여 궁극적으로 이상적인 피부를 이루어 나
간다는 에이지스킨랩만의 방법론적이자 철학을 의미하며 전 세계인
의 피부와 더불어 존재하는 에이지스킨랩은 피부를 지키는 사명을
다 하면서 세계로 뻗어가는 글로벌 회사로 성장할 것입니다.
080
081
L10
A31
L10
D46
ALK Abello
Allbalance Inc.
Ampliqon A/S
Antibody and Receptor Therapeutics
에이엘케이 아벨로
주식회사 올 발란스
엠플리콘
에이앤알쎄라퓨틱스
CEO
ADD
TEL
FAX
E-MAIL
URL
Jens Bager
Bøge Allé 6-8 DK-2970 Hørsholm Denmark
45-4574-7576
45-4574-8690
[email protected]
www.alk-abello.com
CEO
ADD
TEL
FAX
E-MAIL
URL
I
N
T
R
O
D
U
C
T
I
O
Youngseo Park 박영서
3F, Dongam Building, 1485-14, Seocho-Dong,
Seocho-Gu, Seoul, 137-876, Korea
82-2-587-9923
82-2-587-9924
[email protected]
http://www.allbalance.co.kr
N
알레르기 원인의 독특한 치료법인 면역제 치료법 부문에서 세계적
인 리더이며 연구중심의 회사입니다. 우리 회사는 매년 약 20%의 수
익을 새로운 면역제 및 치료법을 개발 연구에 투자하고 있습니다.
WHO에 의해 알레르기의 원인을 치료하는 유일한 방법으로 인정된
다양한 알레르기 치료제를 생산합니다.
ADD
TEL
FAX
E-MAIL
URL
X
H
I
B
I
T
S
전자저울 및 초자세척기
Laboratory instruments & Salvislab Cleaners
N
T
R
O
D
U
C
T
I
O
N
Allbalance Inc. is a company specializing in handling all
aspects of high-end measuring devices, laboratories &
industrial related equipment.
*We provide expert services and solutions to optimize
installations, ensure operational efficiencies and support
to maintain prime condition of all of equipment we
handle.
*With extensive on-site field experiences we ensure best
possible representation of your product to the end-user
customers.
*At Allbalance we pride ourselves in providing only the
best products to industry clients.
안녕하십니까. 분석기기 전문업체 올발란스 입니다. 당사는 매틀러토
레도, 밀레, 안톤파, 샐비스랩의 공식 대리점으로 국내 유수의 제약,
화학, 식품, R&D 분야로의 많은 기술적 경험을 가지고 있습니다. 또
한 GLP, GMP, HACCP 및 USP등의 다양한 규정 하에서 요구되는
실험 장비와 관련된 문제점으 다양한 노하우와 최선의 서비스로 카
운셀링 합니다. 변함없는 고객 여러분의 신뢰와 사랑을 바탕으로 최
고의 제품과 서비스로 보답하겠습니다. 감사합니다.
Helle Nørgaard Thestrup
Stenhuggervej 22 DK-5230 Odense M Denmark
45-7020-1169
45-7020-1179
[email protected]
www.ampliqon.com
URL
ADD
TEL
FAX
E-MAIL
URL
I
E
I
082
CEO
N
T
R
O
D
U
C
T
I
O
Kyoung mi Sung 성경미
Suite 1104, E&C Venture Dream Tower 6-Cha, 19729, Guro-Dong, Guro-Gu, Seoul, 152-719, Korea
82-2-801-9300
82-2-801-9330
[email protected]
http://www.antibodyreceptor.com
N
효소 제조회사로 2002년 설립되어, 화학시약으로 구성된 상품 들을
포함하여 생산품을 확장하였으며, 현재 1000여 개의 다양한 시약 들
을 생산하고 있습니다. 또한 고품질의 DNA중합효소 와 다양한 PCR
효소를 생산하며, 전세계적으로 병원과 연구기관, 생명과학 산업을
위한 시약들을 생산 및 공급합니다.
I
N
T
R
O
D
U
C
T
I
O
N
1.ANRT is a specialized biotech company that develops
fully human therapeutic monoclonal antibody (mAb)
using innovative discovery technology and excellent
human resources for the treatment of human diseases,
such as cancer and inflammatory diseases. Our mission
is to develop a first-in-class and best-in-class mAb for
those target diseases.
2.Mammalian cell expression offers the most comprehensive
post-translational modifications and is ideally suited
for expression of antibodies and proteins where posttranslational modifications are vital. ANRT uses a range
of mammalian cell types and optimization techniques to
enable expression and scale up of recombinant protein
production to suit your research needs.
1.ANRT은 암과 염증성 질환과 같은 인간의 질병의 치료를 위한 혁
신적인 검색 기술과 우수한 인적 자원을 이용하여 치료용 완전
인간항체(단클론 항체)를 개발하는 전문 생명 공학 회사입니다.
우리는 목표는 그 대상 질환에 대해 first-in-class 과 best-inclass의 항체를 개발 하는 것입니다.
2.단백질의 경우 ‘번역 후 수식 (posttranslational modification)’ 양
상이 치료 효능, 체내 안정성 및 면역 부작용 등에 중요한 영향을
미친다는 사실이 알려지면서, 생산량 (quantity) 보다 원형 단백
질과 동일하거나 그 이상의 품질 (quality)을 지닌 단백질을 생산
할 수 있는 기술의 개발이 중요해지고 있습니다. 따라서 ANRT는
E.coli 가 아닌 동물세포 (HEK 293, CHO) 에서 발현 및 정제하여
의약품 원료 수준의 정제 과정을 거쳐 최고 품질의 단백질을 생
산하고 있습니다. 083
A22
R18
M33
AnyGen Co., Ltd.
Apexel Co., Ltd.
애니젠(주)
에이펙셀(주)
CEO
ADD
TEL
FAX
E-MAIL
URL
Kim jae il 김재일
R m. 303, head Quarter Jeonnam Nano Bio
Research Center San 109, Samtae-ri, nam-myun,
Jangseong-gun
82-61-395-1180
82-61-395-1184
[email protected]
http://anygen.com
CEO
ADD
TEL
FAX
E-MAIL
URL
X
H
I
B
I
T
N
T
R
O
D
U
C
T
I
O
Cheong- Ja, Kim 김청자
24-1 Daejeon-Ri, Songra-Myeon, Buk-Gu, Pohang,
Gyeongbuk Korea
82-54-262-4922~3
82-54-262-0896
[email protected]
http://www.apexel.kr
X
H
I
B
I
T
S
Nano 3D Mill (dry type). Nano Calcium, Mulberry Leaves
Nano powder, Mushroom Nano powder, Chitosan Nano
powder.
N
나노분쇄기 (그림), 나노칼슘, 뽕잎나노분말, 차가버섯 나노분말, 키토
산나노 분말, 각종 나노분말.
Anygen was founded in may 2000, as a laboratory
venture company at gwangju institute of science &
Technology(Gist) and has been working in the field of
peptide APIs devellopment and manufacturing for the past
ten years.
We manufacture high-quality custom made peptides by
applying our thorough product managing system(ISO
9001, 14001) in the synthesis and purification of peptides,
and we supply the peptides demanded by customers
by applying costume-made synthesis and purifications
according to the level of difficulty in the synthesis and types
of modification.
I
N
T
R
O
D
U
C
T
I
O
N
Apexel Co., Ltd. has specialized in R&D and production
of nano powder in any sizes of any materials under any
conditions, without dispersant.
The nano powder specially from l000 to 1 nano by topdown method is made by our own equipment"Fworld-best
and world-first Nano 3D Mill (dry type).
We have been supplying excellent nano materials to many
companies, research institutes and universities, sometimes
co-working with them for R&D and manufacturing new
펩타이드 전문기업 애니젠은 2000년 5월 광주과학기술원 내 실험실 materials.
벤처로 창업하여 지난 10여년 동안 펩타이드 원료개발 및 대량생산 We have continuously contributed to our customers to lead
분야에 주력하고 있습니다.
the business in their areas by our best nano technology
애니젠(주)은 펩타이드합성 및 정제에 대한 엄격한 제품관리 시스템
을 도입하여 고품질의 주문자 펩타이드를 제작하고 있으며, 합성의
난이도와 modification의 종류에 따른 맞춤식 합성, 정제법을 적용
함으로서 주문자가 원하는 펩타이드를 신속하게 제공하고 있습니다.
에이펙셀 (주)는 대부분의 물질을 어떠한 조건에서도 분산제 없이 다
양한 입도분포의 나노크기로 제조할 수 있는 능력을 갖추고, 나노분
말제조 및 융합과 나노신소재의 R&D를 수행하는 세계에서 하나뿐인
업체입니다.
특히 1 나노에서 1000나노까지를 top-down 방식에 의해 당사에
서 자체 개발한 장비 (세계최고, 세계유일)Nano 3D Mill (건식)로
생산하고 있습니다.
당사는 많은 기업, 연구기관, 대학에 나노분말과 물질을 공급하고 있
으며, 때로는 신물질개발과 생산에 협업합니다.
084
Asan Medical Center
서울아산병원
S
Peptide APIs, Custom peptide, Cosmetic peptide
I
Arjuna Natural Extracts Ltd
CEO
ADD
TEL
FAX
E-MAIL
URL
Mr. P. J. Kunjachan
P.B.No:126, Bank Road, Alwaye - 683 101, Kerala,
INDIA
91 484 4080400
91 484 2622612
[email protected]
http://www.arjunanatural.com
CEO
ADD
TEL
FAX
E-MAIL
URL
E
E
E
E20
E
X
H
I
B
I
T
Seong-Wook Park 박성욱
#88, Olympic-ro 43 gil, Songpa-gu, Seoul
82-1688-7575
82-2-3010-4182
[email protected]
http://amc.seoul.kr
X
H
I
B
I
T
S
S
-Introduction of Asan Medical Center and its research
activities
-S uccessful technology transfer, joint research and
investment promotion
I
N
T
R
O
D
U
C
T
I
O
N
-Introduction of Asan Medical Center and its research
activities
Arjuna Natural Extracts Ltd (ANEL) is a leading manufacturer
of Natural health food ingredients & Botanical extracts -S uccessful technology transfer, joint research and
investment promotion
used in Dietary supplement Industry. Started in 1989, we
are an ISO 22000:2005 and GMP certified company. Our
facilities are FDA registered and products are Koshered, -서울아산병원의 연구활동 소개
Halal certified and our R&D facility is approved as In-House -국, 내외 제약사와 기술이전 및 전략적 제휴 상담
R&D lab by Govt. of India.
Manufacturers of
N
T
R
O
D
U
C
T
I
O
N
•Advanced botanical extracts (clinically documented & I
patented)
Asan Medical Center, a government designated Research•Standardized Herbal & Spice Extracts
driven Hospital, was established in 1989 and has made
•Omega–3 oil –Vegetable source
every effort to invest in research and clinical excellence.
•Omga-3 oil & powder – Marine source
With an unwavering spirit of “caring for life and sharing
•Essential Oils
with those in need and pain, ” AMC has also attempted to
Key Products – BCM -95
fulfill its responsibility to society. AMC, the proven leader in
•W ORLD'S Largest selling BIO-AVAILBLE TURMERIC patient care is now presenting the exclusive quality in R&D
EXTRACT – BCM-95
competence as a world class Research-driven Hospital.
•7 patents worldwide and there are 10 patents pending
•H ave published animal & human studies; Studies 올해 연구중심병원으로 선정된 서울아산병원은 1989년 개원한 이래
are done in India, USA, Australia, Hong Kong, Italy, 끊임없는 연구개발과 임상진료에 대한 아낌없는 투자로 세계적 수준
의 의료성과를 달성해왔으며 ‘생명존중의 정신’과 이웃의 아픔을 함
Singapore and UK.
•Enhanced oral bioavailability of curcumin in the blood 께하는 ‘나눔 정신’을 실천함으로써 존경 받는 병원으로 사회적 책임
up to 7 to 10 times that of curcumin 95% ; retention of 을 다해오고 있습니다. 이제 진료를 바탕으로 축적된 지식을 첨단 보
건의료의 연구개발과 사업화를 통하여 HT 산업발전을 이끌어가는
curcumin in blood even at 8 hours
세계적 수준의 연구중심병원으로의 성장을 기대합니다.
Other major products
•Garcinia extract
•Boswellia extract
•Green coffee bean extract
•Pomegranate extract
•Amla extract
Food & Ag
085
M39
R22
Association of Biotechnology Led Enterprises
CEO
ADD
TEL
FAX
E-MAIL
URL
E
Dr. P.M. Murali
No 123/C 16th Main Road, 5th Cross, 4th Block,
Koramangala, Bangalore, 560034 India
91 11 23731127
91 11 23731127
[email protected]
www.ableindi.org
X
H
I
B
I
T
S
C45
AT LAB Co., Ltd.
ATMI LifeSciences
(주)에이티랩
에이티엠아이
CEO
ADD
TEL
FAX
E-MAIL
URL
E
Youngtaek, Kim 김영택
#5-105, 89, Seoho-ro, Gwonseon-gu, Suwon-si,
Gyeonggi-do, 441-853 KOREA
82-31-292-8960
82-31-292-8962
[email protected]
http://www.atlabco.com
X
H
I
B
I
T
S
ABLE is a national forum that represents the Indian Cosmetic ingredient
Biotechnology Sector. ABLE has over 270 members
representing all verticals of the sector like agribiotech, bio- 화장품 원료
pharma, industrial biotech and bioinformatics.
I
N
T
R
O
D
U
C
T
I
O
N
AT LAB mainly develops functional cosmetic ingredient
and specialized in encapsulation technology. With a slogan
“Happy life, providing humanity health and beauty”,
we promise that we will provide customers best product
quality and service.
저희 회사는 불안정한 기능성 물질을 안정화하는 독자적인 기술을
보유하고 있고, 이러한 기술을 접목하여 화장품 원료를 주력으로 개
발하는 업체입니다.
인류에 아름다움과 건강함을 제공하여 삶을 이롭게 한다는 경영이념
아래, 저희 모든 임직원은 고객에게 최상의 품질과 서비스를 제공해
드릴 것을 약속합니다.
은 무균적으로 액체나 파우더를 이송, 저장 할 수 있도록 만든 1회용
액체백이나 파우더백, 바이오 믹싱 시스템에서 사용되는 1회용 무균
CEO
정강진
ADD
46-904 2F 198-32 Bora-dong Giheung-gu Yongin4
si Gyeonggi-do, Korea
82-31-217-3671
82-31-217-2673
[email protected]
http://www.Atmi-lifesciences.com
TEL
FAX
E-MAIL
URL
E
X
H
I
B
I
T
믹서백, 세포배앙공정에서 사용되는 1회용 바이오리액터백 등을 제
조하는데 사용되고 있습니다. 또한 1회용 고착 세포 및 바이러스 배
양 시스템 및 1회용 줄기 세포 배양 시스템은 생산하고 있습니다. 이
외에도 ATMI LifeScience는 모든 멸균 과정에서 쓰일 수 있는 1회
용 타이백 멸균백, 메디컬 백, 정전기 방지 백 등의 제품도 제조하고
있습니다. S
Single-use Tyvek Sterilization Bag & Antistatic Bag
Single-use Liquid & Powder Transfer Bag
Single-use Mixing System (PadMixer, LevMixer, MagMixer,
WandMixer, JetMixer)
Single-use Paddle-Stirred Bioreactor
Single-use Adherent cell & Virus Culture System
Single-use Stem cell Culture System
1회용 타이백 멸균백 및 정전기 방지백
1회용 액체백 및 파우더백
1회용 무균믹서 (패드믹서, 레브믹서, 마그네틱믹서, 완드믹서, 제트
믹서)
1회용 패들 교반 바이오리액터
1회용 고착세포 및 바이러스 배양 시스템
1회용 줄기세포 배양 시스템
I
N
T
R
O
D
U
C
T
I
O
N
Headquartered in Danbury, Connecticut, ATMI was
founded in 1986. Now a global company, ATMI has a total
of twelve locations and over 800 employees. ATMI has
three manufacturing locations in USA and Belgium. ATMI
is a leading supplier of materials, materials packaging and
materials delivery systems for semiconductor, flat panel
display and life science manufacturers. Core competencies
include rapid process development, high performance
materials, packaging solutions, single-use, and disposable
material technologies. The company operates under two
divisions- Semiconductor and LifeSciences.
ATMI는 반도체 및 바이오 공정과 관련된 고 청정 제품이나 설비를
생산하는 다국적 기업입니다. 특히, ATMI LifeScience는 모든 바이
오 공정에 사용할 수 있도록 ISO class 5의 고청정 조건에서 블로우
압출기로 TK8이라는 필름을 자체 생산하고 있습니다. 이 TK8 필름
086
087
C30
D20
F39
G39
Avantor Performance Materials, Inc.
Avison Biomedical Research
BCWORLD PHARM. Co., Ltd.
BINEX Co., Ltd.
아반토 퍼포먼스 머티리얼즈 인터내셔널 인크, 한국지점
연세의료원 (에비슨의생명연구센터)
(주)비씨월드제약
(주)바이넥스
CEO
ADD
TEL
FAX
E-MAIL
URL
Robert John Ferguson
8th Fl, Wooduck building, 832-2, Yeoksam-dong,
Gangnam-gu, Seoul, Korea. 135-750
82-2-2052-0483
82-2-571-5401
[email protected]
http://avantormaterials.com
CEO
ADD
TEL
FAX
E-MAIL
E
X
H
I
B
I
T
S
Excipients, chromatography resins and processing chemicals
for Biotech & pharmaceutical developments.
URL
I
N
Sue Goo Rhee 이서구
50 Yonsei-ro Seodaemun-gu, Seoul 120-752, Korea
Yonsei University, College of Medicine
Yonsei Biomedical Research Institute
Avison Biomedical Research Center (ABMRC)
82-2-2228-0610~0613
82-2-2227-8129
[email protected]
http://medicine.yonsei.ac.kr/research/study_ center
T
R
O
D
U
C
T
I
O
N
Avison Biomedical Research Center (ABMRC) was opened
in April 2013. The primary goal of ABMRC lies in being
a facilitator of research collaboration between clinical
and basic medical research departments, and in the
advancement of medical research through our state of
I
N
T
R
O
D
U
C
T
I
O
N
the art infrastructure and immense biomedical research
AvantorTM Performance Materials is a global specialty activities. We expect ABMRC to serve as the foundation
chemical business with a well developed reputation for for the acceleration and industriali -zation of the field of
its high standard of quality products in four demanding biomedical research.
markets, Biotechnology/ Pharmaceuticals, Electronics,
Laboratory Research and Diagnostic. Specially with our
Biotechnology/pharmaceuticals products, we bring
quality to every stage of product development so you can
formulate, manufacture and innovate with confidence.
CEO
ADD
TEL
FAX
E-MAIL
URL
E
Steve Hong 홍성한
Gyung Building, 78, Gaepo-ro, 22-gil, Gangnamgu, Seoul, 135-961. Korea
82-2-2182-0488
82-2-574-5064
[email protected]o.kr
http://www.bcwp.co.kr
X
H
I
B
I
T
S
Sinraci inj. / Mepem inj. Etc.
ADD
TEL
FAX
E-MAIL
URL
E
Myoung Ho Jeong 정명호
7-48, Songdo-Dong, Yeonsu-Gu, Incheon, Korea
406-840
82- 32 - 850 - 3114
82- 32 - 850 - 3299
[email protected]
http://www.bi-nex.com
X
H
I
B
I
T
S
Biologics, Biosimilar, CDMO, Small molecule, ophthalmic
solution
실라신 주사 / 메펨 주 등
바이오의약품과 합성의약품에 개발과 생산에 필요한 각종 부형제, 크
로마토그래피 레진 그리고 각종 프로세싱 화합물.
아반토 퍼포먼스 머터리얼은 전 세계적으로 바이오텍, 제약, 전자 그
리고 실험실연구와 진단 분야에서 우수한 기준과 품질에 맞추어져
개발된 전문화된 화학물 회사입니다.
특히 바이오텍, 제약분야에서는 검증된 기술을 통해 여러분의 합성,
생산 그리고 개발단계에 검증된 품질의 제품을 제공합니다.
CEO
I
I
N
T
R
O
D
U
C
T
I
O
N
BCWORLD PHARM is a R&D driven pharmaceutical
company that has been committed to developing
innovative formulations and only-one products. It strives
to provide quality generics as well as value-added novel
formulation products through cutting-edge technology
including immediate/controlled release as well as fastdissolving DDS, combined formulation, gastro-retentive
system and depot formulation.
Recently BCWORLD PHARM not only has been certified
as Korea Innovative Pharmaceutical Company (KIPC) by
Korea Ministry of Health & Welfare but also designated as
Advanced Technology Center (ATC) by Korea Ministry of
Knowledge Economy. Also, the construction of EUGMP/
cGMP facility is expected to be finished by March 2014.
주│비씨월드제약은 ' Bio . Chemical R & D 중심의 Global
Standard 제약기업'을 지향하며 제제연구 분야에 있어서는 국
내 최고 수준의 R&D 중심 제약회사입니다. 판교 소재의 Global
Research Institute (GRI)는 우수한 제제 및 합성기술을 바탕으로
DDS (약물전달시스템) 및 신약후보물질 개발과 다수의 국책 과제를
진행하고 있습니다. 최근에는 혁신형 제약기업과 우수기술센터로 선
정되었고, 2014년 3월에는 EUGMP/cGMP 공장을 신축할 예정입
니다.
N
T
R
O
D
U
C
T
I
O
N
As the only biologics CDMO in Korea, BINEX plays
the key role in solving the manufacturing bottleneck
of the biopharmaceutical industry with its hands-on
experience with blockbuster biologics and a top-notch
biomanufacturing facility in compliance with the US and
EU-GMP regulations.
BINEX has been able to acquire the commercialization right
for a few biosimilars of blockbuster biologic products from
business partners in return of providing a reliable and high
quality CDMO services for their products.
Binex is equipped with various ophthalmic products,
which covers all the major ophthalmic solution sectors. As
well as with its recently renovated facility in compliance
with cGMP/BGMP standards, BINEX has accumulated the
experience and know-how over 20 years, and it is able to
offer the high quality and superior cost competitiveness to
partners.
We are looking for opportunities to license out, exporting
and commercialize our products all over the world with
domestic and global partners.
cGMP & EU-GMP에 부합하는 바이오 의약품 One-stop CMO 서
비스 제공이 가능한 바이넥스는 다양한 경험을 통해 노하우와 track
records를 축적하였고 고객사들과 전략적 제휴를 통해 특정 지역 내
바이오 의약품의 상용화 권리를 확보하였다.
또한 점안제 사업에 전문성을 갖추고 있는 바이넥스는 최근 부산 합
성 의약품 생산 공장을 cGMP/BGMP 기준으로 리모델링하여 보다
높은 수준의 수탁사업을 파트너들에게 제공하게 되었다.
국내외 협력을 통해 바이오의약품 및 점안제의 license out, 수출,
상용화를 위한 파트너사를 찾고 있다.
088
089
E42
K30
Q10
N20
Bio Convergence, Inc.
Bio-Age Inc.
BioCore Co., Ltd.
BioHealth Innovation (BHI)
(주)바이오컨버전스
(주)바이오에이지
바이오코아(주)
바이오헬스이노베이션
CEO
ADD
TEL
FAX
E-MAIL
URL
Kenny Kim 김경원
313., IL-Shin B/D, Ogumro 13 gil 7 songpa-gu,
seoul Korea
82-2-2243-9488
82-2-3391-2342
[email protected] hanmail.net
http://www.GBSkr.com
CEO
ADD
TEL
FAX
E-MAIL
URL
Youn Jae Chun 윤재춘
5 F Bldg. Samsung-Dong, Gangnam-Gu, Seoul
135-881, Korea
82-2-550-8940
82-2-550-8941
[email protected]
http://www.istech21.com
CEO
ADD
TEL
FAX
E-MAIL
URL
Hyung-Sik Choie 최형식
6 0 - 2 1 I T M i r a e To w e r 8 F, G a s a n - d o n g ,
Geumcheon-gu, Seoul, Korea
82-2-2205-9900
82-2-790-3929
[email protected]
http://www.bio-core.com
CEO
ADD
TEL
FAX
E-MAIL
URL
E
E
X
H
I
B
I
T
NanoAnalytics TisXell Bioshake TSE Scientifica
S
E
X
H
I
B
I
T
S
SALT: Statistical analysis software for clinical and medical
data
나노언알라이틱스 티셀, 바이오쉐이크 티에스이 사이언티피카
SALT: 임상 자료 통계 분석 전문 소프트웨어
I
N
T
R
O
D
U
C
T
I
O
N
Bio-Age Inc. (previously ISTECH Inc.) is a biotech company
based on the bioinformatics and medical informatics
technology in Korea. Bio-Age Inc. focuses on developing
and providing many kinds of analysis softwares and system
such as SALT (clinical data analysis software), GenPlex (gene
expression data analysis software), SNPAnalyzer (SNP data
analysis software), LABIS (electronic laboratory note) and
BioAge-Smart Care (biological age prediction system).
(주)바이오에이지 (구 이즈텍)은 생명정보공학 기술을 바탕으로 한 바
이오 전문 기업입니다. 현재 급속도로 발전하고 있는 인간 유전체 분
석 기술을 이용하여 다양한 연구 프로젝트를 성공적으로 수행해오고
있으며, 축적된 연구 성과를 바탕으로 생명정보공학, 임상, 의료 분
야에 특화된 시스템 및 데이터 분석 프로그램을 개발하여 제품화 하
E
X
H
I
B
I
T
Richard Bendis
22 Baltimore Road, Rockville, MD 20850
1-301-637-6439
1-301-476-4531
rbendisig.com
http://www.biohealthinnovation.org
X
H
I
B
I
T
S
S
‘Korea-Maryland, USA Bio Expo 2013’ & ‘BioMaryland
Temperature Controlled Packaging / Cold Chain Solutions / 2020’ Strategic Plan Introduction
Regulatory Compliance Packaging
한.미 바이오 엑스포 2013 소개 및 메릴랜드 주 바이오 정책 소개
메릴랜드 주 한국무역통상부, JG Business Link International,
I
N
T
R
O
D
U
C
T
I
O
N
Johns Hopkins University, University of Maryland School
Intelsius began operations in 1998, when we developed of Medicine, Montgomery County, University of Maryland
a unique packaging solution for the transportation of BioPark, BioHealth Innovation 총 7개 업체 함께 참여
samples suspected of containing BSE (Bovine Spongiform
Encephalitis or “Mad Cow Disease”). Within a year,
N
T
R
O
D
U
C
T
I
O
N
Intelsius became the first UN-certified BSE sample shipper I
in the world. The company soon went global, becoming Biohealth Innovation will connect market relevant research
widely recognized as one of the market leaders of sample assets to apporopriate fundind, management and markets
transport and temperature-complinat packaging solution. to facilitate the development of commercially viable bio
health products and companies.
영국에 본사를 두고 있는 패키징 전문 글로벌 기업인 인텔시어스는
온도조절 패키징을 이용한 Cold Chain Solutions을 전 세계 40여
개국에 제공하고 있으며, 국제운송규정에 적합한 UN인증 제품들을
공급하고 있습니다. 또한 PCM (상변화물질)과 VIP (진공단열재) 재
료를 이용한 하이엔드급의 포장재를 공급하여 온도에 민감한 의약품,
생물학적제제 및 각종 샘플 등의 안전 운송에 기여하고 있습니다.
BioHealth Innovation은 메릴랜드주 내의 제약사, 연구소, 투자기
업, 마케팅 기업이 연합해서 설립한 기업으로 메릴랜드나 미국 또는
해외기업 중에서 연구.시험과정을 거친 결과물 중에서 가치가 있는
과제를 상업화에 필요한 자금투자부터 마케팅 까지의 과정을 지원해
주는 프로그램을 시행하는 업무를 진행한다.
고 있습니다. 현재 개발되어 상용화된 제품으로는 SALT, GenPlex,
SNPAnalyzer, LABIS, BioAge-Smart Care 등이 있습니다.
090
091
L37
C10
BioMed Central
CEO
ADD
TEL
FAX
E-MAIL
URL
Matthew Cockerill
7th floor, W&H Building, 367-13, Seogyo-dong,
Mapo-gu, Seoul, Korea
82-2-3142-9660
82-2-3142-5768
[email protected]
http://www.biomedcentral.com
A40
Bio-Med Connect Center (BMCC)
Biomedical IT Convergence Center
Biometrix Technology Inc.
삼성서울병원 바이오-의료커넥트센터
IT의료융합기술사업단
(주)바이오메트릭스테크놀로지
CEO
ADD
TEL
FAX
E-MAIL
URL
X
H
I
B
I
T
S
Publishing
I
N
T
R
O
D
U
C
T
I
O
N
BioMed Central is an STM (Science, Technology and
Medicine) publisher which has pioneered the open access
publishing model and is at the cutting edge of ensuring
that the results of scientific research are made openly
available throughout the international community.
Our portfolio of over 250 journals includes a combination
of broad titles and specialist journals across all areas of
biology, medicine and chemistry; 146 of the journals we
publish now have an Impact Factor.
Sa Ik Bang 방사익
81, Irwon-Ro, Gangnam-Gu, Seoul, 135-710, Korea
82-2-2148-7149
82-2-3410-0036
[email protected]
http://www.bmcc.or.kr
CEO
ADD
TEL
FAX
E-MAIL
URL
E
E
E10
X
H
I
B
I
T
Sang Hee Kim 김상희
(730-916) R304 General Business Support Center
350-27 Gumidaero, Gumi, Gyeongbuk, Korea
82-54-464-3211~2
82-54-464-3213
[email protected]
http://bitc.geri.re.kr
CEO
ADD
TEL
FAX
E-MAIL
URL
Kim Taisun 김태선
#2-2 Bioventure Plaza 198-60 Hupyong-dong,
Chuncheon-si. Gangwon-do, 200-160, Korea
82-33-258-6097
82-33-258-6099
[email protected]
http://www.bmtchip.com
S
Consulting, Education and Connect Services on BioMedical Industry
바이오-의료제품의 컨설팅, 교육, 커넥트 서비스
E
X
H
I
B
I
T
S
E
X
H
I
B
I
T
S
Introduction of National Infrastructure Construction Plan HPV 6G DNA kit
for Parts & Materials of Medical Equipment
HPV Genotyping 9G membrane kit
MTB DR-RIF 9G membrane kit
전자의료기기 부품소재 산업화 기반구축사업 소개자료
I
N
T
R
O
D
U
C
T
I
O
N
Bio-Med Connect Center, BMCC, was established in 2009
to lay the infrastructure to facilitate systematic translational
research between Industry-University-Institute and Hospital
for successful market entry of biomedical products
reflecting the needs of final consumers.
BMCC has an advisory board composed of specialists and
professionals from various fields including basic science,
patents, licensing, laws, regulations and management
to provide high-quality services in consulting, education
and connecting for the long-term success of biomedical
companies.
BMCC는 바이오·의료 제품의 성공적인 시장 진입과 경쟁력 제고
를 목표로 산업통상자원부 사업의 일환으로서 2009년 설립되었으
며, 의료기관과 산·학·연간의 양방향 네트워크를 통해서 체계적인
중개연구를 수행할 수 있는 인프라 구축에 노력하고 있습니다.
또한, 전문 의료진을 주축으로 기초과학, 특허, 인허가, 법률, 비즈니
스와 관련된 다양한 분야의 전문가들을 자문위원으로 모시고 바이
오·의료산업 관련 기업에게 컨설팅, 교육, 비즈니스 커넥션 등을 지
원하여 국내 바이오 산업의 발전을 도모하고자 합니다.
I
I
N
T
R
O
D
U
C
T
I
O
N
The mission of the Biomedical IT Convergence Center in
Gumi is to enhance the global competitiveness of topnotch biomedical device equipment industry in Korea. The
center plays an important role in the national infrastructure
construction project for the parts & material of medical
IT convergence equipment and has received funding of
$130 million for 5 years by the Ministry of Trade, Industry
& Energy, Gyeongsangbukdo Province and Gumi city from
2011. It helps to establish the Commercialization R&DB
Center to vitalize biomedical industry and the Industrial
Complex for medical equipment in Gumi that will be the
hub city of a world’s leading industrial cluster for Medical IT
Parts and Materials convergence industry in Korea.
N
T
R
O
D
U
C
T
I
O
N
Biometrix Technology INC. (BTM) are committed to
development of methods for diagnosis of various diseases,
including cancer and viral or bacterial infections, by further
developing our innovative 9G chips technology which
has proven to yield unparalleled levels of sensitivity and
specificity in DNA chips.
(주)바이오메트릭스 테크놀로지 (BMT)는 민감도 및 특이도가 최고수
준인 9G DNAChip 기술을 개발하여 이를 다양한 암 및 바이러스성
감염질환을 조기검진할 수 있는 올리고유전자 칩과 지노타이핑 키트
들을 개발하고 판매하는 바이오칩 전문기업입니다.
IT의료융합기술사업단은 디스플레이, 모바일 및 반도체 부품소재산
업에서 세계적인 경쟁력을 확보하고 있는 구미국가산업단지 내 전자
의료기기 부품소재 산업화 기반을 조성하여, 글로벌 의료클러스터 및
생산단지로 육성하고자 산업통상자원부, 경상북도 및 구미시의 지원
으로 (총 사업비: 1213.5억) 5년간 전자의료기기 부품소재 산업화
기반구축사업을 진행하고 있습니다. 이를 통해 전자의료기기 기술개
발 5대 육성분야에 대한 연구수행을 통해 의료기기 산업단지를 후방
지원할 수 있는 전자의료기기 부품소재 의료 클러스터의 역할을 담
당할 것입니다.
092
093
L10
L10
R14
BioModics ApS
Bioneer
Biorhythm Co., Ltd.
바이오메딕스
바이오니어
(주)바이오리듬
CEO
ADD
TEL
E-MAIL
URL
Peter Thomsen
Gregersensvej 7, 1 DK-2630 Høje Tåstrup Denmark
45-6166-6619
[email protected]
www.biomodics.com
CEO
ADD
TEL
FAX
E-MAIL
URL
I
N
T
R
O
D
U
C
T
I
O
Peter Thomsen
Kogle Allé 2 DK-2970 Hørsholm Denmark
45-4516-0444
45-4516-0455
[email protected]
www.bioneer.dk
CEO
ADD
TEL
FAX
E-MAIL
N
실리콘 기반 의료기기들을 위해 Hypermatrix 기술을 이용하여 혁
신적인 솔루션을 개발하는 회사입니다. 폴리머(polymer) 의료기기
에 적용된 이산화탄소 공정기술특허를 기반으로 의료기기들을 생산
하며, 임플란트, 카데터, 스텐츠 등에 적용 가능한 다양한 솔루션을
개발하며 실리콘 기반 의료기기 및 바이오필름 등을 생산합니다.
I
N
T
R
O
D
U
C
T
I
O
N
북쪽 코펜하겐 25km지점에 본사를 두고 25년 이상 제약, 생명공학
회사 및 제약회사들에게 개선된 약물 개발 프로세스의 개발, 생산성
증진을 목표로 한 기기의 개발, 기술개발 그리고 단백질 생산 및 관
련된 상품 제공하는 회사입니다. 또한, 다양한 치료전략의 개발을 위
한 컨설팅 및 협업을 지원 합니다.
URL
E
Yong-Hyun JUNG 정용현
# 101, Chungbuktechnopark Biocenter, 6864, Yangcheongri, Ochangeup, Cheongwongun,
Chungbuk, South Korea
82-70-8777-0707
82-31-216-7719
[email protected]
www.biorhythm.kr
X
H
I
B
I
T
트를 정부산하 기관과 충남북 지역사회 협력 하에 각 대학교 공동연
구 지원과 함께 수행하며 바이오 생명공학분야의 글로벌프로젝트화
에 온 심혈을 기울이고 있다. 요구르트유산균이 우유나 당류에 배양
한 제품인 반면 김치유산균은 김치파쇄액에 단일 또는 다종의 유산
균 우점종을 배양시킨 순식물성 유산균으로 3단계 코팅 특허등록 공
법을 이용하여 생산하고 있다. 본 제품을 섭취 후 짧은 시간 내에 숙
변제거나 쾌변 및 황금색변과 같은 속효능 반응을 감지할 수 있는 제
품이다. 활용분야는 건강기능식품, 의약품, 화장품, 바이오제품, 동물
의약 품에 응용 적용할 수 있으며, 건강산업에 있어서 상당한 고부가
가치성의 상품이다.
S
마이크로캡슐화 김치유산균
Super Kimchi lactobacillus
I
N
T
R
O
D
U
C
T
I
O
N
* This is made by cultivating a variety of lactobacillus
fermentans, which grows in a Korean indigenous food,
Kimchi, and coating three times with casein protein and
kelp powder, so the lactic acid bacteria in Kimchi can reach
intestines and grow and breed, allowing to intake both
nutrition and lactic acid bacteria in kimchi.
(Tip) Taking the daily amount of lactic acid bacteria
recommended in this product has a same effect of taking
1kg of kimchi.
1.Substance form : yellowish brown kimchi powder in
which 1g of powder has 10 billion LAB (the number of
LAB and the size of a particle are optional)
2.Dosage : 1~2 times/day (1~2capsule/1time :1~2g),
probiotics:10billions /g
3. Intake method : intake with water
* Effect : intestinal comfort in normal and regular motion
without fecal incontinence after continuing intake,
immunity improvement, probiotic effect. This invention
helps to improve immune system against SARS, avian
influenza or virus.
수 천년동안 우리의 선조들의 얼과 숨결이 깃들어 있는 김치 속에 들
어있는 “김치유산균”은 온 인류에게 건강상품으로서 영원하리라 확
신한다. 또한 동결건조 김치의 유용한 성분의섭취를 통한 인체내 흡
수는 물론 김치유산균이 위산, 답즙산에 살아 남아 소장과 대장에서
그 기능을 최대로 발휘할 수 있도록 하였다. 김치관련 다양한 프로젝
094
095
D45
N39
Bionutrigen Co., Ltd.
Biotech Industry Research Assistance
Council (BIRAC)
(주)바이오뉴트리젠
CEO
ADD
TEL
FAX
E-MAIL
URL
R25
BOK SONG HAE 복성해
BVC #207 KRIBB, 52 Eoeun-dong, Yuseong-ku,
Daejeon, S. Korea
82-42-861-0637
82-42-861-0639
[email protected]
http://www.bionutrigen.com
CEO
ADD
TEL
FAX
E-MAIL
URL
Dr. Renu Swarup, MD
A-254, 3rd Floor, Bhisham Pitamah Marg, Defence
Colony, New Delhi – 110 024 India
91-47744500
91-47744511
[email protected]
http://www.birac.nic.in
A21
Biotechnology Industrialization Center
Biotoxtech Co., Ltd.
생물자원산업화센터(주)
바이오톡스텍
CEO
ADD
TEL
FAX
E-MAIL
URL
Yeon-Sil Lee 이연실
# B-806, Gwangmyeong SK Technopark, Sohadong, Gwangmyeng-si, Gyeonggi-do, Rep. of Korea
82-2-2083-3024
82-2-2083-3026
[email protected]
http://
CEO
ADD
TEL
FAX
E-MAIL
URL
E
X
H
I
B
I
T
S
I
N
T
R
O
D
U
C
T
I
O
N
JBB20 (Liver Health Food Ingredient), Slim&Slim (Slimming Govt. of India Enterprise
Food Ingredient)
JBB20 (간 건강소재), Slim&Slim (항비만소재)
I
N
T
R
O
D
U
C
I
T
I
O
N
Bionutrigen Co,.Ltd. was established in 1999 to develop
the new natural edible food grade materials without
toxicity and side effects for maintaining slimming body
line, skin beauty, good liver health, heart health and
metabolism. Bionutrigen's business-goal is to develop nontoxic health food ingredients and products from vegetables
& fruits for maintaining healthy levels of body fat,
cholesterol, LDL, triglyceride, blood sugar and to support
fat control, heart health, liver health, lovely body line, skin
beauty. Our new products Slim&SlimPWH™ and JBB20™
are helpful for achieving the above goals.
(주)바이오뉴트리젠은 비만증, 간질환, 당뇨병 등을 포함하는 다양한
성인병의 예방에 탁월한 건강식품, 음료, 식품첨가제 및 미용식품 소
재 개발과 더불어 독성과 부작용이 없는 의약품 원료개발을 위한 천
연 신소재 개발을 주요 목표로 하고 있다. 현재 비만증, 간질환 및 아
름다운 피부 및 몸매관리에 유용한 Slim&Slim과 JBB20을 개발하는
데 성공하여 E.U, 미국, 중국, 러시아, 일본 등 전 세계에 마케팅을 시
작하여 활발한 성과를 이루고 있다.
096
N
T
R
O
D
U
C
T
I
O
N
Biotechnology Industry Research Assistance Council
(BIRAC) is a Section 25 ‘Not-for-Profit Company’ of
Government of India, that is registered under Indian
Companies Act 1956, and has been set up as Department
of Biotechnology’s interface agency, which serves as a
single window for the emerging biotech industries. BIRAC
is guided by an Independent Board of Directors comprising
senior professionals, academicians, policy makers and
industrialists. As a Government of India enterprise, it
endeavours to bring professionalism, transparency and
efficiency into its functioning while providing support to
catalyze the transformation of the emerging Indian bioeconomy.
I
N
T
R
O
D
U
C
T
I
O
Jong-Koo Kang 강종구
O chang Scientific Industrial Complex, 686-2
Yangcheong-ri, Ochang-eup, Cheongwon-gun,
Chungcheongbuk-do, 363-883, Korea
82-43-210-7777
82-43-210-7778
[email protected]
http://www.biotoxtech.com
N
X
H
I
B
I
T
S
BIC focuses on theintergrated preventive medicine E
Industrialization and R&D which is based on IP (Intellectual •N on-Clinical Field: Toxicity study/ Efficacy study/
Property), TK (Traditional Knowledge) and Bio-Resources of
Histopathology and clinical pathology study
Technical Valuation.
•Analysis field: PK/TK, ADME, RI
•New compound discovery field
•Consulting drug development
•의약품/식품/화장품/세포치료제/화학물질/농약/의료기기 등에 관
한 안전성 시험 수행
•PK/TK, ADME, RI 분석업무
•유효성시험 및 물질 Screening
•임상병리 및 조직병리 업무수탁
•비임상시험에 관한 Consulting 및 대관업무
I
N
T
R
O
D
U
C
T
I
O
N
Biotoxtech is a life science company and a Contract
Research Organization (CRO) that primarily conducts
compliance studies for product safety. Headquartered in
Ochang, Korea, Biotoxtech owns and operates a 146,
300sq.ft. Facility, With 10 years of industry experience,
Biotoxtech conducts compliance safety testing and
research following Good Laboratory Practices (GLP). The
safety studies performed in support of OECD, United States
FDA, Japanese MHLW, and other international regulatory
compliance for products developed from biotech,
chemical, agrochemical and pharmaceutical industries.
The safety services include complete range of toxicology,
acute, sub-chronic, and chronic toxicity, reproductive
toxicity, genotoxicology, ecotoxicology, carcinogenicity,
pharmacokinetics (PK), toxicokinetics (TK), bioavailability,
ADME, analysis and synthesis, Efficacy Evaluation,
Histopathology & Hematology.
097
R15
L20
BKT Co., Ltd.
(주)부강테크
CEO
ADD
TEL
FAX
E-MAIL
URL
E
Il Ho Jung 정일호
4 F, Allnations Bldg, 789-6, Yeoksam-Dong,
Gangnam-Gu, Seoul, Korea
82-2-3453-5221
82-2-556-2205
[email protected]
http://www.bkt21.com
X
H
I
B
I
T
S
FMX (Anti-Fouling Membrane System)
FMX 막오염 저감형 분리막 시스템
I
N
T
R
O
D
U
C
T
I
O
N
• 회사소개
During the initial period of BKT established, BKT aimed
niche market of advanced wastewater treatment in
livestock. As an environmental company, BKT provide the
optimum process of advanced sewage treatment process,
special membrane filtration system (FMX) and anaerobic
digestate process across the business sector.
Based on accumulated technologies in environmental
field, FMX technologies (membrane filtration) application
is expands to various sectors, and BKT also carries forward
bio industry field. By starting supply FMX into CJ amino
acid manufacturing process, it expands business with
Production separation (Bulk filtration), has strong points in
high density culture filtration of downstream process and
Diafiltration sector.
Additionally, bio-industrial sector has great expectation
on vigorous business, through proceeding bulk separation
process in animal medical supplies manufacturing
process and filtration/concentration process in amino acid
manufacturing process etc.
Furthermore, BKT as a leader in environmental green
tech companies, at the same time positioned high density
membrane market leader in bio-industries to become best
membrane technology holding company.
• 제품소개
FMX is the most advanced membrane filtration system
that overcomes technological limitation and maximizes
098
treatment efficiency of high solid, high density and high
viscosity application which conventional membrane system
cannot handle. FMX is able to applied pollutant filtrate/
separation process with accuracy and ease of operation in
various industries such as environmental industrial process,
bio-manufacturing process, and chemical plant etc.
Conventional membrane system has ability of advantage in
raw material recovery/concentration, energy reduction and
reuse of byproducts. Though there were serious problems
of fouling resistance. Especially, characteristic of high
density and high viscosity substance were inappropriate
for the process and may require frequent cleaning issue or
economic loss of membrane replacement plus constraint of
maintenance.
FMX was developed to overcome of obstacles such as
fouling that conventional membrane filtration system
couldn’t handle. By applying vortex generator in FMX, it
prevents membrane fouling and lead to high density and
high viscosity treatment application in various industries.
FMX may effective in separation of micro-organism in biosector and product separation (bulk filtration), filtration
and diafiltration of high density cultivate process. FMX
gives a more than twice of high concentrate results from
the existing membrane separation process and increases
substance recovery rate. Plus, it has expectation of energy
cost saving and reduces production period efficiency
through post-treatment load factor from decreasing inflow
rate of DF water during the general diafiltration process.
FMX quality and durability has been approved worldwidely through acquired of CE (EU certification system)
and ISO (ISO 9001/14001) certification based on the FMX
technical skills. Through technical performance assessment,
FMX is applied in domestic various industries such as
biotech and environment , biopharmaceutical (animal
drug), biofood (amino acid) and chemistry process etc.,
currently.
British Embassy Seoul / UK Trade & Investment
주한영국대사관
-납세 및 관련 법규에 대한 상세한 안내
3. 주요 인맥 소개 및 연결
-해당 산업 전문가 네트워크 연결: 인센티브 전문가, R&D전문가,
사업계획 고문, 연구기관 등의 비지니스 네트워크 형성
CEO
ADD
TEL
FAX
E-MAIL
URL
Scott Wightman (Ambassador)
. 영국 내 사업 부지 선정
British Embassy Seoul, Sejong-daero 19-gil 24, 4
해당 사업에 적절한 지역 및 사업부지 선정 지원
Jung-gu, Seoul 100-120 Republic of Korea
설립과 운영에 필요한 컨설팅 제공
82-2-3210-5612
. 글로벌 기업으로의 도약
5
82-2-3210-5637
-IMF가 인정한 유럽 및 세계시장으로 진출할 수 있는 게이트웨이
[email protected]
저희 투자팀은 위의 모든 사항들이 원할하게 진행되도록 진출 이 전
http://www.ukti.gov.uk
부터 진출 이 후 관리까지 전면 지원해드립니다. 제공되는 모든 서비
스는 무료/ 대외비입니다.
E
X
H
I
B
I
T
S
Government
정부기관
I
N
T
R
O
D
U
C
T
I
O
N
UK Trade & Investment (UKTI) works with UK-based
businesses to ensure their success in international markets,
and encourage the best overseas companies to look to the
UK as their global partner of choice.
UKTI has professional advisers both within the UK and
across more than 100 international markets.
UKTI has a customer commitment to helping its UK and
international customers by providing a range of services, to
a high standard and improve customer service by listening
to customer feedback.
We also have a co-ordination role across government to
establish a more systematic approach to relationships with
companies which are the most economically significant
investors and exporters.
영국무역투자청은 영국과 해외기업 간의 무역 및 투자사업을 지원하
는 기관입니다. UKTI 서울 투자팀은 한국 기업이 영국으로 진출할
수 있도록 도와드립니다. 영국내 투자 및 사업 기회를 찾아드리고 현
지에서 비지니스가 성장하도록 모든 과정에서 적극적으로 지원하고
있습니다.
영국 진출을 위한 투자팀의 지원사항
1. 영국시장 안내
-영국의 시장 동향을 바탕으로 사업성을 파악
-자금조달, 비자, 기업등록, 재정협조 정책, 생산품 분야, 법인세,
현지 직원채용 등에 대한 정보 제공 및 지원
2. 영국정부에 관한 정보 제공
-해당 정부 부처와 협회, 지방자치 기관 등에 한국기업 소개
099
G35
H42
D20
K30
Boryung Pharmaceutical Co., Ltd.
Cactus Communications Korea Ltd
Cancer Hospital / GAP2014
CARIMA CO LTD
보령제약 주식회사
(주)캑터스 커뮤니케이션즈 코리아
연세의료원 (암병원/GAP2014)
캐리마
CEO
ADD
TEL
FAX
E-MAIL
URL
E
Tae Hong Choi 최태홍
(110-750) Boryung Bldg, #66-21, Wonnam-dong,
Chongro-Ku, Seoul, Korea
82-2-708-8168
82-2-708-8439
[email protected]
http://www.boryung.co.kr
X
H
I
B
I
T
S
Kanarb (Anti-hypertensive drug)
N
T
R
O
D
U
ADD
TEL
FAX
E-MAIL
URL
E
Shriram Poonja
121-706, Renaissance Tower # 1701 Mallijae-Ro
14, Mapo-Gu, Seoul, Korea
82-2-538-3177
82-2-703-3177
[email protected]
www.editage.co.kr
X
H
I
B
I
T
C
T
I
O
N
Boryung Pharmaceutical Company (here after Boryung)
founded in 1963 based on company's ideology,
"coexistance and co-prosperity" has led Korean
pharmaceutical industry concentrating its utmost efforts
on the development of new drugs. Boryung makes an
effort to strengthen the product pipelines in the specialty
areas such as cardiovascular drugs, antineoplastics drugs
and antibiotics/antiviral. Boryung devote itself to achieving
aspiration of the company which is "Dedicating to the
health of Mankind" and becoming a global innovative
pharmaceutical company.
Boryung Pharmaceutical has developed Kanarb, an antihypertensive drug that has been approved by the KFDA as
the 15th new drug, and also it is 8th new ARB drug in the
world. Boryung is in the process of exporting Kanarb to 13
countries in South America, BRICs, southeast Asia, the U.S.,
and Europe.
N
T
R
O
D
U
C
T
I
O
N
Editage provides entire service for the overall areas in
Journal Publication like Translation, English Editing &
Journal Publication Support. We have provided Editing
Services for around 214, 000 papers in 112 countries all
over the world. We also have the business area in English
Education, especially in Writing and provide total solution
to the Market.
에디티지는 한.영 번역에서부터 영문교정 및 저널투고서비스에 이르
기까지 영문 학술논문 투고에 있어 전반적인 서비스를 제공하고 있
습니다.
전 세계 약 112개국 214, 000건의 영문교정 실적을 보유하고 있으
1963년 창립된 보령제약은 ‘삶의 질’을 높이는 우수한 의약품을 계 며, 그 밖에 맞춤형 영어교육사업 영역 또한 보유하고 있어 영문학술
속적으로 발매해왔으며 지속적인 혁신을 통해 궁극의 목적인 ‘인류
건강에 공헌’을 영속적으로 실천하는 기업이다. 특히, 심혈관계 질환
과 항암 분야에 파이프라인을 집중하고 있다. 카나브 정은 세계 8번
째 ARB 신약이자, KFDA로부터 15번째로 승인 받은ARB 계열 항
고혈압제 신약으로 중남미 13개국과의 수출 계약을 비롯해BRICs 및
중동아시아, 미국, 유럽 등 전세계적으로 수출을 진행하고 있다.
100
ADD
TEL
FAX
E-MAIL
URL
I
영문교정
저널투고지원
영문논문 작성법 교육 및 워크숍
한.영 번역
I
CEO
S
English-Language Editing
Publication Support
Training and Workshops
Translation
카나브, 원료의약품
I
CEO
논문에 관한 토탈솔루션을 제공하고 있습니다.
N
Sung Hoon Noh 노성훈
Cancer Hospital, 50 Yonsei-ro, Seodaemun-gu,
Seoul 120-752, Korea
82-2-2228-8000
82-2-362-9973
[email protected]
h ttp://sev.iseverance.com/cancer/centerintro/
cancer_hospital/cancer_hospital_intro/
http://www.gap2014.org
T
R
O
D
U
C
T
I
O
N
The Yonsei Cancer Center was established by the Yonsei
University Health System as the first Korean cancer center
in 1969 and has played an important role in Korea’
cancer research and treatment through collaborating with
the Cancer Research Institute. The New Yonsei Cancer
Hospital, which will newly reopen in 2014, will mark a new
era in cancer treatment with comprehensive cancer care,
prevention and research.
The most acclaimed cancer center in the world, MD
Anderson manages the multi-national, multi-organization
GAP program – Global Academic Programs, and organizes
the annual GAP conference, which is the very place
to share research experience and strengthen the sister
institute network. The next GAP conference will be held in
May in Seoul, Korea. The conference will be co-hosted by
the Yonsei Cancer Center, one of the sister institutes of MD
Anderson, in conjunction with Korean Cancer Association.
As the 1st GAP conference held in Asia, GAP 2014
represents the advancing status of Korean cancer research.
We are sure GAP 2014 will be an excellent opportunity
to share experience and bolster the ties of the research
network with international colleagues.
CEO
ADD
TEL
FAX
E-MAIL
URL
E
Byungkeuk, Lee 이병극
157-862 264-26 Yeomchang-dong Gangseogu,
Seoul
82-2-3663-8877
82-2-3283-4466
[email protected]
http://www.carima.co.kr
X
H
I
B
I
T
S
3D Printer Master Plus
I
N
T
R
O
D
U
C
T
I
O
N
Carima has been involved in optical engineering for over
years with research and development for decades, big
investment, Master Plus(3D Printer) came out with our own
optical technology and specific skills
저희 업체에 대해 간략히 소개드리면 캐리마는 1983년 사진현상기
사업으로 출발해 30년간 광학기기 전문기업으로 입지를 다져왔으며
수십년의 연구개발과 수백억원의 거액을 투자, 캐리마의 디지털 광학
기술과 노하우를 총동원해 마스터 플러스(3D 프린터)를 개발해 내었
습니다.
-연세암센터는 1969년 한국 최초로 된 후 연세암연구소와 함께 중
개-임상연구를 긴밀히 협력하며 국내 암연구와 진료를 선도하여
왔습니다. 2014년 암병원 신축을 맞이하여 포괄적 암 진료, 예방,
연구에 이르는 새로운 개념의 최고 암 진료 경험을 추구하는 최고
의 암센터로 재도약 할 것입니다.
-세계 최고의 암센터인 MD 앤더슨 암센터는 세계 유수의 암병원들
과 자매결연을 맺고 매년 성과를 교류하고 네트워크를 발전시키는
국제학술대회인 GAP (Global Academic Programs)을 개최해
왔습니다.. 2014년 5월 연세암센터와 대한암학회는, 아시아 최초
로 GAP 2014를 공동주관하여 개최합니다. 학술적 성과를 교류하
고 국제 연구자들과 협력하는 훌륭한 기회가 될 것입니다.
101
K10, E30
N34
가, 시판되고 있으며, 이러한 성공적인 신약개발 경험을 바탕으로
Chong Kun Dang Pharmaceutical Corp.
thiazolidinedion 유래의 당뇨병 치료제인 CKD-501 (상품명: 듀
(주)종근당
비에)이 2013년 식약처로부터 허가를 획득하고, 2014년 발매 예
정이다. Tubulin 저해기전 항암제인 CKD-516 및 HDAC 저해기
Kim Jung Woo 김정우
CEO
전 항암제 CKD-581이 임상1상 진행 중에 있으며, 2009년 미국
368, 3-ga, Chungjeong-ro, Seodaemun-gu, Seoul
ADD
Zafgen에 기술수출된 고도비만 치료제 CKD-732는 해외에서 임
120-756, Korea
상 2상을 진행하고 있다. 최근에는 바이오사업에 집중 투자하여 바
82-2-2194-0300
TEL
이오시밀러와 백신을 개발하고 있으며, 네스프 바이오시밀러 CKD82-2-2194-0369
FAX
11101과 자궁경부암 예방백신 CKD-12201이 임상 1상을 진행중
E-MAIL [email protected]
에 있다.
http://www.ckdpharm.com
URL
E
X
H
I
B
I
T
S
CKD-501, CKD-732, CKD-828, CKD-841, CKD-11101,
CKD-12201
Center for Cellular and Molecular Platforms
(CCAMP)
CEO
ADD
TEL
FAX
E-MAIL
URL
E
N
T
R
O
D
U
C
T
I
O
N
Chong Kun Dang Pharmaceutical Corp. (CKD Pharm.),
based in Seoul, Korea, is a fully integrated pharmaceutical
company manufacturing both active pharmaceutical
ingredients and finished products. We have experiences
over half century in manufacturing products through
fermentation and synthetic technologies and continuously
strive to develop new drugs. Furthermore, We are trying to
investigate new drugs through drug discovery and delivery
platform technologies in the post-genomic era. In 2012,
our revenue was $419million and CKD invested about $46
million in R&D activities.
CamtobellⓇ was launched in 2004, as the first CKD new
drug developed by own technology. Based upon this
successful experience, DuvieⓇ which is a thiazolidinedion
derivative for type 2 diabetes has been approved by MFDS.
Phase I clinical trials for CKD-516 (Tubulin inhibitor & VDA)
and CKD-581 (Pan-HDAC inhibitor for cancer) are ongoing
currently. In addition, CKD-732 (Fumagillin derivative)
developed by CKD has been licensed to Zafgen and is in
Phase II clinical trials for the treatment of morbid obesity in
Australia. As biologics, both CKD-11101 (biosimilar) and
CKD-12201 (HPV vaccine) are in Phase I clinical trials.
(주)종근당은 원료, 완제의약품을 제조, 판매하는 제약기업으로 지난
반세기 동안 발효 및 합성기술에 의한 제품생산에 많은 경험과 노하
우를 축적해왔다. 4, 612억원 (2012년)매출 규모의 종근당은 축적
된 기술을 바탕으로 신약개발을 위해 꾸준히 노력하고 있으며 2012
년에는 연구개발비로 약 505억원을 투자하였다.
2004년 자체연구를 통해 개발된 캄토벨은 국내에서 항암제로 허
102
Prof. Ramaswamy S
NCBS-TIFR, GKVK Post, Bellary Road, Bangalore
560065, India
91-80-6718-5100
91-80-2363-6662
[email protected]
www.ccamp.res.in
X
H
I
B
I
T
S
N
T
R
Chuncheon Bioindustry Foundation
(재)춘천바이오산업진흥원
CEO
ADD
TEL
FAX
E-MAIL
URL
E
Lee Si-woo 이시우
2 00-161 Hupyong-dong 198-53, Chuncheon,
Gangwon, Korea
82-33-258-6165
82-33-258-6170
[email protected]
http://www.cbf.or.kr
X
H
I
B
I
T
S
Health functional food, Food ingredient, Food additives,
Drug medicin
Standard booth
I
I
E10
O
D
U
C
T
I
O
N
C-CAMP is a Department of Biotechnology(Govt. Of India)
initiative, with a mandate of enabling successful bioscience
research and entrepreneurship.
기능성 식품, 소재, 첨가물, 화장품, 의약품 등
I
N
T
R
O
D
U
C
T
I
O
N
Chuncheon Bioindustry Foundation (CBF) is a non-profit
organization established in January, 2003, aims to promote
the growth of bio-venture companies by collecting and
solving various problems of the biotech companies. CBF
helps to exchange information, support technological
development and activate the exchange of knowledge
and experiences of management and industrialization in
biotech field. CBF also provides systematic support for
business start-up, technology/development, marketing
and manufacturing with a well-organized excellent
infrastructure.
Through this effort, CBF intends to strengthen the
international competitiveness of the national bio-venture
industries and economy, and will contribute to develop
Gangwon regional industry by fostering bio-industry as a
national core strategic industry in the 21 st century.
춘천 Bioindustry 재단 (CBF)는 2003년에 설립된 비영리 단체입니
다 생명 공학 기업의 다양한 문제들을 수집하고 해결함으로써 바이
오 벤처 기업의 성장을 촉진하는 것을 목표로 하고 있습니다. CBF는
정보를 교환 및 기술 개발을 지원하고, 지식과 생명 공학 분야의 관
리 및 산업화의 경험 교류를 활성화하는데 도움이 됩니다. 또한, 훌륭
한 인프라와 기술 개발, 마케팅 및 제조에 대한 체계적인 지원을 제
공합니다.
이러한 노력을 통해 CBF는 국내 바이오 벤처 산업과 경제의 국제 경
쟁력을 강화하고, 21 세기 국가 핵심 전략 산업으로 바이오 산업을
육성하여 강원 지역 산업 발전에 기여할 것입니다.
103
E40
Q21
P20
G10
Chungbuk National University Department of CHUNGBUK NATIONAL UNIVERSITY TLO
충북대학교 산학협력단
Industrial Parmacy
Chungcheong Institute for Regional Program
Evaluation
충북대학교 제약산업특성화대학원
충청지역 의약바이오기업 클러스터
CEO
ADD
TEL
FAX
E-MAIL
URL
CEO
Jin Tae Hong
52 Naesudong-ro, Cheongju Chungbuk 361-763
82-43-261-2800
82-43-268-2732
[email protected]
http://pharm.chungbuk.ac.kr
ADD
TEL
FAX
E-MAIL
URL
Shin Eung-Soo 신응수
(361-763) Chungbuk National Univ., Gaesin-dong,
Heungdeok-gu, Cheongju-si, Chungbuk, Korea
82-043-261-3872
82-043-261-3499
[email protected]
http://sanhak.chungbuk.ac.kr
CEO
ADD
TEL
FAX
E-MAIL
URL
E
X
H
I
B
I
T
S
E
X
H
I
B
I
T
• Perform National Research & Development
•Perform Joint Research & Development with Business
• Register 150 Case Patents of Bio Technology
PR content for department of industrial pharmacy
대학원 안내 및 홍보물
N
T
R
O
D
U
C
T
I
O
충청북도
Lee Si-Jong 이시종
8 2sangdang-ro, Sangdang-gu, Cheongju-si,
Chungcheongbuk-do, Korea
82-43-220-4623
82-43-220-4619
http://www.cb21.net
CEO
Lee kyung mi 이경미
803 8F Deadeok Tech Biz Center, 386-2 Doryongdong, Yuseong-gu, Daejeon, 305-340, Korea
82-42-934-8651
82-42-934-8368
[email protected]
http://chungcheong.irpe.or.kr
S
ADD
TEL
FAX
URL
E
X
H
I
B
I
T
S
충청북도 바이오산업 현황 및 육성시책 등
E
X
H
I
B
I
T
S
medicine and medical supplies
I
N
T
R
O
D
U
C
T
I
O
N
지방자치단체
의약품
I
Chungcheongbuk-do
N
-to educate and train students to become leading opinion
leaders in the area of Pharmaceutical R&D, Regulation,
and Pharmaceutical management of technologies.
-to contribute to the advancement of the pharmaceutical
sciences based on multidisciplinary knowledge through
outreach and public service.
I
N
T
R
O
D
U
C
T
I
O
N
충청지역사업평가원은 충청지역의 강소기업육성을 목표로 광역경제
권선도육성사업 등을 운영하고 있으며 바이오 분야 중 의약바이오
선도산업 지원을 통한 지속성장형 의약바이오 산업 성장동력 창출을
목표로 생물의약품, 합성의약품, 소재, 동물의약품 분야의 기업들을
지원 하고 있습니다.
-제약기업의 R&D관리, 인허가, 기술경영 등 사업화에 있어 핵심역
할을 담당할 석박사급 전문 인력 및 기업에서 혁신리더로 성장할
수 있는 중간 관리자 양성
-글로벌 신약 개발 능력의 혁신성을 높이기 위한 산업체의 인재수
요에 부응하기 위해 약학•의학•경영•법학 등 다학제간 융합지
식을 갖춘 석박사급 전문인재 양성
104
105
E10
P25
L10
B40
ChungDo Pharm. Co. Ltd.
Chungnam Technopark Bio Center
CMC Biologics
CnS
(주)청도제약
(재)충남테크노파크 바이오센터
씨엠시 바이올로직스
(주)씨엔에스
CEO
ADD
TEL
FAX
E-MAIL
URL
Kim Sung-Jin 김성진
202 Hi-Tech Venture Town, 198-53 Hupuyeongdong, Chuncheon, Gangwon-do 200-160, Korea
82-10-2840 4002
82-303-0950 5878
[email protected]
http://www.ichungdo.com
CEO
ADD
TEL
FAX
E-MAIL
URL
Jang Woncheol 장원철
Daehangno 121, Nonsan-si, Chungnam
82-41-980-5461
82-41-735-5629
[email protected]
http://ctp.or.kr/
http://cnasc.or.kr
CEO
ADD
TEL
FAX
E-MAIL
URL
I
E
X
H
I
B
I
T
S
1. Urine test strip & reader
2. Diet-Test Strip
3. Blood Glucose Monitoring System
I
N
T
R
O
D
U
C
E
X
H
I
B
I
T
S
Biomaterials
바이오소재 (동물약품, 건강기능성식품, 화장품 외)
T
I
O
N
I
N
T
R
O
D
U
C
T
I
O
N
N
Claes Glassell
Vandtaarnsvej 83B DK-2860 Soeborg Denmark
45-7020-9470
45-7020-9476
[email protected]
www.cmcbio.com
T
R
O
D
U
C
T
I
O
CEO
ADD
TEL
FAX
E-MAIL
URL
N
E
Ji-sun, Im 임지순
3, Daewharo178, Daedeok-ge.Daejeon, korea
82-42-670-8054
82-42-633-8056
[email protected]
http://www.biocns.com
X
H
I
B
I
2001 년 코펜하겐에 설립된 이후, 생물학적 생산시설인 ICOS Lab, Pilot - fermenter, S, M, B
Biologics를 2007년에 시애틀, 워싱턴에, 2012년에는 버클리, 캘
리포니아에 XOMA를 설비하였고 지금은 400명의 직원들과 함께
N
T
R
O
D
U
C
T
세계 주도적인 CMO가 되었습니다. 임상 전 연구, 임상시험 그리고 I
시장생산을 위한 단백질 기반 치료법의 cGMP 제조를 위한 custom Microbial fermentation, culture apparatus
service를 전문으로 합니다.
T
I
S
O
N
Since 1991, we have exported urine test strip & reader, Diet Chungnam Techno Park Bio Center was established by the
test strip and Blood glucose monitoring system in the world Ministry of Knowledge and Economy. We are a regional
market
center specializing in animal resources. CTP Bio-Center
shall create the 21st.Century“Mecca” of industrial support
1991년 이래 소변검사지 및 분석기, 다이어트검사지, 혈당기를 세계 for agri-businesses related to livestock feed, food and
시장에 수출하고 있는 진단제품 전문기업.
meat processing by networking and co-operation with
industries, universities, R&D centers and governmental
agencies. We conduct to research to support animal related
companies & institutes, by networking and clustering so
that domestic animal industries will become stronger and
more competitive internationally as well as increasing the
economic power of Chungnam province.
한국 바이오산업의 메카 (재)충남테크노파크 바이오센터는 충남지역
의 바이오관련 기술개발, 마케팅, 시제품 개발 등 각종 사업화 지원을
통해 그린바이오 중심의 우수기업 육성을 추진하고 있습니다. 바이오
센터에서는 동물약품, 건강기능성식품, 화장품, 사료첨가제분야 등에
대한 지원기업인 다인네추럴, HvBio, 모든스킨, 하이드로비티 등 6
개 기업의 제품을 출품하였습니다.
106
107
K30
L10
Convergence Technology Exhibition
(Korea Health Industry Development Institute)
융복합 기술전시관 (한국보건산업진흥원)
ADD
TEL
FAX
E-MAIL
URL
E
Covance Laboratories Korea Ltd.
코펜하겐 캐퍼시티
(주)코씨드바이오팜
코반스래버래토리 코리아(주)
CEO
H
I
B
I
T
S
Creative convergence and advanced HT product and
service (HI Korea Invest Fair 2013)
보건산업 창조적 융복합 기술 및 제품
N
Claus Lønborg
Nørregade 7B DK-1165 Copenhagen K Denmark
45-3322-0222
[email protected]
www.copcap.com
T
R
O
하겐에 자리를 잡고자하는 모든 회사들이 비지니스기회를 획득할
수 있도록 한다. 모든 외국회사들에게 서비스는 열려있으며, 무료이
다. 제공하는 서비스의 항목으로 는 시장개요, 산업지식, 신생기업
관련 서비스, 땅 및 재산과 관련된 리서치, 파트너 및 매칭시스템을
포함해 코펜하겐에 대한 비지니스케이스를 만드는 데에도 도움을
준다.
CEO
ADD
TEL
FAX
E-MAIL
URL
Choi Ok Gyu 최옥규
38, Wolgok-Gil, Gangnae-Myeon, CheongwonGun, Chungbuk, 363-792, South Korea<#103, 3rd
building of Business Incubation Center>
82-43-274-9097
82--43-274-9098
[email protected]
http://www.coseed.co.kr
D
U
C
T
I
O
N
Advanced HT Showcase; displays and promotes the
advanced HT products and services and provides
consultation and media interview to foster investment in
HT industry.
국내 보건산업 기업의 기술투자 및 파트너쉽 기회 제공을 위해 개최
되는 ‘HI Korea Invest Fair’와 연계하여 우수기술 전시, 홍보, 기술
정보교류, 미디어 인터뷰, 투자상담 및 기술 포스터전시 등을 운영.
CEO
ADD
TEL
FAX
E-MAIL
URL
E
E
X
H
I
B
I
T
Joe Kim 김용균
2F, Songnam BD, #1358-6, Seocho-dong, Seochogu, Seoul 137-862 Korea
82-2-503-0780
82-2-503-0515
[email protected]
http://www.covance.com
X
H
I
B
I
T
S
S
Non-clinical study, CMO/CMC service, Biotech service, BioCosmetic ingredients - Snail secretion Filtrate, Cosmetic analysis, Regulatory services for US & EU, Phase I clinics,
preservative, Schizandra chinensis Fruit Extract, Forsythia Global Clinical studies.
suspensa Fruit Extract.
Chemical/Biologics의 비임상 시험과 US IND, EU EMEA filing
화장품 원료-달팽이점액여과물, 화장품 방부제, 오미자추출물, 연교 service, Covance 자체 Clinic에서의 Phase I study를 수행하고
있습니다.
추출물,버섯콜라겐
(HI Korea Invest Fair 연계)
I
CoSeedBioPharm Co., Ltd.
KO Kyung-hwa 고경화
1 87 Osongsaengmyeong2 (i)-ro, Osong-Eup, TEL
Cheongwon-gun, Chungcheongbukdo 363-951, E-MAIL
URL
KOREA
82-43-713-8273
82-43-713-8908
I
N
T
R
O
D
U
C
T
I
O
N
[email protected]
투자증진, 비지니스시장확보 및 클러스터성장을 위해 설립된 덴마
http://www.khidi.or.kr
크케피탈(Danish Capital)지역의 기관이다. 비영리기구로써 코펜
X
O20
Copenhagen Capacity
ADD
CEO
Q14
I
N
T
R
O
D
U
C
T
I
O
N
Established in April 2006
-Certified ISO9001(Quality Management System) and
ISO14000 (environmental management system)
- Business certified as INNO-BIZ
- We've been producing 500 Oriental herb extracts.
-We have 18 patents about cosmetic materials including
natural substances as main ingredient.
-We have the efficacy and safety evaluation system and
capacity to develop new cosmetic materials.
-We are scheduled to move into Osong High-Tech
Medical Integrated Complex. (4630m2 -2013.11)
또한 CMC (Radio-synthesis, CMO업무포함), Phase II & III 그리
고 Phase IV에 이르기까지 신약 개발과 관련한 거의 모든 써비스를
제공하고 있습니다.
I
N
T
R
O
D
U
C
T
I
O
N
Covance is one of the world’s largest and most
comprehensive drug development services companies
with more than 10, 000 employees in 60 countries.
Through its nonclinical, clinical and commercialization
services, Covance has helped pharmaceutical and biotech
companies develop one-third of all prescription medicines
in the market today.
1940년 미국에서 설립되었으며, CMC, 독성시험 및 임상시험 대행
- 2006년 4월 법인설립
- 화장품 원료 개발 및 생산기업.
- ISO9001(품질경영시스템), ISO14000(환경경영시스템) 획득
- INNO-BIZ 인증기업.
- 150여 품목의 한방추출물 소재 보유.
-천연물질의주요성분을 함유하는 화장료 조성물에 관한 특허등록
18건.
- 자체 소재개발 및 평가시스템 구축.
- 오송첨단의료복합단지 연구소입주 확정(4630m2)
108
업체입니다. 미국, 영국, 프랑스, 독일에 독성쎈터를 운영하고 있으
며, 영국에 Radio labeling synthesis, 프랑스에 Chemical CMO,
독일에 영장류 쎈터를 운영하고 있습니다. Phase I 을위해 미국 에 (
하와이포함) 10여개 Covance clinic과 스위스/영국에도 Covance
clinic을 운영하고 있습니다.
또한 전세계 60여개국에 지사를 운영하고 있으며, 약 1만여명의 직
원이 일하고 있습니다. 명실상부한 가장 큰 global CRO중 하나이
며, 전년도 매출은 2조5천억원을 기록하고 계속 성장하고 있습니다.
Compound search부터 CMC, 독성시험, IND-filing service,
Phase I, II, III, IV까지 one-stop-service를 지향하고 있습니다.
109
R23
M38
CRH (Converging Research Headquarter) for
Bio-Pharmaceuticals
바이오제약사업본부
CEO
ADD
TEL
FAX
E-MAIL
URL
Criyagen Agri & Biotech Pvt. Ltd.
CEO
Kim Jung-hoe 김정회
Rm905, Main Building, Kaist ICC, 119, Munji-ro,
Yuseong-gu, Daejeon
82-42-350-8414
82-42-350-8410
[email protected]
http://bph.kaist.ac.kr
ADD
TEL
FAX
E-MAIL
URL
X
H
I
B
I
T
S
Panels, brochures
I
N
T
R
O
D
U
C
T
I
O
Dr. Basavaraj Girennavar
Lab 210, IABT, University of Agricultural Sciences,
Dharwad-580005,Karnataka,India
91-9741414048
91-8362446616
[email protected]
http://www.criyagen.com
N
T
R
O
D
U
C
T
I
O
N
Criyagen Agri & Biotech Private Limited, Bangalore, India is
working in the field of Research and development of new
generation biofertilisers, Micro nutrients, plant growth
promoters and hormones.
G32
CRYO DIFFUSION
DAE HWA PHARMACEUTICAL Co., Ltd.
크리오 디푸젼
대화제약 주식회사
CEO
ADD
TEL
FAX
E-MAIL
URL
Phiippe Doinel
49 rue de Verdun, 27690 Lery France
33 2 32 59 62 25
33 2 32 59 00 65
[email protected]
vwww.cryodiffusion.com
CEO
ADD
TEL
FAX
E-MAIL
URL
I
I
E
N30
N
T
R
O
D
U
C
T
I
O
Han-Koo, Lee 이한구
495, Hanu-ro, Hoengseong-eup, Hoengseonggun, Gangwon-do, Korea
82-2-6716-1071~3
82-2-588-3111
[email protected]
http://www.dhpharm.co.kr
N
X
H
I
With more than 50 years of experience Cryo Diffusion has E
developed the most complete range of cryogenic products Plasters, Cataplasma, Patch. etc.
B
I
T
S
50년 이상의 경험을 바탕으로 Cryo Diffusion는 가장 완벽한 극저 첩부제, 카타플라스마, 패취제 등
온 제품들을 개발했다.
N
The Converging Research Haedquarter for BioPharmaceuticals located at KAIST ICC in Daejeon carries
out the Converging Reserch Project for Bio-Pharmaceuticals
with the three Converging Research Centers such as
Bio-molecular process Engineering, BiopharmaceuticalsTailored DDS, and CTC based Cancer Prognosis and
Diagnosis. The headquarter was selected in 2009 as a part
of New Technology Convergence-gype Growth Engine
Program (government program) with an aim to promote
converging researches in the BT sector.
대전 카이스트 문지캠퍼스에 위치한 바이오제약사업본부는 교과부
신기술융합형성장동력사업의 일환으로 2009 선정되어 우리본부가
관리하는 3개의 융합연구단이 (‘분자생물공정 융합연구단’, 바이오의
약품 맞춤형 약물 전달시스템 융합연구단’, ‘혈중 암세포 암예후 진단
융합연구단’) 바이오제약분야의 융합 연구를 수행하고 있습니다.
I
N
T
R
O
D
U
C
T
I
O
N
DAEHWA has been steadily endeavoring to meet
your expectation to have a healthful life and escape
from a hazard of disease. We supply the best quality
pharmaceutical products to the people who earnestly need
them, and realize the dignity of human life through our
research and development. “Nothing is more precious and
valuable than life.” is our permanent spirit and goal.
DAEHWA Pharmaceutical Co., Ltd. was established in 1984
and with the completion of the c-GMP facilities in 2009,
we are striving to produce high quality pharmaceutical
products from“ Raw Material” to “Finished Products”.
1984년 1월 19일 대화제약 (주)를 설립하여 현재까지 의약품을 제
조 판매하는 중견기업으로 강원도 횡성공장 및 향남공장에서 정제,
경질캡슐제, 연질캡슐제, 연고제, 주사제, 플라스타 (파스) 등 150여
품목의 제품을 생산 판매하고 있습니다.
꾸준한 R&D 투자를 통해 경구용 항암제 (DHP107)의 성공적인 임
상시험 완료와 약물전달시스템 (DDS) 기술을 활용한 전문의약품용
패치형 제품을 비롯한 고부가가치 신제품 개발에 역량을 집중하고
있습니다.
“생명력의 극대화, 인간다움의 추구, 긍지와 베품”이라는 사훈과 기
업이념을 실천하고, 주주중시의 경영과 함께 좋은 의약품 개발에 최
선을 다하며 미래 가치를 향상시키는 기업입니다.
110
111
O25
G40
DAE YOUNG FOODS CO, LTD.
Daegu-Gyeongbuk Medical Innovation
Foundation
대영식품(주)
CEO
ADD
TEL
FAX
E-MAIL
URL
D47
Jong Rok, Lee 이종록
32 Geum gu 4Gil, Bo eun-eup, Bo eun-gun, Chung
cheng buk-do, South Korea
82-2-409-6900
82-2-409-6300
[email protected]
http://www.daeyoungfoods.co.kr
대구경북첨단의료산업진흥재단
CEO
ADD
TEL
E-MAIL
URL
DAEJEON TECHNOPARK
Daewon Pharm.Co., Ltd.
(재)대전테크노파크
대원제약
CEO
You Seung Kim 김유승
701-310, 88, Dongnae-ro, Dong-gu, Daegu, Korea
82-53-790-5114v53-790-5189
[email protected]
http://dgmif.re.kr
http://medivalley.re.kr
ADD
TEL
FAX
E-MAIL
URL
E
E
X
H
I
B
I
T
S
E
X
H
I
B
I
T
S
Chewing Gum Items (sugarless and functional), Promotion exhibition
Compressed Candies (Breath Freshener)
대구경북첨단의료산업진흥재단 및 대구경북첨단의료복합단지 홍보
자료
츄잉껌류 및 캔디류
I
N
T
R
O
D
U
C
T
I
O
N
I
N
T
R
O
D
U
C
T
I
O
N
1984년 8월 설립된 대영식품 (주)은 꾸준한 발전을 거듭하여 현재 ※Contribution to Korean medical industry by fostering
충청북도 보은군에 위치한 제1, 2, 3공장 (2013년 4월 준공) 및 연구
Medivalley as a global medical R&D hub. Medivalley
개발실에서 껌류, 초콜릿가공품, 캔디류를 생산하여 할인점, 편의점,
is a medical cluster that is being created as a way of
특수유통에 NB제품 및 PB제품으로 공급 하고 있으며, 수출을 통하여
developing new, high-tech medicines and medical
해외시장에서도 제품의 품질을 인정받고 있는 강소 기업입니다.
equipment.
좋은 환경에서 안전한 제품이 생산된다는 신념아래 ISO9001 및
HACCP (2011년 8월) 인증을 획득하였으며, 자체 냉장 창고를 운영
하여 보다 신선한 제품을 위한 품질관리에 최선을 다하고 있습니다.
특히 최근에는 바이오테크닉을 결합한 여러가지 형태의 기능성 제품
개발에 박차를 가하고 있으며, 자사 브랜드인 "SWEETORY"를 통한
국내 및 해외시장 개척에 더욱 정진하고 있습니다.
현재 대영식품 (주) Main Category인 Gum류 시장 규모는 2003
년이후 자일리톨껌 위주의 기능성 제품 운영으로 2, 300억-2, 400
억 수준의 매출을 유지하고 있으며, 자사는 철저한 시장 세분화 전
략으로 이마트 PL제품과 코스트코코리아등 국내 주요 Channel 및
Account에 판매중에 있으며, 국내 유일 일본 껌시장 개척을 통해 연
간 100억이상의 껌 매출을 달성 (저스코, 무지등)하고 있습니다.
자사의 주력 제품군인 껌류에서는 아직 트랜드 변화 및 컨셉 차별화
포인트가 지지 부진하여, 자사가 기획하고 2009년 런칭한 "이마트 졸
음깨는껌" 출시로 기능성 시장의 리딩 구현이 가능하다고 봅니다.
또한 2011년 "이마트 천연치클껌" 과, 2012년 껌의 Long -Lasting
및 츄잉성 강화 제품 (진라임스타일, 아로마틱스타일)을 국내 시장 및
수출 시장에 런칭하여 매출 증가에 기여 하고 있습니다.
이번 "바이오 코리아 2013"에 기능성 CONCEPT을 응용한 츄잉껌 6
종 (졸음깨는껌, 화이트닝, OUR VITA, 니코프리, 에너지업, 후레쉬
브레스)과 기능성 TABLET 7종 (OUR VITA VITAMINE-A, B, C, D,
E, 칼슘, 루테인)을 출품하여, 기능성 소재의 제형 변화에 대한 고객의
소구 정도 및 건강기능식품군으로의 확대성을 통한 신성장 동력을 창
출할 기회로 보고 있습니다.
112
※대구경북첨단의료복합단지 (Medivalley)는 국가 주도의 프로젝
트로 신약과 의료기기 산업을 전략적으로 육성하기 위해 조성되는
첨단의료산업 클러스터입니다.
DGMIF (대구경북첨단의료산업진흥재단)은 Medivalley의 성공
적 조성 및 발전을 위해 설립된 연구지원기관입니다.
E36
Park Jun-byeong 박준병
305-811 대전시 유성구 유성대로 1662
82-42-930-2880
82-42-930-2889
[email protected]
http://www.daejeontp.or.kr/english/index.php
X
H
I
B
I
T
CEO
ADD
TEL
FAX
E-MAIL
URL
S
I
N
Baek, Seung Ho/ Baek, Seung Ryel 백승호, 백승열
386, Cheonhodaero, Sungdong-gu, Seoul, Korea
82-2-2204-6926
82-2-498-9151
[email protected]
http://www.daewonpharm.com/en
T
R
O
D
U
C
T
I
O
N
Completed product and base material GMP medicine and Since the establishment in 1958 with a founding idea of
medical supplies sample and PR (public relations) catalog “realization of human health”, Daewon Pharm. Co., Ltd.
etc.
has made the best efforts for human health and happiness
through manufacturing and providing specialized
완제 및 원료 GMP 의약품 샘플 및 홍보 카달로그 등
medicines. We produce reliable and safe medicines by
securing world-class manufacturing facilities and superior
R&D capabilities. With its first export to Vietnam in
I
N
T
R
O
D
U
C
T
I
O
N
1994, Daewon Pharm. Co., Ltd. has made eye-opening
Nano and bio businesses by establishing infrastructure and achievements of exports. Now, we export out products
clusters in the functional nano materials and bio industries. to 35 countries including major Asian countries such as
The bio and nano industries are supported through joint China, Latin America, Middle East, CIS, and Africa. Daewon
Pharm. Co., Ltd. is exporting about 50 products and is
R&D, education/training and business networking.
expanding its export volume with products such as Pelubi
나노소재 및 바이오산업의 인프라와 클러스터 구축을 통해 나노 및 tablet, a new chemical entity, and Oramin Capsule, multi바이오 관련기업을 지원하는 기관입니다. 공동연구개발, 교육훈련, vitamin supplement with Korean Ginseng.
기업 간의 네트워크 등을 주도함으로써 바이오나노산업의 거점이 되
겠습니다.
대원제약은 1958년 ‘인류건강의 실현’이라는 창업이념을 바탕으로
설립되어 창업초기부터 현재까지 전문치료제만을 생산, 공급함으로
써 인류의 건강과 행복을 위해 최선을 다해 온 기업입니다. 세계적인
수준의 생산시설과 우수한 R&D 역량을 보유하고 있으며, 현재 아시
아 주요국가와 중남미, 중동, CIS, 아프리카 등 약 35개국에 의약품
을 수출하고 있습니다. 대원제약은 순환기계, 호흡기계 등 모든 치료
영역에 사용할 수 있는 전문치료제를 생산하고 있습니다.
113
G37
Q15
P24
L10
Daewoong Pharmaceutical Co., Ltd.
DAEYON CHEMICALS Co., Ltd.
DAIN NATURAL Co., Ltd.
Dako
대웅제약
대연화학(주)
(주)다인내추럴
다코
CEO
ADD
TEL
FAX
E-MAIL
URL
Lee Jong Wook 이종욱
135-715, 163-3 Samsung-dong, Kangnam-gu,
Seoul, Korea
82-2-550-8533
82-550-8660
[email protected]
http://www.daewoong.com/
CEO
김연두
CEO
ADD
69 Jersey Avenue, New Brunswick, NJ 089017
3605 USA
82-31-702-8734
82-2-3482-8761
[email protected]
http://www.spectrumchemical.com
ADD
TEL
FAX
E-MAIL
URL
TEL
FAX
E-MAIL
URL
Hwang Incheol 황인철
130-33, Gasong-ro, Pungse-myeon, Dongnam-gu,
Cheonan-si, Chungcheongnam-do, 330-913
82-2-3436-1589
82-2-421-1599
[email protected]
http://www.momejon.co.kr
CEO
ADD
TEL
FAX
E-MAIL
URL
I
E
X
H
I
B
I
T
S
Chemical: URSA, Albis, Luphere, Olostar
Biological: Easyef, Caretropin, Nabota
E
X
H
I
B
I
T
S
Bio Chemical
USP/NF, EP, BP, JP Pharmaceutical reagent
HPLC / GC solvents
Bio Chemical
Chemical: 우루사, 알비스, 루피어, 올로스타 등
Biological: 이지에프, 케어트로핀, 나보타 등
N
T
R
O
D
U
C
T
I
O
I
N
T
R
O
D
U
C
H
I
B
I
T
S
N
T
R
O
D
U
C
T
I
O
N
1966년에 덴마크 의사인 Niels Harboe가 설립하였으며, 그는 임
상활용을 위한 항체의 표준화에 선구적 역할을 했습니다. 그 이래로,
Dako는 체외 진단 산업의 병리학 부문에서 선구적 역할을 하며 글
health functional food
로벌 기업으로 성장해왔으며 본부를 덴마크에 두고 미국에도 진출하
였고 시약과 기기, 소프트웨어들은 100군데 이상의 시장에서 팔리고
있습니다.
I
N
Established in 1945, Daewoong Pharmaceuticals is
a leading pharmaceutical company in South Korea,
which maintains the No. 1 position in prescription drug
market domestically and also has a steady presence in
East Asia, as a result of our strong marketing and sales
division. With $1.3 billion USD group revenue, and over
2, 000 employees, we have built a strong internal core
competency for new drug development and cultivated
valuable collaborations, not only regionally, but also
globally. Aiming to become a global healthcare company,
Daewoong has broadened international operations by
strategically establishing branch offices throughout Asia
and the United States, and research centers in China and
India, besides Korea.
X
건강기능성식품 외
USP/NF, EP, BP, JP 약전용 시약, HPLC / GC 고순도 용제
I
E
Lars Holmqvist
Produktionsvej 42 DK-2600 Glostrup Denmark
45-4485-9500
45-4485-9595
[email protected]
www.dako.com
T
I
O
N
Spectrum manufactures and distributes 15, 000 fine
chemical products and 2, 000 USP/NF, BP, EP, JP, FCC grade
products.
The California and New Jersey plants are also FDA
registered drug establishments and operate under current
Good Manufacturing Practices (cGMP).
1971년 미국 캘리포니아 주에 설립되었으며 15, 000여 종의 정밀
화학 제품과 2, 000여 종의 USP/NF, BP, EP, JP, FCC grade 제품
은 제약, 식품 업체의 개발, 생산에 널리 사용되고 있습니다.
N
T
R
O
D
U
C
T
I
O
N
DAIN NATURAL Co., Ltd. performs health food research,
distribution, manufacturing.
Business: New functional food discovery, analysis and
efficacy evaluation DAIN NATURAL Co., Ltd. was exhibiting
products (The Root’s omega-3; ginseng oil-containing,
Ginkgo onion juice; omega-3 containing)
(주)다인내추럴은 건강기능식품 연구, 유통, 제조 등 건강기능식품 전
반적인 분야에 걸쳐 활발한 활동을 하고 있는 업체로 새로운 식품소
제를 탐색, 분석, 효능평가 하는 등의 노하우를 보유하고 있어 건강기
능식품 시장에서 차별성 있는 기술과 제품 개발에 매진하고 있습니다.
(주)다인내추럴에서는 인삼오일이 함유된 뿌리담은 오메가-3와 오메
가-3가 함유된 은행잎 담은 양파즙 제품을 출품하였습니다.
cGMP 요구에 부합되며 미국 FDA와 ISO9001:2008 인증 통과 제
품은 고객이 원하는 최상의 품질을 유지하고 있습니다.
대웅제약은 국내 상위 제약사 중 하나로 영업력과 마케팅력을 바탕
으로 처방 시장에서는 1위를 차지하고 있습니다. 중국, 베트남, 필리
핀, 태국, 인도네시아 등의 아시아 국가에서 해외 지사를 운영 중이
며, 그 외의 많은 국가와도 케미컬, 바이오 의약품, 의료기기 등을 가
지고 해외 사업을 활발히 하고 있습니다.
114
115
D40
G47
무재선충)을 방제하기 위한 약제의 개발을 진행하고 있으며, 현재 중
국 황산지역에서 최종 필드 테스트를 진행중입니다.
두번째로, 탈모를 방지하고, 발모를 유발하는 신규 물질을 개발중입
Dbio.Inc
(주)대덕바이오
CEO
ADD
TEL
FAX
E-MAIL
URL
Sung Chang-Keun 성창근
#411, Agriculture B&B Center, Chungnam National
University, Gung-dong, Yusung-gu, Daejeon,
Korea
82-42-821-6722
82-42-822-2287
[email protected]
http://www.dbio.co.kr
니다. 현재 개발된 신규물질 (Grd301)은 인삼으로부터 발견한 물질
로서, 기존 발모제보다 그 성능과, 안정성이 우수합니다. 현재 임상시
험 중이며, 대한민국 내에서는 Hair Tonic과 Hair Shampoo의 형
태로 제품을 출시하였습니다.
세번째로는, 양파, 마늘, 멜론 등 박류 식물의 뿌리에 기생하는 뿌리
혹선충 방제약제의 개발입니다. 이는 천연물로부터 추출해낸 물질을
주원료로 생산되며, 뿌리혹선충을 방제하고 토양의 지질을 개선하여
작물 생산성을 친환경적 (화학농약이 아님)으로 증대시킵니다.
M34
Darae Law & IP firm
특허법인다래
CEO
ADD
TEL
FAX
E-MAIL
URL
X
H
I
B
I
T
S
Functional Food
Functional Rice
Hair Shampoo & Tonic
N
T
O
D
U
C
T
I
O
N
DBIO, Inc. is a Bio-venture company established in 2, 000.
Our company is founded by Chungnam National University
professors.
We are searching and marketing the new bio materials
through the unique R&D model. Twenty researchers are
the mainly focusing three different topics. Firstly, how to
protect pine tree from the pandemic pine wilt disease in
Asia and Europe. This technology is now field testing in
the Mt. Whang of China. Secondly, how to activate the
epidermal hair follicle cell for bald peoples? Identified
compounds (Grd301) are now in the stage of preclinical
phase, also in the market as a hair tonic. Thirdly, root
nematode could be easily controlled in onions, pepper,
garlic farming. This company is now very success in
marketing with this cash cow products. We are now very
much interested in introducing to international markets.
주식회사 대덕바이오는 2000년에 설립한 국립충남대학교 교수창업
바이오-벤처기업입니다.
당사는 특별한 연구개발모델을 통해 신슈 바이오소재를 끊임없이 탐
색하고, 개발하고 있습니다. 20여명의 전문연구원들이 각기 다른 3
가지 주제를 가지고 연구를 수행중입니다.
첫째로, 아시아와 유럽에 걸쳐 널리 발병중인 소나무시들음병 (소나
116
H
I
B
I
T
CEO
ADD
TEL
FAX
E-MAIL
N
T
R
O
E
X
H
I
B
I
T
S
M 34
I
D
Dr. K. Vijay Raghavan
Ministry of Science & Technology, Block 2, 7th floor,
CGO Complex Lodhi Road, New Delhi 110003,
India
91-11-24365972
91-11-24362884
[email protected]
http://www.dbtindia.nic.in
S
Daraelaw Brochure
Introduction of BT technology
I
R
X
다래 회사 소개
기술이전 대상 기술 홍보자료
건강보조식품
기능성 쌀
기타 화장품
I
Seung-Moon Park 박승문
1 35-080 10th, KIPS, 647-9 Yeoksam-Dong,
Gangnam-Gu, Seoul
82-2-3475-7701
82-2-3475-7778
[email protected]
http://www.daraelaw.co.kr/
URL
E
E
DEPARTMENT OF BIOTECHNOLOGY
(Government of India)
U
C
T
I
O
N
Darae is the 1st IP specialized firm in korea. We strategically
approach every issue with a consideration of not only short
term consequence, but also contractual, regulatory and any
potential risks.
Every matter is thoroughly handled by an integrated team
of attorneys, technical advisers and supporting staffs. The
final review of documents by partners and senior associates
ensure our clients succeed.
Comprehensive one-stop service: A complete service from
filing of application to resolving of disputes in relation to IP
Rights of our clients.
The industry and medial recongnize DARAE’s excellence in
the area of IP. Best IP law firm by chamber & partners (Asia),
2008, 2009, 2010, 2012.
다래는 특허법원 판사 출신 변호사, 특허심판원 심판관 출신 변리사 중
심으로 설립되었으며, 2008~2012년 5년 연속으로 Chambers Asia
에서 국내 최고의 지적의 지적재산권 전문 로펌으로 선정되었습니다.
사업범위는 특허출원 부터 R&D 기획단계에서의 특허전략, 특허맵,
선행기술조사, 대학 기업 보유특허평가 및 자산실사, 등의 IP 컨설팅,
기술사업화 및 마케팅 활동 뿐아니라 지적재산권의 법률 분쟁해결
까지 지적재산권 관련한 전부분야를 포함하고 있습니다.
N
T
R
O
D
U
C
T
I
O
N
The Department of Biotechnology (DBT), under the
Ministry of Science and Technology was established in
1986 to give a new impetus to the development of the
field of modern biology and biotechnology in India.
The department has made significant achievements
in the growth and application of biotechnology in the
broad areas of agriculture, health care, animal sciences,
environment, and industry. The department has more than
14 autonomous institutes. The impact of the biotechnology
related developments in agriculture, health care,
environment and industry, has already been visible and the
efforts are now culminating into products and processes.
More than 5000 research publications, 4000 post-doctoral
students, several technologies transferred to industries
and patents filed including US patents. Department of
Biotechnology (DBT) has been interacting with more than
5, 000 scientists per year in order to utilise the existing
expertise of the universities and other national laboratories.
Necessary guidelines for transgenic plants, recombinant
vaccines and drugs have also been evolved.
※ space included, within 150 characters
특히, BT 분야는 미래창조부의 R&D 우수성과물을 대상으로 기술사
업화 과제를 진행하여 성공적인 성과를 도출한 경험을 보유하고 있
습니다.
117
E40
G30
Department of Industrial Pharmaceutical
Science, School of Pharmacy,
SungKyunKwan University
ADD
TEL
FAX
E-MAIL
URL
E
X
H
I
Dongguk Medical Device Innovation Center
동화약품
동국대학교 의료기기 개발촉진 센터
ADD
Eui-Kyung Lee
2066 Seobu-ro, Jangan-gu, Suwon, Gyeonggi-do
440-746, Korea
82-31-299-7786
82-31-292-8800
[email protected]
http://pharmind.skku.edu/index.asp
B
I
T
S
Video contents and PR leaflet for graduate school of
industrial pharmaceutical science at SungKyunKwan
University
L32
DONG WHA PHARM
CEO
성균관대학교 제약산업학과
CEO
A10
TEL
FAX
E-MAIL
URL
Je Hwa Park 박제화
5 Soonwha-dong, Joong-gu, Seoul Korea
82-2-2021-9300
82-2-778-2336
[email protected]
http://dong-wha.co.kr
Kim Sung Min 김성민
425 Industry & Academy Collaboration Foundation
Dongguk Univ. 814 -9 Siksa-dong, Ilsandong-gu,
Goyang-si, Gyeonggi-do, Korea
82-31 961 5605
82-31 961 5610
www.dmicweb.or.kr
CEO
ADD
TEL
FAX
URL
E
X
H
I
B
I
T
I
자보플록사신, 까스활명수
N
T
R
O
D
U
C
T
I
두바이 제약 및 제약기기 전시회 & 컨퍼런스
CEO
ADD
TEL
FAX
E-MAIL
URL
Abdul Salam Al Madani
#504, 503 Nonhyun-ro Gangnam-gu Seoul Korea
82-2-6000-4718
82-2-6499-1027
[email protected]
http://www.duphat.ae
S
Zabofloxacin, Gas Whal Myung Su-Q
I
Dubai International Pharmaceuticals and
Technologies Conference and Exhibition
O
N
Established as the first Korean pharmaceutical company
in 1897, Dong Wha remained committed to bringing
성균관대학교 제약산업특성화대학원 소개 동영상 및 홍보 리플렛
happiness to customers and employees with its
management focucing on happiness of people.
R&D Pipeline
I
N
T
R
O
D
U
C
T
I
O
N
Quinolones Antibiotics Zabofloxacin (DW224) - Phase III
The graduate school of industrial pharmaceutical science at
Diabetic Nephropathy DW1029 - Phase II
SKKU was established by Ministry of Health and Welfare’s
support to accelerate new drug development and global
동화약품은 1897년 대한민국 최초 제약기업으로 설립된 이래 인간
expansion of domestic pharmaceutical companies in 2012.
행복 경영을 통하여 고객 및 직원 모두의 행복을 추구하여 왔습니다.
The graduate school has been focusing on educating and
연구소는 1973년 설립되어 까스활명수, 후시딘연고, 판콜 등 많은
training the elite who can lead the” age” of pharmaceutics.
신제품을 개발하였으며, 2010년 현재의 최첨단 연구소를 경기도 용
To achieve this, multidisciplinary(pharmacy, medicine,
인에 신축, 이전해 연구 기반을 한 차원 높이고, 신약과 신제품 연구
technology, business and law) convergent curriculum
에 매진하고 있다. 세계 최초 방사성 간암 치료제 '밀리칸주' 의 신약
for convergent education of 3 tracks(Regulatory affairs,
개발을 성공하였으며, 현재는 퀴놀론항균제 (DW224), 당뇨병성 신
Pharmacoeconomics and Management of pharmaceutical
증 치료제 (DW1029)의 개발을 통해 세계적으로 인정 받을 수 있는
technology) based on practices according to sciences and
동화의 두번째, 세번째 신약이 탄생 될 수 있도록 최선의 노력을 다
regulations has been developed and operated.
N
T
R
O
D
U
C
T
I
O
N
E
X
H
I
B
I
T
The Dongguk University Medical Device Innovation Center DUPHAT 2014
uses a web-based project management system called
‘I-Portal’ and seeks to discover growth tools for the medical 중동 유일의 제약 및 제약기기 전문전시회 DUPHAT 소개
device industry, such as surgical instruments, electronic
devices, communication network based U-health devices
I
N
T
R
O
D
U
C
T
I
and medical materials.
S
O
N
DUPHAT – Dubai International Pharmaceuticals and
Technologies Conference and Exhibition has evolved to be
one of the most important annual pharmaceutical event
(Surgical Instruments), 전기전자 의료기기 (Electronic devices), since its inception in 1995.The event is held under the
네트워크 통신망을 기반으로 하는 유헬스 의료기기 ( U-health patronage of H.H. Sheikh Hamdan Bin Rashid Al Maktoum,
devices), 의료용 재료 (medical materials) 등 미래 의료기기 산업 Deputy Ruler of Dubai, Minister of Finance, UAE and
의 성장 동력 아이템을 발굴하기 위해 노력하고 있습니다.).
President of Dubai Health Authority
동국대학교 의료기기 개발촉진센터는 ‘I-Portal’이라는 웹기반의 프
로젝트 관리 시스템을 갖추고, 수술에 사용하는 전문 시술용 기구
중동의 최대 제약 및 제약기기 전문전시회 DUPHAT에 많은 한국기
업들의 관심과 성원 부탁드립니다.
하고 있습니다.
성균관대학교 제약산업특성화대학원은 국내 제약기업의 신약 개발
및 글로벌 진출을 촉진하기 위해 2012년에 보건복지부 지원으로 설
립되었다. 제약산업 핵심인력 양성을 위해 의약품인허가/경제성평
가/제약기술경영 등 3개 트랙의 이론/실무 융합형 교육을 위해 다학
제적(약학, 의학, 공학, 경영학 등) 교육 커리큘럼을 개발하여 운영하
고 있다
118
119
L10
L22
L24
Ecron Acunova A/S
Embassy of Canada
에크론 아쿠노바
주한캐나다대사관
CEO
ADD
TEL
FAX
E-MAIL
URL
Klaus D. Wiedey
Agern Allé 13 DK-2970 Hørsholm Denmark
45-4516-8800
45-4516-8801
[email protected]
www.ecronacunova.com
ADD
TEL
FAX
E-MAIL
URL
1, Jeongdong-gil(Jeong-dong), Jung-gu, Seoul
2
100-120 Korea
82-2-3783-6000
82-2-3783-6147
[email protected]
www.korea.gc.ca
L21
Embassy of Poland Trade & Investment
Promotion Section
N
T
R
O
D
U
C
T
I
O
N
국제적인 임상시험수탁기관(CRO)이며, 덴마크, 스칸디나비아, 서유
럽뿐만 아니라 동유럽에도 그 지점을 보유하고 있으며 아시아에 국
가 및 미국에도 진출하였습니다. Phase I에서 Phase III, BA/BE와
PK/PD연구뿐만 아니라 임상연구에 구체적이고 다양한 경험을 토
대로 Scandinavian 대학시설과 다른 대형 병원들과 다양한 공동연
구를 하고 있습니다.
주한네덜란드 대사관
주한 폴란드대사관 무역/투자 진흥부
CEO
ADD
TEL
FAX
E-MAIL
I
Embassy of the Kingdom of the Netherlands
URL
CEO
Mr. Karol Peczak
D ongkyung B/d 4th F, #604, Hannam-dong,
Yongsan-gu, Seoul
82-2-3785-2471~2
82-2-797-0853
[email protected]
http://seoul.trade.gov.pl
ADD
TEL
FAX
E-MAIL
URL
E
E
X
H
I
B
I
T
S
Information
Paul Menkveld
10F Jeongdong Bldg., 15-5 Jeong-dong, Jung-gu,
Seoul, 100-784
82-2-311-8600
82-2-311-8650
[email protected]
http://southkorea.nlembassy.org/
X
H
I
B
I
T
S
General introduction to Dutch life sciences, one of the
Netherlands’ 10 top sectors, including Leiden Bio Science
Park
정보
네덜란드의 생명과학 분야 선두주자인 라이덴 바이오 산업 단지를
비롯한 바이오 산업 전반에 대한 소개
I
N
T
R
O
D
U
C
T
I
O
N
Our main mission is to strengthen business relations
between Poland and Korea. You can contact us if you look
for the best investment destination and reliable suppliers.
We offer the following information.
-T he information on the market and industry (the
information on Polish economy and each industry, fairs/
expositions
-Opportunity of the investment in Poland
-Business climate in Poland (regulations related to foreign
companies, privatization of the state-owned company,
taxation, labor market etc.)
-Contact points of producers, distribution companies,
associations in Poland.
-C ontact points of Special Economic Zone (SEZ),
technology and industrial park etc.
I
N
T
R
O
D
U
C
T
I
O
N
Embassy of the Kingdom of the Netherlands makes an
effort to strengthen business relations and promote
cooperation in science and technology between Korea
and the Netherlands. We have free service of providing
from general information to customized consultation
for the companies who are interested in extending their
business to the Netherlands. For research organizations and
universities, we hold a joint seminar and help to arrange
meetings for R&D matchmaking. We try to connect our
projects with the 9 top sectors designated by the Dutch
government and life life-sciences are one of them.
Leiden Bio Science Park is to be the focus of the exhibition.
Leiden Bio Science Park is the leading life sciences cluster
in the Netherlands and ranks among the top five most
주한 폴란드대사관 무역/투자 진흥부의 주요 업무는 양국의 비즈니 successful science parks in Europe. It is fully dedicated to
스 관계를 강화하는 것입니다. 최고의 투자처를 찾고 계시거나 신뢰 biomedical life sciences and offers opportunities for both
할 수 있는 공급업체를 찾고 계신다면 저희에게 연락을 주시기 바랍 start-ups and established companies.
니다. 저희는 다음과 같은 분야와 관계된 정보를 제공하고 있습니다.
-시장 및 산업정보 (폴란드 경제 및 각 산업분야에 관한 정보, 폴란
드 전시회 및 박람회 정보)
-폴란드 투자기회 (투자 인센티브 시스템 등)
-폴란드 비즈니스 환경 (외국인 비즈니스와 관련된 법률, 공기업의
민영화, 세법, 노동시장 등)
주한 네덜란드 대사관은 한국과 네덜란드 양국 간 비즈니스 관계를
강화하고, 과학기술 분야의 협력을 증진시키기 위해 노력하고 있습니
다. 특히 네덜란드 정부가 지정한 9개의 Top sector에 역량을 집중
하고 있는데, 생명과학도 그 중 하나입니다. 이번 전시는 유럽 지역에
서 가장 성공적인 5대 첨단 과학 단지 중 하나로 손꼽히는 라이덴 바
이오 산업단지를 중심으로 구성됩니다.
-폴란드 제조업체, 유통업체 및 협회 등의 연락처
-특별경제구역 (SEZ), 기술 및 산업 파크 기타 폴란드 기관 연락처
120
121
A35
B25
B36
E10
Encopharm
EU Gateway Programme Korea Office
Eubiologics Co., Ltd.
Farming association corp. BBKO
엔코팜
EU 게이트웨이 프로그램 사무국
유바이오로직스
영농조합법인 비비코
CEO
ADD
TEL
FAX
E-MAIL
URL
KIM KYUNG SOO 김경수
7 3-28, Singok2-dong, Daeheung Bldg 2nd F1
Uijeongbu-si, Gyeonggi-do, Korea
82-2-566-5772~3
82-2-555-0752
[email protected]
http://www.encopharm.net
CEO
ADD
TEL
FAX
E-MAIL
URL
Mr. Taesung Kim 김태성
(135-090) 5F., Trade Tower, World Trade Center,
Samsung-dong, Gangnam-gu, Seoul, Korea
82-2-6000-5208
82-2-6000-6702
[email protected]
http://www.eu-gateway.kr
CEO
ADD
TEL
FAX
E-MAIL
URL
Baik Yeong Ok 백영옥
200-160 BioVenture Plaza 3rd Floor 3-2, 3-3 56
Soyangang-ro, ChunCheon-si, Gangwon-do, Korea
82-33-258-6131
82-33-258-6135
[email protected]
http://eubiologics.com/
CEO
ADD
TEL
FAX
E-MAIL
URL
E
X
H
I
B
I
T
S
Translation Services Company for Bioindustries
바이오 산업 번역교정 전문회사
I
N
T
R
O
D
U
C
T
I
O
N
ENCO-PHARM is a translation company specialized for bio
and technological industries. The quality of ENCO-PHARM’s
translation service for clinical trial-related documents has
recently been recognized. We have signed contracts for
translation services with 200 institutions, including worldclass CROs such as Quintiles, CMIC Korea Co., Ltd., LG Life
Sciences Ltd., Donga ST, Daewoong Pharmaceutical Co.,
Ltd., and Pharmabcine. ENCO-PHARM has been signing
contracts with leading institutions in Korea for the past
five years, thanks to the support from a number of our
clients, which has helped us accumulate a rich experience in
translating different types of documents in a wide variety of
specialized fields. When you need consulting for translation
services in the bio and technological industries, please let
ENCO-PHARM help you. All the members of ENCO-PHARM
will always do our best to improve our services. Thank you.
E
X
H
I
B
I
T
S
The 2014 Exhibition promoting business cooperation
between EU and Korean companies, will take place at the
COEX InterContinental Hotel Harmony Ballroom on 11 and
12 March. Through the Programme, Korean visitors may
expect to get followings:
•Make new contacts and strengthen the relationships
with EU companies
•I d e n t i f y p o t e n t i a l s u p p l i e r s , s u b c o n t r a c t o r s ,
representatives, importers and distributors
•Discover current & future trends in the EU markets
2014년 3월 11일 (화)~12 (수) 코엑스 인터컨티넨탈 호텔 하모
니볼룸에서 개최되는 ‘2014 헬스케어/의료기술 전시상담회 (2014
Healthcare & Medical Technologies)’는 기술적, 재정적으로 그
적합성을 검증 받은 EU기업들의 우수한 제품과 기술을 국내 관련 기
업들에게 소개하고 일대일 비즈니스 상담을 진행합니다. 주요 전시분
야는 유럽 재활의학/건강관련기기, 임상/검사용기기, 진찰/진단용기
기, 의료용품, 의료정보시스템, 치과관련기기, 병원설비 등 입니다.
I
N
T
R
O
D
U
C
T
I
O
I
N
T
R
O
D
U
C
T
I
O
Ryu Jea-Young 유재영
2 26 Ocean Bio Center, Gangneung Science
Developmentt Foundation, 641-22Saimdang-ro,
Gangrneung-si Gangwon-Do
82-33-643-0226
82-33-648-0226
[email protected]
http://bbko.kr
N
EuBiologics Co., Ltd. is a biopharmaceutical company
supplying a wide range of CRMO (Contract Research
and Manufacturing Organization) services for
biopharmaceuticals and safe and effective vaccines with
the goal of improving global public health.
We provide customized CRMO services in accordance with
clients’ project stages including cell line development,
manufacturing process development, GMP production and
validation as well as regulatory support.
(주)유바이오로직스는 바이오의약 제품개발과 관련해 세포주 제
작, 제조공정 및 분석법의 개발과 밸리데이션, 비임상 및 임상시험
용 제품의 GMP 수탁생산 등에 대한 통합적인 서비스 (CRMO,
Contract Research and Manufacturing Organization)를 제공
하는 바이오 벤처기업이입니다. 유바이오로직스의 CRMO서비스를
활용하면 다음 6가지의 효과를 기대할 수 있습니다.
시설투자 절감, 다수의 임상개발과제 진행시의 비용 절감, 개발업무
E
X
H
I
B
I
T
S
Leached Tea
오죽잎차
I
N
T
R
O
D
U
C
T
I
O
N
organic ojuk tea produced in ojukheon of f Gangneung,
a pristine area. Non-caffeine organic tea made with clean
baby leaves
청정 강원 강릉 지역의 오죽헌 주변에서 자생, 재배하는 오죽잎으로
차를 제조하는 회사로 2011년 창업하여 잎차 이외에 같은 재료로
분말, 환, 엑기스 등을 제품화. 전국 최초로 오죽잎의 제품화에 성공.
집중을 통한 연구생산성 향상, 선진 GMP 운영 및 실사에 대한 부담
경감, 시장출시 기간의 단축, 상업화 및 시장예측 실패에 따르는 위험
최소화.
N
Launched in Korea in 2009, the EU Gateway Programme
is funded and managed by the European Union. The
저희 엔코팜은 바이오기술 산업분야의 특화된 번역전문회사이며, 최 Programme provides support for small and medium-sized
근 임상시험 번역의 우수한 품질을 인정받아 세계적인 CRO인 퀸 EU companies with advanced products and technologies to
타일즈, (주)시믹코리아, LG생명과학, 동아ST, 대웅제약, (주)파멥신 develop business partnerships with Korean companies.
등 200개 기관과 약정을 맺고 번역서비스를 진행하고 있습니다. 지
난 5년동안 많은 고객들의 도움으로 국내유수의 기관들과 약정을 맺 EU 게이트웨이 프로그램 (EU Gateway Programme)은 유럽연합
어왔으며, 그로 인해 다양한 수많은 특수분야 문서등 을 번역해왔습 (The European Union)의 예산으로 운영되는 비즈니스 협력 프로
니다. 바이오 및 기술산업의 전반적인 번역과 관련하여 상의하실 사
그램으로, 국내 헬스케어 및 의료기술분야 기업과의 비즈니스 관계를
항이 있으시면 엔코팜을 찾아주시기 바랍니다. 앞으로 저희 EncoPharm의 직원들과 더불어, 최선을 다하는 모습과 늘 향상되는 모습
을 보여드리겠습니다.
감사합니다.
개척하고 발전시키고자 하는 EU기업 지원을 목적으로 합니다.
122
123
B10
K30
Q20
Fermentec
Fit.Life Inc.
퍼멘텍
(주)휘트닷라이프
CEO
ADD
TEL
FAX
E-MAIL
URL
Lee, Heung Yong 이흥용
1108-13, Namchon-ri, Oksan-myeon, Cheongwon
-gun, Chungcheonbuk-do, Korea
82-43-231-3500
82-43-218-6073
[email protected]
http://www.fermentec.co.kr/eng
CEO
ADD
TEL
FAX
E-MAIL
URL
E
X
H
I
Fermenter, Bio- reactor
B
I
T
Yoosuk Jung 정유석
F 4 0 5 , R & D B C e n t e r, 1 0 5 G w a n g g y o - ro ,
Yeongtong-gu, Suwon, Gyeonggi-do, Korea, 443766
82-31-888-5144
82-31-888-5145
[email protected]
http://www.fitdotlife.com
R25
Foundation of Research and Business,
Chungnam National University
Gangneung Science Industry Foundation
Marine Bio Industry Support Center
충남대학교산학협력단
(재)강릉과학산업진흥원 해양바이오사업단
Dongil, Seo 서동일
(305-764) 대전광역시 유성구 대학로 99 충남대학교 산
CEO
ADD
ADD
학연연구본부
TEL
FAX
E-MAIL
URL
82-42-821-7173
82-42-821-8710
[email protected]
http://tlo.cnu.ac.kr/
TEL
FAX
E-MAIL
URL
S
E
X
H
I
B
I
T
S
Fitmeter (Physical Activity Monitor)
E
X
H
I
B
I
T
E
I
N
T
R
O
X
H
I
B
I
T
S
Marine Bio Products, Functional Foods
휘트미터(활동량측정기)
I
Chung Sang Key 정상기
Gangneung Science Industry Park, Saimdang-ro
641-22, Gangneung-city, Gangwon Province, 210340, Republic of Korea
82-33-650-3352
82-33-648-2162
[email protected]
http:// www.gsif.or.kr
S
시제품, 판넬 등
발효기, 미생물 반응기, 배양기
D
U
C
T
I
O
N
We provide technology-intensive devices and services
conducive to promotion of health with pleasure, pursue
long-term mutual interests for all the parties concerned and
establish the corporate culture for encouraging experts and
creating synergy systematically.
Our main product is a physical activity monitor(Fitmeter)
which is world's best accuracy level and support exercise
program of American College of Sports Medicine the
world's first.
(주)휘트닷라이프는 사람들이 즐겁게 건강을 증진시킬 수 있는데 도움
이 되는 기술집약적 제품과 서비스를 제공하고, 모든 관계인들의 장기
적 상호 이익을 추구하며, 전문가들이 자신의 장점을 키우고 활용하면
서 조직적으로 시너지를 일으킬 수 있는 기업문화를 확립합니다.
우리의 주요 제품은 활동량 측정기인 휘트미터로 임상검증된 세계
최고 수준의 정확성을 지녔으며, 활동량 측정기 중에서는 세계 최초
로 미국스포츠의학협회(ACSM)의 질환별 운동 프로그램을 연동했습
니다.
124
CEO
N
T
R
O
D
U
C
T
I
O
N
해양바이오 기능성 제품
패혈증 예방 및 치료용 약학 조성물
방광압 진단 키트 기술
I
N
T
R
O
D
U
C
T
I
O
N
Gangneung Science Industry was established in 2007
sponsored by the Ministry of Knowledge Economy, Ministry
of Education, Science & Technology, the Gangwon province
and Gangneung city Major Businesses - Attract promising
companies located in other regions - Post-BI (Business
Incubator) / TBI (Technological Business Incubating) projects
- Joint R&D and technology transfer projects - Information
exchange projects, business matching / exchange
programs.
-Education & Training Project / Business Support Project
-Management and support service
-Build-up&develop Gangneung Science Industry complex
강릉과학산업진흥원 해양바이오사업단은 강원영동권 해양바이오 제
품 개발 및 고부가가치 창출 시스템을 구축하고 해양바이오기업체의
단기적 고도기술 접목 및 상품화를 위한 장비 구축 296종 355대를
구축하고 해양바이오지원센터, 벤처공장, 산업단지를 연결하는 기업
지원 선순환적 체제를 구축하고 있다. 특히 현장애로 기술지도 및 시
제품 공동연구개발을 통한 제품 품질 강화와 혁신체제 및 네트워크
구축으로 지역경제 활성화에 일익을 담당하고 있다.
125
R25
D41
J10
R19
GinSeng
GL Biotech Inc.
Green Cross Corporation
(주)진생
(주)지엘바이오테크
녹십자
CEO
ADD
TEL
FAX
E-MAIL
URL
Hong youg gi 홍용기
BI Center 110, 599 Daewon Univ. Sinwol-dong,
Jecheon-si, Chungvuk, Korea
82-43-652-7350
82-43-653-7350
[email protected]
http://gscodes.com
CEO
ADD
TEL
FAX
E-MAIL
URL
E
X
H
I
B
I
T
Kim Won-Dae 김원대
N 506 Industry-Academy Cooperation Center,
Pai-Chai University #1337, Gwapyung-dong,
Yuseong-gu Daejeon, Korea
82-42-671-4455
82-42-671-4457
[email protected]
http://www.glbt.co.kr
S
ADD
TEL
FAX
E-MAIL
URL
X
H
Apply sweet herb syrup, Tea for a strong man, Tea for
beautiful women
Healthfood, cosmetics
I
B
I
T
S
건강보조식품, 화장품
Il-Sup Huh 허일섭
303 Bojeong-dong, Giheung-gu, Yongin, 446-770,
Korea
82-31-260-9527
82-31-260-9408
[email protected]
http://www.greencross.com
X
H
I
B
I
T
N
T
R
O
D
U
C
T
I
O
N
I
N
T
R
O
D
U
C
T
I
O
ADD
TEL
FAX
E-MAIL
Soo Han Kwon 권수한
5 2 Naesoodong-ro Heungduk-gu Cheongju,
Chungbuk 361-763, South Korea
82-43-261- 3666
82-43-263-3664
[email protected]
www.nueris.or.kr
X
H
I
B
I
T
S
Green Cross Corporation is displaying the R&D pipeline E
with the explanation of representative late stage products. Mulberry&Mulberry Leaf Mask Pack, Cosmetics, Health
Functional Food
녹십자는 R&D 파이프라인 및 주요 글로벌 프로젝트의 포트폴리오를
뽕잎/오디 마스크팩, 화장품, 건강기능성식품
N
we are researching herbal materials and developed
products with industry-academic cooperation which are
domestic Universities, research institutes, government
agency and domestic individual enterprises for several
years. we have Arthritis Health food, Atopic cosmetics,
황기젤리, 남다른차, She 비밀스런차, 발라먹는조청, 천년숨결 진홍삼 pimple trouble care cosmetics, Feminine hygiene
cosmetics.
(주)진생은 자연의 생명력을 담아 맛과 전통을 계승하는 먹거리를 만
들자는 사명으로 식품사업에 진출하였습니다. 고객의 소중한 건강을
위해 바이오 기술분야를 향한 끊임없는 연구를 통해 한국적 가치와
건강한 자연의 맛을 담은 제품들로 국민들이 안심하고 먹을 수 있는
건강한 먹거리를 만들어 갈것입니다.
천연물을 연구하는 바이오기업으로 한국에너지기술연구원, 중소기업
청, 한밭대학교, 충북대학교, 서원대학고, 대전 테크노파크, 다움코스
텍, 대화약품 등과의 산학연 연구를 통해 개발되었습니다. PCT 국제
특허 출원, ISO9001인증, 미국 FDA 등록 등을 완료하였습니다. 자
사의 제품으로는 퇴행성 관절염, 골다공증 등 관절 질환 보조 식품,
아토피성 피부 개선용 화장품, 여드름 피부 개선용 화장품, 여성 청결
또는 생리통 완화제를 개발하였습니다.
126
CEO
S
전시하고 있습니다
I
충북대학교 녹색성장 누에산업 RIS사업단
URL
E
E
한방조청, 한방차, 한방젤리
CEO
Green-Growth Silkworm-Industry Regional
Innovation System
I
N
T
R
O
D
U
C
T
I
O
N
Green Cross Corporation (GCC) is one of the leading
pharmaceutical companies in Korea which made
approximately $682 Million in revenue for the 2012 sales
year. Since its establishment in 1967, GCC has pioneered
in the field of biopharmaceuticals including vaccines,
plasma-derivatives, recombinant proteins and therapeutic
antibodies.
I
N
T
R
O
D
U
C
T
I
O
N
충북대학교 녹색성장 누에산업 RIS사업단은 누에산업관련 제품을 먹
을거리, 입을거리, 바를거리로 나누어 누에와 뽕을 활용한 누에산업
을 신성장 바이오산업으로 육성하기 위해 기술개발을 통한 지역기업
의 애로기술 및 품질고도화 지원, 마케팅 활성화 등을 수행
1967년 창립 이래 녹십자는 국내 생명공학산업을 선도해 온 대표적
인 연구개발 중심기업으로 백신, 혈액제제, 재조합 단백질 및 항체 등
바이오 의약품 분야에서 국제적인 생명공학 전문기업이다. 세계 세
번째 B형간염백신 및 세계 최초 유행성출혈열백신을 개발하였으며
최근에는 유전자재조합 A형 혈우병 치료제와 신종플루 백신을 잇따
라 개발하는 등 차별화된 노하우와 경쟁력을 확보하고 있다.
127
L36
F10
GVK Biosciences Private Limited
CEO
ADD
TEL
FAX
E-MAIL
URL
E31
Gyeonggi Institute of Science & Technology
Promotion
Mr. Manni Kantipudi
Plot No. 28 A, IDA Nacharam, Hyderabad- 500076.
India
[email protected]
http://www.gvkbio.com
재단법인 경기과학기술진흥원
CEO
ADD
TEL
FAX
E-MAIL
URL
E
X
H
I
B
I
T
S
CRO
I
I
N
T
R
O
D
U
C
T
I
O
N
GVK BIO is a global Contract Research Organization
(CRO) and a preferred partner of choice to over 267
global Lifescience, Cosmetic, Electronic and Fine chemical
manufacturers, and research institutions. Our discovery
services consist of Chemistry, Analytical, Biology,
Informatics, and Custom Synthesis and Manufacturing
(KFDA, USFDA, EDQM, PMDA, cGMP approved); the
development services include Clinical research, Clinical
pharmacology and Process R&D.
N
T
R
O
D
U
C
T
I
O
N
The GSTEP is committed to the advancement of the
regional industries and economic development through
research and promotion of science and industrial
technologies.
Our Key functions :
1.Establish and operate research and supporting facilities
2.Support the development of science and industrial
technologies
3.Develop and support medical, bio and pharmaceutical
industries
4.Conduct S&T policy research and develop policy
implementation strategy
5.Build R&D project feedback system including
performance assessment and evaluation
6.Promotion cooperation and exchanges in science and
industrial technologies and provide relevant information
설립목적 : 과학 및 산업분야 기술에 관한 연구와 진흥을 통하여 지
역 산업의 고도화와 경제발전에 기여
주요기능
1. 연구 및 지원시설의 설치 운영
2. 과학 및 산업분야 기술개발 지원
3. 의료, 바이오, 제약산업 육성 및 지원
4. 과학기술정책 연구 및 추진전략 수집
5. 연구개발사업 성과분석, 평가 등 환류시스템 구축
6. 과학, 산업기술에 관한 협력, 교류, 정보지원
한 비전을 선포했으며, 현재 서울 역삼동 본사, 10개 지방사무소, 충
북 음성 공장에 750여명의 임직원이 근무하고 있습니다.
주요 전문의약품으로는 ▲당뇨병치료제 아마릴, 아마릴M, 아마릴멕
스, 가브스 ▲고혈압치료제 테베텐, 트리테이스, 트리아핀 ▲폐동맥
(주)한독
Young-Jin KIM, Churl-Joon KIM 김영진, 김철준
132 Teheran-ro Gangnam-gu Seoul 135-755 Korea
고혈압치료제 트라클리어 ▲전립선치료제 자트랄XL ▲폐질환치료
82-2-527-5114
제 닥사스, 온브리즈 ▲백신 아다셀, 뉴모 23 등이 있으며, 일반의약
82-2-527-5001
품으로는 소화제 훼스탈, 금연보조제 니코스탑, 여드름치료제 클리어
http://www.handok.co.kr/english/
CEO
Park Chung-Taek 박정택
G wanggyo-ro 147, Yengtong-gu, Suwon,
Gyeonggi-do 443, 270, Korea
82-31-888-6893
82-31-888-6899
[email protected]
http://www.gstep.re.kr
고 ‘대한민국을 대표하는 혁신적인 글로벌 헬스케어 기업’이 되기 위
HANDOK Inc.
ADD
TEL
FAX
URL
틴 등이 있습니다. 또한 ▲진단검사의학분야의 의료기기와 시약 ▲
E
X
H
I
B
I
T
S
Company, R&D Introduction
기업 및 연구개발 소개
I
N
T
R
O
D
U
C
T
I
O
N
Handok is committed to innovation on many levels and its
business has grown both through strategic partnerships
with other companies as well as innovative research.
Handok was founded in1954 and has been listed on the
Korea Stock Exchange since 1976. The company has never
recorded a deficit year since establishment.
Handok grew as a joint venture with Hoechst/Aventis/
Sanofi from 1964 to 2012. Handok has also established
strategic collaborations in several areas with multiple
multinational pharmaceutical companies. In 2013,
Handok changed its company name from Handok
Pharmaceutical Co., Ltd to Handok Inc. and declared its
vision to become Korea’s leading global total healthcare
company. We are working to bring new products to
Korea through partnerships, internal R&D, and state-ofthe art manufacturing with a global standard compliance
program.
Handok’s businesses mainly focus on prescription drugs
along with consumer health care products, medical devices
and In Vitro Diagnostics business, food supplements
and medical nutrition. Handok’s flagship products
include Amaryl and Amaryl M (antidiabetics), Teveten
(antihypertensives), Tritace (CV protectives) and Xatral XL
(BPH). Also Handok’s representative OTC products include
Festal, Nicostop, and Allegra D.
건강기능식품 네이처셋 (NatureSet) ▲메디컬 뉴트리션 (Medical
Nutrition: 특수의료용도식품) 사업을 하고 있습니다.
한독은 당뇨 복합치료제 아마릴 엠과 아마릴 멕스를 개량신약으로
개발하여 국내에 출시했으며, 세계로 수출하고 있습니다. 또한, 혁신
신약, 바이오 의약품, 개량신약, 의료기기 등 적극적인 연구개발 활동
을 전개하고 있습니다.
한독 음성공장은 국내는 물론 WHO, FDA 의 GMP 기준에 맞게 설
계•건설되어 KGMP, cGMP의 엄격한 품질관리 기준을 준수하고
있으며, 첨단 자동화 설비와 검증된 공정관리를 통해 국내 유수 기업
에 우수 의약품을 공급하고 있습니다.
한독은 1954년 설립 이후 훽스트, 아벤티스, 사노피 등 세계적 제약
회사들과의 협력을 통해 우리나라 제약산업의 선진화에 기여해 왔으
며, 윤리경영을 바탕으로 지속적인 혁신을 통해 대한민국 제약회사로
성장하고 있습니다. 2013년 한독약품에서 한독으로 사명을 변경하
128
129
G38
O10
HANLIM PHARM Co., Ltd.
Health industry TLO council
(Korea Health Industry Development Institute)
한림제약(주)
CEO
ADD
TEL
FAX
E-MAIL
URL
JAE YOON KIM 김재윤
1656-10, Seocho-Dong, Seocho-Gu, Seoul, Korea
82-2-3489-6000
82-2-3489-6101
[email protected]
http://www.hanlim.com
보건의료 TLO협의체관 (한국보건산업진흥원)
CEO
ADD
TEL
FAX
E
X
H
I
B
I
T
S
DAGES CAP.
LODIEN TAB.
HYALURON EYE DROPS.
NASATIVE NASAL SPRAY
N
T
R
O
E-MAIL
URL
R25
HIMEDIA LABORATORIES PVT. T.D
농업회사법인(주)에이치맥스
CEO
KO Kyung-hwa 고경화
1 87 Osongsaengmyeong2 (i)-ro, Osong-Eup,
Cheongwon-gun, Chungcheongbukdo 363-951,
KOREA
82-43-713-8273
82-43-713-8908
[email protected]
http://www.khidi.or.kr
HMAX Inc
ADD
TEL
FAX
E-MAIL
URL
E
Mr. V.M. Warke
A-516, Swastik Disha Business Park, LBS Marg,
Mumbai 400 086, India
91-22-61471919
91-22-61471920
[email protected]
http://www.himedialabs.com
X
H
I
B
I
T
S
Chemicals, Foods, Environment, Microbiological Products
E
D
U
C
T
I
O
X
H
I
B
I
T
S
Health industry TLO council Technology Exhibition
TLO : Technology licensing Office
다제스캡슐, 로디엔정, 히아루론점안액, 나자티브나잘 스프레이
I
L35
N
‘보건의료 TLO 협의체’ 기술전시
TLO : Technology licensing Office
As one of the leading companies in Korea, HANLIM
N
T
R
O
D
U
C
T
I
O
N
specializes in R&D and manufacturing of API/BPIs, I
pharmaceutical product and has an experience in exporting KHIDI (Korea Health Industry Development Institute), as
a range of products to China, the USA, Nigeria etc.
the sole organization provides supports for the health
industry, has inaugurated ‘Health Industry TLO Council’ in
한림제약은 한국의 선도 기업으로서, 제약분야의 기술개발, 원료 및
May, 2013. The TLO Council organizes the show case to
완제 제조를 전문으로 하고 있으며, 중국, 미국, 나이지리아 등에 다
promote the advanced technology and products of Korea
양한 의약품 수출 경험을 보유하고 있다.
Health Industry at BIO KOREA 2013 exhibition.
한국보건산업진흥원은 국내유일의 보건산업 육성기관으로 2013년
5월에 보건산업의 기술사업화 활성화를 위한 ‘보건의료 TLO협의체’
를 발족을 하여, 이번 ‘BIO KOREA 2013’ 전시회에서 협의체 기관
및 기술의 우수성을 알리고 글로벌 경쟁력을 강화하기 위한 기술전
시, 홍보관 운영.
I
N
T
R
O
D
U
C
T
I
O
N
Manufacturer and exporter of microbiological products,
dehydrated culture media, raw materials i.e. peptones,
tryptone, yeast extract, agar agar powder for the
fermentation and bulk drug manufacturing industries,
tissue culture media for production of vaccine,
biochemicals, laboratory chemicals, vegetable peptones,
vegetable extracts, vegetable hydrolysates and infusion.
We offer a full range of vegetable peptones from plant
proteins which are free from BSE/TSE. Vegetable peptones
can replace animal origin peptones in microbiological
culture media, fermentation and food industry. Our
company is a ISO, CE Mark, WHO-GMP certified company.
We are exporting our products to over 127 countries
around the world.
CEO
ADD
TEL
FAX
E-MAIL
URL
E
Chan-Ho Lee 이찬호
Zip 350-290, 992 WangAm-dong, Jecheon City,
ChungBuk, KOREA
82-43-642-7890
82-43-642-7891
[email protected]
http://www.teaterra.co.kr
X
H
I
B
I
T
S
Fermented Licorice TEA-TOX
Korean RED GINSENG with Fermented Licorice.
Oriental Herbal Tea Value Class 4 Set (No worries Tea, Body
Line helper Tea, Clean Blood Red Tea, Body Defence Tea)
Herbal Teas 6 Set (Feeling much lighter FENNEL TEA, Young
& full of life PEPPERMINT TEA, Comforting CAMOMILE
TEA, Black tea in South Africa ROOIBOS TEA, for ladies
HERBAL TEA, for men HERBAL TEA)
발효감초 티톡스차
발효감초 홍삼차
한방 침출차 밸류클래스 4종세트
(걱정제로차, 맵시라인차, 깨끗한차, 보디가드차)
허브차 6종세트 (가벼워지는 펜넬티, 생기발랄 페퍼민트티, 편안한
캐모마일티, 남아공의 홍차 루이보스티, 여성 허브티, 남성 허브티)
I
N
T
R
O
D
U
C
T
I
O
N
HMAX (Brand Name:TeaTerra) supplies almost 100 various
kinds of natural and organic whole Korean herbs (treated
whole herbs, fermented herbal raw herbs, infusion teas and
traditional Korea teas) and other products since 2004. Our
products are made to focus on gender-specific, symptomspecific and seasonal teas. All products made by HMAX (Tea
Terra) meet the following principles and standards.
저희 HMAX (브랜드명:티테라)는 2004년에 설립되었으며 약 100
여 가지의 다양한 종류의 자연그대로의 유기농 한국 허브를 공급하
고 있습니다.
자연상태의 허브와 발효허브, 그리고 이런 허브와 약재를 함께 우려
낸 차 그리고 한국 전통 차 모두를 취급합니다.
저희 제품들은 특정 성별과, 특정 증상에 초점을 맞추어 만들어 지고
있으며 계절의 특성에도 맞게 만들어집니다. HMAX (티테라)의 모
든 제품들은 원칙과 기준에 맞춰 제작됩니다.
130
131
L23
P21
Hungary
F20
HV BIO
Hwasun County Vaccine Industry District
(Regional Specialized Development District)
헝가리
CEO
ADD
TEL
FAX
URL
Tibor Baloghdi
(140-809) 58 Jangmunro, Yongsan-gu, Seoul
82-2-793-7883
82-2-792-2126
[email protected]
Oh Hong Guen 오홍근
#410, CTP BIOCENTER Daehangno 121, Nonsan-si,
Chungnam
83 63-851-7061
83-63-850-7558
http:// huvet.koreasme.com
CEO
ADD
TEL
FAX
URL
H20
화순백신산업특구 (지역특화발전특구)
CEO
ADD
TEL
E-MAIL
URL
E
X
H
I
B
I
T
S
Feed additive, CRO R&D
사료첨가제, 전임상실험
I
N
T
R
D
U
C
T
I
O
N
HV bio continues to make efforts on study and develop
constantly for harmonizing world with human and animal.
As our corporate ideal is respect human and animals,
we try to become advanced, contributed company for
social welfare which will meet such thinking: 1. increasedtechnology 2. future-oriented 3. mutual-communion
between human and animals 4. environment-friendly.
HV bio has released various feed additives made
with natural calcium and will place on fulfillment of
environment-friendly animal husbandry by improving
level of immunity of numbers of disease like AI, as well as
increasing productive capacity of rural households.
HV bio는 사람과 동물의 조화로운 세상을 열기 위해서 지속적인 연
구·개발을 수행해나가고 있습니다. 인간과 동물을 존중하는 기업이
념으로 발전하는 기업, 사회에 헌신하는 기업이 되도록 노력하고 있
으며 1. 기술발전적인 사고 2. 미래지향적인 사고 3. 인간과 동물과의
상호교감 사고 4. 친환경적인 사고 이 4가지를 사훈을 삼고 있습니
다. HV bio는 많은 연구개발 실적을 토대로 천연칼슘을 소재로 한 각
종 동물용사료첨가제를 출시하고 있으며 농가의 생산성 향상, 조류독
감 예방등 각종 질병에 대한 면역력을 증진시켜 친환경축산을 실현
시킬수 있는 토대를 만들어 드리겠습니다.
132
현대마이크로(주)
CEO
Hong I Sik 홍이식
Donghungil 23 Hwasun-eup, Hwasun County,
South JeollaProvince 519-805, Korea
82-61-374-0001
[email protected]
h ttp://www.hwasun.go.kr/2011/en/county/01/
index03.php
http://sezone.smba.go.kr
ADD
TEL
FAX
E-MAIL
URL
E
Young-taek, Kim 김영택
4th Floor, Hyobong B/D 223 Ipjeong-Dong, JungKu, Seoul, South Korea
82-2-2273-8490~2
82-2-2273-8493
[email protected]
http://hdmicro.co.kr
X
H
I
B
I
T
S
Plasticware of bio-Industry for laboratory, Syringe/
Membrane Filter, Filter Paper, Biocontainer Assemblies,
Facilities and Main Business Area of Hwasun County Cartridge Filter etc.
Vaccine District
Lab용 플라스틱웨어, 시린지필터, 멤브레인필터, 여과지, 멸균바이오
E
O
HYUNDAI Micro Co., Ltd.
X
H
I
B
I
T
S
2012년 우수연구특구로 지정된 화순 백신특구에 입주해있는 전남 백, 카트리지필터 등
생물산업진흥원 생물의약연구원과 한국화학융합시험연구원 헬스케
어연구소, 녹십자 백신공장, 전남대학교병원 등의 우수 연구기관
I
N
T
R
O
D
U
C
T
I
O
N
Hwasun County Vaccine Industry District has been
established in 2010, to develop Vaccine Research and
Development, Preclinical and Clinical Trial, and manufacturing
Service in one place.
In Hwasun Vaccine District, there are JBF Biopharmaceutical
Research Center, KTR Healthcare Canter, Greencross
Vaccine Factory and Jeonnam University Hospital.
화순백신특구는 2010년 전남 화순군 화순읍등 2개 읍면에 면적
985,860m2 규모로 생물의약일반산업단지와 전남대병원을 중심으
로 지역특화발전특구로 지정되었습니다. 특구지정을 통해 바이오 클
러스터와 메디컬 클러스터를 조성하여 백신 산업화와 생물의약품 완
제라인을 전남생물산업진흥원 생물의약연구원에 구축하고, 생물의약
품의 전임상을 담당할 한국화학융합시험연구원의 헬스케어연구소,
임상을 담당할 전남대학교병원, 그리고 백신을 제품화하는 녹십자백
신공장 등을 구축하였습니다.
I
N
T
R
O
D
U
C
T
I
O
N
We, HYUNDAI Micro have provided Syringe filters and
Plastic ware such as cell culture dish, petri dish and conical
tube which are necessarily used in bio industry field to
domestic and abroad markets. These products
are manufactured in our own plants.
Also, we have imported cartridge filters and various filters
in order to close to the customers. We will be a company
which can give customers more trusts with competitive bio
products.
당사는 바이오산업 분야에서 필수적으로 사용되고 있는 페트리디쉬,
코니칼 튜브 셀컬쳐디쉬 등의 플라스틱웨어 제품들과 시린지필터를
직접 제조, 생산하여 국내외에 공급해드리고 있습니다. 또한 카트리
지필터를 비롯하여 각종 필터 제품들도 수입하여 고객사께 다가가고
있습니다. 더욱 경쟁력 있는 바이오산업 관련 제품으로 신뢰받는 귀
사의 파트너가 되겠습니다.
133
F34
F40
G33
F45
HYUNDAIPHARM. Co., Ltd.
IIAMHUB
ILDONG PHARMACEUTICAL Co., Ltd.
IL-YANG PHARMACEUTICAL. Co., Ltd.
현대약품(주)
(주)이암허브
일동제약 주식회사
일양약품(주)
CEO
ADD
TEL
FAX
E-MAIL
URL
Yoon chang hyun 윤창현
204-4, Nonhyeon-Dong, Gangnam-Gu, Seoul, Korea
82-2-2600-3848
82-2-2693-7628
[email protected]
http://www.hyundaipharm.co.kr
CEO
ADD
TEL
FAX
E-MAIL
URL
E
X
H
I
B
I
T
Kyoyoung Ku 구교영
140-872 5F, 51-1, Hangangno 2ga, Yongsan-gu,
Seoul, Korea
82-2-792-2398
82-2-792-2396
[email protected]
http://www.iiam.co.kr
S
X
H
I
B
I
T
S
Technology Valuation
PantrosIP
마이녹실, 버물리, 나또밸런스, 루핑
ADD
TEL
FAX
E-MAIL
URL
JUNG CHI LEE 이정치
137-733 2, Baumoero 27-gil, Seocho, Seoul, Korea
82-2-526-3114
82-2-526-3031
[email protected]
http://www.ildong.com
X
H
I
B
I
T
N
T
R
O
D
U
C
T
I
O
N
Hyundai Pharm, established in 1965, has been selected
as one of innovative pharmaceutical companies and ATC
(Advanced Technology Center) based on 3 R&D centers
focusing on developing new drugs.
Hyundai Pharm also signed on Technology Transfer
Agreement with about 40 local companies in Korea.
There are about 170 products distributing by Hyundai
Pharm such as OTC products (MoolPas, Bumooly, Minoxyl
and so on) and ETC products (CV, Respiratory, OBGY, CNS
and so on).
Hyundai Pharm has been transferred its technology to the
global market like Europe and it was based on its R&D for
IMDs.
I
N
I
T
R
O
D
U
C
T
I
O
N
PantrosIP’s solution significantly improves R&D and IP
processes providing for ample cost savings potential
and improved technological position. Solutions include
private corporate portfolio management, industry analysis,
competitive patent intelligence, and unparalleled patent
informatics.
기술가치평가 : 경제성 분석 및 기술가치평가의 다년간의 경험과 체
계적이고 표준화된 모델을 기반으로 신뢰성 있고 객관적인 근거를
제시하는 가치평가를 수행합니다.
PantrosIP : 대량 특허의 포트폴리오 관리, 등급평가를 통한 특허 자
현대약품 (1965년 창립)은 3곳의 연구소를 기반으로 신약개발에 주력
을 하여 혁신형 제약기업 및 ATC (우수기술연구센터)에 선정되었음.
국내 40여개사와 제제기술 계약을 체결함.
일반의약품 (물파스, 버물리, 탈모치료제 마이녹실 등)과 전문의약품
산의 효율적 관리, 거래 대상 특허의 재무적 가치평가를 통해 라이센
싱 전략수립, 특허분쟁 대응 근거 마련 등 전략적 의사결정을 지원하
는 솔루션입니다.
TEL
FAX
E-MAIL
E
Anticancer product, Probiotics, APIs, CMO business
N
T
R
O
D
U
C
Dong Yeon, Kim 김동연
110, Hagalro, Giheung-gu, Yong-in-si, Gyunggiido, Korea
82-2-570-3700~7
82-2-570-3708~9
[email protected]
http://www.ilyang.co.kr
X
H
I
B
I
T
S
Supect (Radotinib), Noltec (Ilaprazole), Vaccine, ETC/OTC,
Health Functional Food, Drinks
항암제, 유산균 제품, 원료의약품, CMO사업
PantrosIP
ADD
S
기술가치평가
I
CEO
URL
E
E
Minoxyl, Bumooly, Natto Balance, Ruping
CEO
T
I
O
N
ILDONG PHARMACEUTICAL Co., Ltd. has been
contributing to healthier and happier lives since 1941. We
are developing creative and outstanding finished products
and APIs utilizing all knowledge and know-how available.
Especially, we have constructed dedicated Anti-cancer
building and Cephalosporins building in 2010 which are
high-end production system pursuing for global market.
일동제약은 1941년 창립 후 인류의 건강과 행복에 기여하는 기업으
로 성장해왔다. 올해 출시 50주년인 아로나민과 대표 품목인 비오비
타 등 OTC 제품이 소비자들에게 잘 알려져 있으며, 큐란, 후루마린
등의 전문 의약품들도 의약사들에게 유명한 제품이다. 완제공장인 안
성공장과 원료공장인 청주공장에서 최고품질의 제품이 생산되고 있
으며, 특히 항암제, 세파 항생제 생산능력은 국내 최대이다.
슈펙트, 놀텍, 백신, OTC/ETC의약품, 건강기능식품, 드링크 등
I
N
T
R
O
D
U
C
T
I
O
N
Global leader in R&D of new chemicals and biological
products
Since 1946, based on the company's slogan 'Respect
humanity', 'Promote human's health' and 'improve
welfare', IL-Yang Pharmaceutical has dedicated to people’s
health by manufacturing superior medicines.
With the start of 'NOLTEC (Ilaprazole)', so-called future
generation's antiulcer medicine, we are developing
'SUPECT (Radotinib)', a super leukemia cure and expanding
into the field of vaccination business and BIO medication.
IL-Yang has been advancing into a top-ranking
pharmaceutical company in the world through its R&D
capabilities with development of new chemical entities and
innovative biological products.
신약 개발의 글로벌 리더 일양약품
(고혈압, 호흡기, 산부인과, 정신계 약물, 외과 등) 170 여 제품을 판
매함.
1946년 창업이래 “인간존중의 사명을 갖고 인류의 건강과 복지를
위하여 정성을 다한다” 라는 기업이념 속에 한국제약산업의 발전사
Unmet needs가 충족된 개량신약에 대한 연구를 통해 해외유럽 기
와 그 맥을 함께해왔습니다. 차세대 항궤양제로 불리우는 국산 14호
신약 “NOLTEC”, 차세대 슈퍼 백혈병 치료제 “SUPECT”, 백신사업
및 새로운 성장 동력인 BIO 혁신신약 개발 능력 확대를 기점으로 일
양약품은 글로벌 신약기업으로의 명성을 점차 확대 해 나가고 있습
니다.
술수출을 하고 있음.
134
135
A12
Q22
Incheon Free Economic Zone
Industry-Academic Cooperation Foundation
JEJU NATIONAL UNIVERSITY
인천광역시 경제자유구역청
CEO
ADD
TEL
FAX
E-MAIL
URL
E
Lee Jong Cheol 이종철
G-Tower, 175 Art Center-daero, Yeonsu-gu, Incheon
406-840, Korea
82-32-453-7363
82-32-453-7389
[email protected]
http://www.ifez.go.kr
X
H
I
B
E10
I
T
S
제주대학교 산학협력단
CEO
ADD
TEL
FAX
E-MAIL
URL
I
N
T
R
O
D
U
C
E
Lee Nam-Ho 이남호
1 02 Jejudeahakno, Jeju-si, Jeju Special SelfGoverning Province, 690-756, Korea
82-64-754-2474
82-64-702-2461
[email protected]
http://iucf.jejunu.ac.kr/
T
I
O
N
As one of the central focuses of the Korean government’s
‘Northeast Asia Economic Centralization strategy’, the
Incheon Free Economic Zone (IFEZ) was first nationally
designated in August, 2003, and includes Songdo,
Yeongjeong and Cheongna, for a total area of 169.5km2.
IFEZ is an international city for global business to become
the driving engine for the best economic activity.
Songdo Bio Front in Songdo, IFEZ is attracting research,
manufacturing and service businesses in the fields of bio
pharmaceutical and medical industries. Songdo Bio Front
already attracted many global companies as Samsung
Biologics, Dong-A Pharm, Celltrion, Ajinomoto, etc.
Songdo Bio Front has many strengths as below.
1)C onvenience in import and export thanks to the
Incheon International Airport and Incheon Sea Port,
both located in IFEZ.
2) World-class bio pharmaceutical production capacity.
3) Easy access to the major domestic market including the
Seoul, and eco-friendly living environment.
인천경제자유구역은 2003년 8월 송도, 영종, 청라국제도시에 총
169.5㎢ 규모로 우리나라 최초의 경제자유구역으로 지정되었습니
다. 인천경제자유구역은 글로벌 비즈니스 전진기지로 최고의 경제 활
동을 보장하는 국제도시입니다.
인천경제자유구역 송도지구 내 위치한 송도 바이오 프론트는 의료·
바이오 기업 및 바이오 분야 서비스 기업 등 글로벌 앵커 기업 유치
를 추진하고 있습니다. 삼성바이오로직스, 동아제약, 셀트리온, 아지
노모도 등 글로벌 기업이 이미 송도 바이오 프론트를 선택하여 입주
하였습니다. 송도 바이오 프론트는 1)바이오 산업 글로벌화의 필수
인프라인 인천국제공항과 인천항을 보유 2)세계적 수준의 개발 및 생
산규모 확보, 3)수도권에 입지하고, 송도 국제도시의 우수한 거주환
경 등의 강점을 지니고 있어 명실상부한 바이오 클러스터로 국내·
외의 이목이 집중되고 있습니다.
136
X
H
I
B
I
T
S
Excellent patent technology exhibition
우수특허 기술 전시
I
N
T
R
O
D
(주)이뮨메드
CEO
Introduction of IFEZ and Songdo Bio Front
인천경제자유구역 및 송도 바이오 프론트 소개
ImmuneMed, Inc.
U
C
T
I
O
N
Our main role is efficient research funds administration
and enforcement, academic support program activities,
intellectual property management, business operations
include collaboration with foreign institutions.
산학협력단의 역할로는 교수과제연구비 관리 및 집행, 학술활동지원,
지식재산관리, 대외기관과의 협력사업 운영 등이 있습니다
ADD
Sun-Mi Kim 김선미
Room #304, Bld.#2 Biotown, 32 Soyanggangro,
Chuncheon-si, Gangwon-do, South Korea, 200161
82-33-253-1669
82-33-241-1664
[email protected]
http://www.immunemed.net
IgM and IgG from species-specific antigens at the same
time. Some of items are currently sold in South Korea and
exported to southeast Asia from 2013.
본사에서는 인간 자체의 면역력을 활용하는 것이 감염성 질환에 대
한 가장 기본적인 해결책이라는 신념을 가지고, 다년간에 걸쳐 연구
를 진행하고 있다.
- Virus Suppressing Factor (VSF)
VSF는 interferon과 유사하게 생체에서 만들어지는 물질이지만
FAX
동물실험에서 더 많은 범위의 바이러스에서 interferon보다 훨씬
E-MAIL
더 효과적인 항바이러스능을 보였으며 부작용이 없었다. 만일 VSF
URL
가 항바이러스 치료제로서 개발된다면, interferon외에 다른 합성
바이러스 치료제의 한계를 극복할 것이다. 또한, 본사는 VSF에 대
하여 2010년 4월에 미국 특허를 받았으며, 전세계적으로 인간화
I
N
T
R
O
D
U
C
T
I
O
N
된 VSF에 관한 특허를 제출할 준비가 되어있다.
ImmuneMed Inc. promises to become a world-trusted
company based on creative high-tech intensive research 현재 VSF의 연구개발은 전임상 단계에 와 있으며, 개발에 필요한
자금은 ①정부연구개발비, ②진단키트 판매와 ③외부투자를 할 계
and sound management. We believe that the human
획이다. 자금의 회수는 상장등을 통한 방법으로 진행될 것 이며,
immune system itself is the most effective defense system
VSF 개발의 성공은 항바이러스 치료제 시장에서 혁신적인 결과물
of our body in curing various infectious diseases.
이 될 것이다.
-Virus Suppressing Factor (VSF)
VSF is produced in the body, similar to that of interferon: -급성열성질환 진단키트
급성열성질환 (쯔쯔가무시병, 렙토스피라증, 유행성출혈열, 발
however it shows much greater antiviral activity and over
진열)은 세계적으로 새롭게 확산되는 질병이다. 특히 국내 (연간
the wide ranges of viruses in animal experiments than
100, 000명 내외) 및 중국을 포함한 동남아에서 가을철에 발발하
interferon and no side effects. Therefore, if developed
는 전염병으로, 전 세계적으로 매년 천만명 이상에서 발병하는 질
as an antiviral therapeutic, VSF can overcome many of
환이다. 본사는 급성열성 진단 사업을 회사 설립이전부터 실시해
the limitations of existing synthetic antivirals as well as
오고 있었으며 세계 최고수준의 본사 연구력으로 진단키트는 개발
interferon. Also, The company received a US Patent in
완료단계에 있으며, 2013년부터 일부 품목에 대하여 시판 (동남
April 2010 and is ready to submit a patent regarding
아 수출 포함)에 들어갔다. 본사의 진단키트는 종특이항원을 개발
appropriated human VSF worldwide.
하여 사용하였으며, 이에 대한 IgM과 IgG를 동시에 확인하므로
The current stage for research and development of VSF
민감도와 특이도를 높였으며, 그 결과를 10분내로 판독할수 있다.
is ready to enter a preclinical trial. The sources of this
국내외의 일반병원, 임상검사소, 농촌 보건소, 군부대 진료소 등이
project will be ① the government research grant, ② sales
주 사용처가 될 것이다.
of diagnostic kit, and ③ investment from the outside.
The retrieve of funds will be processed through a listed
company and so on. The success of VSF development
will be an innovative product in the antiviral therapeutics
market.
-Acute Febrile Illness (AFI) Diagnostic Kit and Vaccine
Acute febrile illnesses (scrub typhus, leptospirosis,
pandemic haemorrhagic fever with renal syndrome,
murine typhus) are newly spreading infectious diseases
in the world. These infections occur in Korea, Southeast
Asia, and China, causing epidemics particularly in
autumn. More than 10 million people are estimated
to be infected worldwide annually. We have focused
on developing a rapid, accurate, and reproducible AFI
diagnostic kit with high sensitivity and specificity using
TEL
137
A13
C10
Industry-academic Cooperation Foundation,
Keimyung University
계명대학교 산학협력단
CEO
ADD
TEL
FAX
E-MAIL
URL
E
H
I
B
I
T
S
Bio-patent
바이오 분야 특허
I
N
T
R
O
D
U
C
T
I
O
N
The IACF was established in September 2004 with the
intent of contributing to local economic growth and
school development by internally promoting research and
academics and externally reinforcing industrial cooperation.
-「산업교육진흥및산학협력촉진에관한법률」의 규정에 따라 우수연
구 진흥 및 산학협력을 강화함으로서 학교의 발전과 지역산업에
이바지함을 목적으로 2004년 4월에 설립 되었음.
- 고부가 식품/식료품, IT융복합 의료기기, 자동차부품, 스마트IT기기
등 전 분야에 걸쳐 우수기술 및 연구인력을 보유하고 있으며, 특허
청 발표에 따르면 2006년~10년 국내 216개 대학 중 식품/식료
품 분야에서 서울의 주요대학을 제치고 상위권 (전국 4위)를 차지
하는 등 특허 명문대학 임.
-중소기업청 주관 2011년도 산학연공동기술개발사업 수행기관
평가에서 최우수기관으로 선정되어 대통령표창을 수상하였으며,
LINC사업단, 창업지원단, 중소기업산학협력센터 등과 연계하여
산학공동기술개발, 기술사업화 및 기술창업 등을 지원하고 있음.
138
Institute for Refractory Cancer Reseach
E10
International Pharmaceutical Federation (FIP)
삼성서울병원 난치암연구 사업단
CEO
Nam Jae-yeol 남재열
1095 Dalgubeoldaero, Dalseo-Gu, Daegu, 704701 Korea
82-53-580-6742
82-53-580-6947
[email protected]
http://sanhak.kmu.ac.kr
X
M24
ADD
TEL
FAX
E-MAIL
URL
International Scientific Standards
인터내셔널 사이언티픽 스탠다드
Do-Huun Nam 남도현
81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea
82-2-2148-9775
82-2-2148-9829
[email protected]
http://www.Smcircr.re.kr
CEO
ADD
TEL
FAX
E-MAIL
URL
Mr. Luc Besancon
Andries Bickerweg 5, 2517 JP The Hague, Netherlands
31-302-1971
31-70-302-1999
[email protected]
http://www.fip.org
CEO
ADD
TEL
FAX
E-MAIL
URL
I
N
T
R
O
D
U
C
T
I
O
N
IRCR seeks to build a global hospital-based platform for the
development of new biologics by strengthening its human
and technology networks. We are cooperating with leading
domestic and overseas institutions and are scounting
technology for the discovery of new potential drugs. Based
on these, we are expanding the institution’s pipeline and
are establishing an open innovating system.
This system is built on a strong infrastructure of preclinical
translational research organizations that can accurately
evaluate the efficacy of new drug candidates and can
serve as a foundation for developing and industrializing
novel treatments that can treat refractory cancer. We
believe we have what it takes to make significant and
impactful contribution to the medical industry and assist in
humanity’s conquest of diseases.
난치암연구 사업단은 세계수준의 병원기반 바이오신약개발 플랫폼
구축을 통한 국내의 우수기관과 연구협력으로 인적/기술적 네트워크
를 강화하고, 유망과제 발굴을 위한 기술 스카우팅을 통해 오픈이노
베이션 기반 개방형 사업단 파이프라인 구축이 가능한 모델을 개발
하고 있습니다. 이러한 전문화된 인프라를 바탕으로 난치암을 치료할
수 있는 개인 맞춤형 바이오 신약을 지속적으로 발굴하고 산업화하
여 의료산업 발전 및 인구 질병극복에 이바지하고 자 합니다. E
X
H
I
B
I
T
Pharmaceutical Sciences World Congress (PSWC)
Bradley Ashbrook
32, Soyanggang-ro, Chuncheon-si, Gangwon-do,
200-161, Korea
82-33-258-6300
82-33-258-6299
[email protected]
http://www.isslab.co.kr
S
E
X
H
I
B
I
T
S
-Full range of analytical services in state-of-the-art GLP
facilities
I
N
T
R
O
D
U
C
T
I
O
N
- Bio analysis
- Bioassay service
5th FIP Pharmaceutical Sciences World Congress (PSWC)
Join leading pharmaceutical scientists from around the - Clinical monitoring service
world to discuss cutting edge research and up-and-coming - Regulatory consulting and strategic intelligence services
- Global GxP regulatory Services
developments in Melbourne, Australia 13-16 April 2014.
www.fip.org/pswc2014/
I
N
T
R
O
D
U
C
T
I
O
N
ISS delivers comprehensive high value solutions for
international pharmaceutical industry clients through
innovation, unmatched quality and excellence. As a Battelle
company, ISS plays an important role among a global
network of integrated science and technology services
delivered by one of the world most advanced research and
development organizations.
ISS는 세계 최대 규모의 독립적 R&D 기관인 바텔연구소의 자회사로
서, 바텔이 제공하는 통합과학기술서비스 네트워크를 기반으로 성장
하고 있습니다. 과학적 전문 지식과 기술 능력을 토대로 통합서비스
를 통해 고객 맞춤형 서비스를 제공할 것이며, 더 나아가 ISS는 민간
독립 연구소로 성장하여 업계 연구개발의 어려움에 대한 해결책을
제공하는 역할을 하고자 합니다.
139
K30
C43
R21
B20
IntroMedic Co., Ltd.
IWOO scientific coporation
JBK Natural medicine Institute
(주)인트로메딕
(주)이우 과학교역
제이비케이자연의학연구소
CEO
ADD
TEL
FAX
E-MAIL
URL
Andrew Shim 심한보
Suite 1104, E&C Venture Dream Tower 6-Cha,
197-29, Guro-Dong, Guro-Gu, Seoul, 152-719,
Korea
82-2-801-9300
82-2-801-9330
[email protected]
http://www.intromedic.com
CEO
ADD
TEL
FAX
E-MAIL
URL
X
H
I
B
I
T
S
CEO
ADD
TEL
FAX
E-MAIL
URL
Kyung mee Leem 임경미
441-853 1-203 89 SeahoRo GwonseonGu, suwon
City KyungkiDo korea
82-31-278-5772
82-31-278-5773
[email protected]
http://aronia.co.kr
X
H
I
B
I
T
S
E
X
H
I
B
I
Liquid Handler for Protein Crystallization, Liquid Handler
JBK Aronia, Bio-Clean, NOUFA 369
단백질 결정화 실험용 장비, PCR mix 셋업용 장비
장봉근 아로니아, 바이오클린, 노유파 369
T
R
O
TEL
FAX
E-MAIL
Kee, Young Hwan 기영환
Wanam-dong 660, Jecheon-City, Chungcheongbuk
-Do, 390-250 Republic of Korea
82-43-647-1011
82-43-647-1022
[email protected]
http://www.jcbio.or.kr
X
H
I
B
I
T
S
Korean Medicine Food etc.
한방식품, 한방제약, 기타
I
T
ADD
E
MicroCam® (캡슐내시경)
N
CEO
S
MicroCam® (Capsule Endoscope)
I
제천한방바이오재단
URL
E
E
Hyuncheol, Kang 강현철
5 F, Yangwoo Bldg., 1503-15, Seocho-dong,
Seocho-gu, Seoul
82-2-3473-2332
82-2-579-8873
[email protected]
http://www.iwoo.co.kr
Jecheon Korean Medicine Bio Promotion
Foundation
D
U
C
T
I
O
N
IntroMedic is a medical device manufacturer, specializing
in development of innovative technologies to advance the
field of a Capsule Endoscopy.
MicroCam® is the capsule endoscope with size of
11x24mm and is intended for visualization of the small
bowel mucosa as an adjunctive tool in the detection of
abnormalities of the small bowel with a wireless camera
contained in a capsule.
N
T
R
O
D
U
C
T
I
O
N
N
T
R
O
D
U
C
T
I
O
N
This company sells JBK Aronia and Bio-Clean, contain I
Aronia anthocyanins (C3G), patented material and NOUFA Jecheon herbal medicine through biotechnology
369, contains five kinds of non-oxidative oils. These biotechnology industry infrastructure based on a network
Products may maintain or improve the health of the cells. of organizations are supporting the growth of local
businesses.
특허물질 아로니아 안토시아닌(C3G)를 함유한 장봉근아로니아와 바
이오클린, 무산화방식으로 착유한 5종 혼합유제품인 노유파 369 관 제천한방바이오 인프라 구축을 통한 한방바이오산업 네트워크의 거
련 제품을 개발 판매하는 회사입니다. 이들 제품은 세포의 건강을 유
점기관으로 지역기업의 성장을 지원하고 있습니다.
지 또는 개선합니다.
(주)인트로메딕은 세계 최초 수준의 고화질 영상을 가진 최첨단 캠슐
내시경 시스템인 MicroCam® 을 개발하여 국내와 세계 80 여개
국가에 공급하고 있는 의료기기 전문 벤처기업입니다.
캡슐내시경은 기존의 내시경과 달리 검사에 따른 피검사자의 고통
없이 알약 모양과 크기의 캡슐을 삼키어 소화기 질환 진단에 필요한
영상을 회득하고, 회득한 영상을 가지고 피검사자의 질환 등을 분석,
진단할 수 있는 효과적이며 안전한 의료기기 입니다. 140
141
F20
N20
Jeonnam BioPharmaceutical Research
Center (JBRC)
전남생물산업진흥원 생물의약연구원
CEO
ADD
TEL
FAX
E-MAIL
URL
E
H
I
B
I
T
S
-Research Products of 7 centers of JBF
-Main Business Area of 7 centers of JBF
-전남생물산업진흥원은 산하에 7개 특화센터를 보유하고 기업을 위
한 연구와 생산지원을 하고 있습니다. 7개 특화센터는 식품산업연
JID Corporation Co., Ltd.
Johns Hopkins University
제이지 비지니스 링크 인터네셔널
(주)제이아이디코퍼레이션
존스 합킨스 대학교
TEL
FAX
E-MAIL
URL
0410 Observation Dr. Suite 105, Germantown,
2
MD 20876 USA
1-301-916-7210
1-301-916-7212
[email protected]
www.jgbli.com
E
X
H
I
B
I
T
T
R
O
D
U
C
T
I
O
N
Jeonnam Bioindustry Foundation (JBF) has been established
to boost and develop the bioindustry of Jeollanamdo
(South Jeolla Province) since 2002.
JBF has 1 HQ and 7 research centers, which are Bio Food
Technology Center, Biopharmaceutical Research Center,
Nano Bio Research Center, Institute for Natural Resources
Research, Marine Bioindustry Center, Development
Institute of Korean Traditional Medicine, and Bio Control
Center.
전남생물산업진흥원은 생물산업에 관한 연구개발 역량을 높이고, 전
남의 지역 경제 활성화와 지역산업 발전에 기여하고자 2002년 출범
한 기관입니다.
재단 산하에는 7개 바이오산업 관련 센터가 있어, 식품산업 연구 및
기업 지원을 위한 나주의 식품산업연구원, 신약개발 및 의약품 산업
지원을 위한 화순의 생물의약연구원, 나노기술연구 및 산업지원을 위
한 장성의 나노바이오연구원과 천연자원 및 환경을 이용하여 소재개
발 및 연구를 추진하는 장흥의 천연자원연구원, 한방산업 구축 및 우
수한약재 인증을 위한 장흥의 한방산업진흥원, 해양바이오전문기업
육성과 연구개발을 위한 완도의 해양바이오산업원, 생물방제연구를
위한 곡성의 생물방제연구원이 활발한 연구활동과 기업지원을 진행
하고 있습니다.
142
ADD
TEL
FAX
E-MAIL
한.미 바이오 엑스포 2013 소개 및 메릴랜드 주 바이오 정책 소개
메릴랜드 주 한국무역통상부, JG Business Link International,
Johns Hopkins University, University of Maryland School
of Medicine, Montgomery County, University of Maryland
BioPark, BioHealth Innovation 총 7개 업체 함께 참여
E
T
R
O
D
U
C
T
I
O
N
JG Business Link International (JGBLI) specializes in business
networking and relationship management. JGBLI is
committed to research and development for the vitalization
of Bio Technology, Information Technology, and Green
Energy projects.
JG Business Link International has partnerships and
agreements with Amarex, Cangene BioPharma, Duane
Morris, Calibre Systems, University of Maryland at
Baltimore, Johns Hopkins University, Bio Health Innovation,
BioCentury, and the University of Maryland BioPark.
This year we are providing a number of programs to
provide services to partner U.S. and Korean companies. Our
programming will create opportunities for FDA approval,
patent applications, investment and research funding, and
sales and marketing for products in both markets.
제이지 비지니스 링크 인터네셔널 (JG BLI)은 마케팅을 전문으로 하
는 컨설팅 회사입니다. JG BLI는 바이오 산업, 정보 통신 기술 산업,
에너지 산업과 관련하여 활발한 사업을 펼치고 있으며, 한국 중.소 기
업들이 미국 시장에 진출 할 수 있는 발판을 마련해 주고 있습니다.
한.미간 바이오 기업들의 정확한 정보 및 지식교류, FDA 승인 및 특
허, 투자연구비 및 판매에 이르기까지 최선의 서비스를 제공해 드리
며, 대형 CRO, CMO 회사와의 임상시험 대행과 위탁 생산 컨설팅
을 제공합니다.
또한, 매년 ‘Korea-Maryland, USA Bio Expo’를 개최함으로써 한
국과 미국 사이의 사업연계, 계약 및 양해각서 체결을 도와줍니다.
X
H
I
B
I
T
S
N
T
R
O
D
U
C
400 North Charles St., Baltimore, Maryland 21218,
3
U.S.A.
1-410-516-4600
http://www.jhu.edu/
ADD
TEL
URL
E
X
H
I
B
I
T
S
‘Korea-Maryland, USA Bio Expo 2013’ & ‘BioMaryland
2020’ Strategic Plan Introduction
한.미 바이오 엑스포 2013 소개 및 메릴랜드 주 바이오 정책 소개
메릴랜드 주 한국무역통상부, JG Business Link International,
Johns Hopkins University, University of Maryland School
of Medicine, Montgomery County, University of Maryland
BioPark, BioHealth Innovation 총 7개 업체 함께 참여
쎄니터리 다이아프램 밸브, 산업용 밸브
플라스틱 다이아프램 밸브, 글로브&컨트롤밸브
솔레노이드밸브, 하이퓨리티 밸브
센서&디스플레이 장치
멜라닌폼 (보온재), 체크밸브, 플렉시블호수
I
N
Yim Kyung Jae 임경재
Honglk Jeil B/D, 478-12, Seokyo-Dong, Mapo-Gu,
Seoul, 121-839, Korea
82-2-326-5545
82-2-326-5549
[email protected]
http://www.jidcorp.com
S
‘Korea-Maryland , USA Bio Expo 2013’ & ‘BioMaryland
2020’ Strategic Plan Introduction
I
N
CEO
URL
구원, 생물의약연구원, 나노바이오연구원, 천연자원연구원, 한방산
업진흥원, 해양바이오연구원, 생물방제연구원입니다.
I
N20
JG Business Link International
ADD
Shin Hyun Kyoung 신현경
San15-12 Dongsudong Naju, Jeollanamdo, South
Korea
82-61-339-1324
82-61-333-8076
[email protected]
http://www.jbf.kr
X
C23
T
I
O
N
I
N
T
R
O
D
U
C
T
I
O
N
GEMU-JID Corporation은 GEMU고객의 한국내 유일한 공식 공 The Johns Hopkins University is a private research university
based in Baltimore, Maryland, United States. Johns Hopkins
고객의 Need에 부응하여 만족할 만한 높은 기술력과 품질을 갖춘 pioneered the concept of the modern research university
독일 GEMU사의 밸브를 제공해 드리고 있습니다. 제약 및 생명바이 in the United States and has ranked among the world's
오산업, 식품산업, 전기도금, 제철산업, 화학 및 석유화학산업 등 널 top such universities throughout its history. The National
리 적용되고 있습니다. 또한 그밖에 제품으로 멜라닌폼 (보온재), 체 Science Foundation has ranked Johns Hopkins #1 among
크밸브, 플렉시블 호수가 있습니다. 고객 여러분께 전문적인 제품정 U.S. academic institutions in total science, medical and
보, 정확학 제품, 정직한 가격, 보다 빠른 납기 그리고 철저한 사후 서 engineering research and development spending for 31
비스를 제공해 드리는 신뢰 할 수 있는 기업입니다.
consecutive years. As of 2011, thirty-five Nobel Prize
winners have been affiliated with Johns Hopkins, and the
university's research is among the most cited in the world.
급업체입니다.
존스합킨스 대학교는 미국 메릴랜드 주 볼티모어에 위치한 명문 사
립대학교이며, 특히 의학, 공공보건, 국제학 분야의 명성이 높이 알려
져 있습니다. National Science Foundation은 존스합킨스 대학교
를 과학, 의학, 공학 연구 분야 최고의 학교로 선정했으며, 세계 상위
10~20위권 대학에 포함될 정도로 명성이 높습니다. 존스합킨스 대
학교 출신 중 37명의 노벨상 수상자가 배출되었으며, 2011년에는
아담 리스 (Adam Riess)가 노벨 물리학상을 수상한 바 있습니다. 존
스합킨스 대학교 안에는 바이오기술 연구소, 정보보안연구소, 생명윤
리연구소, 알츠하이머 연구소 등 160개 이상의 연구소가 위치해 있
습니다.
143
G42
E10
E33
K30
JUNGJIN INT'L IP LAW FIRM
JW CreaGene Inc.
JW PHARMACEUTICAL
JW PHARMACEUTICAL
정진국제특허법률사무소
JW크레아젠
JW중외제약
JW중외제약
CEO
ADD
TEL
FAX
E-MAIL
URL
Soon Woong Kim 김순웅
6F Ace Techno Tower 5th, 197-22, Guro-dong,
Seoul, 152-766, Korea
82-2-6677-7600
82-2-2109-6901
[email protected]
http://www.jjpat.com/
CEO
ADD
TEL
FAX
E-MAIL
URL
E
X
H
I
B
I
T
S
Patent/Utility Model, Design, Trademark, Korean IP Law &
Consulting
국내외 특허출원 및 소송, 기술이전, 특허 및 기술 컨설팅
I
N
T
R
O
D
U
C
T
I
O
N
We sincerely believe that JungJin Intellectuall Property Law
Firm is able to grow and develop continuously thanks to
continuous trust of our clients. And, to meet our clients'
various needs, we will make every effort to maintain
commitment to excellence incessantly.
정진국제특허법률사무소는 지식재산권 분야의 전문지식을 가진 직
원들이 고객 여러분께서 맡겨주신 지식재산권 분야의 국내 업무와
PCT출원 등의 국제출원업무, 특허심판, 감정, 기술평가 및 특허침해
소송 등 지식재산권에 관한 전반적인 서비스 업무를 신의에 따라 성
실하고, 신속 정확하게 처리해 드리고 있습니다.
저희 정진국제특허법률사무소는 언제나 고객의 눈높이에서 고객이
원하는 바를 찾아 고객이 필요로 하는 특허법률서비스를 제공하겠습
니다.
Kim, Jin Hwan 김진환
462-120. 2F Jungang Induspia V, 138-6 Sangdaewon
-dong, Jungwon-gu, Seongnam-si, Gyeonggi-do,
Korea
82-31-737-3300
82-31-737-3301
[email protected]
http://www.creagene.com
CEO
ADD
TEL
FAX
E-MAIL
URL
E
LEE KYUNG HA 이경하
(137-864) 2477 Nambusunhwan-ro, Seocho-gu,
Seoul, Korea
82-02-840-6777
82-02-841-1213
[email protected]
http://www.jw-pharma.co.kr
X
H
I
B
I
T
S
CEO
ADD
TEL
FAX
E-MAIL
URL
E
LEE KYUNG HA 이경하
(137-864) 2477 Nambusunhwan-ro, Seocho-gu,
Seoul, Korea
82-02-840-6777
82-02-841-1213
[email protected]
http://www.jw-pharma.co.kr
X
H
I
B
I
Research & Clinical Development Pipeline
Global Business Portfolio
I.V. Solutions
Research & Clinical Development Pipeline
Global Business Portfolio
I.V. Solutions
연구개발 및 임상개발 현황
글로벌 사업 현황
수액 전문생산
연구개발 및 임상개발 현황
글로벌 사업 현황
수액 전문생산
I
N
T
R
O
D
U
C
T
I
O
N
JW Pharmaceutical has been striving to produce and
provide innovative new technologies and services heading
for healthy lives of human beings. Based on leading
competitiveness in the prescription drug market, JW
Pharmaceutical has built up strong sales network across
the country and superior pipelines in I.V- solutions,
antibiotic, cardiovascular, gastrointestinal, nephrology/
antianaemic, anticancer and neuropsychiatry. Moreover,
JW Pharmaceutical is making efforts to provide medical
equipments, various self-modification products and
OTC products satisfying the requirements for prevention
and diagnosis of diseases. Also, JW Pharmaceutical has
diligently opened up itself to the overseas market with
competitive APIs and finished products developed on a
basis of our creative technologies. JW Pharmaceutical will
go together for the life and the nature.
I
N
T
R
O
D
U
C
T
T
I
S
O
N
JW Pharmaceutical has been striving to produce and
provide innovative new technologies and services heading
for healthy lives of human beings. Based on leading
competitiveness in the prescription drug market, JW
Pharmaceutical has built up strong sales network across
the country and superior pipelines in I.V- solutions,
antibiotic, cardiovascular, gastrointestinal, nephrology/
antianaemic, anticancer and neuropsychiatry. Moreover,
JW Pharmaceutical is making efforts to provide medical
equipments, various self-modification products and
OTC products satisfying the requirements for prevention
and diagnosis of diseases. Also, JW Pharmaceutical has
diligently opened up itself to the overseas market with
competitive APIs and finished products developed on a
basis of our creative technologies. JW Pharmaceutical will
go together for the life and the nature.
JW중외제약은 글로벌 기준에 부합하는 혁신신약 개발기술과 강력한 JW중외제약은 글로벌 기준에 부합하는 혁신신약 개발기술과 강력한
144
오리지널 파이프라인, 이미페넴 퍼스트 제네릭 세계 최초 개발 등 오
랜 경험과 기술력을 바탕으로 ‘생명존중, 개척정신’의 창업이념을 실
현하며 국내 전문의약품 시장 선도하고 있는 대표적인 제약기업이자
오리지널 파이프라인, 이미페넴 퍼스트 제네릭 세계 최초 개발 등 오
랜 경험과 기술력을 바탕으로 ‘생명존중, 개척정신’의 창업이념을 실
현하며 국내 전문의약품 시장 선도하고 있는 대표적인 제약기업이자
세계 5대 수액제 전문 생산기업으로 글로벌 헬스케어 그룹으로 거듭
나고 있습니다. JW중외제약은 글로벌 시장에서 경쟁력 있는 신기술
및 제품 개발과 동시에 사회적 책임을 실천하며, '사람&환경&미래'
라는 브랜드 슬로건 아래 인류의 건강과 함께 환경까지 생각하는 초
일류 기업으로 도약해 나갈 것입니다.
세계 5대 수액제 전문 생산기업으로 글로벌 헬스케어 그룹으로 거듭
나고 있습니다. JW중외제약은 글로벌 시장에서 경쟁력 있는 신기술
및 제품 개발과 동시에 사회적 책임을 실천하며, '사람&환경&미래'
라는 브랜드 슬로건 아래 인류의 건강과 함께 환경까지 생각하는 초
일류 기업으로 도약해 나갈 것입니다.
145
M22
M25
KBI BIOPHARMA
L10
KCRN Research, LLC
N35
Kem-En-Tec Diagnostics
KEOSYS Medical Imaging
캠엔택 다이그노스틱스
CEO
ADD
TEL
FAX
E-MAIL
URL
Joe Mcmahon
1101 hamlin Road, durham, nc 27704 USA
1-630-518-2172
1-630-983-6017
[email protected]
http://www.kbibiopharma.com
CEO
ADD
TEL
FAX
E-MAIL
URL
I
N
T
R
O
D
U
C
T
I
O
Hugh Lee 이형주
20271 Goldenrod Lane Suite 2014, Germantown,
MD 20876 USA
1-301-540-2600
1-877-310-9158
[email protected]
http://www.kcrnresearch.com
CEO
ADD
TEL
FAX
E-MAIL
URL
N
I
X
H
I
B
I
T
S
Contract services for biologic drugs such as monoclonal E
antibodies including analytical method development, Clinical and regulatory service on early phase drug
formulation development, process development , cGMP development in US
manufacturing of recombinant proteins by fermentation
and cell culture, lot release, ICH stability studies.
초기 미국 임상시험과 관련 RA 서비스
I
N
T
R
O
D
U
C
T
I
O
T
R
O
D
U
C
T
I
CEO
ADD
TEL
FAX
E-MAIL
O
N
효소면역측정법(substrates)과 면역측정법(immunoassays)을 위
한 완충용액 (buffer)들을 생산하는 유럽의 선두적인 생산업체입니
다. 본사와 제조시설들은 덴마크 코펜하겐의 외각지역에 위치해 있으
URL
E
Mr. Jerome FORTINEAU
1, impasse Augustin Fresnel, ZA du Moulin Neuf,
BP 60227 44815 SAINT HERBLAIN Cedex, FRANCE
33 2 40 92 26 13
33 2 40 92 26 14
[email protected]
[email protected]
http://www.keosys.com
X
H
I
B
I
T
S
Medical Imaging Services for Clinical Trials
며, 미국지사를 두고 프리미엄 ELISA, 면역 블로팅법(단백질 분석 기
법)과 면역조직화학을 위한 성분들을 제공해오고 있습니다
I
N
T
R
O
D
U
C
T
I
O
N
KEOSYS is a global provider of medical imaging data
management solutions and full central reading services for
clinical trials.
N
KCRN Research is the first Korean CRO in US with handson clinical and regulatory experiences in US clinical studies
and regulatory affairs and provides hands-on services
with ‘low cost high efficiency’ through practical strategies
for the early phase drug development in US of Korean
pharmaceutical/biopharmaceutical companies
N
Henrik Christensen
Kuldyssen 10 DK-2630 Taastrup Denmark
45-3927-1771
45-3920-0178
[email protected]
www.kem-en-tec.com
'
KCRN Research은 미국 임상시험과 관련 RA 실무 경험을 갖춘 최
초의 한국 CRO로서, 한국 제약/바이오 회사들의 글로벌 신약 개발
초기 단계에 ‘low cost high efficiency’ 의 실무서비스를 제공하고
있습니다.
146
147
A30
E37
으로 하여 교육, 연구, 산업분야는 물론 바이오, 의료진단 분야의 제
품들로 글로벌 시장에 진출하여 세계 일류기업으로 도약하는 기틀을
마련하고자 하며, 특히 고성장이 예상되는 체외진단 분야에 성공적으
K-MAC
케이맥(주)
CEO
ADD
TEL
FAX
E-MAIL
URL
로 진출 하고자 케이맥의 R&D 센터는 시장의 다양한 요구에 부합할
Joong-whan Lee 이중환
수 있는 획기적인 선도기술을 가진 체외진단기기 신제품들을 출시하
554 Yongsan-dong, Yuseong-gu, Daejeon, 305기 위하여 오늘도 끊임없이 연구 개발에 매진하고 있습니다.
500 Korea
82-42-930-3800
82-42-930-3979
[email protected]
http://www.kmac.com/eng
한국콜마(주)
CEO
ADD
TEL
FAX
E-MAIL
URL
E
E
X
H
I
B
I
T
S
Real-time PCR
Automatic Diagnostic System
I
N
T
R
O
D
U
C
T
I
O
N
Since1996, K-MAC (Korea Materials & Analysis Corp.)
has developed and supplied the unique and advanced
analytical solution for Semiconductor, Flat Panel Display,
Electronic Materials, Chemical Analysis and Life Sciences.
K-MAC, a technology leader and driving force of the
measurement and diagnostics markets, has accomplished
a remarkable growth from its establishment and achieved
worldwide recognition for its exceptional performance.
To face new challenges and opportunities, K-MAC has
made endless commitments for research and development.
K-MAC has been developing diverse IVD products for
human-kinds. We improved quality of our products
persistently by knowhow of professionals and our own core
technology. In addition, R&D Center is preparing for grand
launching of new and innovative IVD products according to
customer’s needs.
케이맥은 1996년 설립 이래 반도체, 평판디스플레이, 정보소재, 생
명공학 및 화학분석 분야에서 세계 일류의 기술력으로 시장을 선도
하기 위해 최선을 다하고 있습니다. 더불어 급변하는 산업의 요구에
부응하면서 끊임없는 도전과 지속된 연구로 성장에 성장을 거듭한
결과, 오늘의 케이맥은 명실상부한 측정•분석기기 산업의 대표주자
가 되었으며, 평판 디스플레이 공정용 박막두께 측정기를 비롯한 계
측검사 장비는 글로벌 시장에서도 그 기술력을 인정받아 현재 세계
유수의 기업들과 파트너십을 맺고 있습니다.
하지만 오늘의 성공에 그치지 않고 지속 가능한 성장 잠재력을 가진
시장으로 사업을 다각화하며 끊임없는 기술 개발을 통해 어디에도
비교될 수 없는 단단한 내일을 준비하고 있습니다. 평판 디스플레이
산업용 장비에서 구축된 브랜드 파워와 기술력에 대한 신뢰를 근간
148
품, 건강기능식품의 연구, 개발에서부터 생산에 이르는 토털 서비스
를 제공하고 있습니다.
한국콜마는 의약품의 제조와 품질관리 등에 대한 엄격하고 철저한
생산시설과 품질관리 기능을 갖추고 의약품의 내용액제, 외용액제,
KOLMAR KOREA Co., Ltd.
Cho, Hong-Koo 조홍구
18 Saimdang-ro, Seocho-gu, Seoul, Korea
82-2-3485-0398
82-2-515-1532
[email protected]
http://www.kolmar.co.kr
X
H
I
B
I
고형제, 연고, 크림제를 생산할 수 있는 KGMP (우수의약품제조 및
품질관리기준) 시스템을 구축하고 있습니다.
T
S
Bondan Tab (Ibandronate Sodium 150mg)
Talniflumate Tab (Talniflumate 370mg)
Pelium Syrup (Pelargonium Sidoides Ext.)
Hiforge Tab (Valsartan Amlodipine besylate)
Kolmar Desmopressin Tab (Desmopressin acetate 0.2mg)
Mitra Cap (Itaconazole 100mg)
Tablets, Soft Capsules, Hard Capsules, Liquid Capsules, Dry
Syrups, Granulates, Powders, Ointments/Creams
본단정 (Ibandronate Sodium 150mg)
탈니플루메이트정 (Talniflumate 370mg)
펠리움 시럽 (Pelargonium Sidoides Ext)
하이포지정 (Valsartan Amlodipine besylate)
콜마 데스모프레신정 (Desmopressin acetate 0.2mg)
마이트라캡슐 (Itaconazole 100mg)
내용고형제 (정제, 캡슐, 파우더), 내용액제, 외용액제, 연고, 크림제
I
N
T
R
O
D
U
C
T
I
O
N
No 1. Pharmaceutical CMO Company in Korea We, Kolmar
Korea, have been specialized in Contract Manufacturing
Service of Pharmaceutical Products in Korea. One-stop
solution of Pharmaceuticals based on fast supply, highly
strict Q/C system and low-cost competitiveness is provided
to our customers
Kolmar Korea operates two production sites which provide
a technology that covers oral dosage forms and external
dosage forms such as liquid, solution, ointment, creams.
With extensive know-how and years of experience in
approving marketing authorization of 300 products from
KFDA, we have the skills you need in a partner.
한국콜마는 1990 년 화장품 OEM 기업으로 시작하여 국내에서
ODM Network라는 새로운 비즈니스 모델을 업계최초로 도입하여
정착시켰습니다. 우수한 품질력과 제조기술을 기반으로 화장품, 의약
149
B45
H22
센터를 두고 있으며, 그 중 오창센터에서는 고자기장 자기공명장치
Korea Basic Science Institute
한국기초과학지원연구원
CEO
ADD
TEL
FAX
E-MAIL
URL
E
Kwang Hwa Chung 정광화
169-148 Gwahak-ro, Yuseong-gu, Daejeon 305806, Korea
82-42-865-3663
82-42-865-3645
[email protected]
http://kbsi.re.kr
X
H
I
B
I
T
S
(900 MHz NMR)·초고분해능 질량분석기 (15 T FT-ICR MS)·고
분해능 이차이온 질량분석기 (HR-SIMS) 등 세계적 수준의 대형 연
구장비를 구축.운영하고 있습니다. ‘기초과학 진흥을 위한 연구지원
및 공동연구 수행’을 미션으로 하고 있는 기초 (연)은 이러한 대형 연
구장비와 탁월한 장비 운용 및 분석 지원 능력을 토대로 전국적인 네
트워크를 활용한 연구지원 및 공동연구를 수행하고 있습니다.
A33
KITECH (Korea Institute of Industrial Technology) KOMA BIOTECH
한국생산기술연구원
고마바이오텍(주)
CEO
나경환
CEO
TEL
82-41-5898-114
http://kitech.re.kr
ADD
URL
E
X
H
I
줄기세포 배양용 재조합성장인자
재생의학용 3D printer
홍보동영상, 리플렛, 연보, 등
I
N
T
R
O
D
U
C
T
I
O
N
Korea Basic Science Institute is a government funded
institute estalished in 1988 with the goal of promoting
basic science research. The institute has been developing
analytical technology, performing research support
activities and operating large-scale research facilities as a
sole research support institute for basic science in Korea.
KBSI is composed of Daedeok Headquarters, Ochang
Center and nine regional centers across the country and
provides distinctive support for national R&D through
these regional bases. We have installed and have been
operating world-class research equipments such as the
second largest High Voltage Electron Microscope (HVEM)
in the world installed in Daedeok HQs, High Field-Nuclear
Magnetic Resonance (HF-NMR), Fourier Transform Ion
Cyclotron Resonance Mass Spectrometer (FT-ICR MS) and
High Resolution-Secondary Ion Mass Spectrometer (HRSIMS), which are installed in Ochang Center. As our mission
statement proclaims, KBSI contributes to 'research support
and collaboration to advance national basic science' on the
basis of our large-scale research equipment, its effective
operation and high quality of analytical services through
our vast national network.
I
T
3D cell culture scaffold
Recombinant growth factors for stem cell culture
3D printer for regenerative medicine
3차원 세포배양 지지체
Promotional Video, Leaflet, Annual Report, etc.
B
S
TEL
FAX
E-MAIL
URL
E
Sang Hoon Moon 문상훈
19F, IS BIZ Tower, Sunyudo Station 1cha, Yangpyeongdong, 5ga 1-1, Yeongdeungpo-gu, Seoul 150-105,
Korea
82-02-579-8787
82-02-578-7042
[email protected]
http://www.komabiotech.co.kr/
X
H
I
B
I
T
S
Luminex system & Multiplex assay kit, Drug discovery
service, Cytokine ELISA Kits, Assay kits, Electrophoresis
system & Pre-Cast Gels, PCR reagents, Cell culture media,
7X Cleaning solutions, Muse cell analyzer, Antibodies,
Inhibitors, Enzymes, stem cell Biochemicals
루미넥스 & 멀티플렉스 분석 키트, 신약개발분석서비스, 엘라이자,
다양한 종류의 분석 키트, 전기영동 관련 제품 및 프리케스트 젤,
PCR 관련 제품, 세포배양 배지, 7X 실험전용 세척액, 세포 카운팅 &
분석기기, 항체, 인히비터, 엔자임, 바이오케미칼
I
N
T
R
O
D
U
C
T
I
O
N
KOMA BIOTECH manufactures and provides reagents and
tools for life science research, including molecular biology,
immunology, cell biology, proteomics and genomics
research. Key products include protein electrophoresis
systems & pre-cast gels, PCR amplification reagents,
Transfection reagent, Direct PCR, nucleic acid purification
kits and ELISA kits for cytokines, immunoglobulins.
고마바이오텍(주)는 생명과학 연구를 위한 다양하고 품질 좋은 시약
및 소모품, 장비 등을 공급해오고 있으며, 좀 더 편리하고 사용하기
쉬운 연구용 실험시약의 자체개발과 생산에 힘쓰고 있는 바이오 벤
처 기업입니다. 항체, 인히비터, 바이오케미칼, 다양한 종류의 분석
키트, 멀티플렉스 키트와 루미넥스를 이용한 분석서비스 제공에 이르
기까지 생명공학 연구에 필요한 모든 시약 제품을 제공해드립니다.
한국기초과학지원연구원은 기초과학 진흥을 목적으로 1988년 설립
된 정부출연연구원입니다. 기초 (연)은 대한민국 기초과학발전을 위
한 연구지원 및 분석과학, 대형 연구장비 운용 등 기초과학 연구지원
을 수행하는 기관입니다. 또한, 초고전압투과전자현미경이 설치.운용
되고 있는 대덕 본원과 오창센터를 중심으로 전국 9개 지역에 지역
150
151
I10
E45
뜻을 모아 2011년 9월 출범했습니다.
후보물질에서 비임상·임상시험까지 신약개발 전주기에 걸쳐 혁신적
Korea Drug Development Fund
범부처신약개발사업단
CEO
ADD
TEL
FAX
E-MAIL
URL
E
Dongho Lee 이동호
14th Fl, KT&G Seodaemun Tower, 21-1, Migeundong, Seodaemun-gu, Seoul, 120-020, Korea
82-2-361-3600
82-2-361-3609
[email protected]
http://www.kddf.org
X
H
I
B
I
T
S
Posters
포스터
I
N
T
R
O
D
U
C
T
I
O
N
The Korea Drug Development Fund (KDDF) is a government
-initiated drug development program established in 2011
and is government-initiated drug development program
that manages a total budget of US $1 billion. The program
is backed by a collaborative effort of healthcare related
Korean ministries.
Signaling a new change in gover nment funded
strategy, KDDF operates through close management
of development projects, linking grant support to the
achievement of milestone-based research objectives. This
investment in the country’s future is aimed at nurturing
success that is initially driven by government and then
transformed into a sustainable growth engine through
valued researchers and industry partners. We openly
welcome foreign investment and partnerships with
international organizations who seek to gain a competitive
edge in the next ten years.
Since our establishment we have reviewed over 132
proposals and now have 37 projects were funded under
our management. We actively focus on supporting
business development and partnering activities for
licensing out and also aim to establish international expertnetworking to move Korea into a global position of
leadership in new drug R&D.
범부처신약개발사업단은 세계 시장에 진출할 신약을 개발하고 신약
개발 분야 글로벌 경쟁력을 확보하고자 교육과학기술부 (현 미래창조
과학부)와 지식경제부 (현 산업통상자원부), 보건복지부 3개 부처가
152
인 투자•관리 체계를 갖추기 위해 부처 간 R&D 경계를 초월한 협력
을 바탕으로 출범한 사업단은 국내 최고의 전문가들이 역량을 발휘
할 수 있도록 2020년까지 9년간 1조600억원 (정부 5300억원, 민
간 5300억원)을 지원, 국내에서 글로벌 신약을 개발하는 결실을 맺
고자 합니다.
사업단은 2013년 현재까지 접수된 총 132개의 연구과제 중 37개
를 선정, 신약개발 연구를 지원하고 있습니다. 체계적인 시스템의 선
정과정과 과제 경쟁력을 높이는 관리로 지원 과제가 잘 성숙해 갈 수
있도록 돕고 있으며, 국내 신약개발 연구 역량을 강화할 수 있는 사
업개발 및 라이센싱-아웃을 위한 파트너링 활동 등에도 적극 나서고
있습니다.
훌륭한 연구자들 및 기업들과 국내외 전문가 네트워크를 통하여 글
로벌 신약개발 사업 추진체계를 구축하여 한국이 글로벌 신약개발
국가로 도약하는데 기여할 것입니다.
Korea Health Industry Development Institute
(Medical Korea)
한국보건산업진흥원 (메디컬코리아)
CEO
ADD
TEL
FAX
E-MAIL
URL
E
Ko Kyung-hwa 고경화
K orea Health Industry Development Institute,
Osong Health Tethnology Administration Complex.,
187 Osongsaengmyeon 2 (i)-ro, Chungcheongbukdo South Korea (Zip 363-700)
82-43-713-8234
82-43-713-8906
[email protected]
http://medical-korea.org/home/en/main/main.asp
X
H
I
B
I
T
-홍보부스 운영 : 국내외 관련 기관 약 60여 테마별 부스 전시 예
정
*국가별 환자식 전시 및 시식회, 해외환자 선도업체 등 다양한 테마
별 부스 운영
-병원체험행사 : 중국, 중동 및 동남아, CIS 등 주요 전략국가 정
부기관 및 의료기관, 해외 환자유치 에이전시, 글로벌 보험사 관
계자 등 11개국 40여명 참가 예정
S
Medical Korea 2014 : Global Healthcare & Medical Tourism
Conference
메디컬 코리아 2014: 제5회 글로벌헬스케어 & 의료관광 컨퍼런스
I
N
T
R
O
D
U
C
T
I
O
N
The annual Global Healthcare & Medical Tourism
Conference has now secured its position as the largest
platform for information exchange in Asia.
And Medical Korea 2014 - the 5th Global Healthcare &
Medical Tourism Conference will bring a central issue in
the field of medical tourism in the form of seminar, panel
discussion etc.
Moreover, promotional exhibitions and business meetings
will enrich your international networks and provide you a
quality healthcare information.
Especially, BIO KOREA 2014, which is the biggest Biorelated exhibition in Asia, will simultaneously be held at the
same location so that it makes your insight widen.
메디컬 코리아 2014: 제5회 글로벌헬스케어 & 의료관광 컨퍼런스
목적
-아시아 최대 글로벌 헬스케어 비즈니스의 장을 마련하여 한국의
료 브랜드 인지도 강화 및 의료관광 선도국으로서 위상 제고
-국내 의료기관과 유치업체의 글로벌 네트워크 확대를 지원하여
주요 타켓 국가별 유치채널 확보 및 관련 상품 개발 촉진
내용
컨퍼런스 : 글로벌헬스케어 최신 트렌드 관련 발표 및 토론
-비즈니스 미팅 : 사전 온라인매칭을 통한 운영 (해외 바이어 50
여명)
153
P10
J20
G20
R25
Korea Biomedicine Industry Association
Korea Institute of Oriental Medicine
Korea Institute of Toxicology
한국바이오의약품협회
한국한의학연구원
안전성평가연구소
Kim Myung-Hyun 김명현
5 F, Mokchon B/D Sajikno 119 5th Nejadong,
Jongno-Gu, Seoul, Korea
82-2-725-8432
82-2-725-8439
www.kobia.kr
CEO
ADD
TEL
FAX
URL
CEO
ADD
TEL
FAX
E-MAIL
URL
I
N
T
R
O
D
U
C
T
I
O
Choi Seung-hoon 최승훈
1672 Yuseong-daero, Yuseong-gu, Daejeon 305811, Republic of Korea
82-42-8689580
82-42-8689616
[email protected]
http://www.kiom.re.kr
CEO
ADD
TEL
FAX
E-MAIL
URL
Korea Licorice Farming Association
Corporation
LEE Sang-Joon 이상준
1 41 Gajeongro, Yuseong-gu, Daejeon 305-600,
KOREA
82-42-610-8250
82-42-610-8085
[email protected]
http://www.kitox.re.kr
N
한국감초영농조합법인
CEO
ADD
TEL
FAX
E-MAIL
E
X
H
I
B
I
T
S
KOBIA was established on May 17th of 2011. Under E
business initiative by Main founder like Samsung, SK, Institution Overview & Research Achievements
CJ, Celltrion and etc, we have been conducting product
commercialization service in field of R&D and RA of 기관 소개 및 연구성과
biopharmaceuticals and globalization of those products
Also, wa have been doing international business for
I
N
T
R
O
D
U
C
T
I
O
N
facilitative in and out licensing for member companies.
KIOM is the only government-funded research institute
한국바이오의약품협회는 2012년 5월 17일 창립되었다. 삼성, CJ, for traditional Korean medicine. Since its establishment in
SK, 셀트리온, 세원셀론텍, 메디포스트, 드림씨아이에스등의 발기하 1994, KIOM has strived to develop future-oriented original
에 바이오의약품의 연구개발, 임상, 인허가 등 제품화를 지원하고 글 technology for Korean medical treatments, develop core
로벌 진출을 가속화하기 위한 사업을 추진 중이다. 바이오의약품 전 technology of Korean medicine-based herbal drugs to
문가 양성을 추진하고 바이오의약품 기업 간 제품/기술 등 교류를 추 support the National Agenda, and establish Korean medical
진하는 가교역할을 수행 중이다. 정부와 기업간의 원활한 소통과 협 knowledge and the informatics infrastructure based on
력을 위한 공동, 위탁 사업 등도 적극 수행 중이다.
Korean medical knowledge accumulated over centuries.
Through these efforts, the institute is taking the lead in
scientific advancement, standardization, industrialization
and globalization of Korean medicine.
한국한의학연구원은 1994년 설립된 한의학 분야 유일의 정부출연연
구기관입니다. 우리 연구원은 수천 년 동안 축적된 한의학 지식을 바
탕으로 미래 선도형 한의치료원천기술개발, 국가 아젠다 해결형 한약
제제 개발, 한의기술인프라 구축 추진을 위해 최선을 다하고 있으며,
이러한 노력을 통해 한의학의 과학화와 표준화, 산업화, 세계화를 선
도하고 있습니다.
E
X
H
I
B
I
T
S
Nonclinical Services
KIT가 제공하는 다양한 비임상분야 연구ㆍ시험 서비스
Yong-sang jang 장용상
390-810 충북 제천 송학면 무도길 65
82-43-651-1015
82-43-648-1015
[email protected]
X
H
I
B
I
T
S
감초원물 (500g, 300g, 100g, 50g)
I
N
T
R
O
D
U
C
T
I
O
N
감초영농조합법인은 대부분 수입에 의존하고 있던 감초 대량재배에
I
N
T
R
O
D
U
C
T
I
O
N
Korea Institute of Toxicology (KIT) is a world-class
prestigious nonclinical contract research organization
located in South Korea.
KIT’s GLP system has been certified by Korean and
international regulatory authorities based on OECD and US
FDA GLP criteria.
Also, KIT is the first organization in Asia accredited by
AAALAC International for human laboratory animal
treatment.
KIT offers a full range of nonclinical research with high
scientific standards and competitive prices.
성공하였으며, 우리지역 제천에서는 국산감초 생산량의 약 80%에
해당하는 47톤이 생산되고 있습니다. 대량으로 재배되는 감초를 대
량으로 더 안전하게 가공하고, 나아가 지역농가의 소득증대에 기여하
는 기업이 되고자 노력하고 있습니다
안전성평가연구소 (KIT)는 안전성평가 기술에 관한 연구 개발을 주도
하고 관련 분야 전문시험 서비스를 제공함으로써, 국민 보건 향상과 인
류 복지 증대에 이바지함을 목적으로 2002년 1월에 설립되었습니다.
국가 안전성평가 체계구축과 관련 기술 축적에 20여 년의 역사를 가
지고 있는 KIT는 국내의 보건복지부 (1988), 환경부 (1998), 농림
부 (2002) GLP인증에 이어 일본 농림수산성 GLP인증 (1990)과
2000년 OECD GLP 상호방문평가에 이어 2005년과 2012년 미국
FDA의 실태조사 결과 적격 (VAI)기관 인증을 받은 바 있습니다.
신약 및 각종 화학물질에 대한 안전성평가 (독성평가)를 다양한 실험
동물 (쥐, 토끼, 개, 영장류)을 통해 진행하고 있는 KIT는 대전연구소
에 이어 최근
전북영장류시험본부 (2010)와 경남환경독성본부
(2012)를 새로이 마련, 국제적 수준의 GLP 시설과 전문인력, 과학적
시스템을 재정비함으로써 ‘세계 TOP10 안전성평가기관’ 도약의 비
전을 실현하고 있습니다.
154
155
E46
D10
을 위해 2010년 3월 보건복지부 인가의 사단법인 한국국제의료협회
로 출범하였습니다.
Korea International Medical Association
사단법인 한국국제의료협회
CEO
ADD
TEL
FAX
E-MAIL
URL
E
Byung-Hee Oh 오병희
363-700 Secretariat 4th Froor, Korea Health Industry
Development Institute Osong Health Technology
Administration Complex 187 Osongsaengmyeong2ro, Gangoe-Myeon Cheongwon-Gun, ChungcheongbukDo, Republic of Korea
82-43-713-8353
82-43-713-8906
[email protected]
http://www.koreahealthtour.co.kr
X
H
I
B
I
T
S
홍보 동영상 및 홍보 책자 등
I
N
T
R
O
D
U
C
T
I
O
N
KIMA was found in 2007 as a public-private joint
conference group to promote the excellent services of the
Korean medical institutions to changed to a corporation
aggregate authorized by the Ministry of Health and
Welfare in 2010.
Over the past 5 years, KIMA has undertaken a variety of
activities including holding a road show and FAM tour with
pride and belief that Korean provides a world- class medical
service, besides, it has played a pivotal role in Global
healthcare business through supporting to foster human
resources in the field of global healthcare, producing
promotional booklets in 4 languages (English, Chinese,
Russian, Arabic), and managing the KIMA websites.
Now a total of 36 renowned teaching hospitals, general
hospitals, and special clinics have joined and actively
engaged as a member, and as for an government
institutions, the Ministry of Health and Welfare, the Korea
Healthcare Industry Development Institute (KHIDI) and
Korea tourism Organization (KTO) participate as a special
member.
Hence forward, KIMA will play a leading role to contribute
to international society and globalization of Korean medical
technology & services by providing medical education and
charity to underdeveloped countries.
한국국제의료협회는 한국의 우수한 의료서비스를 해외환자들에게 홍
보하기 위해 2007년 설립된 민관 공동의 협의체로 원활한 사업수행
156
협회는 지난 5년간 한국의 의료서비스는 곧 세계적 수준이라는 자부
심과 신념으로 의료기관 해외로드쇼, 한국병원 체험행사 등 다양한
활동을 전개함과 동시에, 국제의료 관련 인적 인프라 구축지원, 4개
국어 (영•중•러•아랍어) 홍보책자 제작, 홈페이지 운영사업 등을
통해 해외환자유치에 중추적인 역할을 해왔습니다.
현재 국내 유수의 36개 대학병원, 종합병원, 전문클리닉이 회원으로
가입되어 활동 중이며, 정부기관으로는 보건복지부, 한국보건산업진
흥원, 한국관광공사가 특별회원으로 함께 참여하고 있습니다.
향후 협회는 저개발국가에 대한 의료교육 및 의료봉사를 통해 국제
사회에 기여함과 동시에 한국의 의료기술 및 서비스가 세계화될 수
있도록 선도적인 역할을 하겠습니다. 또한 다양한 사업과 홍보를 통
해 세계에 대한민국의 의료브랜드를 높이는 데 중추적인 역할을 하
겠습니다.
I42
Korea National Enterprise for Clinical Trials
KOREA PHARM 2014
국가임상시험사업단
제4회 국제의약품전
CEO
ADD
TEL
FAX
E-MAIL
URL
I
N
Sang-Goo SHIN 신상구
1F. BioMedical BLDG. 101 Daehangno, Jongno-gu,
Seoul 110-744, Korea
82-2-3668-7609
82-2-3675-4777
[email protected]
http://www.konect.or.kr
T
R
O
D
U
C
T
I
O
N
As a government funded organization responsible for
expanding the infrastructure of clinical trials in Korea,
Korea National Enterprise for Clinical Trials(KoNECT)
manages regional clinical trial centers, operates clinical
trials training academies and provides clinical trial
technology development programs. KoNECT is leading the
way in promoting Korea as the global hub of clinical trials.
국가임상시험사업단은 의료산업의 지역 균형 발전과 임상연구 인력
개발 및 핵심기술 개발을 위해 정부, 학계, 제약산업계가 뜻을 모아
보건복지부 지정 사업단으로 2007년 12월 출범했다.
국가임상시험사업단은 대한민국의 임상시험 인프라 구축을 위해 지
역임상시험센터 지정 및 시설 장비 확충, 임상시험 전문인력 양성, 임
상시험 신기술개발을 지원하고 있다. 또한, 국내외 관련 기관 및 연
구자 간의 네트워크를 활성화해 ‘대한민국을 세계적인 임상시험 허브
로’ 도약하기 위한 구심점 역할을 수행하고 있다.
이번 바이오코리아에는 CTC(가톨릭대, 건국대, 경북대, 고려대구로,
고려대안암, 동아대, 서울대, 이대목동, 인제제대부산, 인하대, 전남
대), CRO(드림CIS, C&R리서치, LSK Global, GDFI, 메디칼엑셀런
스, ICON, 에이플러스, Novotec, Quintiles, Paraxel, PPD)가 공동
으로 부스를 운영한다.
CEO
ADD
TEL
FAX
E-MAIL
URL
E
Kim Young Soo 김영수
Rm. 501, Geumsan Bldg., 750, Gukhoe-daero,
Yeongdeungpo-gu, Seoul, 150-727, Korea
82-2-785-4771
82-2-785-6117
[email protected]
http://www.koreapharm.org
X
H
I
B
I
T
S
KOREA PHARM 2014 (The 4th International Pharmaceutical
Ingredient Exhibition)
June 10 (Tue.) ~ 13 (Fri.), 2014
KINTEX 1, KOREA
I
N
T
R
O
D
U
C
T
I
O
N
As KOREA PHARM 2014 is hosted by MFDS (Ministry
of Food and Drug Safety), organized by KPMA (Korea
Pharmaceutical Manufacturers Association), Kyungyon
Exhibition Corp., KOREA PHARM 2014 becomes the most
important industrial event of pharmaceutical field in Korea.
On behalf of Organizer, we cordially invite you to KOREA
PHARM 2014 to be held on June 10~13, 2014, KINTEX,
KOREA. The government in South Korea has announced
capital and institutional support to boost pharmaceutical
manufacturing, with the aim of becoming one of the
world's Top seven global pharmaceutical producing
countries by 2020.
At the same time, the Korea Drug Development Fund was
set up in 2011 with $1.6 billion to develop at least 10 new
drugs by 2020 for the global market. Under the theme
above, KOREA PHARM 2014 will be the best platform to
initiate or expand your market share in Korea as well as
Asia-Pacific region.
국산의약품의 홍보 및 세계화를 추진하고, 해외시장진출 지원을 목적
으로 개최하는 KOREA PHARM 전시회는 식품의약품안전처가 주
최하고 한국제약협회, 경연전람이 주관하는 국내 유일의 국제의약품
전시회입니다.
KOREA PHARM은 유력 해외바이어 초청은 물론 식약처 주최 의약
품 정책설명회, GMP 정책설명회, 해외바이어 초청 수출상담회, 각
종 의약품 관련 세미나 등 다채로운 행사가 동시 개최되어 제약업계
에 새로운 비즈니스의 장을 마련합니다.
157
C13
F20
Korea Research Institute of Bioscience and
Biotechnology
한국생명공학연구원
ADD
TEL
FAX
URL
O10
Korea Testing & Research Institute
KOREA UNITED PHARM. INC.
Korea University Medical Center
한국화학융합시험연구원
한국유나이티드제약(주)
고려대학교 의료원
CEO
Tae Kwang Oh 오태광
125 Gwahak-ro, Yuseong-gu, Daejeon 306-809,
Korea
82-42-860-4114
82-42-861-1759
http://www.kribb.re.kr/eng
CEO
K30
ADD
TEL
FAX
E-MAIL
URL
Choi Hyeongki 최형기
155, Beodeunaru, Yeongdeungpo-gu, Seoul, 150038, Korea
82-02-2164-0011
82-02-2164-0011
[email protected]
http://www.ktr.or.kr
CEO
ADD
TEL
FAX
E-MAIL
URL
Gang Deok Young 강덕영
2 5-23, Nojanggongdan-gil, Jeondong-myeon,
Sejong-si, Republic of Korea
82-2-558-8612
82-2-558-8613
[email protected]
http://www.kup.co.kr
CEO
ADD
TEL
FAX
E-MAIL
URL
E
E
X
H
I
B
I
T
S
E
X
H
I
B
I
T
S
Introduction to business organizations (testing, certification,
consulting)
- Main Achievements with products
-To protect patent right and facilitate technology transfer
of research outcomes
기관 업무 소개 (시험, 인증, 컨설팅)
-Introducing National Biosafety Framework and
KBCH(KoreaBiosafety Clearing House) activity
I
- 연구원 대표성공사례
-연구성과의 확산 및 기술사업화 촉진을 위한 특허관리 및 전략적
기술 마케팅
-바이오안전성 국가관리체계 소개 및 한국바이오안전성정보센터
(KBCH) 활동 홍보
I
N
T
R
O
D
U
C
T
I
O
N
KRIBB is the only government research institute dedicated
to biotechnology research in Korea across a broad span
of expertise, from basic studies for the fundamental
understanding of life phenomena to applied studies such
as new drug discovery, novel biomaterials, integrated
biotechnology, and bioinformation.
한국생명공학연구원은 생명현상의 근본적 이해를 위한 기초연구를
비롯하여 보건의료, 식량증산, 바이오신소재, 환경정화, 신 에너지개
발 등 첨단 생명공학연구를 수행하고 있는 국내 유일의 바이오전문
정부출연 연구기관입니다.
N
T
R
O
D
U
C
T
I
O
N
Korea's representative testing, certifying, consulting
institute, KTR. KTR (Korea Testing and Research institute),
established on National Standards Law, is an international
testing certifying institute and conducts tests, inspections
and product certifications for bio-industry including
the areas of chemistry, the environment, agrichemicals
and new medicine areas as well as, engineering and
construction, material parts, electronics and electrics, EMI,
and IT.
23 countries, 92 organizations network worldwide, KTR is
a partner for national companies for global market.
KTR is a laboratory for Korean product development and
quality improvement, helping save money and time in
acquiring such international certifications as CE, GOST-R,
JIS, NSF, REACH, IECEE, EnergyStar and FCC. required for
exports overseas.
한국을 대표하는 시험·인증·기술컨설팅 기관 KTR.
국가표준기본법에 의해 설립된 KTR은 화학을 비롯한 전기전자, 자동
차·조선, 토목·건축, 금속, 환경, 의료기기, 헬스케어 신재생에너지
및 녹색산업 등 산업 전분야에 대한 종합 시험·인증·기술컨설팅
업무를 실시하고 있는 국제공인 시험•인증기관입니다.
전세계 23개국 및 국제기구 92개 기관과 네트워크, KTR은 세계속으
로 뻗어나가는 국내기업의 파트너입니다.
E
X
H
I
B
I
T
S
Clanza CRⓇ tab.
Cilostan CRⓇtab.
Clavixin DuoⓇ cap.
Leen Kim 김 린
73, Inchon-ro, Seongbuk-gu, Seoul 136-705
82-2-2286-1535
82-2-2286-1120
[email protected]
http://www.kumc.or.kr/main/index.do
X
H
I
B
I
T
S
Medical Device etc.
의료기기 외
클란자CRⓇ정
실로스탄CRⓇ정
클라빅신듀오Ⓡ캡슐
I
N
T
R
O
D
U
C
T
I
O
N
We, Korea United Pharm. Inc., have been manufacturing,
marketing, and selling over 500 pharmaceutical products,
since 1987. At present, We have branch offices in the
Philippines, the USA, Myanmar and Vietnam and have
been exporting to 30 countries around the world. We
have exellent researchers and increased investment in
our Research & Development program, which allows
us to manufacture products at the highest quality. We
are expending our presence globally by out-licensing
of Incrementally Modified Drugs to Eastern Europe and
China.
한국유나이티드제약은 1987년 설립되었으며, 미국, 베트남, 필리핀
지사를 통해 국내는 물론 세계 30여개국에 수출하는 한국인이 주인
인 다국적 제약기업입니다. 지속적인 R&D투자로 고품질의 의약품과
신개품 개발에 힘쓰고 있으며 현재 3개의 개량신약을 출시하여 업계
내 개량신약 선두주자로 거듭났습니다. 현재 개량신약 제품은 동유럽
과 중국과의 라이센스 아웃계약으로 세계적으로 한국의 제약기술을
널리 알리고 있습니다.
KTR은 KC, KS 등 국내인증은 물론, 해외 23개국, 2개 국제기구의
92개 기관과 사업 파트너십을 구축, 유럽 러시아 일본 미국 등 해외
주요수출국에서 발행하고 있는 CE, GOST-R, JIS, IECEE-CB, FCC,
NSF, 에너지스타 등의 해외인증을 짧은 기간에 저비용으로 받을 수
있도록 지원하고 있습니다.
158
159
E35
B20
B38 & 37
O10
Kwangdong Pharmaceutical Co., Ltd.
Kyeong Bang Co., Ltd.
Kyongshin Scientific Co. Ltd
광동제약
(주)경방
경신과학(주)
CEO
ADD
TEL
FAX
E-MAIL
URL
CHOI, SUNG WON 최성원
1577-4 Seocho-dong, Seocho-gu, Seoul, Korea
82-2-6006-7258
82-2-6006-7024
[email protected]
http://www.ekdp.com
CEO
ADD
TEL
FAX
E-MAIL
Eu Su oK 어수옥
112 Business incubator, Daewon university college,
316 DaeHak-ro, Jecheon City, Chungbuk, Korea
82-43-648-3777
82-43-648-3776
[email protected]
CEO
ADD
TEL
FAX
E-MAIL
E
X
H
I
B
I
T
S
E
X
H
I
B
Pharmaceutical, Cosmetic, Health functional Food
PropolisSuYeonPeer-JinToothpaste
의약품, 화장품, 건강기능식품
프로폴리스수연피어진치약
I
N
T
R
O
D
U
C
T
I
O
N
Kwang Dong first started serving the people 50 years ago
with the goal of providing scientific benefits of the Oriental
medicine.
Keeping the goal in mind, all Kwang Dong employees
have endeavored to improve the health and quality of life
of people around the world. Our feature products have
commanded the patronage of numerous consumers,
including, for example, herbal cold syrup “Kwang Dong
Tang” and chewable Woo Whang Chong Shim Won,
which is casually deemed some form of the Oriental
panacea.
Furthermore, we have made continuous R&D investments
to develop various cancer drugs, which in turn have
laid sound foundations for creation of diverse products
covering everything from over-the-counter drugs to
prescription drugs to health.
저희 광동제약은 한방과학화를 창업이념으로 50년동안 독창적인
약품 개발과 우수한 기술도입을 통해 국민보관과 삶의 질 향상에
력을 다해왔습니다.
특히 한방감기약 "광동탕"과 동의보감 처방의 "우황청심원"은 수십
간 국민들의 사랑을 받고 있으며, 아울러 전문치료제 시장에서도
암제를 위한 우수 의약품 개발을 중앙연구소를 통해 지속적으로
진함으로써 일반의약품, 전문의약품, 건강드링크, 건강식품이라는
별화된 산업기반을 구축해 가고 있습니다.
160
의
전
년
항
추
차
I
N
T
R
O
D
U
I
T
S
URL
T
I
O
N
Teeth whitening and plaque removal and periodontal
disease is to suppress the toothpaste. In order to minimize
the stimulation of toothpaste propolis (honey) extract,
Peer-Jin (Cnidium, Angelica, Angelica dahurica root,
Artemisia capillaris, licorice, herbs extracted from pine
extract) was added to toothpaste.
By improving the effectiveness and usability of medicinal
plants in the oral cavity for the prevention of bacterial and
inflammatory improve sterilizing dental and oral cleanliness
can be maintained. The prevention and treatment of dental
caries and periodontal disease have the ability to added
herbal extracts herbal toothpaste.
치아미백과 프라그 제거 및 치주질환을 억제하기 위한 통상적인 치
약에 프로폴리스 (벌꿀)추출물, 피어진 (천궁, 당귀, 백지, 사철쑥, 감
초, 솔잎으로부터 추출한 한약재추출물)을 첨가하여 충치 및 치주염
을 예방하며 치료하는 기능을 가지는 한방추출물이 첨가된 한방치약
입니다.
-특허출원제품 (10-2012-0021647)
-규 격 : 170g*3ea
자연주의를 추구하며, 제천지역에서 생산, 판매되는 친환경 한약재를
사용하여, 우리가 일상 생활에서 매일 접하는 샴푸, 바디클린져, 치약
등을 생산, 판매하는 업체입니다.
Sangpyo Yook 육상표
(6th Fl. Namseoul BD., Yangjae-dong) Dongsanro
13gil 48, Seocho-gu Seoul, Republic of Korea,
137-896
82-2-576-6303
82-2-576-6309
[email protected]
http://www.kyongshin.co.kr
경북대학교병원 모발이식센터
CEO
ADD
TEL
FAX
E-MAIL
URL
URL
E
C
KYUNGPOOK NATIONAL UNIVERSITY
HOSPITAL HAIR TRANSPLANTATION CENTER
X
H
I
B
I
T
JUNGCHUL KIM 김정철
6F, Daegu City Center, #611, Gukchaebosang-ro,
Jung-gu, Daegu, Korea
82-53-200-4100
82-53-200-4123
[email protected]
http://knuh.kr
http://hair.knu.ac.kr
S
X
H
I
Hudson Robotics (PlateCrane, Solo Robotic pipettor, E
Micro10X Dispenser) / Bertin Technologies (Precellys24, Hair Transplantation, Shampoo
Precellys24-Dual, Minilys) / Zymo Research (DNA/RNA kit) /
Axis-Shield (Density Gradient media)
모발이식, 샴푸
I
N
T
R
O
D
U
C
T
I
O
N
I
N
T
R
O
D
B
U
I
C
T
T
I
S
O
N
Kyongshin Scientific Co., Ltd. have strived to identify
most exciting new technology companies and to supply
high quality research products focused on cell biology,
pharmaceutics, proteomics, genomics and diagnostics to
the life science community in Korea.
KNUH Hair Transplantation Center is Korea’s first hair
transplantation center established at a university hospital in
1996.
The follicular unit hair transplantation technique,
developed by Professor Jung-Chul Kim, makes it possible
to transplant 1, 000-1, 500 hairs per hour. With this
경신과학 (주)에서는 해외 선진 기업들의 우수한 품질의 제품을 발굴
technique, the survival rate of transplanted hairs exceeds
하여 국내에 공급하고 있습니다. 전시제품은 실험 자동화 장비 및 실
92%, thus guaranteeing the most natural looking result.
험결과를 빠르게 도출할 수 있는 시약키트 입니다.
The Center and its nationwide network of hospitals, with
Center-trained doctors, provide high-quality service for
hair-loss patients.
KNUH Hair Transplantation Center opens a new chapter
in male-pattern baldness through continuing research and
development.
경북대학교병원 모발이식센터는 1996년 국내 최초로 대학병원 내
설립되었으며 20년 이상의 임상경험과 높은 기술력을 보유하고 있습
니다.
본 센터에서는 김정철 교수가 개발한 모낭군 이식술과 KNU 식모기
를 이용하여 시간당 1, 500-2, 000여개 모발을 이식할 수 있으며,
이식된 모발의 생존율이 92%를 상회하므로 가장 자연스러우면서도
최상의 결과를 보장합니다.
경북대학교병원 모발이식센터는 끊임없는 연구와 개발을 통해 남성
형 탈모 치료의 새로운 지평을 열고 있습니다.
161
I20, F33
K30
이미 세계적인 기술과 제품력을 확보해오고 있으며, 이러한 연구개발
LG Life Sciences
력과 노하우를 바탕으로 의약, 동물의약, 정밀화학 등 3개 분야를 집
중 육성하고 있습니다.
LG생명과학
CEO
ADD
TEL
FAX
E-MAIL
URL
E
인체의약 분야에서는 국내 최초로 미국 FDA 승인을 획득한 차세
Iljae Jung 정일재
대 퀴놀론계 항균제 '팩티브' (03)를 비롯해 인터페론 '인터맥스 감마'
L G Gwanghwamun Bldg., 58, Saemunan-ro,
(89)와 '인터맥스 알파' (92), B형 간염백신 '유박스B' (92), 인성장호
Jongno-gu, Seoul, Korea 110-783
르몬 '유트로핀' (93), 퇴행성 관절염치료제 '히루안플러스' (05), 배란
82-2-6924-3366
유도제 '폴리트롭' (06), 서방형 성인성장호르몬 '디클라제' (07) 등을
82-2-6924-3051
독자기술로 개발, 상품화했습니다.
[email protected]
동물의약 분야에서는 세계 두번째로 젖소산유촉진제 'BST' (94)를 개
http://www.lgls.com
발해 미국을 제외한 세계 각국에서 시장점유율 1위를 기록하고 있으
며, 치료개념이 도입된 젖소 유방염 백신 '마스터백' (06)을 개발, 상
X
H
I
B
I
T
S
정밀화학 분야에서는 독자기술로 국산 신물질 1, 2호인 벼제초제 '피
안커' (97)와 살균제 '가디안' (99) 그리고 토양과 경엽 동시 적용이
가능한 신규제초제 '플럭소' (04)을 개발, 상품화한 바 있습니다.
LG 생명과학은 '세계적 신약을 보유한 초우량 생명과학회사'라는
Vision 달성을 위해, 개발후보 발굴 능력과 전략적 제휴를 확대하여
세계적인 신약 개발을 가속화하고 있으며, 선진시장에 대한 Global
Marketing 역량 확보에도 주력하고 있습니다.
LG생명과학은 대표적 고부가가치 두뇌산업으로 부각되고 있는 생명
과학, BT 산업분야의 국내 리더기업으로서 거듭나겠습니다.
Korea’s first diabetes treatment- Zemiglo
Sustain-released growth hormone – Eutropin Plus
Korea’s first multi vaccine – Euforvac-Hib
국내최초 당뇨치료제- 제미글로
소아용 서방형 성장호르몬 – 유트로핀플러스
국내최초 5가백신 – 유포박-히브
I
N
T
R
O
D
U
C
T
I
품화했습니다.
O
N
In August 2002, LG Life Sciences was upgraded from a
business division to a full-fledged LG affiliate in order to
grow as a life sciences specialist and maximize shareholder
value.
LG Life Sciences began research in genetic engineering
in 1981 and has invested steadily in the life sciences
ever since. This effort has already resulted in world-class
technology and product capabilities. The company has
focused R&D resources and know-how on three areaspharmaceuticals, animal health and specialty chemicals.
LG Life Sciences has developed and commercialized an
array of pharmaceuticals over the years. These include
interferon in 1989 (Intermax-gamma) and 1992 (Intermaxalpha), hepatitis B vaccine in 1992 (EUVAX B™), human
growth hormone in 1993 (EUTROPIN™), degenerative
arthritis treatment in 2005 (HYRUAN Plus™), rhFSH
(recombinant human follicle stimulating hormone) in 2006
(Follitrope™), and SR-hGH (Sustained Release-human
Growth Hormone) in 2007 (Declage™). A company
milestone was reached in 2003, when its next-generation
quinolone antibiotic (FACTIVEⓇ) was approved by the FDA
in the United States.
N25
Legochem Biosciences, Inc.
Marken Ltd
(주)레고켐 바이오사이언스
마켄
CEO
ADD
TEL
FAX
E-MAIL
URL
Yong Zu Kim 김용주
8 -26 Munpyeongseo-ro Daedeok-gu Daejeon,
306-220, Korea
82-42-861-0688
82-42-861-0689
[email protected]
http://www.legochembio.com
CEO
ADD
TEL
FAX
E-MAIL
URL
E
X
포스터판넬
H
I
B
I
T
Wes Wheeler
150-737, 10F Kyobo Securities Bldg, Yoido-dong,
97, Euisadang-daero, Youngdungpo-gu, Seoul,
Korea
82-2-6336-6776
82-2-6336-6886
[email protected]
http://www.marken.com
S
E
X
H
I
B
I
T
S
Domestic and Int’l Services
Depot Services
I
N
T
R
O
D
U
C
T
I
O
N
Cold Chain Management (Packagings for Ambient,
L egoChem Biosciences(“LCB”)is a leading chemistry- Refrigerated, Frozen, Cryogenic, Temperature Monitor)
based venture company working on the discovery and IATA DG (Infectious substances, Toxic) packaging solutions
Pre-clinical Services (Live Animal Transportation)
development of new small molecule drugs.
LCB’s current therapeutic areas include antibiotics, IP Drug Destruction, Kit production etc
anticoagulants, anticancer and ADC(Antibody-Drug국내 및 해외 운송
Conjugates). LCB is listed up KOSDAQ(May.2013)
Team : CEO has 30 years’ of experience in drug discovery 의약품 보관 Depot 서비스
and development including LG Life sciences as a research 콜드체인매니지먼트 (온도조건별/사이즈별 포장재 제공, 온도모니터
director. CTO and Key scientists also have 10~20 years’ 서비스 제공)
experiences in various research areas. Currently LCB have 감염성, 독성 등 위험물 포장 및 운송 서비스
38 research scientists(including 7 Ph.Ds), of which are 23 전임상 서비스 (생동물 운송 등)
organic chemistry part and 15 biology and development 임상의약품 폐기, Kit production 등
part.
∙ Technology : “LegoChemistry”
N
T
R
O
D
U
C
T
I
O
N
→ Scaffold-based and fragment-based approaches I
based on strong medicinal chemistry. LCB also has drug- In existence since 1980, Marken prides itself on discerning
like screening technology, such as in vitro early ADME/T and satisfying the premium logistical needs of the
∙ Pipeline : Currently 11 ongoing projects
pharmaceutical, biotechnology and clinical research
∙ Phase I : OXa.Antibiotics, FXa Inhibitor(coagulant)
industries Marken is the leading global clinical supply chain
∙Preclinical : next generation OXa.Antibiotics service provider dedicated 100% to the pharmaceutical
Gram (-) Antibiotics ->licensed-out to Astrazeneca in and life sciences industries, supporting over 49, 000
Dec., 2012
investigator sites in more than 150 countries, though
strategically-placed offices in 24countries worldwide.
1980년에 설립된 마켄은 의약품, 바이오테크놀러지, 임상시험에 대
한 글로벌 물류기업으로서 라이프사이언스에 100% 특화된 전문물
류회사입니다. 전세계 24개국 전략적 요지에 마켄 지사를 운영하고
있으며, 150여 개국 49, 000개 이상의 임상시험 사이트를 서포트하
고 있습니다.
지난 1981년 유전공학 연구를 처음 시작한 이래 지속적인 투자로
162
163
F40
N20
M20
Markpro co.
Maryland Bio Park
MedClaris Inc.
(주)마크프로
메릴랜드 바이오 파크
(주)메드클래리스
CEO
ADD
TEL
FAX
E-MAIL
URL
E
Cha Sang Jin 차상진
3F, Ace High Tech City Bldg.2, Mullae-dong 3-ga,
Yeongdeungpo-gu Seoul, Korea
82-2-785-3040
82-2-78-3043
[email protected]
http://www.markpro.com
X
H
I
B
I
T
S
ADD
TEL
E-MAIL
URL
01 West Baltimore Street Baltimore, MD 21201,
8
U.S.A.
1 410- 706-5592
[email protected]
http://www.umbiopark.com/
N
T
R
O
D
U
C
T
I
O
N
ADD
TEL
E-MAIL
URL
E
X
H
I
B
I
T
S
‘Korea-Maryland, USA Bio Expo 2013’ & ‘BioMaryland
2020’ Strategic Plan Introduction
Trademark Searching Database services, technology
commercialization, technology research/analysis, 한.미 바이오 엑스포 2013 소개 및 메릴랜드 주 바이오 정책 소개
메릴랜드 주 한국무역통상부, JG Business Link International,
technology evaluation, SMK
Johns Hopkins University, University of Maryland School
마크서치 (MarkSearch), 기술거래서비스, 기술평가, 특허조사 서비 of Medicine, Montgomery County, University of Maryland
스, 기술소개서
BioPark, BioHealth Innovation 총 7개 업체 함께 참여
I
CEO
I
N
T
R
O
D
U
C
T
I
O
N
Markpro is one of the leading global intellectual Property
service companies in the world. We provide professional
patent annuity payment services, Technology Transfer &
Commercialization services, and Trademark Searching
Database services.
The BioPark is a biomedical research park on the vibrant
academic medical center campus of the University
of Maryland, Baltimore (UMB). Its community of life
science companies and academic research centers are
commercializing new drugs, diagnostics and devices and
advancing biomedical research.
(주)마크프로 (2012년 지식경제부 “기술사업화전문회사” 지정)는 국 BioPark building designs maximize flexibility to
내 최고의 IP (Intellectual Property)관리 전문 회사로 특허연차료 accommodate a range of occupancies from small-scale pre관리, 상표검색 서비스, 기술거래 사업화 컨설팅 등의 서비스를 제공 built lab and office space in the BioInnovation Center to full
한다.
floor users. Infrastructure meets the requirements of the
most demanding science environments while permitting
optimum internal planning flexibility with minimum
intrusions.
미국 내 바이오 클러스터는 그 지역의 대학들이 중심이 되어 정부와
기업의 협력으로 세계적인 집적지로 성장 및 발전 되어 왔습니다. 메
릴랜드 대학 바이오 파크는 메릴랜드주립대학과 메릴랜드주 몽고메
리 카운티의 '바이오 인큐베이터'가 2003년부터 공동으로 추진한 바
이오 클러스터입니다. 이곳에서는 암, 게놈, 백신, 혈관 생물학 및 재
생의료 등 각 분야 1, 200명의 교수진을 갖춘 메릴랜드메디컬 스쿨
을 기반으로 초기단계 바이오 기업이 성장할 수 있도록 높은 수준의
실험실 환경과 사무실을 제공합니다.
I
Julie Yi 이주연
#1203-Yongbiuchonga, Jongo-gu, Naesu-dong,
Seoul 110-070 Republic of Korea
82-2-6351-3652
[email protected]
http://www.biologicsconsultinggroup.com
http://www.biovian.com
N
T
R
O
D
U
C
T
I
O
북유럽에 소재한 Biovian사는 바이오의약품 생산 전문 CMO로서,
2003년 설립 이후 다수의 commercial product (DP)와 임상 물질
(DS) 을 생산하고 있음
유럽 EMA인증 cGMP 기관으로서, 미국 FDA의 inspection을 받은
후 Drug Firm Registration으로 등록되어 있음
N
1. Biologics Consulting Group
Biologics Consulting Group, Inc. is the leading regulatory
consulting firm in product development and regulatory
strategy for Biologics, Drugs, and Medical Devices. For
almost 20 years, Biologics Consulting Group has supported
clients in the preparation and review of CBER, CDER and
CDRH regulatory applications, product development
strategies, Quality (or CMC) requirements, pre-clinical and
clinical study designs, GLP/GCP/GMP audits, and strategic
business planning.
2. Biovian
Biovian is a one-stop-shop CMO for cGMP manufacture
and development of biopharmaceuticals. Biovian’s offers
cell line development, mammalian cultivation, microbial
fermentation, protein purification, viral vector production,
formulation, aseptic filling, labeling and QP release.
Biovian's 2300 m2 facilities are located in Turku, Finland.
Biovian is EMA and FDA certified for cGMP production
of investigational and commercial products (including
biopharmaceuticals, gene therapy and sterile products).
Biovian, founded in 2003, is privately-owned, independent
company entirely focused on customer projects.
(주) 메드클래리스는 2012년 설립된 바이오의약품 개발 및 해외 허
가 컨설팅 회사로 해외 유명 CRO와 CMO와 연계하여 국내 제약사
의 제약 연구 개발을 지원합니다.
1. Biologics Consulting Group
미국 버지니아 주에 소재한 Biologics Consulting Group 사
(BCG)는 바이오제재를 포함한 의약품과 의료기기의 임상, 허가 컨설
팅을 전문으로 하는 전문 컨설팅그룹임
US FDA reviewer들로 구성된 BCG는 의약품 및 의료기기의 개발
단계부터 허가까지 고객 맞춤 컨설팅 서비스를 제공하고 있음
2. Biovian
164
165
L10
E10
B46
B20
MEABCO A/S
MEDIAN Diagnostics Inc.
Medical Writing
Mediogen Co., Ltd.
미압코
(주)메디안 디노스틱
메디컬라이팅
주식회사 메디오젠
CEO
ADD
TEL
E-MAIL
URL
Stig Loefberg
Richard Mortensens Vej 61, 1 DK-2300 Copenhagen
Denmark
45-3246-0370
[email protected]
www.meabco.com
CEO
ADD
TEL
FAX
E-MAIL
URL
I
N
T
R
O
D
U
C
T
I
O
Myung-Jin, Cha 차명진
Geodudanji 1-gil 41, Chuncheon, Gangwon-do,
200-883 Republic of Korea
82-33-244-0100
82-33-244-4634
[email protected]
http://www.mediandiagnostics.com
N
암과 anti-방사선치료에 초점을 두고 있는 제약회사로 질병과 컨디
션을 타깃으로 하는 혁신적인 상품들의 포트폴리오를 개발하기 위
해 BP-Cx-1기술 플랫폼을 사용하며, Anti-Cancer BP-C1, AntiRadiation BP-C2등을 생산합니다
CEO
ADD
TEL
E-MAIL
URL
X
H
I
B
I
T
S
X
H
I
B
I
T
I
R
O
D
U
C
T
I
O
N
MEDIAN Diagnostics Inc. have more than 1, 300 hybridoma
cell lines for human and animal diagnostic. This is the
largest holding amount in south korea.
(주)메디안 디노스틱은 2001년 동물진단용의약품 제조업을 허가받
은 국내 최초 기업으로 “돼지열병바이러스 항체검사 ELISA”를 시초
로 지금까지 10 여종의 동물용 체외진단 의약품의 품목 허가를 취득
하고 동물진단 기술의 사업화를 꾸준히 추진하고 있는 기업입니다.
뿐만 아니라 진단 시약 제조에 필요한 동물용 및 인체용 항체, 항원
원료 등을 공급하는 분야로 사업영역을 확대하여 체외진단 제품 및
원료 공급 전문선도기업으로 성장하였습니다.
FAX
E-MAIL
N
T
Nam-Soo Paek 백남수
#981, Wangam-dong, Jechon-city, Chungcheongbuk
-do, 390-250, Korea
82-43-644-4216~7
82-43-644-4215
[email protected]
http://www.mediogen.co.kr/index-e.html
X
H
I
B
I
T
S
Probiotics (Lacticacid bacteria, materials), Probiotics
(Finished products), Fermented natural materials (Food,
Cosmetics)
항체, 항원, FBS, BSA 등 원료 제품
T
TEL
E
Service Information Leaflet
서비스 소개 자료
N
ADD
S
Antibodies, Antigens, FBS, BSA
I
CEO
URL
E
E
Hye-Ryon Kim 김혜련
#409 Nam Yang Building, 49-5, Samjeon-dong,
Songpa-gu, Seoul 138-838, Korea
82-70-7687-7210
[email protected]
http://medicalwriting.co.kr
R
O
D
U
C
T
I
O
N
프로바이오틱스 (유산균, 원료), 프로바이오틱스 (완제품), 발효천연문
Clinical QA and medical writing services by specialized 농축액 (식품, 화장품용 원료)
professionals
전문 auditor와 medical writer의 특화된 서비스 (임상시험QA, 계
획서/보고서 작성 및 번역)
I
N
T
R
O
D
U
C
T
I
O
N
MEDIOGEN Co is a growing bioventure corporation based
on the life science. We are promoting the research and
development steadily so that it can provide the probiotic
products of the highest quality that can be applied
health functional foods, dairy products, fermented herbal
products, cosmetics, and animal medicine and having mass
production of 20 kinds of lactic acid bacteria. Particularly
MEDIOGEN produces probiotics with the characteristics
for gastric juice and bile acid resistance and probiotics
finished products is very advantageous because of having
high survival rate in long-term storage. In addition we
provide fermented herb products that enhance more the
physiological activity and absorption rate than original herb
by bioconversion.
주식회사 메디오젠은 생명과학을 기반으로 성장하는 바이오 벤처기
업입니다. 당사는 건강기능식품, 유제품, 생약 발효물, 화장품 및 동
물 의약품등에 응용할 수 있는 최상급 품질의 probiotics 제품을 제
공할 수 있는 꾸준한 연구개발과 20여종의 유산균을 대량생산을 하
고 있습니다. 특히 메디오젠의 probiotics 제품은 내산성과 내담즙
성의 특징을 보유하여 장관내의 생존율이 높고 장기 보존시 낮은 사
멸율로 완제품 유통시 매우 유리 합니다. 또한 생약을 발효하여 유효
성분을 생물전환 시키므로서 보다 생리활성이 높고 흡수율이 증강된
생약 발효물을 제공하고 있습니다. 또한 그간 축적된 기술을 근간으
로 다양한 제형의 완제품을 개발, 생산, 납품하고 있습니다.
166
167
N10
A24
J42
C48
Merck Ltd. Korea
META BIOMED
MetaBio, Inc.
MicroDigital Co., Ltd.
머크 주식회사
메타바이오메드
메타바이오 주식회사
마이크로디지탈
Michael Grund
15th, Floor, Haesung-2-Bldg., 942-10, Daechi-2dong, Gangnam-Gu, Seoul, 135-725, Korea
82-2-2185-3800
82-2-2185-3900
http://www.merckmillipore.com
CEO
ADD
TEL
FAX
URL
CEO
ADD
TEL
FAX
E-MAIL
E
X
H
I
B
I
T
S
Total Solutions for Bioindustry through USP to DSP
URL
E
Seok Song Oh 오석송
O song Bio-Health Science Technopolis, 270,
Osongsaengmyeong1ro, Osong-eup, cheongwongun, Chungbuk, South Korea, 363-951
82-43-218-1981
82-43-217-1988
[email protected]
http://www.meta-biomed.com
X
H
I
B
I
T
S
-Synthetic Absorbable Suture
-Bone Restoration Materials
Merck Millipore (Protein research assays and reagents, -Non-absorbable Surgical Mesh
cell culture solutions and drug discovery services for
biopharmaceutical companies as well as laboratory -흡수성 봉합사
chemicals for research, analytical and hospital laboratories) -골 대체제
-요실금 메쉬
I
N
T
R
O
D
U
C
T
I
O
N
I
N
T
R
O
D
U
ADD
TEL
FAX
E-MAIL
URL
C
T
I
O
N
(주)메타바이오메드는 보건의료산업발전을 위해 의료용구 제조업체
로 1990년 설립 된 이후 지속적인 연구개발을 통하여 치과용 제품
뿐만아니라 외과용 새운해성 수술용봉합사 등 우수한 신제품을 개발,
생산하여 미국, 유럽을 포함한 80여 개국에 수출하고 있습니다. 또한
정형외과용 골수복재에 대한 연구를 차세대 신기술과제로 진행하고
있습니다. 이러한 끊임없는 연구개발로 메타바이오메드는 생명공학
분야의 창조적인 기업으로 성장해 나갈것이며 이를 위해 전 임직원
은 새로운 가치창조를 추구하고 있습니다.
KIM MOON BO 김문보
358-10 Cheonho-Dong, Gangdong-Gu, Seoul, KOREA
82-2-482-5690
82-2-482-8670
[email protected]
http://www.metabio.co.kr
CEO
ADD
TEL
FAX
E-MAIL
E
X
H
I
B
I
T
S
URL
Kim KyungNam 김경남
#A-101, Korea Bio Park B/D, 694-1, SamPyungDong, Bundang-Gu, Sungnam-Si, GyungGi-Do,
463-400, KOREA
82-31-628-2207
82-31-628-2222
[email protected]
http://www.md-best.com
Tumorgraft (orthotopic cancer model mouse)
X
H
I
B
3-D Histoculture Drug Response Assay (in vitro chemosensitivity E
test)
1. Integrated Sample Banking System
2. MicroPlate Luminometer
3. Quantitative Real-time PCR
I
Since its foundation in 1990 as a manufacture of medical
devices to contribute to the development of health &
medical industry. META-BIOMED Co., Ltd has manufactured
excellent products such as not only biodegradable surgical
sutures but also dental products through sustained R&D and
are exporting such products to over 80 countries including
the USA and Europe. Creativity and challenge.
As a result of positively focusing on R&D investment as
a technology-intensive small/medium enterprise since
its foundation, the company could be positioned as an
enterprise that is capable of manufacturing superior
products being acknowledged at home and abroad
including world best products and localized products being
selected as the products of new technology.
168
CEO
N
T
R
O
D
U
C
T
I
O
I
T
S
N
Metabio, Inc. is a venture company specializing in cancer
research and biomedicine, established in 2000. We
have close working links with cancer centers in general
hospitals where we are fulfilling our medical purpose of
individually customized cancer programs. First goal is to
build “Anticancer susceptibility test system” from which
personal anti susceptibility can be forecasted by using
patient’s cancer tissue. Second goal is to make it realized
the followings:
1.To predict individual medical treatment through “ Mini
cancer patient (Avarta mouse) model” that has the
same cancer as that of patients.
2.To improve cancer patients’ life quality based on
patients’ individual information regarding the cancer.
Also, Metabio, Inc. as “ Medicine and medical supplies
quality control institution”, performs various tasks such
as study of biomedicines and quality control and we are
making our ways to realization of individual customized
medical treatment and as well as development of new
medicines by using in variety of disease-model animals
and DNA chips.
1. 통합검체보관시스템
2. 유전자발현 발광측정기
3. 실시간유전자증폭기기
I
N
T
R
O
D
U
C
T
I
O
N
MicroDigital is a manufacturer and developer of biomedical
instruments for laboratories in hospitals and institutes.
Based on Optical Detection and Lab Automation System,
we produce Microplate Luminometer, Quantitative RealTime PCR and Sample Banking Total Solution. And
Multi-mode Microplate Reader, Disposable Bioreactor,
and Toxicity Monitoring Instrument are currently in
development. Countless general hospitals and institutes
are currently taking advantage of MicroDigital's cuttingedge technology. MicroDigital is firmly holding its place
as a leading company in the field of biomedical through
constant research and development.
(주)마이크로디지탈은 바이오메디칼 장비 제조/판매 회사로서, 광학
측정 및 자동화 분야의 독보적인 기술을 기반으로 iSBS (통합검체보
관 솔루션), LuBi (발광측정장치), AmVer (Real-Time PCR)를 생
산/판매하고 있으며, 많은 병원, 대학교, 연구기관에서 마이크로디지
탈의 제품을 사용하고 있습니다.
또한 멀티모드 마이크로플레이트 리더, 일회용 배지 혼합 시스템, 생
태독성 모니터링 장치 등의 제품을 정부연구과제와 연계하여 개발
중에 있습니다.
(주)마이크로디지탈은 혁신적인 기술을 바탕으로 바이오메디칼 장비
분야의 선도기업으로 발돋움 하고 있습니다.
169
N23
P22
Missouri Trade & Investment Office - South
Korea
미국 미주리 주정부 한국사무소
CEO
ADD
TEL
E-MAIL
URL
Montgomery County
MPI Research
(주)모든스킨
몽고메리 카운티
엠피아이 리서치
ADD
TEL
FAX
E-MAIL
URL
E
X
H
I
B
I
T
Woong–ho Cha 차웅호
# 2203 Saengsankwan, CTP, 43-5 Sameun-Ri,
Jiksan-Eup, Cheonan-Si, ChungNam, S.Korea 330858
070-7819-1002
0303-3442-1002
[email protected]
www.drjina.com
S
Injectable dermal fillers
- RPC (Rapidly polimerizing collagen)
- NanoMatrix (gold nanoparticle-collagen matrix)
E
X
H
I
B
I
T
S
Cosmetics
화장품
I
N
T
R
O
D
U
C
T
I
O
B35
MODNSKIN Inc.
CEO
Luis Jimenez
1610 S Providence Rd. Columbia, MO, 65211, USA
1-573-319-9020
[email protected]
http:// www.eternogen.com
N20
N
EternoGen is a medical Bio-Tech company with a focus on
I
N
T
R
O
D
U
C
T
I
O
N
designing and manufacturing a novel collagen scaffolds for
Dr.JinaCha is health & beauty venture enterprise based on
soft tissue therapeutic applications.
pharmacy Doctor & cosmetic researcher.
Dr.JinaCha will try to make an effort to creat beauty and
keep healthy using bio mechanism within cosmetics,
healthy foods, and new functional ingredients.
기능성 화장품 브랜드Dr.JinaCha는 미국 약학박사인 Jina Cha와
화장품 개발자이자 오빠인 Woong-ho Cha가 뜻을 모아 만든 것에
서 시작되었습니다.
“From Natural" 이라는 모토로 효능이 있는 화장품을 만들기 시작
합니다.
S tella B. Werner Council Office Building 100,
Maryland Avenue Rockville, MD 20850, U.S.A.
1-240-777-7900
http://www.montgomerycountymd.gov/
ADD
TEL
URL
CEO
ADD
TEL
FAX
E
X
H
I
B
I
T
S
‘Korea-Maryland, USA Bio Expo 2013’ & ‘BioMaryland
2020’ Strategic Plan Introduction
한.미 바이오 엑스포 2013 소개 및 메릴랜드 주 바이오 정책 소개
메릴랜드 주 한국무역통상부, JG Business Link International,
Johns Hopkins University, University of Maryland School
of Medicine, Montgomery County, University of Maryland
BioPark, BioHealth Innovation 총 7개 업체 함께 참여
I
N
T
R
O
D
U
C
T
I
O
N
Montgomery County is a county in the U.S. state of
Maryland situated just north of Washington, D.C., and
southwest of Baltimore. It is one of the most affluent
counties in the USA, and has the highest percentage
(29.2%) of residents over 25 years of age who hold postgraduate degrees.
Montgomery County is the epicenter for biotechnology in
the Mid-Atlantic region. It is the third largest biotechnology
cluster in the USA, holding the principal cluster and
companies of large corporate size in the state.
E-MAIL
URL
E
William U. Parfet
54943 North Main Street, Mattawan, MI 490719399, USA
1-269-668-3336
1-269-668-4151
[email protected]
http://www.mpiresearch.com
X
H
I
B
I
T
S
We will introduce MPI Research's services to visitors
엠피아이 리서치에서 수행하는 연구/시험 서비스를 소개 합니다.
I
N
T
R
O
D
U
C
T
I
O
N
엠피아이 리서치는 의약품, 생물의약품, 의료기기, 동물의약품, 그리
고 농약개발을 위해 필요한 전임상 및 초기 임상 연구/시험 대행서비
스를 제공합니다. 1995년 미국 미시간 주에 설립되어 현재 전 세계
시장을 대상으로 그 영역을 넓히고 있으며 (주)다인토탈솔루션을 통
하여 국내에 소개되고 있습니다.
MPI Research is a privately held Midwestern company
that focuses on the preclinical and early clinical research
needs of the biotech, pharmaceutical, medical device,
animal health, and agrichemical industries. Our success
is attributed to the mastery of effective teamwork and to
being the very best in our field.
몽고메리 카운티는 미국 메릴랜드 주 동부 해안에 위치한 카운티로
미국 내에서 인구가 가장 많은 도시 중의 하나이며 자원이 풍요로운
행정중심지입니다. 또한 25세 이상 인구 중 가장 많은 박사학위 보유
자 (29.2%)가 거주하고 있는 도시이기도 합니다.
몽고메리 카운티는 미국 동부 지역의 바이오 산업 발전의 진앙지이
며, 미국에서 세번째로 큰 바이오 클러스터가 위치해 많은 기업이 밀
집해 있습니다.
170
171
Q18
O13
A15
H10
NANOSCOPE SYSTEMS, INC.
National Cancer Center
Natural Bio-Materials Inc.
나노스코프시스템즈(주)
국립암센터
(주)엔비엠
CEO
ADD
TEL
FAX
E-MAIL
URL
CHUN BYUNG SEON 전병선
Unit 333 Hanshin S-MECA Gwanpyeong-dong
Yuseong-gu Daejeon 305-509 Republic of Korea
82-42-862-0772
82-42-336-4774
[email protected]
http://www.nanoscope.co.kr/
CEO
ADD
TEL
FAX
E-MAIL
URL
X
H
I
B
I
T
S
K1-Fluo, NS-3500
I
N
T
R
O
D
U
C
T
I
O
N
NANOSCOPE SYSTEMS, INC. the nation's first highresolution three-dimensional laser scanning confocal
microscope developed with its own technology was first
commercialized in Korea brand.
K1-Fluo biochemical studies in the field of the high
sensitivity of fluorescence confocal microscopy for imaging
observations, currently holds a regular microscope can be
mounted in a frame which is practical and economical
product is configurable.
A world-class NS-3500 laser scanning confocal microscopy
techniques have been implemented as a product, threedimensional observation of micro-meter level in a variety of
fields that require measurement only is used as a module or
universal instrument.
나노스코프시스템즈 (주)는 국내 최초로 고해상도 3차원 레이저 스캐
닝 공초점 현미경을 자체 기술로 개발하여 최초의 한국 브랜드로 제
품화 하였습니다.
K1-Fluo 는 생화학 연구 분야에서의 고감도 영상 관측을 위한 형
광 공초점 현미경으로, 현재 보유하고 있는 일반 현미경 프레임에 장
착할 수 있어 실용적이고 경제적인 구성이 가능한 제품입니다.NS-
3500 은 세계 수준의 레이저 스캐닝 공초점 현미경 기술이 구현된
제품으로서, 마이크로미터 수준의 3차원 관측이 필요한 다양한 분야
CEO
ADD
TEL
FAX
E-MAIL
URL
I
E
Jin-Soo Lee 이진수
410-769 경기도 고양시 일산동구 일산로 323
82-31-920-2148
82-31-920-2139
[email protected]
http://www.ncc.re.kr
N
T
R
O
D
U
C
T
I
O
NET/GH CERTIFICATION
(Korea Health Industry Development Institute)
Tae-Ho Kwon 권태호
8 09-2, yongam-ri, Bondong-eup, Wanju-gun,
Jellabuk-do, Korea
82-63-223-4555
82-63-223-4550
[email protected]
http://www.nbms.co.kr
국립암센터는 2000년도 설립 이후 암 연구 수행 및 지원, 암환자 진
료, 국가암관리사업 지원, 암전문가 교육훈련 등을 통해 우리나라 국
민의 암부담을 줄이기 위해 지속적으로 노력하고 있습니다. 특히 암
관리정책 개발, 국내 암연구 진흥, 국내 암전문 의료기관 및 국제기
구와의 협력 네트워크 강화 등을 통해 2006년도부터 시작된 정부의
제2기 ‘암정복10개년계획’의 추진을 적극 뒷받침하고 있습니다.
CEO
ADD
TEL
FAX
E-MAIL
N
Ever since its inception in 2000, the National Cancer
Center has persevered to lessen the burden of cancer
for Koreans by conducting and offering assistance to
cancer research, diagnosing and treating cancer patients,
assisting in the National Cancer Control Initiatives, and
finally, educating and training cancer specialists. Moreover,
the NCC is aggressively backing the government's 2nd
"10-year Cancer Control Plan (2006)" by devising cancer
control policies, promoting cancer research in Korea,
and by strengthening the cooperative network forged
between Korean cancer-specialized medical institutions
and international organizations.
NET.GH 인증관 (한국보건산업진흥원
E
X
H
I
B
I
T
S
URL
KO Kyung-hwa 고경화
1 87 Osongsaengmyeong2 (i)-ro, Osong-Eup,
Cheongwon-gun, Chungcheongbukdo 363-951,
KOREA
82-43-713-8280, 8343
82-43-713-8908
[email protected], [email protected]
http://ghmark.or.kr
-재조합단백질 (animal free, biotoxin free)
E
X
H
I
B
I
T
-Enterokinase, Trypsin, hGM-CSF, hG-CSF외
-Plant derived recombinant proteins (animal free, biorisk- NET (New Excellent Technology) Certification
free)
-Enterokinase, Trypsin, hGM-CSF, hG-CSF etc.
NET, GH 인증마크 제품 (의약품, 의료기기, 식품, 화장품 등)
I
N
T
R
O
D
U
C
T
I
O
S
N
NBM Inc. is a privately owned company established in
2007. NBM is an innovative company that is committed
to economically viable and enabling solutions for the
production of recombinant proteins, such as growth
factors, cytokines and proteases, using transformed plants.
The company is approaching the medical scientific research
community and the cell culture media and diagnostics
market with its products. Our product portfolio has
expanded steadily to meet the needs of our customers with
biorisk-free growth factors and cytokines.
(주)엔비엠은 식물을 이용하여 난발현성 단백질인 단백질 분해효소
(Trypsin, chymotrypsin, Enterokinase, TEV endopeptidase
등)와, 사이토카인 (GM-CSF, G-CSF, INF 등)의 대량생산과 함께
분자농업 기술을 활용하여 희귀병 (고셔병, 헌터증후군, 고뇨산혈증
등) 치료제를 중심으로 한 바이오시밀러 의약품의 생산을 진행하고
I
N
T
R
O
D
U
C
T
I
O
N
GH (Goods of Health) Certification (Medicines, Medical
devices, Foods, Cosmetic, etc)
한국보건산업진흥원은 국내유일의 보건산업 육성기관으로 보건신기
술 (NET)와 우수 보건제품 (GH) 품질인증 사업을 수행하고 있습니다.
보건신기술과 우수 보건제품의 우수성을 알리고 글로벌 경쟁력을 강
화하기 위하여 통합홍보를 합니다.
Korea Health Industry Development Institute (KHIDI) is an
organization that helps improve the national healthcare
service which service New Excellent Technology (NET)
and Goods of Health (GH) Certification. To inform the
excellence and enhancement the global competitiveness of
New Excellent Technology (NET) and Goods of Health (GH),
Korea Health Industry Development Institute is planning
every effort via integrated marketing communication
있으며, GM작물을 이용한 분자농업의 산업화를 위하여 LED를 기반
으로 한 폐쇄형 식물공장 (크린룸)을 구축하여 국내에서 최초로 분자
농업의 산업화를 이루었습니다.
에서 전용 측정 모듈 또는 범용 측정기로 활용되고 있습니다.
172
173
K30
A11
NEOFECT
NFEC (National Research Facilities &
Equipment Center)
네오펙트
CEO
ADD
TEL
FAX
E-MAIL
URL
Hoyoung Ban 반호영
Jongjadong 158-6 Mosun building 5th floor,
bundanggu, Seongnam, Kyunggi
82-70-4235-0215
82-31-711-7057
[email protected]
http://www.neofect.com
국가연구시설장비진흥센터
CEO
ADD
TEL
FAX
E-MAIL
URL
E
E47
X
H
I
B
I
T
S
T
R
O
D
U
C
T
I
O
S
(주)노아닉스
누스코
ADD
TEL
FAX
E-MAIL
URL
Brad Choi 최형준
7 11 Sejung Techno Valley, 134 Gongdanro,
Heongdeokgu, Cheongju, Chungbuk, 361290
82-43 905 0972
82-43 715 9202
[email protected]
http://www.noanix.com
CEO
ADD
TEL
E-MAIL
URL
Changwoo Baek 백창우
137-061 201ho, 833-27, Bangbae 1-dong, Seocho
-gu, Seoul, Korea
82-70-8292-7708
[email protected]
http://www.nousco.com
E
X
H
I
B
I
T
X
H
I
B
I
T
S
S
EHR Platform, Case Management Tool, Template Editor
Spray Coater, Automated Liquid Dispensing System,
Precision Pump, Spray Nozzle
EHR 플랫폼, Case관리툴, 템플릿 에디터
스프레이코터, 자동분주기, 정량펌프, 스프레이노즐
I
N
네오펙트는 디지털 뇌졸중 재활 솔루션을 만들고 있는 회사입니다. 디
지털 뇌졸중 재활 솔루션은 센서가 부착된 재활 기구와 게임화된 재
활 컨텐츠를 통해서 환자의 재활 효과를 극대화 시키는 제품입니다.
NOUSCO
E
-NTIS 국가연구시설장비관리서비스 (http://nfec.ntis.go.kr)
-ZEUS 장비이용자서비스 (http://zeus.nfec.go.kr)
NEOFECT is developing a digital rehabilitation system for -FEEL 시설장비전자도서관 (http://feel.nfec.go.kr)
stroke patients. A digital rehabilitation system motivates
patients with rehabilitation game and sensor devices and
I
N
T
R
O
D
U
C
T
I
O
helps them to improve their motor performance.
N
Noanix Corporation
CEO
Kyung Man You, Director, 유경만 센터장
169-148 Gwahangno, Yusung-gu, Daejeon, 305806, Korea
82-42-865-3579
82-42-865-3559
[email protected]
http://www.nfec.go.kr
X
H
I
B
I
T
Electronic glove with motion sensor for stroke rehabilitation E
and rehabilitation game
-National Science & Technology Information, NTIS
-Zone for Equipment User Service, ZEUS
뇌졸중 재활 장갑 및 재활 게임
-Facilities & Equipment Electronic Library, FEEL
I
K30
The National Research Facilities and Equipment Center
(NFEC) performs overall management for the advance
of research facilities and equipment through ‘strategic
investment’, ‘promotion of share-use’, ‘equipment
Engineer’, and ‘enhancement of development capabilities’
of national research facilities and equipment. NFEC support
policy-making and legislating of research facilities and
equipment, to construct and operate the Deliberative
Council of Research Equipment Budget for the efficiency of
national R&D investment.
국가연구시설장비진흥센터 (NFEC)는 범부처 연구시설·장비 총괄
전담기관으로 국가 연구시설·장비의 고도화 추진 및 효율적 운영관
리를 위해 ‘전략적 투자', '공동활용 촉진', '전문인력 양성', ’총괄 운영
T
R
O
D
U
C
T
I
O
N
NOUSCO is developing EHR platfrom and medical
information system and softwares since establishment in
Noanix Corporation designs and provides several products 2008 for leading technology and contribute our country.
for microfluidics.
Main products are Spray Coater, Automated Liquid 누스코는 2008년 설립이래 최고의 기술로써 국가 발전에 이바지한
다는 일념으로 EHR 플랫폼 및 의료정보 시스템, 각종 시스템 소프트
Dispensing System, Precision Pump and Spray Nozzle.
For example, Spray coater is used for thin film coatings for 웨어 기술을 개발해오고 있습니다.
mainly BioMedical applications.
I
N
N
N
T
R
O
D
U
C
T
I
O
N
의료 분야
(주)노아닉스는 미세유체 분야의 숨은 강자입니다. 주 제작품은 스프
레이코터, 자동분주기, 스프레이노즐, 정량펌프입니다.
대표적인 스프레이코터는 박막코팅이 필요할 때 쓰이는 정밀한 유체
기기입니다.주 타켓은 바이오메디칼입니다.
-국제표준 EHR 플랫폼 개발 (ISO/HL7, ISO/CEN 13606 동시지
원)
-국제표준 응용 프로그램 저작용 IDE 개발
-DICOM 뷰어 & 클라이언트 개발
-모바일 PHR 개발
시스템 분야
-국방 & 의료용 RTOS 커널 개발
-보안 운영체제 개발
-하이퍼바이저 개발
-C/C++ 지원 가상머신 개발
관리‘의 4대 전략목표 수립하고, 과학기술하부구조의 고도화를 위하
여 최선의 노력을 다 하고 있습니다. NFEC는 국가연구시설장비 정
책 수립 및 법·제도 개선지원, 국가연구개발 예산편성을 위한 연구
장비예산심의위원회 구성·운영 등의 역할을 수행하고 있습니다.
174
175
C20
L10
L10
A23
NOVAPRO., Ltd
NOVO Nordisk
Novozymes Biopharma DK A/S
NTS Co., Ltd.
(주)노바프로
노보노디스트
노보자임 바이오파마
엔티에스 주식회사
CEO
ADD
TEL
FAX
E-MAIL
URL
Yim Min Jae 임민재
Honglk Jeil B/D, 478-12, Seokyo-Dong, Mapo-Gu,
Seoul, 121-839, Korea
82-2-338-0059
82-2-338-0079
[email protected]
http://www.cryste.co.kr
CEO
ADD
TEL
FAX
E-MAIL
URL
X
H
I
B
I
T
S
*INFORS
Minifors - 소형바이오리엑터
Multitron & Minitron - 교반형 인큐베이터, CO2-습도-온도 컨트
롤
*CRYSTE
PURICUBE-Clean Bench
PURISUC-Suction Master
PURIFUME-Fume Hood
PURISTER-Autoclave
PURICELL-Incubator
PURICELL CO2-CO2 Incubator
PURI LOW-Low Temp. Incubator
PURIFROZ-Refrigerator
PURIVEN-Drying Oven
PURIVEN VACUUM-Vacuum Oven
PURIKER-Shaker
PURIBATH-Water Bath
I
N
T
R
O
D
U
CEO
ADD
TEL
FAX
E-MAIL
URL
Peder Holk Nielsen
Krogshoejvej 36 DK-2880 Bagsvaerd Denmark
45-4446-2896
45-4446-1080
[email protected]
www.biopharma.novozymes.com
CEO
ADD
TEL
FAX
E-MAIL
URL
I
E
Lars Rebien Sørensen
Novo Allé 2 DK-2880 Bagsvaerd Denmark
45-4444-8888
45-4449-0555
[email protected]
www.novonordisk.com
N
T
R
O
D
U
C
T
I
O
N
당뇨 치료에 있어 90년간의 지속된 글로벌 의료 기업으로, 스칸디나
비아에 인슐린이 제품으로 처음 소개된 1923년 덴마크에 설립되었
습니다. 본사는 덴마크에 있으며 현재 75개국에서 약 35,000명의
직원을 두고 180개국 이상에서 제품을 판매하고 있습니다. 당뇨병
외에도 혈우병 치료, 성장 호르몬 치료, 그리고 호르몬 대체 요법을
개발 및 생산하고 있습니다.
I
N
T
R
O
D
U
C
T
I
O
JeongCheol Jae 제정철
410, Yongsu-ri, Chowol-eup, Gwangju-si, Gyeonggido, Korea 464-865
82-31-765-5620
82-31-767-7260
[email protected]
http://www.nts2002.com
N
바이오 이노베이션에서 세계적인 선두주자로서 내일의 산업적인 바
이오 솔루션을 창조해 내는 기업입니다. 약 25년간 바이오 제약 산업
에서 특화된 기술과 재 조합된 알부민(albumin), 약물 투여의 필요
성과 의료장비 산업에 맞게 만들어진 히알루론산과 같은 재 조합된
상품들을 생산 및 제공하고 있습니다.
E
X
H
I
B
I
T
S
TSI: BioTrak, 7510, 9500
Rap ID: SPE RamanID+Metal ID, Layer Explorer
SISTEMA : FOGGER Particle Generator
Thermo Scientific: Prima pro, Standard Particle
I
N
T
R
O
D
U
C
T
I
O
N
NTS Co., Ltd. is conduction business of importing for the
various analyzers, measuring equipments and process
monitors those are related to pharmaceutical, chemical,
semiconductor and electronics production line as well as
atmospheric environment.
당사는 환경에 관한 토탈 솔루션 제공을 목표로 설립되어, 주로 반도
체 / FPD 생산라인 환경과 관련한 분석 장비의 수출입 업무 및 관련
SYSTEM 의 제작과 일반환경, 제약, 화학 식품공정 라인상의 측정
장비 등을 취급하고 있으며 이와 관련된 각종 서비스 (설치, 유·무상
서비스, 장비 임대 서비스)및 컨설팅 업무를 제공하고 있습니다.
C
T
I
O
N
저희 CRYSTE는 세계 일류 이화화학기기 제조업체로 도약하기 위
해 생산전문가, 영업전문 인력, 서비스 기술자 그리고 제품디자이너
에 이르기까지 목표를 향해 최선의 노력을 다하고 있는 저희 회사는
향후에도 증대되는 시장의 요구사항에 부합하는 제품생산을 위해 최
상의 성능을 유지하는 제품을 지속적으로 공급하고자 합니다. 아울
러 최상의 품질 기준 을 충족 시키고 있는 최첨단 공장에서 생산되는
CRYSTE는 저희 회사만의 고유의 열정과 책임감 그리고 신념을 가
지고 시장을 선도해 나갈것입니다.
176
177
R25
O22
식품제조사업은 국/탕/찌개, 면, 육가공, 냉동밥, 반찬, 베이커리 등
우리 식탁을 풍성하게 채워주는 다양한 카테고리의 제품을 생산하고
있습니다.
OUR HOME
(주)아워홈
CEO
ADD
TEL
FAX
E-MAIL
URL
Seung-woo Lee 이승우
5F Meritz Tower, 382, Gangnamdae-ro, Gangnamgu, Seoul, Korea
82-70-8685-2806
82-2-6713-6531~3
[email protected]
http://www.ourhome.co.kr/
특히 2007년부터 HMR을 대표하는 200여가지 다양한 상품군을 선
보이며 소비자의 맛과 품질에 대한 신뢰를 바탕으로 비약적인 성장
을 거듭하고 있습니다.
이번 박람회에 소개드리는 오곡감초 삼계탕은 몸에 좋은 5가지 곡물
(찹쌀, 흑미, 현미, 보리, 율무)에 GAP인증 제천산 감초를 더한 영양
강화형 삼계탕으로 불필요한 첨가물을 사용하지 않고 몸에 좋은 재
료와 건강한 레시피로 만들었습니다.
B30
OLYMPUS KOREA Co., Ltd.
Orient Bio Inc.
올림푸스한국(주)
주식회사 오리엔트바이오
CEO
ADD
TEL
FAX
E-MAIL
URL
KATSUHIKO INADOMI
Olympus-Tower B-dong 4th floor, 114-9 SamseongDong, Gangnam-Gu, Seoul, Korea.
82-2-6255-3200
82-2-6255-3377
[email protected]
http://www.olympus-scope.com
ADD
TEL
FAX
URL
I
E
X
H
I
B
I
T
S
Five Grains & Licorice Ginseng Chicken Soup
오곡감초삼계탕
I
N
T
R
O
D
U
C
T
I
O
N
OURHOME is a food specialty brand that seeks to contain
the love and care of mothers.
OURHOME continues to grow with customers from a
leader in food service into a super excellent general food
company covering food supplies, restaurants, and food
manufacturing.
Among the many businesses, Food business produce a
broad array of products encompassing almost the entire
range of culinary culture and tradition in korea, including
the many soups, stews, noodles, processed meat, frozen
rice dishes and food, side dishes, bakery, and so forth.
Especially we launched an HMR brand in 2007, deploying
200 or so products and has continued with its explosive
growth based on customer trust in the taste and quality.
At the fair, we introduce the five grains & Licorice Ginseng
chicken soup (samgyetang).
Five kinds of salubrious grains (gluinous rice, black rice,
brown rice, barlay, and adlay) and added the GAP certified
Jecheon licorice to fortified chicken soup.
We make our products with healthy and fresh ingredients,
minimizing the use of additives.
*HMR: Home Meal Replacement
*GAP: Good Agricultural Practices
E
X
H
I
B
I
T
Jae-Jin Jang 장재진
3 22, Galmachi-ro, Jungwon-gu, Sungnam-si,
Gyeonggi-do, Korea
82-31-730-6100
82-31-730-6715
http://www.orientbio.co.kr
CEO
N
T
R
O
D
U
C
T
I
O
N
S
Orient Bio Inc. has contributed to the development of
Biological Microscopes, Metallurgical Microscopes, new drug and biotech research industry in Korea by
introducing, producing and supplying highest quality of
Industrial Videoscopes, Endoscopes, Video Equipment
research animals, which is core composition of biotech.
금속현미경, 생물현미경, 산업내시경, 의료내시경, 영상기기
With the help of technical cooperation with the World’s
best research animal providers, we supply IGS (International
Genetic Standard) research models from rodents to nonI
N
T
R
O
D
U
C
T
I
O
N
rodents and a variety of research equipments and facilities.
The first product produced by Olympus was a microscope, Also, through our affiliated CRO company - Genia Inc., we
introduced in 1920. Since then, Olympus has become the carry out studies on new drug development, safety and
leading provider of precision microscopes and microscope efficacy test, xenograft and disease models.
systems to clinical laboratories, science, engineering,
education and research industries. Olympus bioimaging (주)오리엔트바이오는 바이오산업의 근간이 되는 국제표준의 고품질
technologies are assisting a variety of the latest scientific 실험동물 도입·생산·공급함으로써 한국의 신약 및 바이오 연구개
researches in biology and medicine, which will help define 발에 기여하고 있습니다. 이를 위해 세계최고의 실험동물 기업과 기
the next generation of healthcare, including mechanisms 술 제휴를 통해 설치류부터 중대형동물까지 국제표준 실험동물과 다
양한 실험장비 및 실험설비를 공급하고, 비임상시험 기관인 자회사
for drug action and immunity mechanisms.
올림푸스한국은 현미경 및 산업용내시경으로 국내 반도체를 비롯한
정밀산업 전반, 생물학 및 의학발전에 이바지하고 있습니다. 금속현
미경은 기계 및 금속의 표면 검사 및 측정장비로 사용되고 있으며 생
물현미경의 경우 각종 병원, 학교, 국가기관, 기업연구소에서 기초과
학부터 임상연구까지 광범위하게 사용되며 암치료제 개발, 각종 세포
제니아를 통해 신물질 탐색, 안전성 및 유효성 시험, 이종장기 이식연
구와 질환모델 연구 등을 진행하고 있습니다.
치료제 개발 등 의학 발전의 핵심 역할을 하고 있습니다.
아워홈은 어머니의 정성과 요리 전문가의 손맛을 가득 담은 브랜드
입니다.
아워홈은 Food service 분야 리더에서 식재, 외식, 식품제조에 이르
는 초일류 종합요리식품기업으로 고객과 함께 성장해 갑니다. 그중,
178
179
K30
J47
A14
N31
PANAGENE, Inc.
PCL, Inc.
Pharma Line Inc
주식회사 파나진
피씨엘(주)
파마라인(주)
CEO
ADD
TEL
FAX
E-MAIL
URL
Sung Kee Kim 김성기
305-510, 54, Techno 10-ro, Yuseong-gu, Daejeon,
Korea
82-42-861-9295
82-42-861-9297
[email protected]
http://www.panagene.com
CEO
ADD
TEL
FAX
E-MAIL
URL
In-kyu Kim 김인규
(153-777) #701, 99, Digital-ro 9-gil, Geumcheongu, Seoul 153-777 REPUBLIC OF KOREA
82-70-4673-3455
+82-70-4673-3443
[email protected]
http://www.pclchip.com
CEO
ADD
TEL
FAX
E-MAIL
URL
Pharma Stores LLC
Lee du yong 이두용
IF, 24Dangjin-ro32beon-gil, Gwonseon-gu Suwoncity, Gyeonggi-do, korea
82-31-505-5207
82-31-505-5209
[email protected]
http://www.pharmaline.co.kr
CEO
ADD
TEL
FAX
E-MAIL
E
E
X
H
I
B
I
T
S
Molecular Diagnostic Kit, PNA Oligomer
E
X
H
I
B
I
T
S
SolB Complete Kit, sciFLEXARRAYER, Sensovation fluorescence
/colorimetric scanner, Hi3 multiplex diagnostics
유전자 진단시약, PNA Oligomer
N
T
R
O
D
X
H
I
B
I
T
S
U
C
T
I
O
N
Panagene is a worldwide custom PNA (peptide nucleic acid)
oligomer provider, and has focused on developing various
molecular diagnostic products based on PNA oligomers.
With strong patent portfolio for manufacturing PNA
products, Panagene succeed to commercialize diagnostic
kits for somatic mutation and infectious disease.
N
T
R
O
D
U
C
T
I
O
H
I
B
I
T
S
Medicine, Foods
I
N
T
R
O
D
U
C
T
I
O
N
Pharmaceutical & Medical Devices
N
피씨엘 (주)는 한국, 보스톤 (USA) 에 사무실을 두고 있는 바이오 벤
처 회사로써 SG CapTM 이라는 원천 기술을 바탕으로 연구용 시
약인 SolBTM complete kit 과 혈액 선별용 진단칩 개발과 신약
타겟 물질 동정 서비스를 진행하고 있음. 또한 독일의 Scienion 사
의 국내 독점 대리점으로 microarrayer 를 판매하고 있으며, 독일
의 Sensovation 사의 대리점으로 fluorescence/colorimetric
scanner 의 판매를 진행하고 있음.
X
Nova Matrix R-3d.Bead Generator
세포배양키트, 비드생성기
I
I
E
Dr. Mohammed Sadiq Hussain Alias Khalid
P.O. Box : 39803. Dubai, U.A.E. Creek Tower, Site
no. 22-B, 22nd Floor.
97-14-229-6655
97-14-229-6363
[email protected]
I
N
T
R
O
D
U
C
T
I
O
N
Kit for 3D cell culture in alginate scaffolds Encapsulation
system for immobilization of materials
알지네이트 지지체의 3차원 세포 배양을 위한 키트 비드 생성기
파나진은 2001년 창업하여 인공 DNA인 PNA의 세계 유일한 대량
생산법을 개발하고 PNA의 전세계 독점 판매권을 취득하여 판매하
고 있다. 유전자 진단 PNA 칩을 개발하여 세계 최초로 상용화에 성
공하였으며, 맞춤형 암치료에 필수인 암 유전자 변이 진단 키트, 결
핵 진단 키트 등 다양한 유전자 진단 제품을 출시하여 판매하고 있는
International biotec co. PCL, Inc has offices in Seoul, S.
Korea and Boston, USA. PCL offers three categories of
products based on its proprietary SG Cap™ technology
and SolB™ reagents: 1) Blood-based diagnostic tests, 2)
Research reagents and tools and 3) Drug discovery R&D
유전자 진단 전문 회사이다. 자궁경부암 진단 PNA 칩으로 2010년 services. PCL is local distributor of Scienion, non-contact
Frost & Sullivan 사로부터 제품혁신상을 수상하였고, 암 유전자변 type microarrayer supplier and Sensovation, fluorescence /
이 진단 키트는 기술력과 경쟁력을 인정받아 2012년 지식경제부장 colorimetric scanner supplier in Germany
관으로부터 세계일류상품 인증을 받았다.
180
181
K30
L38
P15
N36
Pharmabcine
Pharmaphenix S.L.
PIPC (Patent Information Promotion Center)
(주)파멥신
파마페닉스
한국특허정보원 특허정보진흥센터
CEO
ADD
TEL
FAX
E-MAIL
URL
Jin-San Yoo 유진산
305-811 Daejeon BioVentureTown, 461-8, JeonminDong, Yuseong-Gu, Daejeon, Republic of Korea
82-42-863-2017
82-42-863-2080
[email protected]
http://pharmabcine.com
CEO
ADD
TEL
E-MAIL
URL
N
T
R
O
D
U
C
T
I
O
N
PharmAbcine is a specialized biotech company that
develops fully human therapeutic monoclonal antibody
(mAb) using innovative discovery technology and
excellent human resources for the treatment of human
diseases, such as cancer and inflammatory diseases. We
build competitive pipelines & drug discovery platform
(Tanibirumab & Bi-Specific Antibody) by in-house approach.
파멥신은 암치료를 위한 항체 신약개발을 목표로하는 바이오벤처
기업으로 2008년 설립이후 Novartis, OrbiMed, (주)녹십자 등
국내외 유수의 벤처 캐피탈의 투자를 유치하였으며, 세계적 수준
의 완전인간화 치료용항체 및 이를 기반으로 한 이중표적항체 연
구를 진행하고 있다. 특히, 당사의 파이프라인 가운데 선도물질인
Tanibirumab은 현재 임상1상이 진행중에 있으며, 2014년 IPO 성
공을 통해 세계적 기업으로의 성장을 목표로 하고 있다.
182
CEO
ADD
TEL
FAX
E-MAIL
URL
E
I
Pascal Nizet
Parc Cientìfic de Barcelona, Carrer Baldiri Reixac
4-8, 08028 Barcelona, Spain
34-93-449-7649
[email protected]
http://www. pharmaphenix.com
X
H
I
B
I
T
N
T
R
O
D
U
T
I
O
N
Pharmaphenix is a boutique international pharmaceutical
consulting company established in 2008 that has
specialized in all aspects of the Business Development
chain. Our clients include a broad range of investors,
biotechs, start-up ventures, and pharmaceutical companies
located in Europe, North America and Asia.
We focus on the rapidly emerging markets of Latin
America, MENA and Korea. Our in-depth corporate
experience gives us a global reach with a contact base that
includes key players (companies and people) in our target
markets, but also allows us to reach the rest of the world
thanks to our unique platform.
Our objective is to make our customers grow through
the development of new businesses (new markets, new
products or new structures) and assess them in that
process.
For BioKorea, we look for biotechs and pharmaceutical
companies interested in looking for marketing partners
for their products, either in development or even already
marketed in Korea.
X
H
I
B
I
T
Mr Vijay Shah
247 Business Park, A - Wing, 6th Floor LBS Marg,
Vikhroli (West) Mumbai 400083, India
91-22-3096-6666
91-22-3096-6665
http://piramalpharmasolutions.com
CEO
ADD
TEL
FAX
URL
I
E
C
Park Jeong Ryeol 박정렬
146-8 Donggyo-dong, Mapo-gu, Seoul, Korea
121-816
82-2-6915-6250
82-2-6915-6497
[email protected]
http://www.pipc.or.kr
S
Consulting, license in, out-licensing
I
Piramal Healthcare Ltd.
N
T
R
O
D
U
C
T
I
O
N
S
Pharma Solutions is the contract development and
manufacturing (CDMO) division of Piramal | Healthcare,
a part of the Piramal Enterprise. We are one of the
largest custom manufacturing companies in the world
민간에 제공하는 특허정보서비스 (KIWEE), KIWEE 검색, IP리서치, that provides flexibility and scalability of operations. We
have created a vast network of contract development
IP컨설팅, 특허평가·통계 서비스 등
and manufacturing facilities located in North America,
Europe and Asia that offers a multitude of services that
I
N
T
R
O
D
U
C
T
I
O
N
cover the entire drug-cycle, from development and
PIPC (Patent Information Promotion Center), a public commercial manufacturing to off-patent supplies of Active
institution affiliated with KIPO (Korean Intellectual Property Pharmaceutical Ingredients (APIs) and formulations.
Office), supports the KIPO’s policies and offers various
patent information services such as IP research, analysis,
evalution and consulting. etc.
IP information services (KIWEE)
IP research, IP consulting, Patent evalution (K-PEG). etc
특허청 산하의 공공기관으로서, 특허청의 정책업무를 지원하는 동시
에 특허정보 조사·분석·평가·컨설팅 등 다양한 특허정보서비스를
민간에 제공하고 있습니다.
183
M23
L31
PRA International
CEO
ADD
TEL
FAX
E-MAIL
URL
K30
Propharma Medical Supplies
Colin Shannon
4130 ParkLake Avenue, Raleigh, North Carolina,
27612
1 (919) 786-8200
1 (919) 786-8201
[email protected]
http://www.praintl.com
CEO
ADD
TEL
FAX
E-MAIL
URL
Dr. Mohammed Abuelkhair
Plot-C2 Meena Store Abu Dhabi, U.A.E.
971-2-673-4781
971-2-673-4768
[email protected]
www. propharma.ae
R20
ProteomeTech Inc.
Puretech P&T Co., Ltd.
(주)프로테옴텍
(주)퓨어테크피앤티
CEO
ADD
TEL
FAX
E-MAIL
URL
Lim, Kook Jin 임국진
B 202 Yonsei Dairy Building, 50 Yonsei-ro,
Seodaemun-gu, Seoul 120-110 Korea
82-2-323-8325
82-2-323-8379
[email protected]
http://www.proteometech.com
CEO
ADD
TEL
FAX
E-MAIL
URL
E
X
H
I
B
I
T
S
E
X
H
I
B
I
T
S
E
Human IgG Rapid
CRO
N
T
R
O
D
U
C
T
I
O
X
H
I
B
I
T
S
Viral Clearance studies, Viral Safety Testing, The
Immunoprofiling LAB, Viral Safety and Immunology Services
휴먼 이뮤노글로불린G 래피드
I
Kim, Tae Bong 김태봉
Western Tower II, A-dong 704ho, 24, Jeongbalsanro, Ilsandong-gu, Goyang-city, Gyeonggi-Province,
410-838, KOREA
82-31-908-6870
82-31-908-6873
[email protected]
http://www.ipuretech.com
N
As a leading CRO, PRA is transforming clinical trials through
our people, innovation and operational transparency. With
5,000+ employees in 80+ countries, PRA provides a full
suite of services across all phases. We have conducted
the pivotal or supportive trials that led to FDA and/or
international regulatory approval of 40+ drugs marketed
across several therapeutic areas.
Since our inception in 1976, we have amassed a level
of expertise that enables us to work on a variety of
compounds, ranging from niche treatments and therapies
to blockbuster drugs. PRA clients benefit from our strategic
investment in key therapeutic programs and research areas,
including neurology/psychiatry, oncology/hematology,
infectious diseases, biosimilar products, cardio-metabolic
diseases, and rare diseases.
PRA’s advanced technological tools and finely tuned
systems ensure seamless delivery and transparency
throughout our organization. Our dynamic services and
forward-thinking approach to drug development programs
are making a difference to healthcare patients worldwide.
I
N
T
R
O
D
U
C
T
I
O
N
Human IgG Rapid of Proteometech is research reagents
monitoring Human IgG content in real time by immune
chromatographic techniques
프로테옴텍은 “나를, 회사를, 사회를 행복하게” 라는 경영이념을 가
지고, Biomarker분석연구 및 rapid 정량기술 등을 통하여 고객의
unmet need 충족을 위해 항상 노력하며 성장하는 기업입니다. 프
로테옴텍의 Human IgG Rapid는 면역 크로마토그래피기술을 이용
하여 인간 유래 면역글로불린 G (Human IgG, hIgG)의 함량을 실
시간으로 모니터링 할 수 있는 연구용 시약입니다.
바이러스 제거 연구, 바이러스 안전 테스트, Immunoprofiling 연구
소, 바이러스 안전 및 면역학 서비스
I
N
T
R
O
D
U
C
T
I
O
N
Puretech P&T is a service provider providing cutting- edge
technologies, tools and services for Biopharmaceuticals,
Pharmaceuticals, Food &Beverage, Semiconductor, Chemicalmanufacturing. Our company have three strategic business
unit. Filtration Unit related with Filter and Resin. This unit is
working with MERCK MILLIPORE, ENTEGRIS (MYKROLIS),
DOW (RHOM & HASS), TAMI, KOCH, MEGA, VSEP.
Engineering unit provide custom purification system.
Service unit is working with TEXCELL, INTERTEK, LONZA
HUSTON as a strategic partner, we collaborate with
customers to confront the world’s challenging industry
issues.
(주)퓨어테크피앤티는 바이오, 제약, 식품 및 반도체 업계에 공정용
필터 및 수지, 정제 장비 제조, 대행생산 및 대행실험을 제공하는 전
문 기업입니다. MERCK MILLIPORE, ENTEGRIS (MYKROLIS),
DOW (RHOM&HASS), TAMI, KOCH, MEGA, VSEP사의 제품
판매 분야와 제품을 기반으로한 고객 맞춤 설비 ENGINEERING분
야, TEXCELL, INTERTEK, LONZA HOUSTON의 CRO & CMO
서비스 분야에서 고객과 함께 일하고 있습니다. 현재 여러 기업에 대
한 컨설팅 및 엔지니어링 그리고 판매 서비스를 담당하고 있으며, 차
별화된 전문성을 기반으로 고객 친화 서비스를 실현해 가고 있습니다.
184
185
K30
E10
I40
REGENPRIME Co., Ltd.
Regeron, Inc.
REP. OF NEW BRUNSWICK SCIENTIFIC CO., INC
리젠프라임(주)
(주)리제론
(주)한국 엔비에스
CEO
ADD
TEL
FAX
E-MAIL
URL
E
J.H. Yoon 윤정호
5F Seoyeong plaza, 518-3, Uman-dong, Paldal-gu,
Suwon, Gyeonggi-do, S.Korea
82-31-217- 4011 ~ 4
82-31-217-4015
[email protected]
http://regenprime.com/
X
H
I
B
I
T
S
ArtiFilm, CorneFilm, SIS sheet, SIS Powder, PCP, PCP-WS
N
T
R
O
D
U
C
T
I
O
ADD
TEL
FAX
E-MAIL
URL
E
Dahlkyun Oh 오달균
103 Bio-2, Hi-Tech Venture Town, 40 SoyanggangRo, Chuncheon, Kangwon-Do, South Korea
82-33-258-6263
82-33-258-6264
[email protected]
http://www.regeron.com
X
H
I
B
I
N
리젠프라임 (주)은 생체소재 (의료기기)와 세포치료제 개발을 하는 재
생의료 전문기업입니다.
‘05년에 설립하여, ‘10년에 생체소재 제품을 국내 최초로 인허가를
받았으며, ‘12년에는 ISO9001 인증을 받았습니다. 이후 2종의 소재
제품과 2종의 세포치료제를 개발하고 있습니다. 허가 받은 제품 ‘아
티필름’은 무릎 연골손상 환자에게 치료를 하는 수술보조기기로, ‘13
년 3분기에 국내판매 개시, ‘14년 CE 인증을 통한 유럽판매 예정입
니다.
두 번째 소재제품인 안과 수술용 보조재 (코니필름)도 ’14년 임상,
‘15년 허가승인을 통해 판매 예정입니다. 세포치료제는 개발진행 중
이고 주로 무릎연골손상 치료제로 개발하고 있습니다.
또한 경기 바이오 센터에 KGMP인증 제조시설을 구축하여 세포치료
제, 의료기기 생산시설을 완비해 명실상부한 글로벌 조직 및 장기 재
생 전문기업의 초석을 마련했습니다.
당사는 이미 확보된 원천 기술과 새로운 기술을 시장에 맞게 상용화
하여 국내 조직재생 시장을 선점함은 물론 해외 시장에서도 인정받
는 선두업체가 되겠습니다.
S
N
T
R
O
D
U
C
T
I
O
N
Regeron, Inc. was born as a research institute at 2000.
6 year of hard work from the beginning of Regeron,
we developed human growth hormone into cosmetic
ingredient as world first. Step by step and one by one we
have developed highly functional cosmetic ingredients
in this ground breaking bio-ingredient field. To share the
passion for re-youth with everyone, we are providing from
core-tech-made-ingredients to cosmetics (OEM services
and own brand).
리제론은 연구기관으로서 탄생한 이래 6년에 걸친 독자개발과정을
걸쳐 세계최초로 인간성장호르몬을 화장품원료로써 개발하였습니다.
그 후 기능성 화장품원료 개발의 최전선에서 성장인자단백질을 통한
화장품과 그 원료개발에 매진해왔습니다. 그리고 지금은 리제론 탄생
의 원동력이였던 젊음에 대한 열정을 고객과 함께 실현코자
최고의 서비스를 제공하고 있습니다.
ADD
TEL
FAX
E-MAIL
URL
E
Kim Han Ip 김한입
#201 SungGwang BLDG, 351-8, Yangjae-Dong,
M2P社로부터 Mini-Bioreactor를 국내에 도입하였습니다. 장비 외
Seocho-Gu, Seoul, Korea
에도, Single Use Bag (ASI社), Tubing 제품 (Walton-Mallow社
82-2-587-8558
, Flowsmart社)등을 공급하며, 우리나라 의약산업의 발전에 헌신 할
82-2-583-5874
수 있도록 최신기술의 장비와 서비스를 제공해 드리도록 항상 노력
[email protected]
하고 있습니다.
http://WWW.knbs.co.kr
X
H
I
B
I
T
S
발효기
백
-주름개선 특효, 미백 특효, 여드름 특효
I
CEO
저희 한국엔비에스는 여기에 그치지 않고 미국 Refine社와 독점계약
을 맺어, 차세대 Perfusion System인 ATF system를 국내 처음으
로 성공적으로 도입 및 지속적으로 공급하고 있으며, 최근에는 독일
BIOREACTOR
ASI BAG
화장품 : 엔씨지와이/오피나인/프리스틴클레어–리버스에이징, 주름
개선, 미백
화장품원료 : 성장인자단백질 화장품 원료
1. 핵심기술로부터 탄생한 기능성 원료의 제공
2. 자사브랜드화장품
3. OEM 화장품 제조 (최고급 기능성) 등
186
T
Cosmetics
Skincare - NCGY / OP9 / Pristeen Claire
Hair care - Pristeen
Cosmeceuticals - BioLetDAge CS line
아티필름, 코니필름, SIS sheet, SIS Powder, PCP, PCP-WS
I
CEO
및 CO2 Incubator 등 내구성 강한 연구 기자재를 최고의 조건으로
제공 및 서비스하고 있습니다.
I
N
T
R
O
D
U
C
T
I
O
N
Our company, K.NBS started business 13 years ago in
1999 with New Brunswick an eppendorf Company
Brand product which company is very well known for in
manufacturing the Fermentor as well as the Bioreactor over
the world. At the early of our business stage, we could
successfully introduce the Fermentor and Bioreactor to our
Korean biotechnology field. And until now, NBS product
became one of our mother based business to growing up
and extending our business areas.
Also, we successfully introduced the ATF System (Newgeneration perfusion system) in Korea for the first time by
getting exclusive supplier contact with Refine company in
U.S. And, recently, we bring the Mini-Bioreactor from M2P
company in Germany.
Besides these Biotech devices, we are taking care of
disposal products such as Single Use Bag (ASI), Tubing
Products (Walton-Mallow, Flowsmart). we always trying
our best to finding our valuable items to meet the
customer’s detailed and sophisticated requirement and to
contribute to our Korean Biotechnologies.
(주)한국엔비에스 ( K . NBS Inc .)는 60 년 전통의 세계최고성능
을 자랑하는 미생물 발효 및 생명공학 연구장비 생산업체인 New
Brunswick an eppendorf Company 社의 한국대리점으로서 지
난 20년간 Fermentor 와 Cell Culture Bioreactor 장비를 수 많
은 제약 회사 및 연구소에 제공해오고 있습니다. 그 외에도 Shakers
187
R25
C10
A34
REXGENE BIOTECH Co., Ltd.
Samsung Medical Center (Clinical Trial Center)
Rev-Med, Inc
(주)렉스진바이오텍
삼성서울병원 (임상시험센터)
(주)레보메드
CEO
ADD
TEL
FAX
E-MAIL
URL
Kwon, Suk Hyung 권석형
94, Gangni 1-gil, Ochang-eup, Cheongwon-gun,
Chungbheongbuk-do Korea
82-43-218-0510
82-43-218-0517
[email protected]
http://www.rexgenebio.co.kr
CEO
ADD
TEL
FAX
E-MAIL
URL
N
T
R
O
D
U
C
T
I
O
N
CEO
ADD
TEL
FAX
E-MAIL
URL
I
I
Young Suk Park 박영석
81 Irwonro, Gangnam-gu, Seoul 135-710, Korea
82-2-3410-0916
82-2-3410-0958
[email protected]
http://ctc.samsunghospital.com
N
T
R
O
D
U
C
T
I
O
N
Samsung Medical CTC was established to promote the
RexGene Biotech opened in 1996 by the Onnuri Chain international standards in clinical trials, to support the
Drugstores, the first and the biggest pharmacy franchise development of clinical research and to provide optium
in Korea. The philosophy of our company is to make life research environment for investigators in 1999.
happier and healthier for people by providing health food
of good quality. We are committed to producing the 저희 삼성서울병원 임상시험센터는 지난 1999년 세계 최고 수준의
highest quality supplements using the latest in technology 임상연구 수행을 위하여 설립되었고, 우리나라가 세계적인 임상시험
and state-of-the-art manufacturing facilities in Ochang, 허브로 성장하는데 기여하는 임상시험센터가 되도록 노력하고 있습
ChungBuk, Korea. Our plant meets or exceeds all Korea 니다.
Food and Drug Administration and other health and
nutrition standards. Our facilities also operate using current
GMP established by the Korea FDA. Our scientists in Life
Science Institute meet with professors, medical doctors,
nutritionists and other healthcare experts on a regular
basis to ensure we are providing products and services
that meet the demand of our consumers. By collaborating
with many experts in research institutes, we are developing
new products and delivering accurate information to our
customers. As we have grown over the years, so has our
commitment. We have set the standard in the health
and nutrition industry by demanding truth in labeling,
ingredient safety and potency, while remaining on the
cutting edge of nutritional science. We keep helping our
customers improve their quality of life through better
nutrition and healthier living.
E
I
N
T
R
O
D
U
C
T
I
O
N
• Foundation : 2009.Jan
• Staff : 20
• Sales/Year : usd15M
Shin Bong Guen 신봉근
462-806 513-22 Sangdaewon-dong Joongwon-gu • Product line
1.Cell including stemcell concentration or separation
Sungnam-city, kyungki-do Joongil EinsPlatz #301
products
82-31-741-0996
PRP kit/Bone marrow stemcell kit/ Adipose stemcell
82-31-741-0976
harvest kit
[email protected]
2.Minimally invasive Herniated disc treatment
http://www.revmedinc.com
equipments
Plasma D30 Spine system (PDCT)
X
H
I
B
I
T
S
1. TriCeLL PRP kit
· Perfect separation : Interlocking bar
· You can see the PRP line : bottle neck shape
· PRP density is adjustable from 1cc to 5cc
· 100% closed system : Most safety and clean
·4~10 times more platelet than whole blood (1,000,000
platelet/uL is guaranteed)
CE / USA FDA approval
• 설립일자: 2009년 1월30일
• 직원수 : 20명
• 제조품목 :
1. TriCeLL PRP Kit (자가혈 줄기세포 및 혈소 판농축기)
2. TriCeLL BMC kit (골수줄기세포농축기)
3. 자가지방이식용 지방세포 분리기
2. TriCeLL BMC kit (Bone Marrow StemCell)
· 100% closed system : The most safety and clean
· First in the world, Built in bone marrow filter system
· Powerful concentration of CD34+ & MSC
· You can see stemcell line with its bottle neck shape.
· Perfect separation with interlocking bar system
CE / USA FDA 510-K pending
1. TriCeLL prp kit
·인터락킹바를 통한 완벽한 혈액 분리
·병목구간을 이용하여 혈소판층을 육안으로 확인가능
·Prp의 농축도를 조절가능
·완벽한 밀봉구조로 안전성 극대화
·전혈대비 약 4배에서 10배의 혈소판 농축가능 (1ul당 1,000,000
개이상의 혈소판 보장)
CE/FDA 승인
2. TriCeLL BMC (골수줄기세포농축) 기
·적혈구층의 완벽한 격리가능
·완벽한 밀봉구조를 구현하여 안전성 극대화
·골수의 불순물제거용 필터를 키트내부에 내장하여 안전성 및 편
의성 극대화
·CD34+ 및 MSC 의 농축력이 우수함
·병목구간을 통해 줄기세포 층을 육안으로 확인가능
CE/FDA 510-Kpending
188
189
M10
P13
conservation
The purpose to participate Bio Korea 2013 are as below:1.Tropical herbs and functional agricultural products as
경제개발 투자청
dried super powder (up to 500nano size)
2.Biomass from Palm Oil Mill
Datuk Dr. Mohd. Yaakub Hj. Johari. JP
3.Investment supporting program to Sabah state
lot 1 wisma SEDIA, Off Jalan Pintas Penampang,
government, Malaysia
P.O.Box 17251
60-88-450-650
사바 경제개발 투자청은 사바주 개발 코리도의 기초계획, 조정, 홍보
60-88-450-699
를 촉진하기위한 원스톱 기관으로서 생활, 업무 및 투자 최적지로서
[email protected]
의 선도적인 경제발전 지역으로 말레이지아 사바주개발 코리도의 성
http://www.sedia.com.my
공을 촉진하며 이를위한 사회적이고 성장 지속적인 개발을 최우선으
SEDIA (Sabah Economic Development and
Investment Authority
사바
CEO
ADD
TEL
FAX
E-MAIL
URL
E
X
H
I
B
I
T
S
1.Nano process machinery
2.Tropical herbs and functional agricultural products as
dred super powder (up to 500nano size)
3.Biomass from Palm Oil Mill
4.Investment supporting program to Sabah government,
Malaysia
1. 나노기계
2.열대 허브및 기능성 농작물을 500나노사이즈의 초미세 분말로 가
공한 제품과 기술
3. 팜공장에서 발생하는 유기물
4. 말레이지아 사바주 정부의 투자지원 프로그램.
I
N
T
R
O
D
U
C
T
I
O
N
SEDIA has been entrusted as the One-Stop Authority to
drive Sabah Development Corridor (SDC), with the primary
responsibility to plan, coordinate, promote and accelerate
the development of the SDC.
The Objectives of SEDIA are as follows:
To Promote and accelerate the development of the SDC
into a leading economic region and a choice investment
destination for investment, work and living; and To ensure
that social development and sustainable development are
kept as priorities whilst driving economic growth in the
SDC.
The SDC programs are underpinned by the three key
principles that will guide development in Sabah, namely
the need to:
- Capture higher value economic activities
- Promote balance economic growth with distribution
-Ensure sustainable growth via environmental
190
로함을 목적으로 한다.
사바주 개발코리도의 프로그램은 다음과같은 사바주 개발의 세 가지
핵심 원칙에 의해 뒷받침된다 :
- 고부가가치의 경제활동 영위
- 성장과 나눔의 균형
- 환경보존을통한 지속적인 성장
이번 Bio Korea 2013의 참가목적은 다음과같다.
1.열대 허브및 기능성 농작물을 500나노사이즈의 초미세 분말로 가
공한 제품과 기술
2. 팜공장에서 발생하는 유기물
3. 말레이지아 사바주 정부의 투자지원 프로그램.
A20
Samwoo S&T
SCAS-BTT Bioanalysis
삼우에스앤티
(주)스카스비티티바이오애널리시스
CEO
ADD
TEL
FAX
E-MAIL
URL
E
Lee Sang Hoon 이상훈
10F MarkCity-Yellow BDG, 963 WoonJoon-Dong
Bundang-Gu, Gyeonggi-Do Korea
82-31-755-0350
82-31-754-9645
[email protected]
http://www.samwoosnt.com
X
H
I
B
I
T
S
Amicon, Amicon-Pro, IT4, Lab Scale, Quik Scale, NovA
mixer, NovA Valve, NovA Septum, Equinox pump, Milliflex
quantum, EZ-stream pump, Microfil, MAS100, Milli-Q
integral, Q-Pod, Milli-Q Direct system, Tank, Water
purification system
CEO
ADD
TEL
FAX
E-MAIL
URL
E
N
T
R
O
D
U
C
T
I
O
N
Samwoo is one of the best distributor of Merck Millipore
Korea, we started business with them already over 20
years. The main line of business is all of the filter for Bio
industry. our organization growing constantly and very
hopeful company.
(주)삼우에스앤티는 생명공항, 제약업계, 병원 및 이화학계열 업
체에 실험기자재를 비롯한 생산장비를 공급하는 전문기업으로
Merck Millipore사의 Amicon, 초순수제조장치, bio process
필터 및 시스템, 미생물 측정장치, Column 및 관련 Media를 제
공하며 그 밖에 MP-BIO의 바이오케미칼 등을 취급, JNC 제품의
Chromatography media를 취급하고 있습니다.
X
H
I
B
I
T
S
Development of Bioanalytical Method Validation,
Validation of Analysis Methods, Concentration test of PK &
TK, Measure drug concentration of clinical Trial (I, II, III, IV),
Measure drug concentration of Bioequivalence Test
I
I
Kang Jong-gu 강종구, Sakaue Shigeyuki
4 43-270 Gyeonggi Bio-center, Iui-dong,
Yeongtong-gu, Suwon-si, Gyeonggi-do
82-31-888-6454
82-31-888-6460
[email protected]
http://www.scas-btt.com
N
T
R
O
D
U
C
T
I
O
N
SCAS-BTT Bioanalysis, the largest comprehensive analysis
company in Japan called Sumika Chemical Analysis Service
(SCAS) and the first leading of nonclinical CRO company
in Korea which is BIOTOXTECH, based on the highest level
of analysis techniques. SBB is Biological Method Validation
CRO which established to contribute for development
of new drugs. SBB has a variety of experience, the best
analytical techniques, the latest equipment and facilities,
using the internationally respected CRO of Biological
Method Validation, as a high-quality analysis, testing the
shortest time and competitive price for developing as
early as possible new drugs on the market. SBB wants to
contribute for promoting the welfare of all mankind and
health.
(주)SCAS-BTT Bioanalysis는 일본 최대규모의 종합분석회사인 (주)
스미카분석센터와 한국 민간 최초 및 최대 규모의 비임상시험CRO
인 (주)바이오톡스텍이 최고 수준의 분석기술을 바탕으로 신약 개발
에 공헌하기 위해 설립한 생체 시료 분석 CRO입니다. (주)SCASBTT Bioanalysis는 다양한 경험, 최고의 분석 기술, 최신 기기 및 설
비를 이용하여 국제적으로 신뢰받는 생체시료분석CRO로서, 고품질
의 분석시험을 최단 기간 및 최적 가격으로 수행하여 하루라도 빨리
신약이 시장에 출시되어 인류의 복지 및 건강에 기여할 수 있도록 노
력하고 있습니다.
191
Q13
D30
B13
D20
sellus Co., Ltd.
SEOUL METROPOLITAN GOVERNMENT
Seoulin Bioscience
Severance Hospital Gene Bank
주식회사 셀루스
서울특별시 마곡사업추진단
(주)서린바이오사이언스
연세의료원 (세브란스유전자은행)
CEO
ADD
TEL
FAX
E-MAIL
URL
E
Kim Ji Woon 김지운
6 2 0 - 2 7 , Yo n g t a n - d o n g , C h u n g j u - s i ,
Chungcheongbuk-do, Korea
82-43-856-7588
82-43-856-7591
[email protected]
http://www.sellus.co.kr
X
H
I
B
Creant Mise Toothpaste, Boan Cream
I
T
S
PARK WON – SOON 박원순
110, Sejong-daero, Jung-gu, Seoul, 100-744 Korea
82-2-2133-1528
82-2-2133-1015
http://english. seoul.go.kr
CEO
ADD
TEL
FAX
URL
ADD
TEL
FAX
E
X
H
I
B
I
T
S
E-MAIL
URL
Eul Moon Hwang 황을문
4F. #A, KOREA BIO PARK, 694-1, Sampyeong,
Bundang-gu, Seongnam-si, Gyeonggi-do 463400, Korea
82-1670-5911
82-31-628-3006
[email protected]
http://www.seoulin.co.kr
CEO
ADD
TEL
FAX
E-MAIL
URL
Hogeun Kim 김호근
Yonsei University Health System (YUHS), 134
Sinchon-dong, Seodaemun-gu, Seoul, Korea
82-02-2228-7810
82-02-312-9792
[email protected]
http://sev.iseverance.com/dept_clinic/center/gene/
Etc (Yonsei University Health System)
SEOUL MAGOK R&D INDUSTRIAL DISTRICT
E
I
N
T
R
O
D
U
C
T
I
O
N
Seoul city is developing Magok, "last massive land
development project of Seoul" to make it the cradle of
cutting edge industries. Magok is a urban type of R&D
cluster which can use abundant workforce and convenient
transportation of Seoul, capital city of dynamic korea and
at the same time, eco-friendly new city of high quality
equipped with large scale park and green area. And also
Magok has the advantage of supplying the industrial
districts at production costs. Magok will be the best choice
for the bio-tech company dreaming of taking a leap.
서울시는 ‘서울의 마지막 남은 땅‘ 마곡을 첨단산업의 요람으로 만들
고자 '서울 마곡 R&D 산업단지’를 개발하고 있습니다. 마곡은 서울의
풍부한 연구인력과 교통을 활용할 수 있는 ‘도시형 연구단지’인 동시
에, 대규모 공원과 녹지를 갖춘 ‘친환경 명품 신도시’입니다. 또한 산
업용지를 조성원가로 공급하는 이점도 있어 도약을 꿈꾸는 바이오기
업에게 최고의 선택이 될 것입니다.
192
CEO
X
H
I
B
I
T
S
I
N
T
R
O
D
U
C
T
I
O
N
Thermo Scientific HyClone Animal culture serum free The purpose of the Gene Bank is to provide samples
medium, Disposable bags.
collected from Severance Hospital to support biomedical
Applikon Bioreactor, Purfusion system, Fermentor.
research for the prevention and treatment of human
disease. We always collect samples with consent of the
donors and by complying with the bioethics and safety
I
N
T
R
O
D
U
C
T
I
O
N
regulations without harming the donors. We perform
As leading total solutions in life sciences, Seoulin Bioscience efficient collection, storage, and fair supply of samples
is providing animal culture serum free medium, Bioreactor, for the development of biotechnology, thereby striving
to contribute to health and quality of life of the public.
Disposable bags.
Currently, the Gene Bank has collected a large amount of
(주)서린바이오사이언스는 생명공학 선도기업으로 바이오 의약품 제 materials that are essential for development of diagnostic
조 시에 필요한 동물세포 배지, 시약, 배양기, 일회용 bag을 제공하 and therapeutic biomarkers for malignant tumors and
고 있습니다.
other incurable diseases.
세브란스병원 유전자은행은 연세대학교 세브란스병원에서 사람으로
부터 유래한 검체를 이용하여 수행하는 연구가 생명윤리 및 안전기준
에 따라 인간의 존엄과 가치를 침해하거나 인체에 위해를 주는 것을
방지하고, 생명과학기술이 인간의 질병 예방 및 치료 등을 위하여 개
발.이용 될 수 있도록 유전자 검사용 검체 수집 및 보관, 유전자 연구
를 위한 검체 공급, 정확한 유전자 검사 등에 대한 여건을 조성함으로
써 국민의 건강과 삶의 질 향상에 이바지함을 목적으로 한다. 현재 세
브란스 유전자은행은 악성 암이나 난치성 질환의 진단과 치료에 대한
바이오마커 발굴에 필수적인 많은 양의 검체를 보유하고 있다.
193
D20
E32, F47
Severance Integrative Research Institute for
Cerebral & Cardiovascular Diseases (SIRIC)
연세의료원 (세브란스 뇌심혈관질환융합연구사업단)
CEO
ADD
TEL
FAX
E-MAIL
URL
I
N
Dong Ik-Kim 김동익
Yonsei University Health System, 50 Yonsei-ro,
Seodaemoon-gu, Seoul, Korea
82-2-2228-0381 ~ 0385
82-2-2227-7906
[email protected]
http://www.siric.re.kr/
T
R
O
D
U
C
T
I
O
E38
R13
SHIN POONG PHARM
SK Chemicals
SNC-Lavalin Korea
신풍제약(주)
에스케이케미칼
에스엔씨라발린코리아
CEO
ADD
TEL
FAX
E-MAIL
URL
Kim Chang Kyun 김창균
Yoksam-Ro, Kangnam-Ku Seoul korea 135-925
82-2-2189-3400
82-2-558-0565
[email protected]
http://www.shinpoong.co.kr
Lee In Serk 이인석
3 10 Pangyo-ro, Bundang-gu, Seongnam-si,
Gyeonggi-do, 463-400 Korea
82-2-2008-2008
82-2-2008-2959
http://www.skchemicals.com
CEO
ADD
TEL
FAX
URL
세브란스 뇌심혈관질환 융합연구사업단은 2008년 12월 보건복지부
선정 선도형 연구중심병원사업으로 발족되었다. 병원의 우수한 인력
을 중추로 한 총 3개 단위, 12개의 산·학·연 세부 팀들이 뇌심혈관
질환의 극복을 위해 예방, 진단, 치료의 전 과정에서 공동으로 연구를
수행하며 체계적이고 효율적인 융합연구의 새로운 패러다임을 만들
고 있다.
ADD
TEL
FAX
E-MAIL
URL
E
X
H
I
B
I
T
S
E
X
H
I
B
I
Medicurtain Inj. 1.2 ml, 2ml, 5ml etc
Medicines, Vaccine, Blood Derivatives
메디커튼 주 1.2ml, 2ml, 5ml 등
의약품, 백신, 혈액제 등
T
Todd Farrell
4F, Joongpyeong Building, 748-15, Yeoksam-dong,
Gangnam-gu, Seoul, Korea
82-2-566-1400
82-2-566-5633
[email protected]
http://www.snclavalin.com
S
E
X
H
I
B
I
T
S
Engineering & Construction
N
Severance Integrative research Institute for Cerebral &
Cardiovascular Diseases (SIRIC) was initiated in December
2008 as The project of Leading research-centered hospital
under the support of Korean Ministry of Health and
Welfare. The SIRIC aims to present a new paradigm for
systematic and effective integrated research. This is to
enable clinical doctors, basic researchers and experts from
industry to conduct joint studies for prevention, diagnosis
and treatment of cerebrovascular and cardiovascular
disease.
CEO
엔지니어링 & 건설
I
N
T
R
O
D
U
C
T
I
O
N
SHIN POONG has contributed to human community
with company mission of “For the health of the people”
since its foundation in 1962, and now is the one of best
pharmaceutical company in Korea with its remarkable
growth.
We are headquarted in Korea with 5 oversea subsidiaries,
getting the spotlight as the best pharmaceutical company
in terms of ETC prescription of domestic market in
Korea and keeping its global presence in more than
40 countries. Medicurtain Inj. to exhibit at this time is
optimal combination of sodium hyaluronate has effect of
a physical barrier in preventing adhesion formation and
hydroxyethylstarch has effect of inhibiting blood clot as risk
factors for the occurrence of adhesion.
I
N
T
R
O
D
U
C
T
I
O
N
SK Chemicals is recording continuous sales expansion
such as Sunpla the domestic new drug No.1 anti-cancer
medicine, Joins the domestic natural new drug No.1, Mvix
the domestic new drug No.13, blood derivatives, and
medical devices etc. Also our company has set to build
a new type of cell culture-based vaccine manufacturing
facility as a next step for the global vaccine manufacture.
I
N
T
R
O
D
U
C
T
I
O
N
Founded in 1911, SNC-Lavalin (SNC-Lavalin Inc., its
subsidiaries and affiliates) is one of the leading groups
of engineering and construction companies in the world
and a key player in the ownership and management
of infrastructure and facilities. The company provides
engineering, procurement, construction, project
management and project financing services to a variety of
SK케미칼은 국내신약 1호 선플라 (항암제), 국내천연물신약 1호 조 sectors.
인스, 국내신약 13호 엠빅스, 혈액제, 의료기기 등을 바탕으로 지속
적으로 사업 영역을 확장하고 있다. 또한 세포배양기술의 백신을 개 1911년에 설립된 SNC-Lavalin (SNC-Lavalin (주)와 그 계열회사
발하여 글로벌 백신회사로의 발전을 진행하고 있다.
들)은 설계 및 건설 분야를 선도하는 세계적인 기업들 중 하나이며,
다양한 인프라와 시설들을 소유 및 관리하는 대표적인 기업입니다.
SNC-Lavalin은 여러분야에 대한 설계, 조달, 건설, 프로젝트 관리
및 프로젝트 파이낸싱 서비스를 제공합니다.
신풍제약은 1962년 창립 초기부터 국산화를 위해 원료합성기술을
개발하고 원료합성 및 완제품 생산 공장을 모두 갖추어 원료의약품
및 완제의약품을 생산하여 국내 판매와 해외 수출을 지속적으로 추
구하고 있다. 이러한 노력으로 글로벌 국산 신약 피라맥스정 개발에
성공하였으며, 세계화를 위한 새로운 도약으로 충북 오송생명과학단
지 내에 세파계 항생제 전용공장을 완공하여 우수한 의약품을 생산
중에 있다. 이번에 전시할 메디커튼주는 HA 와HES 성분의 새로운
조합으로 개발된 유착방지제로 혈전 형성을 억제해 유착을 방지하는
제품이다. 또한, 중앙연구소와 제제개발 연구소를 분리 이원화하여
선택과 집중을 통한 연구 역량을 극대화하고 있다.
194
195
Q23
B24
R10
F38
Song Am Trading Corp.
Soon Chun Hyang Lab-based Industry Cooperation
SPIRAXSARCO KOREA
ST Pharm. Co., Ltd.
송암교역
순천향대학교 LINC사업단
한국스파이렉스사코(주)
에스티팜(주)
CEO
ADD
TEL
FAX
E-MAIL
URL
Seo Jeong Moon 서정문
#1005 Daeyoung Golden Valley 290-2, GocheonDong, Uiwang-City, Gyeonggi-Do
82-31-450-6681
82-31-450-6684
[email protected]
http://www.songamnano.com
CEO
ADD
TEL
FAX
E-MAIL
URL
E
X
H
I
B
I
T
KIM HAK MIN 김학민
5F Entrepreneur ship Soon Shun Hyung University,
Shinchang-myun, Chungcheongnam-do, Sonth
Korea
82-41-530-4851
82-41-530-4783
[email protected]
http://linc.sch.ac.kr
I
T
S
순천향대학교 산학협력
N
T
R
O
D
U
C
T
I
ADD
TEL
FAX
E-MAIL
URL
Jang chang woo 장창우
71B-14L Namdong 2nd Industrial Complex 64013, Gojan-dong, Namdong-gu, Incheon 405-817,
Korea
82-32-820-3970 ~ 5
82-32-811-0321
[email protected]
http://www.watson-marlow.com/kr
CEO
ADD
TEL
FAX
E-MAIL
URL
Lim Geun Jo 임근조
S hihwa Industrial Complex 1Na-802. 1241-2,
Jungwang-dong, Siheung-si, Gyeonggi-do 429912, Korea
82-2-527-6393
82-2-561-6006
[email protected]
http://www.stpharm.co.kr
S
X
H
I
B
Tumbler Mixer, Microcapsule equipment, High pressure E
homogenizer
Soon Chun Hyang Lab-based
Industry Cooperation public relations
Tumbler Mixer, Microcapsule 설비, 고압 분산기/균질기
I
CEO
O
N
SongAm Trading Corp is a importing company about bio /
nano facilities. We are trying to develop national industries
to introduce unique equipments to Korea Companies.
In this time, we are introducing some instruments here
bellow.
We can lend you some equipment and test.
1. Accelerate your Protein Formulation Development
(complete in 45 days)
2. Microcapsule Equipment
3. High Pressure Homogenizer
4. Tumbler Mixer (Three Dimensional Mixer)
5. Bio Centrifuge
6. Jet Mill
당사는 해외 기술을 국내에 소개함으로써 국가 산업 발전에 이바지
하고자 노력하고 있습니다.
이번 전시를 통하여 당사가 새로운 혁명적인 여러 설비를 아래와 같이
소개 드립니다.
선도대학 (LINC) 육성사업단 홍보
I
N
T
R
O
D
U
C
T
I
O
N
SCH LINC for Medi-Bio & New IT Convergence Industry
public relations
“교육과학기술부 지원” 순천향대학교 산학협력 선도대학 (LINC) 육
성사업단 의약바이오-New IT 컨버전스 산학협력 선도대학 육성사업
홍보
E
X
H
I
B
I
T
S
I
N
T
R
O
D
U
C
T
I
O
N
Watson-Marlow Pump, Medical OEM Pump, Flexicon Filling ST Pharm [a member of Dong-A Socio group] has been
& capping machine
offering excellent custom manufacturing services of APIs
and their intermediates to meet global pharmaceutical
c o m p a n y ’s h i g h e x p e c t a t i o n o f c o m p l i a n c e t o
I
N
T
R
O
D
U
C
T
I
O
N
cGMP requirements for their uses in pharmaceutical
Watson-Marlow Pumps is acknowledged as the world's development.
leading manufacturer of positive displacement pumps. Our facilities are inspected and approved by US-FDA, EMA,
Founded on over 50 years of supplying engineering, our ANVISA, TGA, PMDA, KFDA etc.
pumps are tried, tested and proven to deliver.
ST Pharm is also globally recognized as top-tier manufacturer
of nucleoside APIs and RNA/DNA oligonucleotides APIs in
왓슨말로우 펌프는 50년 이상 엔지니어링 및 프로세스 전문기술을 various drug applications.
제공하고 있으며, 전 세계에 100만대 이상의 펌프가 설치되었고, 다
양한 현장에 적용/검증되었습니다.
1983년 설립 후 생명과학분야의 원료의약품 전문회사로 발전해온
에스티팜은 뉴클레오시드 항바이러스제 약물의 원료 및 중간체 개발
에 집중해 왔으며 그 결과 세계 초일류 제약사들과 장기적인 공급 계
약을 체결하여 안정적인 원료 공급을 해오고 있습니다.
미국 FDA를 비롯하여 유럽, 일본, WHO등의 유관 기관들로부터
cGMP 인증을 받은 국제적인 생산시스템을 운영 중에 있습니다.
한편, 에스티팜은 2010년 6월 동아쏘시오그룹의 일원이 되었으며,
사명 (社名)을 ST (Science & Technology) Pharm으로 하고, 보다
커다란 비젼을 추구하는 Global 선진기업이 되고자 합니다.
그룹 시너지 효과를 극대화하여 현재의 위치에 만족하지 않고 미래
의 생명과학분야를 선도하는 세계적인 기업으로 도약하기 위해 최선
을 다하겠습니다.
일부 설비에 관하여는 국내보유하고 있으며 임대 및 당사에서 Test
가능합니다.
1. Protein Formulation 설비 (45일 완성)
2. Microcapsule 설비
3. 고압 균질기
4. 3차원 Mixer
5. Bio Centrifuge
6. Jet Mill
196
197
N23
L39
State of Missouri
N20
Strex, Inc.
미국 미주리 주정부 사무소
CEO
ADD
TEL
E-MAIL
URL
Luis Jimenez
1610 S Providence Rd. Columbia, MO, 65211, USA
1-573-319-9020
[email protected]
http:// www.eternogen.com
X
H
I
B
I
T
S
Injectable dermal fillers
- RPC (Rapidly polimerizing collagen)
- NanoMatrix (gold nanoparticle-collagen matrix)
I
N
T
R
O
D
U
기업이 탄생되는 곳이며 현재 500개 이상의 바이오 관련 기업이 입
주해 있습니다. 이에 메릴랜드 주 한국무역통상부는 한국기업이 미국
시장에 진출할 수 있도록 기초 창업단계에서부터 공동연구, 임상실
메릴랜드주 한국무역통상부
CEO
ADD
TEL
FAX
E-MAIL
E
주립대학을 중심으로 생명공학단지를 조성하여 수많은 바이오 벤처
State of Maryland Business Office-Korea
C
T
I
URL
E
Norio Ishida
Shashin-kaikan 4F, 2-7-14, Minami-Semba, Chuoku, Osaka, Japan, 542-0081
81-6-6271-9373
81-6-6271-9372
[email protected]
http://www strex.co.jp/
X
H
I
B
I
T
S
Process/Machinery
O
N
I
N
T
R
CEO
ADD
TEL
E-MAIL
URL
E
Gun-Seon, Lee 이근선
험, FDA 승인에 이르기까지의 모든 컨설팅 업무를 지원합니다.
20410 Observation Dr. Suite 105 Germantown,
MD 20876, U.S.A.
+1 301-528-2200
[email protected]
www.sombok.org www.kmbioexpo.com
X
H
I
B
I
T
S
‘Korea-Maryland, USA Bio Expo 2013’ & ‘BioMaryland
2020’ Strategic Plan Introduction
O
D
U
C
T
I
O
N
EternoGen is a medical Bio-Tech company with a focus on STREX instruments apply various stretched or compressed
designing and manufacturing a novel collagen scaffolds for stress to culturing cells, and can simulate in vivo
soft tissue therapeutic applications.
environment.
한.미 바이오 엑스포 2013 소개 및 메릴랜드 주 바이오 정책 소개
메릴랜드 주 한국무역통상부, JG Business Link International,
Johns Hopkins University, University of Maryland School
of Medicine, Montgomery County, University of Maryland
BioPark, BioHealth Innovation 총 7개 업체 함께 참여
I
N
T
R
O
D
U
C
T
I
O
N
State of Maryland Business Office-Korea is officially
designated, from Maryland, to connect and develop
businesses between Korea and the U.S. Maryland is
located in the Mid-Atlantic Region; bordering Washington,
D.C. and 19 federal regulatory agencies such as NIH,
FDA, and NIST which are located in Maryland. There are
over 500 bioscience companies such as Human Genome
Sciences and MedImmune which are also headquartered
in Maryland, and this creates the most innovative
biotechnology cluster in the entire United States. State
of Maryland Office-Korea is here to provide consulting
services from the basic, clinical trials, joint research, and
FDA approval process.
The 2ndannual ‘Korea-Maryland, USA Bio Expo’will be held
in Oct.9th-12th, 2012 in Maryland. Business partnering
sessions, Health and Life Science Forums and Medical
Robotics Forums are prepared. Please visit us to find the
right partner to develop innovative technologies.
메릴랜드 주 한국무역통상부는 한.미간 산업 교류 및 발전을 위해 메
릴랜드주로부터 공식 지정된 정부기관입니다. 미국의 수도 워싱톤
DC 바로 옆에 위치한 메릴랜드 주는 NIH, FDA, NIST를 포함한 19
개의 연방 규제기관이 위치해 있고, 존스합킨스 대학교와 메릴랜드
198
199
Q19
C40
E34
L23
Synex Consulting Ltd.
TAEJIN ENG Co., Ltd.
Taejoon Pharmaceutical Co., Ltd.
사이넥스
(주)태진이엔지
태준제약
CEO
ADD
TEL
FAX
E-MAIL
URL
E
Young Kim 김 영
1 0th Floor Daejong Building 435, Teheran-ro,
Gangnam-Gu, Seoul 135-527, Korea
82-2-6202-3300
82-2-2040-6250
[email protected]
http://www.synex.co.kr
X
H
I
B
I
T
S
International Healthcare Market Access
Regulatory Affairs, Clinical Research
Reimbursement Approval, Market Research
CEO
ADD
TEL
FAX
E-MAIL
URL
E
Kang Hee Cheol 강희철
138BL-9LT Namdong Industrial Complex 709-8
Gojan-dong, Namdong Gu, Incheon 405-821 Korea
82-32-899-1842
82-32-818-8477
[email protected]
http://www.taejineng.co.kr
X
H
I
B
I
T
S
Center Table, Corner Table, Sink Table, Reagent Cabinet,
Safty Cabinet
CEO
ADD
TEL
FAX
E-MAIL
URL
E
Taiwan Bio Industry Organization
(BioTaiwan 2014)
Mr. Tae Young Lee 이태영
8, Daesagwan-ro 31-gil, Yongsan-gu, Seoul, Korea
82-2-798-6601~7
82-2-798-6610
[email protected]
[email protected]
http://www.taejoon.co.kr
X
H
I
B
I
T
S
T
R
O
D
U
C
T
I
O
N
N
T
R
O
D
U
C
T
I
O
N
(주)태진이엔지는 산업용철제가구, 클램핑툴 및 물류운반기기를 전
We are multifunctional because it is important to your 문적으로 생산하는 회사로 국내시장을 선도하는 동종업계 최대의 기
업으로 인체공학적 설계에 의해 제작된 실험실가구는 제품의 내구성
success.
사이넥스는 헬스케어 시장진입에서 중요한 영역의 과제를 통합적으
로 서비스하는 전문 컨설팅 회사 입니다.
TEL
FAX
E-MAIL
URL
E
I
I
I
N
ADD
증대, 효용성 증대 및 실험실환경과 연구원의 안전을 최대한 고려한
제품입니다.
Johnsee Lee
7F-1, No.3-2, YuanQu St., Nankang Dist., Taipei
City 115, Taiwan
886-2-2655-8692
886-2-26557419
[email protected]
http://www.biotaiwan.com.tw
X
H
I
B
I
T
S
Xalost, Xalost Plus, Infresh Plus, Hyaluni, Iobrix Inj., Government /Organization / Institution
Radisense Inj., Qretin tab, CoolPrep powder
중앙실험대, 코너실험대, 싱크테이블, 시약장, 위험물보관함
보건의료사업 진입전략 및 수행 허가, 임상시험, 보험, 시장조사
I
CEO
N
T
R
O
D
U
C
T
I
O
N
Established in 1978 under the slogan, “to create a healthy
world, ” Taejoon Pharmaceutical Co., Ltd. (“Taejoon”) is
one of the leading specialty pharmaceutical companies in
ophthalmology and contrast media with a global presence
in Europe, Africa, Asia Pacific Region and the United States
of America.
Taejoon began to look beyond its national boundary in
early 2000s. As the first step of its globalization, Taejoon
built a state-of-the art factory to the standard of cGMP
certification in 2005. The next step of its globalization was
to obtain the GMP certification from the European Union
(the “EU”). In 2008, Taejoon became the first ophthalmic
product manufacturer in Korea to obtain GMP certification
from the EU and started exporting its first product to the EU
in 2009 and to the United States in 2013, respectively. In
recent years, Taejoon has expanded into a number of new
markets and increased its presence in existing key markets.
Currently, Taejoon’s products are marketed in 39 countries
worldwide
N
T
R
O
D
U
C
T
I
O
N
With the synergy of exhibition, one-on-one partnering,
BioBusiness Asia conference, plenary luncheon and
conference on Greater China opportunity, BioTaiwan 2013
attracts more than 60, 000 visitors. BioTaiwan 2014 will be
held on July 24-27 in Taipei. Join BioTaiwan 2014; come
meet your Taiwan and Asian partners!
35년간 인류의 생명과 건강을 위해 최선을 다해 온 태준제약은 국내
최초로 혈관조영제의 국산화를 이룩하였으며, EU로부터 GMP인증
을 받아 국내 최초로 녹내장 치료제인 잘로스트 점안액을 유럽에 수
출하였습니다. 안구건조증 치료제인 인프레쉬플러스점안액을 미국에
수출하는 등 현재 태준제약의 제품은 세계 39개국에 수출되고 있습
니다.
태준제약은 2012년 혁신형제약기업에 선정되었으며 쿨프렙 등 10
개 품목이 한국보건산업진흥원으로부터 GH품질인증을 받는 등 실질
적인 품질 우수 제약기업입니다.
200
201
C33
L10
<INNOVATIVE RESEARCH>
-Title: The function of tetherin (BST-2) in viral release and
control of the tetherin effect
-Institute/Organization: Korea University
TEPIK (Transgovernmental Enterprise for
Pandemic Influenza in Korea)
신종인플루엔자 범 부처 사업단
CEO
ADD
TEL
FAX
E-MAIL
URL
E
Woo Joo Kim 김우주
<R&D INFRASTRUCTURE>
3F Koryo-guro Bldg. #226 Gugo-dong, Guro-gu
-T itle: Influenza research information and national
Seoul.Korea
reference material repository
82-2-2626-2434
-Institute/Organization: Centers for Disease Control and
82-2-2626-2466
Prevention/National institute of health
[email protected]
http://www.tepik.or.kr
• TEPIK전시부스 참여기관
X
H
I
B
I
T
S
Agencies that participate in TEPIK exhibition
과제명: 세포배양 기술을 활용한 인플루엔자 백신 제품화 (SK케미칼)
사업단 전시부스 참여 연구기관 및 과제명 소개
I
N
T
R
O
D
U
C
<백신개발 분야>
과제명: 인플루엔자 백신효능증가 원천기술 개발 (세종대학교)
과제명: 재조합아데노바이러스 기반 차세대 신종인플루엔자 백신 개
발 (이화여자대학교)
T
I
O
N
• Agencies that participate in TEPIK exhibition
<VACCINES>
-Title: Development of an adjuvant for influenza vaccine
-Institute/Organization: Sejong University
-T itle: Developing recombinant adenovirus-based next
generation flu vaccines
-Institute/Organization: Ewha Womans University
-T itle: Influenza vaccine commercialization using cell
culture technique
-Institute/Organization: SK chemicals
<치료제 개발 분야>
과제명: 계절성 및 유행성 인플루엔자 예방 및 치료용 항체 개발 (셀
트리온)
과제명: 유기저분자 화합물 유래의 항인플루엔자 바이러스제 후보물
질 발굴 및 효능 평가 (한국화학연구원)
<진단기술개발 분야>
과제명: 인플루엔자 주요 아형 감별이 가능한 고민감도 및 고특이도
를 보이는 인플루엔자 현장용 신속진단법 개발 (고려대학교)
<창의 분야>
과제명: 인플루엔자 바이러스 방출 억제에 미치는 테더린 (BST-2)의
기능과 이의 조절 (고려대학교)
<연구 인프라 분야>
<THERAPEUTICS>
과제명: 인플루엔자 연구정보 및 국가 표준품 뱅크 확충 (질병관리본
-T itle: Development of Prophylactic and Therapeutic 부)
Antibody for Seasonal and Pandemic Influenza
-Institute/Organization: Celltrion
-T itle: Discovery and validation of anti-influenza drug
candidates via chemical synthesis of small organic
compounds
-Institute/Organization: Korea Research Institute of
Chemical Technology
H23
Technical University of Denmark
testo Korea Ltd.
덴마크공과대학
테스토코리아
CEO
ADD
TEL
FAX
E-MAIL
URL
I
N
Anders Bjarklev
Anker Engelunds Vej 1 Bygning 101A DK-2800
Kgs. Lyngby Denmark
45-4525-2525
45-4588-1799
[email protected]
www.dtu.dk
T
R
O
D
U
C
T
I
O
N
사회에 유익하게 하기 위한 자연과학과 기술과학을 이용하여 가치
를 창조하고 개발하기 위해 1829년 설립된 덴마크 내 최고의 공
과 대학입니다. 토목공학, 건축, 우주공학, 바이오 지속가능성(biosustainability), 음식(food), 그린기술(green-tech), 기후연구, 재
생에너지, 에너지혁신 분야 에서 연구중심의 교육뿐만 아니라 고급
의 공공 컨설팅 사업, 기술혁신, 기술이전과 전략적 국제협력 능력으
로도 알려져 있으며 북유럽국가들과 유럽뿐만 아니라 한국의 KAIST,
및 세계의 여러 대학들과 교류를 하고 있습니다.
CEO
ADD
TEL
FAX
E-MAIL
URL
E
Martin Winkle
4 -1 KT & G Building 5F, Mullae-dong 5-ga,
Yeongdeungpo-gu, Seoul, Korea
82-2-2672-7200
82-2-2679-9853
[email protected]
www.testo.co.kr
X
H
I
B
I
T
S
Wireless Data Logger system Saveris, Temperature &
Humidity Data Logger, Multi Function of Temperature/
Humidity/Velocity, etc
무선 온습도 측정 시스템, 온습도 데이터로거, 다기능 환경 측정기 외
I
N
T
R
O
D
U
C
T
I
O
N
testo (Korea) Ltd is German Company supplying
Thermometer, thermal Imager, Hygrometer, Anemometer,
Flue Gas Analyzer, Pressure, Data Logger Water Analysis,
Tachometer, Sound level meter, Light/Sound etc by
completing best quality of products with more than 50
years’ Experiences. We Test (Korea) Ltd are doing endless
research and development to show upgrade model.
Furthermore we are developing dew point measurement,
installed Temperature & Humidity exchanger, Flue gas leak
detection etc to satisfy customer’s variety of needs for
comfortable, accurate and suitable instruments at variable
working condition.
테스토 코리아 (유)는 온도계, 열화상 카메라, 습도계, 풍속계, 연소가
스분석기, 압력계, pH미터, RPM 측정기, 소음측정기, 조도계 등 다
양한 산업용 환경 휴대형 측정 장비를 50여 년의 역사와 함께 세계
최고의 품질로 완성시켰으며 끊임없는 연구와 개발로 현재까지 지속
적인 업그레이드 모델을 선보이고 있는 독일계 자회사입니다. 추가로
공조기용 노점 측정기, 설치용 온습도 변환기, 연소가스 누출감지기
등도 개발하여 고객의 다양한 작업환경에 맞는 편리하고 정확한 첨
단장비를 만들어내기 위해 최선을 다하고 있습니다.
<DIAGNOSTICS>
-T itle: Development of Rapid and multiple influenza
diagnostic kit for field assay
-Institute/Organization: Korea University
202
203
L10
O10
The Embassy of Denmark
The National Project for Personalized
Genomic Medicine
주한 덴마크 대사관
CEO
ADD
TEL
FAX
E-MAIL
URL
H20
차세대 맞춤의료 유전체사업단
Peter Lysholt Hansen
서
울시 용산구 이태원동 260-199 남송빌딩 501호
82-2-795-4187
82-2-796-0986
[email protected]
http://sydkorea.um.dk/ko
CEO
ADD
TEL
FAX
I
N
T
R
O
D
U
C
T
I
O
N
주한 덴마크 대사관은 한국과의 정치, 경제적인 관계뿐만 아니라 문
화, 영사를 비롯한 다양한 영역에서 덴마크의 이해관계를 대표합니
다. 또한 한국에서 활동하고 있거나 진출을 희망하는 덴마크 회사, 연
구기관 및 단체들에게 맞춤 서비스도 제공하고 있습니다. 우리는 한
국 내 덴마크 비즈니스와 연구 커뮤니티를 위한 최고의 업무 컨디션
을 제공하며 한국과 덴마크 사이의 상업, 과학, 기술, 및 혁신을 기초
로 이노베이션 센터의 확장을 포함한 협력을 제공합니다.
E-MAIL
URL
I
N
R
O
D
U
C
TNT Express
Tracer Pharma
티엔티 익스프레스
트레이서 파마
CEO
Hyung-Lae Kim 김형래
BLDG A#408, School of medicine, Ewha Medical
Center, 911-1, Mok-dong, Yangcheon-gu, Seoul,
158-710, Korea
82-2-2654-8734
82-2-2652-2555
[email protected]
http://pgm21.or.kr
T
L10
T
I
O
N
•Established in April 2011
•P GM21 is comprised of five different centers for
Translational Genomic research, Pharmacogenomics
center, Clinical Proteomics center, BI center, ELSI center
•Brings out a new era in clinical diagnostics and medical
treatments through the translation of genomic research
and implementation of personalized medicine
•Mission
-Scientific: Global hub for implementing genomicsbased personalized medicine
-M edical: Practical application of theragnosis &
genomics-base disease prediction
-Wellbeing: Decrease disease burden & increase quality
of life
-Socioeconomic: Decrease healthcare expenditure &
Promote healthcare industry by leading personalized
medicine
•2011년 4월에 발족
•PGM21 중개임상, 약물유전체센터, 단백체 연구센터, BI센터,
ELSI 센터로 구성
•맞춤의학의 구현과 중개임상연구를 통한 임상진단 및 의료치료의
새로운 시대를 도모
• 미션
-과학 기술적: 유전체기반 맞춤의료기술 지식을 사업화하는 글로
벌 거점 육성
-의료기술적: Theragnosis와 유전체기반 예측기술의 실용화
-보건의학적: 질병의 경감과 삶의 질 향상
-경제사회적: 보건의료비용절감과 맞춤의학신사업의 활성화
ADD
TEL
FAX
E-MAIL
URL
Jongchul Kim 김종철
TNT Building 687-8, Gonghang-dong, Gangseogu, Seoul
82-2-2669-0566
82-2-6678-6633
[email protected]
http://www.tnt.com/express/en_kr
CEO
ADD
TEL
E-MAIL
URL
I
E
X
H
I
B
I
T
S
1.Domestic & International Transportation Service for
Healthcare pharmaceutical and biological products
2.Storage & Distribution Service for Healthcare
pharmaceutical and biological products
3.P a c k i n g s o l u t i o n s f o r t e m p e r a t u re s e n s i t i v e
pharmaceutical and biological products
I
N
T
R
O
D
U
C
T
I
O
N
John Bo Jacobsen
F rederiksborgvej 399, bldg. 124N DK-4000
Roskilde Denmark
45-2939-5200
[email protected]
www.tracer-pharma.com
T
R
O
D
U
C
T
I
O
N
의약용 활성 성분의 품질 계약 제조회사이며 핵 의학의 방사선 의약
품에서는 중간 제조업체입니다. 우수의약품제조관리기준(GMP)기준
에 따라 운영되며 소규모 제조공장 설립 등 특정한 고객들의 필요나
주문제작을 해결하며, 고객의 요구에 빠르고 만족스러운 결과를 제공
하는 것에 가장 큰 가치를 두고 있는 기업입니다.
N
TNT Express is one of the world's largest express delivery
companies. TNT Express delivers to more than 200 countries
and operate road and air transportation networks in Europe,
the Middle East and Africa, Asia-Pacific and the Americas.
TNT Express has a strong position in Europe market and
provides value-added services for specific industry sectors
(e.g. automotive, healthcare, high tech, life-style).
Door-to-door customized delivery service of clinical
demonstration samples and related good from hospitals
and pharmaceutical companies with TNT Clinical Packing
Solution and dedicated team’s support.
· Stable data transfer though web interface
·Locate controlled agencies in Chuncheon, Choongju,
and Gwangju aside existing TNT depots
·Packing materials for clinical demonstrations (Dry ice
packing on requests)
·Thorough management from designated CS and clinical
express with proactive POD and etc.
· Operate dedicated clinical express vehicles
TNT Express는 제약, 바이오 분야 운송 서비스 No.1 회사로써, 전
세계 네트워크, 온도 솔루션, 전문 인력을 바탕으로 시간과 온도에 민
감한 의약품, 바이오 물품을 신속하고 안전하게 배송하여 귀사의 성
공적인 비즈니스를 위한 경쟁력을 보장해 드립니다.
현재 TNT Express는 시간과 온도에 민감한 의약품 및 바이오 물품
을 위한 해외/국내 배송, 보관, 통관, 온도 관리, 포장 솔루션 등을 제
공하는 통합 물류 서비스를 제공하고 있습니다.
204
205
N33
K30
Translational Health Science and
Technology Insitute (THSTI)
CEO
ADD
TEL
E-MAIL
URL
Dr. G. Balakrish Nair
496, UDYOGVIHAR PHASE 3, GURGAON 122016
INDIA
91 124 2876300
[email protected]
http://www.thsti.res.in
K30
U&I CORPORATION
Unhwa Co., Ltd.
University of Maryland School of Medicine
유앤아이(주)
(주)운화
메릴랜드 약학 대학
CEO
TEL
FAX
E-MAIL
URL
E
E
X
H
I
B
I
T
S
N20
Ja-Kyo Koo 구자교
82-31-852-0102 (ext713)
82-31-852-0128
[email protected]
http://www.ldisq.com
X
H
I
ADD
TEL
FAX
E-MAIL
URL
B
I
T
S
L’DISQ, L’DISQ C, L’DISQ C.7
E
61-360 전라북도 전주시 덕진구 장동 452-79
5
82-63-240-9818
82-63-240-9566
[email protected]
http://unhwa.com
X
H
I
B
I
TEL
URL
E
T
S
식품, 화장품
I
N
T
R
O
D
U
COMPANY: WWW.YOUIC.COM
THSTI is an autonomous institute founded by Department PRODUCTS : WWW.LDISQ.COM
of Biotechnology, Ministry of Science & Technology,
Government of India. It is part of an emerging health 회사소개: WWW.YOUIC.COM 참조
biotech science cluster with an ambitious initiative to create 제품소개: WWW.LDISQ.COM 참조
the unique institutional environment for the conduct of
truly multidisciplinary research that translates scientific
and technological advancements into medical innovations
that will improve public health. It also seeks to establish
collaborations with research institutions and hospitals
around the World, making this a national undertaking
through its centers.
206
N
T
R
O
D
U
C
T
I
O
X
H
I
B
I
T
S
‘Korea-Maryland, USA Bio Expo 2013’ & ‘BioMaryland
2020’ Strategic Plan Introduction
food, cosmetic
Academic Research Institute
I
20 W. Lexington St., Baltimore, Maryland, U.S.A.
6
1-410-706-3100
http://www.umaryland.edu/
ADD
C
T
I
O
N
N
I
N
T
R
O
D
U
C
T
I
O
N
Unhwa Corporation is making an aggressive progress in
R&D and commercialization under its corporate mission of
contributing to prolongation of human life, promotion of
health and improvement in quality of life. Departing from
conventional cell culture method, Unhwa has succeeded
in isolation and mass culture of plant stem cell (also
called “immortal cell”), which is known as the origin of
plant vitality. This technology, which received scholastic
recognition through its publication on the cover page of
Nature Biotechnology (November 2010), is a core platform
technology that can be applied to various industrial sectors
including high value-added biomaterial and botanical drug
development. In addition to conducting joint research with
a number of prominent institutions at home and abroad,
Unhwa promotes commercialization in drug, nutrition,
and cosmetic business by forming strategic alliance with
global leading companies in respective industries. Unhwa
will make an utmost effort to become the world’s best food
and cosmetic ingredient company by 2017 and to achieve
its corporate value of respecting human life.
한.미 바이오 엑스포 2013 소개 및 메릴랜드 주 바이오 정책 소개
메릴랜드 주 한국무역통상부, JG Business Link International,
Johns Hopkins University, University of Maryland School
of Medicine, Montgomery County, University of Maryland
BioPark, BioHealth Innovation 총 7개 업체 함께 참여
I
N
T
R
O
D
U
C
T
I
O
N
University of Maryland, Baltimore comprises some of the
oldest professional schools in the nation and world and it
is part of the University System of Maryland. The campus
is composed of 58 buildings located near Camden Yards
and Baltimore's famous Lexington Market. UMB comprises
7 professional schools; School of Medicine, School of Law,
Dental School, School of Pharmacy, School of Nursing,
Graduate School, School of Social Work, and School of
Public Health.
메릴랜드 약학 대학은 미국에서 가장 오래된 전문 대학교이며, 메릴
랜드 대학 시스템에 속해 있습니다. 메릴랜드 약학 대학은 총 7개의
전문 분야를 가르치고 있는데, 이에는 약학대학, 법학대학, 치과대학,
의학대학, 간호대학, 대학원, 사회복지 및 공공정책 학과가 속합니다.
207
B23
G22
H47
VGX International, Inc.
Vivagen Co., Ltd.
브이지엑스인터내셔널(주)
(주)비바젠
CEO
ADD
TEL
FAX
E-MAIL
URL
Young K. Park. 박영근
#1903 Keungil Tower, 677-25 Yeoksam-dong,
Gangnam-gu, Seoul, Korea
82-2-527-0600
82-2-557-6784
[email protected]
http://www.vgxi.com/en
CEO
ADD
TEL
FAX
E-MAIL
URL
E
X
H
I
B
I
T
N
T
R
O
D
E
E
U
C
X
H
I
B
I
T
S
Water purification system, pipette, tips, pH meter, Balance,
test paper, filter paper, syringe filter
플라스미드 DNA백신, 바이오의약품 위탁생산
I
Park Joon Sang 박준상
Suite 618, Woolim Lion’s valley I, 311-3 SangdaewonDong, ungwon-Gu, Seongnam-Si, Gyeonggi-Do,
South Korea 462-806
82-31-737-2080
82-31-737-2083
[email protected]
http://www.vivagen.co.kr
S
Plasmid DNA Vaccine, CMO
T
I
O
N
Bio/Chemistry/Medicals as well as Semiconductor, Display.
Wonwoo has been doing our best to set up one-stop
(주)원우시스템즈
system for sales, repair, maintenance and application
counseling for customers also developing optimized
Woo, Won Kyun 우원균
CEO
S antevill 106-209, #719, Shindaebang-dong, software for custom application.
ADD
Dongjak-gu, Seoul, Korea
Optical sensing part 및 광 계측, 성분분석용 장비 전문 공급업체
82-2-533-6720
TEL
(주)원우시스템즈는 2000년 회사설립 이래로, 반도체 및 디스플레
82-2-3289-1293
FAX
이 분야뿐 아닌 바이오/화학/의약학 분야 장비 개발 업체를 위한 다
E-MAIL [email protected]
양한 optical part, OEM spectrometer, sub modules, 각종 광
http://www.wonwoosystem.co.kr
URL
원 및 optical accessories 에서부터 분석장비에 이르기까지 total
solution을 제공합니다. 저희는 제품 판매뿐 아니라 유지, 보수, 관
WONWOO SYSTEMS Co., Ltd.
초순수 제조 장치, 피펫, 팁, pH 미터, 미세저울, 테스트 페이퍼, 필터
페이퍼, 시린지 필터
VGX International, with its proprietary technology,
manufacturing ability, and strong IP position, will continue
N
T
R
O
D
U
C
T
I
O
N
to move forward with its DNA vaccine clinical studies for I
a number of different indications and will continue to Founded in 2003, Vivagen Co., Ltd. is the company
increase its dominant position in the DNA vaccine market. which consists of experts who have more than 10 years
experience in sales, marketing and R&D.
VGX인터내셔널은 DNA백신 분야에서 앞선 연구성과와 저명한 전 Vivagen Co., Ltd. provides differentiated services to
문가 집단을 보유한 선도기업으로 감염성 질환을 타깃으로 DNA백 customers in various experiments such as filtration,
신 개발을 진행하고 있으며, 플라스미드 DNA 생산분야의 오리지널 purification, concentration, incubation and analysis. We are
기술력과 특허를 바탕으로 바이오의약품 위탁생산 (CMO) 사업을 sure our expertise and technical know-how help customers
수행하고 있습니다.
solve their complex problems and achieve their goals.
(주)비바젠은 여과. 분리, 정제, 농축, 배양, 분석 등 다양한 실험 분야
에서 영업, 마케팅, 연구개발업무로 10년 이상 경험을 쌓아온 전문가
들로 구성된 회사입니다.
저희 비바젠은 필드에서의 폭넓은 경험과 풍부한 지식으로, 고객 여
러분께 최적의 제품과 차별화된 서비스를 제공해 드릴 것을 약속 드
립니다.
X
H
I
B
I
T
S
리까지 원스톱 시스템을 구축하는데 최선을 다하고 있습니다.
Optical parts, sub module and analyzing equipments for
Bio, Medical application
•Optical sensing part/OEM spectrometers
- EMBED 2000+ spectrometer
- STS spectrometer
•Sub-system modules
- Absorbance measurement module (pulsed Xe lamp,
Custom cuvette holder, USB2000+ spectrometer)
•Analyzing Equipment
-Stand-alone analyzer: This is a stand-alone desk-top
integrated system with a small on-board computer
-ACUMAN Raman system: desk-top Raman system
바이오, 의약 분야를 위한 성분 분석 장비 개발을 위한 sensing 파
트, sub module 및 분석장비 (Absorbance, Raman 측정장비)
•광학 센싱 파트/OEM spectrometer
-EMBED2000+
-STS spectrometer
•서브시스템 모듈
-Absorbance measurement module (pulsed Xe lamp,
Custom cuvette holder, USB2000+ spectrometer)
•Analyzing Equipments
-Stand-alone analyzer (desk-top integrated system with a
small on-board computer
-ACCUMAN 라만시스템
I
N
T
R
O
D
U
C
T
I
O
N
Since 2000, WonWoo systems Co., Ltd. has supplied the
advanced optical sensing parts such as OEM spectrometers,
optical part, sub modules, light sources and optical
accessories, optical measuring and analyzing equipments
to equipments’ manufacturers in the business fields of
208
209
G24
F40
-의약품 및 바이오 국제/국내 프리미엄 운송 서비스 (Door to
Door)
-Cold Chain Management Service (상온/냉장/냉동/극저온
WORLD COURIER KOREA., LTD.
월드쿠리어 코리아
CEO
ADD
TEL
FAX
E-MAIL
URL
John Butler
#1205, Woori Venture Town II, 82-29 Mullae-dong
3-ga, Yeongdeungpo-gu, Seoul, Korea
82-2-6335-8538
82-2-6335-8539
[email protected]
http://www.worldcourier.co.kr
외)
-바이오 의약품 원료, 완제 및 연구 시료에 대한 운송 솔루션 제공
-수출입 관련 인허가 및 서류 검토 및 절차 가이드 제공
-Qualified / Validated 특수 포장재 제공
-운송중 온도 기록 및 모니터링 서비스
-냉매 (Dry Ice 및 Gel Pack, 액화질소) 제공 및 보충 서비스
-실험용 생동물 및 Animal Product 운송 (검역, 통관, 운송 일괄
서비스)
-관련 교육 (IATA 전염성품목 운송규정/콜드체인)
-임상용 의약품 보관 및 배송 서비스 (인도, 중국, 남미, 러시아 외)
-Clinical Logistics Service: Customized Logistics solutions, -24hours x 7days, 365일 휴일 및 야간 운송 서비스
24-hour collection and delivery of biological specimens -위험물, 전염성 물질 운송 / UN / IATA 인증 Package 제공
(including infectious samples), bulk investigational drugs,
kits and other study materials and supplies
I
N
T
R
O
D
U
C
T
I
O
N
-Cold Chain Services including temperature controlled
packaging, supplies and expertise in-transit dry ice/gel Established in 1969, World Courier is the global leader in
the transportation of clinical samples, investigational drugs
pack replenishment and temperature monitoring
-Temperature-controlled Packing Solutions: We offer a and clinical trial supplies, Infectious substances for the
full range of temperature controlled packaging solutions pharmaceutical industry, with over 38 years of experience
to fit any volume, budget or temperature need from a in the handling of time – critical and temperature
bulk consignment of investigational drugs at 2˚C to 8˚C controlled shipments. We have handled the logistics for
or minute quantities of an irreplaceable pharmaceutical thousands of clinical trials world wide, we understand
compound at -70˚C, the in-house temperature control intimately your timeline and demanding supply chain
and Quality Assurance experts in each World Courier requirements. World Courier has wholly owned global
office can recommend packaging options to protect your network over 140 offices, 2500 employees throughout the
world.
sensitive shipments.
-Individual monitoring of each shipment from p ick-up to
delivery – including real-time online tracking via our web- 1969년 설립이래, 월드쿠리어는 바이오 제약 물류 분야의 선도 기
업으로 국내의 유수의 제약사와 병원, 연구소, 국가기관의 물류파트
based Customer Resource Center, automatic e-mail alert
너로서 포괄적이고 전문화된 운송서비스를 제공해 오고 있습니다.
and confirmation
-Specialized brokerage assistance, customs clearance 오랜 경험과 노하우, 글로벌 네트웍을 통하여, 임상, 전임상, R&D 검
and delivery of consignments in over 220 territories and 체 및 의약품, API, 감염성 물질 및 연구용 생동물에 이르기까지 고객
의 Needs에 가장 적합하고 안전한 운송 솔루션을 제공해 드릴 것을
nations
약속 드립니다.
-Assistance with permit applications including import
permits, Ministry of Health authorizations, etc.
-GMP compliant Clinical Trial Material Storage Facility
& Distribution in Latin America, India, China, Australia,
Russia, South Africa
-Laboratory Live animal transportation (Rat, Mice)
-Training Courses (Cold Chain Management, IATA
shipping guidelines for infectious Substances)
-Strict adherence to global SOPs for all temperature
ranges
E
210
X
H
I
B
I
T
S
I47
WIPS Co., Ltd.
WON INTERNATIONAL PATENT & LAW FIRM
주식회사 윕스
원 국제특허법률사무소
CEO
ADD
TEL
FAX
E-MAIL
URL
E
LEE HYUNG CHIL 이형칠
DMC Tower 18-19th Floor, 189 Sungam-ro, Mapogu, Seoul, South Korea 121-904
82-2-726-1100
82-2-777-7334
[email protected]
http://wipscorp.com
X
H
I
B
I
T
S
TEL
FAX
E-MAIL
URL
E
LEE, Won-Hee 이원희
8th Floor, Sung-ji Heights II, 642-16, Yoksam-dong,
Gangnam-gu, Seoul 135-080, Republic of Korea
82-2-3453-0507, 82-2-3453-0508
82-2-3453-8155, 82-2-3453-8156
[email protected]
http://www.wonpat.com
X
H
I
B
I
T
S
회사 및 기술이전대상 소개/특허상담
윈텔립스
N
ADD
Firm and Technology Introduction/Patent Consulting
WINTELIPS
I
CEO
T
R
O
D
U
C
T
I
O
N
WIPS is a designated search institute by the Korean
Intellectual Property Office, and it provides qualified prior
art, PCT, trademark & design services and customized IP
consulting services with fully evaluating and analyzing each
client's IP workflows and processes.
Since its founding in 1999, WIPS Keeps holding the
number one on-line IP (Intellectual Property) market share
position in South Korea. And with its accumulated IP
knowledge and skills, WIPS finally released WINTELIPS.
WINTELIPS is an integrated Patent Search and Analysis
Online Service with fully functional In-depth analysis,
Statistical Analysis, and Report Services for Patent
Attorneys, IP Legal Experts, IP Consultants, or IP
Researchers to easily establish a successful IP Strategy.
(주)윕스는 특허, 상표, 디자인에 이르는 지식재산 Total Service 분
야의 국내1위 기업으로, 각 산업별로 R&D에서 특허, 그리고 사업화
로 이어지는 독보적인 서비스 제공 전문기업입니다.
윕스의 스마트 특허정보 솔루션 윈텔립스는 업무목적 별로 활용 가
능한 다양한 검색과, 특허전략 수립을 보다 용이하게 할 수 있는 특
허동향분석 및 심층분석 기능, 업무결과를 원클릭으로 해결하는 리포
트 기능을 제공합니다.
I
N
T
R
O
D
U
C
T
I
O
N
Since the foundation in 1995, WON International Patent
& Law Firm focused on the goal of increasing the value of
the clients’ intellectual property. By the turn of 21 century,
the IP environment has dynamically changed, and WON
International is equipped with in-depth understanding on
the technologies to provide one-stop solution integrating
from preparing an application until registration thereof,
assessment on the patentability of technologies and
transfer and license.
The Life Science Dept. and Chemical Dept. are the two
major forces of our firm, which work independently from
each other based on their own expertise specialized to
respective technical fields. Further, Patent Attorneys and
staff at WON International are mostly with master’s degrees
or doctor’s degrees, who continue in their efforts to come
up with the best option to satisfy client’s demands.
WON International will continue to provide customized
service based on its experiences, expertise and ability it
accumulated in the IP field.
원국제특허법률사무소는 1995년 설립이래 고객의 무형자산인 지식
재산권의 가치를 높이기 위해 최선을 다해왔으며, 출원 및 등록절차
물론 기술의 특허가치평가 및 이전, 라이센싱까지 통합솔루션을 제공
해드리고 있습니다. 특히 당소는 바이오분야와 화학분야가 독자적인
팀으로 구성이 되어있어 각 분야의 전문성을 바탕으로 한 최적의 서
비스 제공이 가능하다는 것이 장점이며, 당소의 석박사급의 변리사
및 구성원들은 지식재산권에 대한 고객의 기대에 부응하고자 매순간
최선의 방안을 강구하고 있습니다. 당소는 IP분야에서 쌓아온 경험과
전문성, 능력을 주요한 자산으로 앞으로도 고객맞춤형 서비스를 지속
하여 제공해드리겠습니다.
211
B20
D33
Yakchoin
Yonsei Medical Device Development &
Promotion Center
약초인
연세대학교 의료기기개발촉진센터
CEO
박경배
ADD
90-890 충북 제천시 탐안로 28길 22
3
82-70-4119-9485
82-70-4369-9488
http://약초인.kr
TEL
FAX
URL
D20
CEO
ADD
TEL
E
X
H
I
B
I
도라지청, 도라지생강청, 칡청, 도라지가루, 하수오가루
T
S
FAX
E-MAIL
URL
E
H
I
B
I
T
S
Government·Organization
I
N
T
R
O
D
U
C
Yonsei University Health System
Yonsei University Wonju Severance Hospital
연세의료원 (특허출원 및 기술사업화/연구중심병원)
연세대학교 원주세브란스병원
CEO
Kim Young Ho 김영호
Medical Industry Venture Center 408, 1272, Maeji,
Heungup-myun, Wonju-si, Gangwin-do, 220-842,
Korea
82-33-760-2848
82-33-763-1953
[email protected]
http://www.ymdpc.com
X
D38
T
I
O
N
Public Health Department and Yonsei University Medical
Device Development and Promotion Center supervise
health medical technology quickly industry domestic put
into practical use for the benefit of from May 2010 until
March 2015 plan 105, 000, 000 estimated training
Idea realization a variety a kind of restriction it can be.
Expert technology, knowledge, and through expense,
a group of people risk, marketability, preceding design,
many patent infringement we center sponsor replacement
performance.
ADD
TEL
FAX
E-MAIL
URL
Lee chul 이 철
50 Yonsei-ro, Seodaemoon-gu, Seoul, Korea
82-2-2228--1214~5, 1218, 1211
82-2-2227-8000
[email protected]
http://www.iseverance.com
CEO
ADD
TEL
FAX
E-MAIL
URL
I
N
T
R
O
D
U
C
T
I
O
Yeoseung Yun 윤여승
20 in Gangwon province Dobaru Ilsan (220-701)
Yonsei University Wonju Severance Hospital
82-33-741-1704
82-33-746-1704
[email protected]
http://ctc.yonsei.ac.kr
N
연세의료원은 의료산업화를 선도하는 기관으로 지난 4월 연구중심병
원에 선정됨과 아울러 의료사업화에 매진하고 있습니다. 1996년부
터 2013년 7월말 기준으로 연세의료원에서 출원한 전체 특허수는
745건으로 국내 출원이 569건, 국제 출원이 176건 입니다. 도출된
특허가 HT 산업화를 위해 적극 활용될 수 있도록 연세의료원 의과학
연구처는 관련 산업체와 언제든지 논의할 준비가 되어 있습니다.
I
N
T
R
O
D
U
C
T
I
O
N
This center was designated as a Medical Device Clinical
Trial Center by the Ministry of Health and Welfare in 2010
May. The aim of this center is to establish the infrastructure
for medical device clinical trials and to obtain the highly
developed technology for the clinical trials. Finally we
expect that our domestic medical devices could be more
reliable and competitive in the global market.
본 센터는 2010년 5월 보건복지부로부터 의료기기임상시험센터로
지정되어 선진국 수준의 맞춤형 의료기기임상시험센터 조성 및 인프
라 구축과 첨단 의료공학과 연계하는 의료기기임상시험 기술 확립을
목적으로 의료기기의 제품 경쟁력 강화와 이를 통한 지역 및 국가경
제 발전에 이바지하기 위해 최선을 다하고 있습니다.
본 사업은 보건복지부와 연세대학교 의료공학연구원 의료기기개발촉
진센터가 주관하여 보건의료신기술 (Health Technology, HT)을 신
속하게 산업화 내지는 실용화 하기 위하여 2010년 5월부터 2015년
3월까지 총 사업비 102.78억의 예산으로 수행 중에 있습니다.
본 사업은 기존 R&D 사업과는 달리 이 사업은 개방형 시스템을 바탕
으로 의료기기에 대한 창의적인 아이디어를 실현화할 수 있는 기반
을 구축하는 사업입니다. 전문적인 기술과 지식, 시간과 비용으로 인
한 리스크, 시장성, 선행기술과 특허침해 등 많은 문제점을 저희 센터
가 제안자를 대신해서 실행하는 사업입니다.
212
213
K20
O23
B33
J40
Young Sciences, Inc.
YUJIN HITECH Co., Ltd.
ZETACORPORATION
(주)FMS-KOREA
(주)영사이언스
유진하이텍(주)
주식회사 제타
(주)에프엠에스코리아
CEO
ADD
TEL
FAX
E-MAIL
URL
Chung Kwang Duk 정광덕
301-1304, Bucheon TechnoPark Ssangyong 3rd,
No.36-1, Samjeong-dong, Ojeong-gu, Bucheon-si,
Gyeonggi-do
82-32-624-4500
82-32-624-4505
[email protected]
http://www.youngscience.com
CEO
ADD
TEL
FAX
E-MAIL
URL
BK SEO 서병권
# 917, WOOLIM LION’S VALLEY 1B/D, 311-3
Sangdaewon-Dong, Jungwon-Gu, Seongnam-Si,
Gyeonggi-Do, 462-806, Korea
82-31 737 2315
82-31 737 2318
[email protected]
http://www.yujinhitech.com
CEO
ADD
TEL
FAX
E-MAIL
URL
E
E
X
H
I
B
I
T
S
E
X
H
I
B
I
T
S
Single-use Bioreactor, Filtration, Purification & Separation YSI 당분석기, GEA Niro-Soavi high pressure homogenizer,
Solutions, Virus Safety Testing Service, Sealer & Welder, Kuhner incubator
Autoclave, BSC, Isolator, VHP Generator, Filling system,
Culture media, Microbiological media
I
N
T
R
O
D
U
C
T
I
O
N
Young Sciences specializes in providing products related
to human, animal &microbiological "CELL CULTURE" and
is conducting joint research with its Celltec Bio-Research
Center. For pharmaceutical customers, Young Sciences
does not only supply sterilizers, BSC, freeze dryers, dry
ovens, and isolators but also provides thorough follow-up
maintenance and validation service.
(주)영사이언스는 1992년 창립이래 국내 바이오산업의 발전과 더불
어 꾸준하게 성장해 왔습니다. 특히 제약관련 분야에서 필수적인 관
련 장비로서 Single-use Bioreactor, VHP Generator, Isolator,
Sterilizer, BSC, Freeze Dryer, Dry oven, Welder 등의 장비들도
공급하고, 철저한 사후관리와 Validation service를 전문적으로 제
공하고 있습니다.
Shin sang min 신상민
SK Ventium, 166 Gosan-ro, Gunpo-si Gyeonggido, Korea
82-31-451-2415
82-31-451-2408
[email protected]
http://zetacorporation.com
X
H
I
B
I
T
S
CEO
ADD
TEL
FAX
E-MAIL
URL
E
CHOI DONG HO 최동호
1 52-2 Dongcheon-dong, sooji-gu, Yongin-si,
Gyeonggi-do, Korea
82-31-266-1586-7
82-31-266-1801
[email protected]
http://www.gfms.co.kr
X
H
I
B
Dispenser, laminator, slitter, cutter2대, mixer
Gio-box, Inmark-box, GU-box, GVP
디스펜서, 라미네이터, 슬리터, 커터2대, 믹서
보냉, 보온. 바이오/의약품 팩키징
I
N
T
R
O
D
U
C
T
I
O
N
Zeta is the leading supplier of equipment for the research,
development and production of diagnostic test strips,
biosensors and biochips.
Using its core technologies in laminators, dispensers,
cutters, slitting/bottling & automatic assembler, we are
expanding market worldwide. Moreover, we take the lead
in the research and development of dispensing technology
applicable for biochips/biosensors and microarray in
collaboration with government institutes and universities.
I
N
T
R
O
D
U
I
C
T
T
I
S
O
N
Korea’s first and best specialized packaging solution
enterprise in the field of distribution’s fresh temperature
management and the safe temperature management for
the bio pharma field.
국내최초, 최고의물류, 유통분야에 대한 신선 온도관리
바이오, 제약분야의 안전온도 관리 팩키징 전문솔루션 기업입니다.
당사는 진단용 테스트키트 (diagnostic test strips and device)
생산장비를 개발 및 제작하는 전문업체로서 Laminator장비, 정밀
Dispenser장비, 각종 Cutter류 및 Auto Assembler, Bottling 장
비 등의 국산화 개발 성공으로 그 기술력을 인정받아 왔으며, 이를
바탕으로 국내는 물론 해외시장을 확대해 나가고 있습니다. 아울러
미래형 융합기술인 바이오칩/바이오센서 산업의 성장에 이바지 할수
있는 dispensing 기술개발에 앞장서고 있습니다. 또한, 한층 업그레
이드된 Microarray 및 나노리터단위의 정밀 디스펜싱 기술개발로
바이오산업의 발전에 이바지하고 있습니다.
214
215
D42
R25
(주)K-Greenbio
(재)충북테크노파크 바이오센터 제천감초산업육
성사업단
(주)케이그린바이오
CEO
ADD
TEL
FAX
E-MAIL
E
Enkhva Kim 김용화
314, ETRI CTRCC, Gajeong-Dong, Yuseong-Gu,
Daejeon, Korea
82-42-389-0058
82-42-389-0060
[email protected]
X
H
K30
I
B
I
T
S
Bio fertilizer
(주)바이오인프라
CEO
남창현
CEO
ADD
90-250 충북 제천시 왕암동 932
3
82-43-270-2614
82-43-270-2699
[email protected]
http://www.cbtp.or.kr
ADD
TEL
FAX
E-MAIL
URL
E
X
H
I
B
K30
TEL
FAX
E-MAIL
URL
I
T
S
감초, 맑은감초음료, 발효감초, 홍삼차, 오곡감초삼계탕, 발효감초 디
톡스차, 발라먹는 조청, 男다른차, she 비밀스러운차 등
E
보령제약(주)
Chul-Woo Kim 김철우
Seoul National University Cancer Research Institute
8F 101, Daehak-ro, Jongno-gu, Seoul Korea
82-2-3668-7941
82-2-3673-0609
[email protected]
http://www.bio-infra.com
X
H
I
B
I
T
S
CEO
ADD
TEL
FAX
E-MAIL
URL
E
Tae Hong Choi 최태홍
(110-750) Boryung Bldg, #66-21, Wonnam-dong,
Chongro-Ku, Seoul, Korea
82-2-708-8168
82-2-708-8439
[email protected]
http://www.boryung.co.kr
X
H
I
B
I
T
S
Kanarb (Anti-hypertensive drug)
판넬, 팜플렛, 리플렛
천연유기질비료
카나브, 원료의약품
I
I
N
T
R
O
D
U
C
T
I
O
N
•Our technology, which involves combing germanium
with fulvic acid and humic acid via coordinate bonding,
assists in the growth and development of the crop, thus
significantly improving the crop’s quality.
•S ince fulvic acids and humic acids assist in plants’
absorption of minerals, our technology is capable of
increasing the concentration of organic germanium
contained in the crop by combining germanium and
humic acid on a molecular level.
•카이스트의 기술력과 환경의 만남
•천연물질로부터 추출한 환경 친화적 물질인 풀빅산, 부식산과 천
연물질로부터 추출한 미네랄 및 아미노산, 비타민등의 시너지 효
과로 식물생장, 생육에 도움을 줘 작물의 품질향상에 도움을 줌
•또한, 풀빅산, 부식산은 미네랄이 식물에 잘 흡수되도록 하는 기능
을 가지므로 이러한 원리에 기초하여 본 사업화 기술은 분자수준
에서 부식산에 게르마늄을 결합시켜 게르마늄 유기복합체를 비료
로 만들어 식물의 유효 유기 게르마늄의 농도를 높이도록 함
N
T
R
O
D
U
C
T
I
O
N
농림축산식품부 향토산업육성사업의 일환으로 운영되는 제천감초산
업육성사업단은 제천의 향토자원인 감초에 대한 가공설비를 구축하
여 감초재배 확산과 농가소득 증대에 기여하고 감초를 이용한 원료
의 고부가가치를 확립하고자 설립되었음.
I
N
T
R
O
D
U
C
T
I
O
N
Multiplex Cancer Early Diagnostics
(In Vitro Diagnostic Multivariate Index Assays)
바이오인프라는 설립 이후 단백질분석 알고 리듬을 개발, 기존 암검
사의 단점을 극복, 암 조기진단의 원천핵심기술을 확보하였고 국민들
에게 의료보편성, 의료공정성, 건강주권부여를 구현하기 위해 노력합
니다.
I
N
T
R
O
D
U
C
T
I
O
N
Boryung Pharmaceutical Company (here after Boryung)
founded in 1963 based on company's ideology,
"coexistance and co-prosperity" has led Korean
pharmaceutical industry concentrating its utmost efforts
on the development of new drugs. Boryung makes an
effort to strengthen the product pipelines in the specialty
areas such as cardiovascular drugs, antineoplastics drugs
and antibiotics/antiviral. Boryung devote itself to achieving
aspiration of the company which is "Dedicating to the
health of Mankind" and becoming a global innovative
pharmaceutical company.
Boryung Pharmaceutical has developed Kanarb, an antihypertensive drug that has been approved by the KFDA as
the 15th new drug, and also it is 8th new ARB drug in the
world. Boryung is in the process of exporting Kanarb to 13
countries in South America, BRICs, southeast Asia, the U.S.,
and Europe.
1963년 창립된 보령제약은 ‘삶의 질’을 높이는 우수한 의약품을 계
속적으로 발매해왔으며 지속적인 혁신을 통해 궁극의 목적인 ‘인류
건강에 공헌’을 영속적으로 실천하는 기업이다. 특히, 심혈관계 질환
과 항암 분야에 파이프라인을 집중하고 있다. 카나브 정은 세계 8번
째 ARB 신약이자, KFDA로부터 15번째로 승인 받은ARB 계열 항
고혈압제 신약으로 중남미 13개국과의 수출 계약을 비롯해 BRICs
및 중동아시아, 미국, 유럽 등 전세계적으로 수출을 진행하고 있다.
216
217
MEMO
Job Fair
Overview
Job Fair Overview
Floor Plan for Job Fair
218
Job Fair Overview
The ‘Job Fair 2013’ will be held to carry out corporate social responsibility to
promote Bio industry and to create more jobs.
The Job Fair will bring a corporate and its job seekers one step closer
allowaccessing thousands of employment and career opportunities in
healthcare and Bio industry. The fair also provides an on-site job interview, a
job consulting, and special lectures.
We welcome individuals who are interested in leading future Bio industry and look forward to meet you at
the fair.
Information
D A T E
2013. 9.11 (Wed) ~ 12 (Thur) 10:00 ~ 17:00
V E N U E
Hall 8A, KINTEX Exhibition Center II
T arget
Job seekers in Healthcare, Bio industry companies
MAY 28 ~ 30, 2014 / KINTEX
Participants
Over 40 Healthcare and Bio industry companies
Brand New Start in MAY!
H O S T
Managed by
Sponsored by
Ministry of Health and Welfare
Ministry of Employment and Labor
Center for Women In Science,
Engineering and Technology
221
Floor Plan for Job Fair
Program
• Employment Section
1:1 job interview with recruiting companies
• Job Support Section
Support communication between corporate recruiters and job seekers
• Consulting Section
Resume, Interview, Image Making consulting for Job seekers
• Exhibition Event Section
Finger Print Personality & Aptitude Test, Job Tarot Card, Photo Shooting for Resume
• Seminar Section
∙ Special Lecture
Jae Chun Choe, Professor, Ewha Womans University
- Consilience: The Unity of Knowledge
Young Sook Park, Chair, Millennium Project Korea
Job Fair
- Future Social Mega-Trends and Future Jobs
∙ Healthcare Industry Job Presentation
Topic: Type of a talented candidateand must have abilities that needed in Pharmaceutical, Medical,
Cosmetic, food corporates
∙ Pharmaceutical Specialized Graduate School Conference
Topic: Pharmaceutical Education & Career Development
222
223
MEMO
Special Event
Overview
The Entrepreneurship Boot Camp 2013
Welcome Reception
Bio-microphotography Exhibition
BIO KOREA 2014 Poster Contest
224
225
Special Event
"The Entrepreneurship Boot Camp 2013"
From the early stage of novel drug development to a successful licensing preparation, BIO KOREA 2013
provides a crucial education program to advance your business to the global world.
De Risking Your Globalisation Strategies-for Korean Life Science Companies.
D A T E
September 10 (Tue), 2013, 10:00~18:00
V E N U E
Conference Rm. 303, KINTEX Exhibition Center II
Organized by
KHIDI, ERA Consulting Group
Program
Time MAY 28 ~ 30, 2014 / KINTEX
Brand New Start in MAY!
Program Speaker
09:30-10:00 Registration
10:00-10:15 Opening Remarks
10:15-11:15 Session 1
Preparing for international regulatory requirements during early stage biopharmaceutical product development Gillian Lennard
11:15-11:30 Coffee Break
11:30-12:30 Session 2
Globalizing your business - How to bring your business to the next level Sebastian Fernandez
12:30 -13:30 Lunch
13:30-14:30 Session 3
GMP Compliance - How to align your business with
Christiane international GMP Requirements
Furstenberg
14:30-14:45 Coffee Break
14:45-15:45 Session 4
Intercultural challenges for Asian companies in partnering with European companies - How to come to an agreement Christian Hofer
15:45-16:00 Coffee Break
16:00-16:20 Panel Discussion
16:20-17:30 Closing Remarks
17:30-18:00
Time allowed for short private consultations and questions
227
Welcome Reception
The valuable opportunity to make cultural exchange and build a strong global network.
D A T E
September 11 (Wed), 2013, 18:00~20:30
V E N U E
Outdoor Fountain Square, KINTEX Exhibition Center II
E V E N T S
Opening Performance, Welcoming remarks and Toast
BIO KOREA 2013 Official Sponsors
BIO KOREA Shuttle Bus Service
Bio-microphotography Exhibition
The great opportunity to comprehend the life science industry as a pop-culture and make an enjoyable time
for all the participants.
BIO KOREA 2014 Poster Contest
Get involved and vote for the new face of BIO KOREA 2014. Meet 15 candidates for BIO KOREA 2014 poster.
D A T E
September 11 (Wed) ~ 13(Fri) 2013, 3days
V E N U E
Hall 7, 8A, KINTEX Exhibition Center II
228
BIO KOREA 2013 Official Sponsors
Gold Sponsors
Silver Sponsors
Bronze Sponsor
MAY 28 ~ 30, 2014 / KINTEX
Brand New Start in MAY!
Speacil Sponsor
Promotion Partner
231
BIO KOREA Shuttle Bus Service
Seoul Stn. (Subway Exit No. 14)  KINTEX II
Service Recurrence 123456
Departure Time 08:0008:3009:0010:0011:0013:00
KINTEX II  Seoul Stn.
Service Recurrence 123456
Departure Time 13:0014:0015:0016:0017:0018:00
Hak-dong Stn (Subway Exit No. 9)  KINTEX II
Service Recurrence 123456
Departure Time 08:0008:3009:0010:0011:0013:00
KINTEX II  Hak-dong Stn
Service Recurrence 123456
Departure Time 13:0014:0015:0016:0017:0018:00
232
BASF Plant Science
BASF Plant Science – a BASF group company
– is one of the world’s leading companies
providing innovative plant biotechnology solutions
for agriculture.
INNOVATION
YIELDS
RESULTS
As “Trait Technology Partner”, BASF Plant Science
accesses markets through partnerships with leading seed and food
chain companies, focusing on yield and quality traits for major crops
such as higher yielding corn, soy, hybrid rice, sugarcane, sugarbeet;
drought tolerant corn; herbicide tolerant soy; healthy fatty acids
from canola; soy and corn with enhanced fungal resistance.
For more information,
please visit www.basf.com/plantscience
Critical Samples.
On time. In perfect condition.
The shipment of infectious or
diagnostic biological samples and
clinical trial supplies requires expert
handling. World Courier is a pioneer
in the transport of sensitive medical
and pharmaceutical shipments,
delivering the first human heart
tissue for transplant in 1984.
Specialising in the transport of
temperature controlled and time critical
samples; World Courier is committed
to handling every consignment on an
individual, priority basis. This translates
into a premium service where our
experienced staff ensure that your
shipment arrives on time and in perfect
condition.
With in-house scientists to understand
your needs, World Courier can
recommend and provide appropriate
packaging and refrigerants to ensure
the integrity of your temperature
controlled shipment. Refrigerants are
routinely checked and replenished
during transit as required.
BASF Company Limited
15F, KCCI Bldg., 45, 4-ga, Namdaemunro, Jung-gu, 100-743 Seoul, Korea
Tel: 82-2-3707-7873 Fax: 82-2-3707-3239
For contact information
visit www.worldcourier.com
Documentation and regulatory
requirements are managed by World
Courier to ensure your shipment
complies with country requirements.
Each World Courier office employs a
team trained in Dangerous Goods. Your
shipment is dispatched on the first
available flight and actively monitored
throughout its journey. Confirmation
of the delivery is provided immediately
upon arrival.
•
All shipments placed on the first available
flight and monitored until delivery
•
Specialists in temperature controlled,
UN/IATA approved packaging
•
Expertise in handling complex
documentation and regulatory
requirements
•
Over 140 company owned offices
worldwide, operating 24 hours a day,
365 days a year
•
Worldwide logistical support for clinical
trials
•
Specialists in live mice transportation
•
IATA accredited Dangerous Goods training
for site personnel
•
Development of Investigator Manuals
www.kiwee.or.kr
서울시 마포구 동교동146-8 TEL. 02) 6915-6114 FAX. 02) 6915-6630 E-mail. [email protected]
BIO KOREA Organizing Committee
Tel +82-2-1661-0810
E-mail [email protected]
www.biokorea.org

Similar documents

DAESUNG MACHINERY CO., LTD

DAESUNG MACHINERY CO., LTD designed specially for automatic process of dry/cooling, transportation and sorting of powder / solid recycle of food chemical stuff & raw material Our Company is has continued to invest in R&D to ...

More information

에이비온 주식회사 - Abion Inc.

에이비온 주식회사 - Abion Inc.  Flu-like Reactions; Depression; Headache; Fatigue  Liver Test Abnormalities

More information

Endoscopy

Endoscopy 전남대병원(광주) 제주대(의대)

More information

110327-111029 화물내지

110327-111029 화물내지 Seoul/SEL(ICN) (+9) --- Los Angeles/LAX (--7/--8) KE203 KE213 KE001 KE001 KE017 KE011 KE061 KE061 KE015 KE005-KE006

More information

(shenzhen)co., ltd.

(shenzhen)co., ltd. * Contact. MPC general manager N. Kang 82-51-510-3027 [email protected]

More information